<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Internal Medicine Clinical Reference Guide</title>
    <style>
        * {
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, sans-serif;
            font-size: 10pt;
            line-height: 1.4;
            margin: 0;
            padding: 0;
            color: #24292e;
            background: #f6f8fa;
        }
        
        .calculator {
            background: #fff3cd;
            border: 2px solid #ffc107;
            border-radius: 8px;
            padding: 15px;
            margin: 15px 0;
        }
        
        .calculator-title {
            font-weight: 600;
            color: #856404;
            font-size: 11pt;
            margin-bottom: 10px;
        }
        
        .calc-item {
            margin: 12px 0;
            padding: 8px;
            background: white;
            border-radius: 4px;
            border: 1px solid #e8e8e8;
        }
        
        .calc-item label {
            display: block;
            font-weight: 600;
            margin-bottom: 6px;
            color: #333;
            font-size: 9.5pt;
        }
        
        .calc-item .hint {
            display: block;
            font-size: 8pt;
            color: #666;
            font-weight: normal;
            margin-top: 2px;
            font-style: italic;
        }
        
        .calc-item select, .calc-item input[type="number"] {
            width: 100%;
            padding: 8px 10px;
            border: 2px solid #ddd;
            border-radius: 4px;
            font-size: 9.5pt;
            background: white;
            transition: border-color 0.2s;
        }
        
        .calc-item select:focus, .calc-item input[type="number"]:focus {
            outline: none;
            border-color: #0366d6;
            box-shadow: 0 0 0 3px rgba(3, 102, 214, 0.1);
        }
        
        .calc-item input[type="number"]::placeholder {
            color: #999;
            font-style: italic;
        }
        
        .calc-item input[type="checkbox"] {
            width: 18px;
            height: 18px;
            margin-right: 8px;
            cursor: pointer;
            vertical-align: middle;
        }
        
        .calc-item.checkbox-item {
            padding: 10px;
            cursor: pointer;
            transition: background 0.2s;
        }
        
        .calc-item.checkbox-item:hover {
            background: #f8f9fa;
        }
        
        .calc-item.checkbox-item label {
            cursor: pointer;
            margin: 0;
            display: inline;
            font-weight: 500;
        }
        
        .calc-result {
            background: #d4edda;
            border: 2px solid #28a745;
            padding: 12px;
            margin-top: 12px;
            border-radius: 6px;
            font-weight: 600;
        }
        
        .calc-result.high-risk {
            background: #f8d7da;
            border-color: #dc3545;
        }
        
        .calc-button {
            background: #0366d6;
            color: white;
            border: none;
            padding: 8px 16px;
            border-radius: 6px;
            cursor: pointer;
            font-size: 9pt;
            margin-top: 10px;
        }
        
        .calc-button:hover {
            background: #0256c7;
        }
        
        .calc-description {
            font-size: 9pt;
            color: #666;
            margin-top: 8px;
            padding: 8px;
            background: #f9f9f9;
            border-radius: 4px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            box-shadow: 0 1px 3px rgba(0,0,0,0.12);
        }
        
        .nav-header {
            background: #24292e;
            color: white;
            padding: 20px 30px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }
        
        .nav-header h1 {
            margin: 0;
            font-size: 22pt;
        }
        
        .nav-header p {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: #0366d6;
            color: white;
            padding: 8px 16px;
            text-decoration: none;
            border-radius: 6px;
            font-size: 9pt;
            margin-top: 10px;
            transition: background 0.2s;
        }
        
        .back-to-top:hover {
            background: #0256c7;
        }
        
        .toc {
            padding: 30px;
            background: #f6f8fa;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 95px;
        }
        
        .toc h2 {
            margin-top: 0;
            color: #24292e;
            font-size: 18pt;
            border-bottom: 2px solid #e1e4e8;
            padding-bottom: 10px;
        }
        
        .toc-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 12px;
            margin-top: 20px;
        }
        
        .toc-item {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 6px;
            padding: 12px;
            transition: all 0.2s;
        }
        
        .toc-item:hover {
            border-color: #0366d6;
            box-shadow: 0 2px 8px rgba(3,102,214,0.15);
            transform: translateY(-2px);
        }
        
        .toc-item a {
            text-decoration: none;
            color: #0366d6;
            font-weight: 600;
            font-size: 10pt;
            display: block;
        }
        
        .toc-item a:hover {
            text-decoration: underline;
        }
        
        .toc-number {
            color: #586069;
            font-size: 9pt;
            font-weight: normal;
        }
        
        .condition-page {
            padding: 0px 30px 30px 30px;
            border-bottom: 3px solid #e1e4e8;
            scroll-margin-top: 130px;
        }
        
        .page-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px 25px;
            margin: 0 -30px 25px -30px;
            border-radius: 0;
        }
        
        .page-header h2 {
            margin: 0;
            font-size: 20pt;
        }
        
        .page-header .subtitle {
            font-size: 10pt;
            margin-top: 5px;
            opacity: 0.95;
        }
        
        .section {
            margin-bottom: 18px;
        }
        
        .section-title {
            background: #0366d6;
            color: white;
            padding: 6px 12px;
            font-weight: 600;
            font-size: 11pt;
            margin-bottom: 8px;
            border-radius: 4px;
        }
        
        .section-content {
            padding-left: 12px;
        }
        
        .label {
            font-weight: 600;
            color: #24292e;
        }
        
        .two-column {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 15px;
            margin: 15px 0;
        }
        
        @media (max-width: 768px) {
            .two-column {
                grid-template-columns: 1fr;
            }
            .toc-grid {
                grid-template-columns: 1fr;
            }
        }
        
        .box {
            border: 2px solid #d73a49;
            background: #ffeef0;
            padding: 12px;
            border-radius: 6px;
        }
        
        .box-title {
            font-weight: 600;
            color: #d73a49;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        .pearl-box {
            border: 2px solid #28a745;
            background: #dcffe4;
            padding: 12px;
            margin: 15px 0;
            border-radius: 6px;
        }
        
        .pearl-title {
            font-weight: 600;
            color: #28a745;
            margin-bottom: 6px;
            font-size: 11pt;
        }
        
        ul {
            margin: 6px 0;
            padding-left: 20px;
        }
        
        li {
            margin: 4px 0;
        }
        
        p {
            margin: 6px 0;
        }
        
        .footer-section {
            background: #24292e;
            color: white;
            padding: 30px;
            text-align: center;
        }
        
        .footer-section p {
            margin: 5px 0;
            opacity: 0.8;
        }
        
        @media print {
            .nav-header, .back-to-top {
                display: none;
            }
            .condition-page {
                page-break-after: always;
            }
            body {
                background: white;
            }
            .container {
                box-shadow: none;
            }
        }
        
        html {
            scroll-behavior: smooth;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="nav-header">
            <h1>Internal Medicine Clinical Reference Guide</h1>
            <p>100 Essential Conditions for Hospital Medicine</p>
            <a href="#toc" class="back-to-top">‚Üë Table of Contents</a>
        </div>
        
        <div id="toc" class="toc">
            <h2>üìã Table of Contents</h2>
            <p style="text-align: center; margin-bottom: 15px;">
                <a href="#system-index" style="color: #0366d6; text-decoration: none; font-weight: 600; font-size: 10pt;">üîç View by Physiologic System ‚Üí</a>
            </p>
            
            <!-- SEARCH BOX -->
            <div style="margin: 20px 0; text-align: center;">
                <input type="text" id="conditionSearch" placeholder="Search conditions (e.g., 'pneumonia', 'stroke', 'DKA')..." 
                    style="width: 100%; max-width: 600px; padding: 12px 16px; font-size: 11pt; 
                    border: 2px solid #0366d6; border-radius: 8px; box-sizing: border-box;">
                <div id="searchResults" style="margin-top: 8px; font-size: 9pt; color: #666; font-weight: 600;"></div>
            </div>
            
            <div class="toc-grid">
                <div class="toc-item">
                    <a href="#acs"><span class="toc-number">1.</span> Acute Coronary Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#heart-failure"><span class="toc-number">2.</span> Heart Failure Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#afib"><span class="toc-number">3.</span> Atrial Fibrillation</a>
                </div>
                <div class="toc-item">
                    <a href="#htn-emergency"><span class="toc-number">4.</span> Hypertensive Emergency</a>
                </div>
                <div class="toc-item">
                    <a href="#cap"><span class="toc-number">5.</span> Community-Acquired Pneumonia</a>
                </div>
                <div class="toc-item">
                    <a href="#copd"><span class="toc-number">6.</span> COPD Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#asthma"><span class="toc-number">7.</span> Asthma Exacerbation</a>
                </div>
                <div class="toc-item">
                    <a href="#pe"><span class="toc-number">8.</span> Pulmonary Embolism</a>
                </div>
                <div class="toc-item">
                    <a href="#sepsis"><span class="toc-number">9.</span> Sepsis/Septic Shock</a>
                </div>
                <div class="toc-item">
                    <a href="#aki"><span class="toc-number">10.</span> Acute Kidney Injury</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperkalemia"><span class="toc-number">11.</span> Hyperkalemia</a>
                </div>
                <div class="toc-item">
                    <a href="#hyponatremia"><span class="toc-number">12.</span> Hyponatremia</a>
                </div>
                <div class="toc-item">
                    <a href="#dka"><span class="toc-number">13.</span> Diabetic Ketoacidosis</a>
                </div>
                <div class="toc-item">
                    <a href="#hhs"><span class="toc-number">14.</span> Hyperosmolar Hyperglycemic State</a>
                </div>
                <div class="toc-item">
                    <a href="#ugib"><span class="toc-number">15.</span> Upper GI Bleed</a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis"><span class="toc-number">16.</span> Cirrhosis with Ascites</a>
                </div>
                <div class="toc-item">
                    <a href="#sbp"><span class="toc-number">17.</span> Spontaneous Bacterial Peritonitis</a>
                </div>
                <div class="toc-item">
                    <a href="#he"><span class="toc-number">18.</span> Hepatic Encephalopathy</a>
                </div>
                <div class="toc-item">
                    <a href="#pancreatitis"><span class="toc-number">19.</span> Acute Pancreatitis</a>
                </div>
                <div class="toc-item">
                    <a href="#cellulitis"><span class="toc-number">20.</span> Cellulitis</a>
                </div>
                <div class="toc-item">
                    <a href="#uti"><span class="toc-number">21.</span> Urinary Tract Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#cdiff"><span class="toc-number">22.</span> C. difficile Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#dvt"><span class="toc-number">23.</span> Deep Vein Thrombosis</a>
                </div>
                <div class="toc-item">
                    <a href="#stroke"><span class="toc-number">24.</span> Acute Ischemic Stroke</a>
                </div>
                <div class="toc-item">
                    <a href="#seizure"><span class="toc-number">25.</span> Seizure/Status Epilepticus</a>
                </div>
                <div class="toc-item">
                    <a href="#meningitis"><span class="toc-number">26.</span> Bacterial Meningitis</a>
                </div>
                <div class="toc-item">
                    <a href="#anemia"><span class="toc-number">27.</span> Anemia</a>
                </div>
                <div class="toc-item">
                    <a href="#neutropenic-fever"><span class="toc-number">28.</span> Neutropenic Fever</a>
                </div>
                <div class="toc-item">
                    <a href="#etoh-withdrawal"><span class="toc-number">29.</span> Alcohol Withdrawal</a>
                </div>
                <div class="toc-item">
                    <a href="#delirium"><span class="toc-number">30.</span> Delirium</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid"><span class="toc-number">31.</span> Hyperthyroidism/Thyroid Storm</a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid"><span class="toc-number">32.</span> Hypothyroidism/Myxedema Coma</a>
                </div>
                <div class="toc-item">
                    <a href="#adrenal"><span class="toc-number">33.</span> Adrenal Insufficiency</a>
                </div>
                <div class="toc-item">
                    <a href="#hypercalcemia"><span class="toc-number">34.</span> Hypercalcemia</a>
                </div>
                <div class="toc-item">
                    <a href="#hypomag"><span class="toc-number">35.</span> Hypomagnesemia</a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo"><span class="toc-number">36.</span> Rhabdomyolysis</a>
                </div>
                <div class="toc-item">
                    <a href="#transfusion"><span class="toc-number">37.</span> Transfusion Reactions</a>
                </div>
                <div class="toc-item">
                    <a href="#pleural-effusion"><span class="toc-number">38.</span> Pleural Effusion</a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax"><span class="toc-number">39.</span> Pneumothorax</a>
                </div>
                <div class="toc-item">
                    <a href="#syncope"><span class="toc-number">40.</span> Syncope</a>
                </div>
                <div class="toc-item">
                    <a href="#pericarditis"><span class="toc-number">41.</span> Pericarditis/Pericardial Effusion/Cardiac Tamponade</a>
                </div>
                <div class="toc-item">
                    <a href="#endocarditis"><span class="toc-number">42.</span> Infective Endocarditis</a>
                </div>
                <div class="toc-item">
                    <a href="#myocarditis"><span class="toc-number">43.</span> Myocarditis</a>
                </div>
                <div class="toc-item">
                    <a href="#cardiogenic-shock"><span class="toc-number">44.</span> Cardiogenic Shock</a>
                </div>
                <div class="toc-item">
                    <a href="#bradycardia"><span class="toc-number">45.</span> Symptomatic Bradycardia/Heart Block (Pacing)</a>
                </div>
                <div class="toc-item">
                    <a href="#vt-vf"><span class="toc-number">46.</span> Ventricular Tachycardia/Ventricular Fibrillation</a>
                </div>
                <div class="toc-item">
                    <a href="#limb-ischemia"><span class="toc-number">47.</span> Acute Limb Ischemia</a>
                </div>
                <div class="toc-item">
                    <a href="#dvt"><span class="toc-number">48.</span> Deep Vein Thrombosis (DVT)</a>
                </div>
                <div class="toc-item">
                    <a href="#pleural-effusion"><span class="toc-number">49.</span> Pleural Effusion</a>
                </div>
                <div class="toc-item">
                    <a href="#pneumothorax"><span class="toc-number">50.</span> Pneumothorax/Tension Pneumothorax</a>
                </div>
                <div class="toc-item">
                    <a href="#ild"><span class="toc-number">51.</span> Acute Exacerbation of Interstitial Lung Disease (ILD)</a>
                </div>
                <div class="toc-item">
                    <a href="#hemoptysis"><span class="toc-number">52.</span> Hemoptysis (Massive)</a>
                </div>
                <div class="toc-item">
                    <a href="#hypercapnic-failure"><span class="toc-number">53.</span> Acute Hypercapnic Respiratory Failure</a>
                </div>
                <div class="toc-item">
                    <a href="#tia"><span class="toc-number">54.</span> Transient Ischemic Attack (TIA)</a>
                </div>
                <div class="toc-item">
                    <a href="#gbs"><span class="toc-number">55.</span> Guillain-Barr√© Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#myasthenia"><span class="toc-number">56.</span> Myasthenia Gravis Crisis</a>
                </div>
                <div class="toc-item">
                    <a href="#delirium"><span class="toc-number">57.</span> Acute Delirium (Non-Alcohol)</a>
                </div>
                <div class="toc-item">
                    <a href="#increased-icp"><span class="toc-number">58.</span> Increased Intracranial Pressure (ICP)</a>
                </div>
                <div class="toc-item">
                    <a href="#cord-compression"><span class="toc-number">59.</span> Spinal Cord Compression</a>
                </div>
                <div class="toc-item">
                    <a href="#influenza"><span class="toc-number">60.</span> Influenza/Severe Viral Pneumonia</a>
                </div>
                <div class="toc-item">
                    <a href="#covid"><span class="toc-number">61.</span> COVID-19 Severe Disease</a>
                </div>
                <div class="toc-item">
                    <a href="#cdiff"><span class="toc-number">62.</span> Clostridioides difficile Colitis</a>
                </div>
                <div class="toc-item">
                    <a href="#pyelo"><span class="toc-number">63.</span> UTI/Pyelonephritis (Complicated)</a>
                </div>
                <div class="toc-item">
                    <a href="#ssti"><span class="toc-number">64.</span> Skin/Soft Tissue Infections (Cellulitis, Necrotizing Fasciitis)</a>
                </div>
                <div class="toc-item">
                    <a href="#tb"><span class="toc-number">65.</span> Tuberculosis (Active)</a>
                </div>
                <div class="toc-item">
                    <a href="#hiv-aids"><span class="toc-number">66.</span> HIV/AIDS Complications</a>
                </div>
                <div class="toc-item">
                    <a href="#opportunistic"><span class="toc-number">67.</span> Opportunistic Infections in Immunocompromised Host</a>
                </div>
                <div class="toc-item">
                    <a href="#hyperthyroid"><span class="toc-number">68.</span> Hyperthyroidism/Thyrotoxicosis (Non-Storm)</a>
                </div>
                <div class="toc-item">
                    <a href="#hypothyroid"><span class="toc-number">69.</span> Hypothyroidism (Non-Myxedema)</a>
                </div>
                <div class="toc-item">
                    <a href="#diabetic-foot"><span class="toc-number">70.</span> Diabetic Foot Infection</a>
                </div>
                <div class="toc-item">
                    <a href="#siadh"><span class="toc-number">71.</span> SIADH (Syndrome of Inappropriate ADH)</a>
                </div>
                <div class="toc-item">
                    <a href="#diabetes-insipidus"><span class="toc-number">72.</span> Diabetes Insipidus</a>
                </div>
                <div class="toc-item">
                    <a href="#pheo"><span class="toc-number">73.</span> Pheochromocytoma Crisis</a>
                </div>
                <div class="toc-item">
                    <a href="#bowel-obstruction"><span class="toc-number">74.</span> Bowel Obstruction (Small/Large)</a>
                </div>
                <div class="toc-item">
                    <a href="#acute-diarrhea"><span class="toc-number">75.</span> Severe Acute Diarrhea/Volume Depletion</a>
                </div>
                <div class="toc-item">
                    <a href="#ibd"><span class="toc-number">76.</span> Inflammatory Bowel Disease (IBD) Flare</a>
                </div>
                <div class="toc-item">
                    <a href="#diverticulitis"><span class="toc-number">77.</span> Diverticulitis (Complicated)</a>
                </div>
                <div class="toc-item">
                    <a href="#cirrhosis-complications"><span class="toc-number">78.</span> Cirrhosis Complications (Variceal Bleeding, Hepatorenal Syndrome)</a>
                </div>
                <div class="toc-item">
                    <a href="#aclf"><span class="toc-number">79.</span> Acute-on-Chronic Liver Failure</a>
                </div>
                <div class="toc-item">
                    <a href="#mesenteric-ischemia"><span class="toc-number">80.</span> Ischemic Bowel/Mesenteric Ischemia</a>
                </div>
                <div class="toc-item">
                    <a href="#ckd-complications"><span class="toc-number">81.</span> Chronic Kidney Disease Complications</a>
                </div>
                <div class="toc-item">
                    <a href="#uremia"><span class="toc-number">82.</span> Uremic Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#rhabdo"><span class="toc-number">83.</span> Rhabdomyolysis</a>
                </div>
                <div class="toc-item">
                    <a href="#tls"><span class="toc-number">84.</span> Tumor Lysis Syndrome</a>
                </div>
                <div class="toc-item">
                    <a href="#hypocalcemia"><span class="toc-number">85.</span> Hypocalcemia</a>
                </div>
                <div class="toc-item">
                    <a href="#magnesium"><span class="toc-number">86.</span> Hypermagnesemia/Hypomagnesemia</a>
                </div>
                <div class="toc-item">
                    <a href="#phosphate"><span class="toc-number">87.</span> Hyperphosphatemia/Hypophosphatemia</a>
                </div>
                <div class="toc-item">
                    <a href="#metabolic-alkalosis"><span class="toc-number">88.</span> Metabolic Alkalosis</a>
                </div>
                <div class="toc-item">
                    <a href="#thrombocytopenia"><span class="toc-number">89.</span> Thrombocytopenia (ITP, HIT, TTP/HUS)</a>
                </div>
                <div class="toc-item">
                    <a href="#dic"><span class="toc-number">90.</span> Disseminated Intravascular Coagulation (DIC)</a>
                </div>
                <div class="toc-item">
                    <a href="#sickle-cell"><span class="toc-number">91.</span> Sickle Cell Crisis (Vaso-occlusive, Acute Chest)</a>
                </div>
                <div class="toc-item">
                    <a href="#hemolytic-anemia"><span class="toc-number">92.</span> Hemolytic Anemia</a>
                </div>
                <div class="toc-item">
                    <a href="#onc-emergencies"><span class="toc-number">93.</span> Oncologic Emergencies (SVC Syndrome, Cord Compression, Hypercalcemia of Malignancy)</a>
                </div>
                <div class="toc-item">
                    <a href="#anticoag-reversal"><span class="toc-number">94.</span> Anticoagulation Reversal/Major Bleeding on Anticoagulants</a>
                </div>
                <div class="toc-item">
                    <a href="#gout"><span class="toc-number">95.</span> Acute Gout/Pseudogout (Crystal Arthropathy)</a>
                </div>
                <div class="toc-item">
                    <a href="#sle"><span class="toc-number">96.</span> Systemic Lupus Erythematosus (SLE) Flare</a>
                </div>
                <div class="toc-item">
                    <a href="#gca"><span class="toc-number">97.</span> Giant Cell Arteritis/Temporal Arteritis</a>
                </div>
                <div class="toc-item">
                    <a href="#anaphylaxis"><span class="toc-number">98.</span> Anaphylaxis</a>
                </div>
                <div class="toc-item">
                    <a href="#overdose"><span class="toc-number">99.</span> Drug Overdose/Toxidromes (Acetaminophen, Salicylates, TCA, etc.)</a>
                </div>
                <div class="toc-item">
                    <a href="#opioid"><span class="toc-number">100.</span> Opioid Overdose/Withdrawal</a>
                </div>
            </div>
        </div>

        <!-- SYSTEM-BASED INDEX -->
        <div id="system-index" class="toc" style="margin-top: 30px;">
            <h2>üîç Index by Physiologic System</h2>
            <p style="font-size: 9pt; color: #666; margin-bottom: 15px;">Quick reference organized by organ system. Some conditions appear in multiple categories.</p>
            
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(280px, 1fr)); gap: 20px;">
                
                <!-- CARDIOVASCULAR -->
                <div style="background: #fff; border: 2px solid #e74c3c; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #e74c3c; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #e74c3c; padding-bottom: 5px;">‚ù§Ô∏è CARDIOVASCULAR</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#acs" style="color: #0366d6; text-decoration: none;">1. Acute Coronary Syndrome</a><br>
                        <a href="#heart-failure" style="color: #0366d6; text-decoration: none;">2. Heart Failure Exacerbation</a><br>
                        <a href="#afib" style="color: #0366d6; text-decoration: none;">3. Atrial Fibrillation</a><br>
                        <a href="#htn-emergency" style="color: #0366d6; text-decoration: none;">4. Hypertensive Emergency</a><br>
                        <a href="#dvt" style="color: #0366d6; text-decoration: none;">23. Deep Vein Thrombosis</a><br>
                        <a href="#syncope" style="color: #0366d6; text-decoration: none;">40. Syncope</a><br>
                        <a href="#pericarditis" style="color: #0366d6; text-decoration: none;">41. Pericarditis/Tamponade</a><br>
                        <a href="#endocarditis" style="color: #0366d6; text-decoration: none;">42. Infective Endocarditis</a><br>
                        <a href="#myocarditis" style="color: #0366d6; text-decoration: none;">43. Myocarditis</a><br>
                        <a href="#cardiogenic-shock" style="color: #0366d6; text-decoration: none;">44. Cardiogenic Shock</a><br>
                        <a href="#bradycardia" style="color: #0366d6; text-decoration: none;">45. Bradycardia/Heart Block</a><br>
                        <a href="#vt-vf" style="color: #0366d6; text-decoration: none;">46. VT/VF</a><br>
                        <a href="#limb-ischemia" style="color: #0366d6; text-decoration: none;">47. Acute Limb Ischemia</a><br>
                        <a href="#dvt" style="color: #0366d6; text-decoration: none;">48. DVT</a>
                    </div>
                </div>
                
                <!-- PULMONARY -->
                <div style="background: #fff; border: 2px solid #3498db; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #3498db; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #3498db; padding-bottom: 5px;">ü´Å PULMONARY</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#cap" style="color: #0366d6; text-decoration: none;">5. Community-Acquired Pneumonia</a><br>
                        <a href="#copd" style="color: #0366d6; text-decoration: none;">6. COPD Exacerbation</a><br>
                        <a href="#asthma" style="color: #0366d6; text-decoration: none;">7. Asthma Exacerbation</a><br>
                        <a href="#pe" style="color: #0366d6; text-decoration: none;">8. Pulmonary Embolism</a><br>
                        <a href="#pleural-effusion" style="color: #0366d6; text-decoration: none;">38. Pleural Effusion</a><br>
                        <a href="#pneumothorax" style="color: #0366d6; text-decoration: none;">39. Pneumothorax</a><br>
                        <a href="#pleural-effusion" style="color: #0366d6; text-decoration: none;">49. Pleural Effusion</a><br>
                        <a href="#pneumothorax" style="color: #0366d6; text-decoration: none;">50. Pneumothorax/Tension</a><br>
                        <a href="#ild" style="color: #0366d6; text-decoration: none;">51. ILD Exacerbation</a><br>
                        <a href="#hemoptysis" style="color: #0366d6; text-decoration: none;">52. Hemoptysis (Massive)</a><br>
                        <a href="#hypercapnic-failure" style="color: #0366d6; text-decoration: none;">53. Hypercapnic Resp Failure</a><br>
                        <a href="#influenza" style="color: #0366d6; text-decoration: none;">60. Influenza/Viral Pneumonia</a><br>
                        <a href="#covid" style="color: #0366d6; text-decoration: none;">61. COVID-19 Severe Disease</a>
                    </div>
                </div>
                
                <!-- RENAL/ELECTROLYTES -->
                <div style="background: #fff; border: 2px solid #9b59b6; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #9b59b6; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #9b59b6; padding-bottom: 5px;">üß™ RENAL & ELECTROLYTES</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#aki" style="color: #0366d6; text-decoration: none;">10. Acute Kidney Injury</a><br>
                        <a href="#hyperkalemia" style="color: #0366d6; text-decoration: none;">11. Hyperkalemia</a><br>
                        <a href="#hyponatremia" style="color: #0366d6; text-decoration: none;">12. Hyponatremia</a><br>
                        <a href="#hypercalcemia" style="color: #0366d6; text-decoration: none;">34. Hypercalcemia</a><br>
                        <a href="#hypomag" style="color: #0366d6; text-decoration: none;">35. Hypomagnesemia</a>
                    </div>
                </div>
                
                <!-- ENDOCRINE -->
                <div style="background: #fff; border: 2px solid #f39c12; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #f39c12; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #f39c12; padding-bottom: 5px;">‚ö° ENDOCRINE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#dka" style="color: #0366d6; text-decoration: none;">13. Diabetic Ketoacidosis</a><br>
                        <a href="#hhs" style="color: #0366d6; text-decoration: none;">14. Hyperosmolar Hyperglycemic State</a><br>
                        <a href="#hyperthyroid" style="color: #0366d6; text-decoration: none;">31. Hyperthyroidism/Thyroid Storm</a><br>
                        <a href="#hypothyroid" style="color: #0366d6; text-decoration: none;">32. Hypothyroidism/Myxedema Coma</a><br>
                        <a href="#adrenal" style="color: #0366d6; text-decoration: none;">33. Adrenal Insufficiency/Crisis</a>
                    </div>
                </div>
                
                <!-- GI/HEPATIC -->
                <div style="background: #fff; border: 2px solid #27ae60; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #27ae60; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #27ae60; padding-bottom: 5px;">ü´Ñ GASTROINTESTINAL & HEPATIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#ugib" style="color: #0366d6; text-decoration: none;">15. Upper GI Bleed</a><br>
                        <a href="#cirrhosis" style="color: #0366d6; text-decoration: none;">16. Cirrhosis with Ascites</a><br>
                        <a href="#sbp" style="color: #0366d6; text-decoration: none;">17. Spontaneous Bacterial Peritonitis</a><br>
                        <a href="#he" style="color: #0366d6; text-decoration: none;">18. Hepatic Encephalopathy</a><br>
                        <a href="#pancreatitis" style="color: #0366d6; text-decoration: none;">19. Acute Pancreatitis</a><br>
                        <a href="#cdiff" style="color: #0366d6; text-decoration: none;">22. C. difficile Infection</a>
                    </div>
                </div>
                
                <!-- INFECTIOUS DISEASE -->
                <div style="background: #fff; border: 2px solid #e67e22; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #e67e22; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #e67e22; padding-bottom: 5px;">ü¶† INFECTIOUS DISEASE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#cap" style="color: #0366d6; text-decoration: none;">5. Community-Acquired Pneumonia</a><br>
                        <a href="#sepsis" style="color: #0366d6; text-decoration: none;">9. Sepsis/Septic Shock</a><br>
                        <a href="#cellulitis" style="color: #0366d6; text-decoration: none;">20. Cellulitis</a><br>
                        <a href="#uti" style="color: #0366d6; text-decoration: none;">21. UTI/Pyelonephritis</a><br>
                        <a href="#cdiff" style="color: #0366d6; text-decoration: none;">22. C. difficile Infection</a><br>
                        <a href="#meningitis" style="color: #0366d6; text-decoration: none;">26. Bacterial Meningitis</a><br>
                        <a href="#neutropenic-fever" style="color: #0366d6; text-decoration: none;">28. Neutropenic Fever</a>
                    </div>
                </div>
                
                <!-- NEUROLOGIC -->
                <div style="background: #fff; border: 2px solid #8e44ad; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #8e44ad; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #8e44ad; padding-bottom: 5px;">üß† NEUROLOGIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#stroke" style="color: #0366d6; text-decoration: none;">24. Acute Ischemic Stroke</a><br>
                        <a href="#seizure" style="color: #0366d6; text-decoration: none;">25. Seizure/Status Epilepticus</a><br>
                        <a href="#meningitis" style="color: #0366d6; text-decoration: none;">26. Bacterial Meningitis</a><br>
                        <a href="#delirium" style="color: #0366d6; text-decoration: none;">30. Delirium</a>
                    </div>
                </div>
                
                <!-- HEMATOLOGIC -->
                <div style="background: #fff; border: 2px solid #c0392b; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #c0392b; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #c0392b; padding-bottom: 5px;">ü©∏ HEMATOLOGIC</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#anemia" style="color: #0366d6; text-decoration: none;">27. Anemia</a><br>
                        <a href="#neutropenic-fever" style="color: #0366d6; text-decoration: none;">28. Neutropenic Fever</a><br>
                        <a href="#transfusion" style="color: #0366d6; text-decoration: none;">37. Transfusion Reactions</a>
                    </div>
                </div>
                
                <!-- TOXICOLOGY -->
                <div style="background: #fff; border: 2px solid #16a085; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #16a085; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #16a085; padding-bottom: 5px;">‚ò†Ô∏è TOXICOLOGY & SUBSTANCE</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#etoh-withdrawal" style="color: #0366d6; text-decoration: none;">29. Alcohol Withdrawal</a>
                    </div>
                </div>
                
                <!-- METABOLIC/MUSCULOSKELETAL -->
                <div style="background: #fff; border: 2px solid #d35400; border-radius: 8px; padding: 15px;">
                    <h3 style="color: #d35400; margin-top: 0; font-size: 11pt; border-bottom: 2px solid #d35400; padding-bottom: 5px;">üí™ METABOLIC & MUSCULOSKELETAL</h3>
                    <div style="font-size: 9pt; line-height: 1.8;">
                        <a href="#rhabdo" style="color: #0366d6; text-decoration: none;">36. Rhabdomyolysis</a>
                    </div>
                </div>
                
            </div>
            
            <p style="margin-top: 20px; text-align: center;">
                <a href="#toc" style="color: #0366d6; text-decoration: none; font-weight: 600;">‚Üë Back to Numerical Table of Contents</a>
            </p>
        </div>

        <!-- PAGE 1: ACUTE CORONARY SYNDROME -->
        <div id="acs" class="condition-page">
            <div class="page-header">
                <h2>1. ACUTE CORONARY SYNDROME (ACS)</h2>
                <div class="subtitle">STEMI ‚Ä¢ NSTEMI ‚Ä¢ Unstable Angina</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Substernal chest pain/pressure >20 minutes, radiation to jaw/left arm/back, diaphoresis, nausea, dyspnea. Pain not relieved by rest or nitroglycerin.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Diabetics/Elderly/Women:</strong> Atypical symptoms - dyspnea alone, weakness, epigastric pain, syncope</li>
                        <li><strong>Silent MI:</strong> No chest pain (30% of diabetics)</li>
                        <li><strong>RV Infarction:</strong> Hypotension with clear lungs, JVD, Kussmaul sign</li>
                        <li><strong>Posterior MI:</strong> Isolated ST depression V1-V3, need posterior leads (V7-V9)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> ECG within 10 minutes, troponin (repeat at 3 and 6 hours if initial negative), CBC, BMP, PT/INR, lipid panel, CXR</p>
                    <p><span class="label">STEMI Criteria:</span> ST elevation ‚â•1mm in 2+ contiguous leads OR new LBBB OR ST depression V1-V3 (posterior MI)</p>
                    <p><span class="label">Calculations:</span> <a href="#calc-heart" style="color: #0366d6;">HEART Score</a>, <a href="#calc-timi-stemi" style="color: #0366d6;">TIMI STEMI</a>, <a href="#calc-timi-nstemi" style="color: #0366d6;">TIMI NSTEMI</a>, <a href="#calc-grace" style="color: #0366d6;">GRACE Score</a></p>
                    
                    <!-- HEART Score Calculator -->
                    <div id="calc-heart" class="calculator">
                        <div class="calculator-title">üßÆ HEART Score Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Risk stratification for chest pain patients to determine if safe for outpatient evaluation. Score 0-3 = low risk (outpatient), 4-6 = moderate risk (observe), 7-10 = high risk (admit).
                        </div>
                        
                        <div class="calc-item">
                            <label>History
                                <span class="hint">How suspicious is the patient's story for ACS?</span>
                            </label>
                            <select id="heart-history">
                                <option value="0">Slightly suspicious - probably not cardiac (0)</option>
                                <option value="1" selected>Moderately suspicious - could be cardiac (1)</option>
                                <option value="2">Highly suspicious - typical angina (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>ECG
                                <span class="hint">Initial ECG findings</span>
                            </label>
                            <select id="heart-ecg">
                                <option value="0" selected>Normal (0)</option>
                                <option value="1">Non-specific repolarization changes (1)</option>
                                <option value="2">Significant ST deviation (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Age
                                <span class="hint">Patient's age in years</span>
                            </label>
                            <select id="heart-age">
                                <option value="0"><21 years (0)</option>
                                <option value="1">21-45 years (1)</option>
                                <option value="2" selected>45-65 years (2)</option>
                                <option value="2">>65 years (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Risk Factors
                                <span class="hint">Count: HTN, DM, smoking, high cholesterol, family history, obesity</span>
                            </label>
                            <select id="heart-risk">
                                <option value="0">None (0)</option>
                                <option value="1" selected>1-2 risk factors (1)</option>
                                <option value="2">‚â•3 risk factors or history of atherosclerotic disease (2)</option>
                            </select>
                        </div>
                        
                        <div class="calc-item">
                            <label>Troponin
                                <span class="hint">Initial troponin level relative to upper limit of normal</span>
                            </label>
                            <select id="heart-trop">
                                <option value="0" selected>Normal - below upper limit (0)</option>
                                <option value="1">1-3√ó upper limit of normal (1)</option>
                                <option value="2">>3√ó upper limit of normal (2)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateHEART()">Calculate HEART Score</button>
                        <div id="heart-result"></div>
                    </div>
                    
                    <!-- TIMI STEMI Calculator -->
                    <div id="calc-timi-stemi" class="calculator">
                        <div class="calculator-title">üßÆ TIMI Risk Score - STEMI</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Predicts 30-day mortality in STEMI patients. Score 0-2 = 2% mortality, 3-4 = 5%, 5-6 = 12%, >6 = 36%.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age65"> Age 65-74 years
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-age75"> Age ‚â•75 years
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-dm"> Diabetes, Hypertension, or Angina history
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-bp"> Systolic BP <100 mmHg
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-hr"> Heart rate >100 bpm
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-killip"> Killip class II-IV (rales, S3, pulmonary edema, shock)
                                <span class="hint">+2 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-weight"> Weight <67 kg (150 lbs)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-anterior"> Anterior STEMI or LBBB
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-stemi-time"> Time to treatment >4 hours
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_STEMI()">Calculate TIMI STEMI Score</button>
                        <div id="timi-stemi-result"></div>
                    </div>
                    
                    <!-- TIMI NSTEMI Calculator -->
                    <div id="calc-timi-nstemi" class="calculator">
                        <div class="calculator-title">üßÆ TIMI Risk Score - NSTEMI/UA</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Risk of death, MI, or urgent revascularization within 14 days. Score 0-2 = 5% risk (low), 3-4 = 13% (moderate), 5-7 = 41% (high).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-age"> Age ‚â•65 years
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-risk"> ‚â•3 CAD risk factors
                                <span class="hint">HTN, DM, smoking, high cholesterol, family history (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-cad"> Known CAD (stenosis ‚â•50%)
                                <span class="hint">Prior cath showing >50% stenosis (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-asa"> Aspirin use in past 7 days
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-angina"> Severe angina
                                <span class="hint">‚â•2 episodes within 24 hours (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-ecg"> ST changes ‚â•0.5mm
                                <span class="hint">ST elevation or depression (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="timi-nstemi-trop"> Elevated cardiac markers
                                <span class="hint">Troponin or CK-MB elevated (+1 point)</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateTIMI_NSTEMI()">Calculate TIMI NSTEMI Score</button>
                        <div id="timi-nstemi-result"></div>
                    </div>
                    
                    <!-- GRACE Score Calculator -->
                    <div id="calc-grace" class="calculator">
                        <div class="calculator-title">üßÆ GRACE Score Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Estimates in-hospital and 6-month mortality in ACS. Low risk <109, intermediate 109-140, high >140. More accurate than TIMI for mortality prediction.
                        </div>
                        
                        <div class="calc-item">
                            <label>Age (years)
                                <span class="hint">Patient's age - typical range 40-80</span>
                            </label>
                            <input type="number" id="grace-age" placeholder="e.g., 65" min="18" max="120" value="65">
                        </div>
                        
                        <div class="calc-item">
                            <label>Heart Rate (bpm)
                                <span class="hint">Beats per minute - typical range 60-100</span>
                            </label>
                            <input type="number" id="grace-hr" placeholder="e.g., 85" min="30" max="250" value="85">
                        </div>
                        
                        <div class="calc-item">
                            <label>Systolic Blood Pressure (mmHg)
                                <span class="hint">SBP at presentation - typical range 100-160</span>
                            </label>
                            <input type="number" id="grace-sbp" placeholder="e.g., 130" min="50" max="250" value="130">
                        </div>
                        
                        <div class="calc-item">
                            <label>Creatinine (mg/dL)
                                <span class="hint">Serum creatinine - normal 0.6-1.2 mg/dL</span>
                            </label>
                            <input type="number" id="grace-cr" placeholder="e.g., 1.0" step="0.1" min="0.1" max="15" value="1.0">
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-arrest"> Cardiac arrest at admission
                                <span class="hint">+39 points</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-st"> ST segment deviation on ECG
                                <span class="hint">ST elevation or depression (+28 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="grace-enzymes" checked> Elevated cardiac enzymes
                                <span class="hint">Troponin or CK-MB elevated (+14 points)</span>
                            </label>
                        </div>
                        
                        <div class="calc-item">
                            <label>Killip Class
                                <span class="hint">Clinical heart failure classification</span>
                            </label>
                            <select id="grace-killip">
                                <option value="0" selected>I - No heart failure signs (0)</option>
                                <option value="20">II - Rales or S3 gallop (+20)</option>
                                <option value="39">III - Pulmonary edema (+39)</option>
                                <option value="59">IV - Cardiogenic shock (+59)</option>
                            </select>
                        </div>
                        
                        <button class="calc-button" onclick="calculateGRACE()">Calculate GRACE Score</button>
                        <div id="grace-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management (MONA-BAH):</span></p>
                    <ul>
                        <li><strong>Morphine:</strong> 2-4mg IV PRN (use cautiously, may worsen outcomes)</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <90%</li>
                        <li><strong>Nitroglycerin:</strong> 0.4mg SL q5min √ó 3 (avoid if RV infarct, SBP <90, recent PDE5 inhibitor)</li>
                        <li><strong>Aspirin:</strong> 325mg PO chewed immediately</li>
                        <li><strong>Œ≤-Blocker:</strong> Metoprolol 25-50mg PO (avoid if HF, bradycardia, hypotension)</li>
                        <li><strong>Anticoagulation:</strong> Heparin bolus + infusion or enoxaparin</li>
                        <li><strong>High-intensity statin:</strong> Atorvastatin 80mg</li>
                    </ul>
                    <p><span class="label">P2Y12 Inhibitor:</span> Ticagrelor 180mg load (preferred) or clopidogrel 600mg load</p>
                    <p><span class="label">STEMI Specific:</span> Door-to-balloon <90 minutes. Call cath lab immediately. If PCI unavailable within 120 min, consider fibrinolytics (tPA, reteplase, tenecteplase)</p>
                    <p><span class="label">NSTEMI Specific:</span> Risk stratify with TIMI/GRACE. High-risk ‚Üí early invasive strategy (<24hr). Low-risk ‚Üí medical management, stress test before discharge</p>
                    
                    <p><span class="label">Post-MI Arrhythmia Monitoring:</span></p>
                    <ul>
                        <li><strong>48-Hour Standard:</strong> Continuous cardiac telemetry monitoring for minimum 48 hours is the standard post-MI observation period. Life-threatening arrhythmias (VF, VT, high-grade AV blocks) are most common in first 48 hours post-infarction, with peak risk in first 24 hours</li>
                        <li><strong>Early Discharge Considerations:</strong> Hemodynamically stable, low-risk patients without complications may be considered for discharge after 24 hours. However, patients discharged before 48 hours remain at elevated risk for arrhythmias and require careful patient selection, thorough education about warning signs, and clear return precautions</li>
                        <li><strong>Extended Monitoring (>48hr) indicated if:</strong> Arrhythmias detected, hemodynamic instability, large infarct, reduced EF (<40%), high-risk features, or persistent ischemia</li>
                        <li><strong>Serial troponins:</strong> Peak at 12-24 hours, trend until downtrending</li>
                        <li><strong>Daily ECG:</strong> Assess for evolution of infarct, new ischemia, conduction abnormalities</li>
                        <li><strong>Echo before discharge:</strong> Assess LV function (EF), wall motion abnormalities, mechanical complications, LV thrombus</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>48-hour arrhythmia window:</strong> Standard telemetry monitoring is 48 hours post-MI. Low-risk patients MAY be discharged at 24 hours if stable, but they remain at elevated arrhythmia risk until 48 hours. Early discharge requires careful patient selection and thorough education about warning signs (palpitations, syncope, chest pain)</li>
                    <li><strong>Sgarbossa Criteria:</strong> Diagnose STEMI with LBBB: ST elevation ‚â•1mm concordant with QRS (5 points), ST depression ‚â•1mm V1-V3 (3 points), ST elevation ‚â•5mm discordant (2 points). Score ‚â•3 = STEMI</li>
                    <li><strong>Wellens Syndrome:</strong> Biphasic or deep inverted T waves V2-V3 in pain-free patient = critical LAD stenosis, high risk of anterior STEMI. No stress test! Go to cath.</li>
                    <li><strong>RV Infarction Pearl:</strong> If inferior STEMI with hypotension, always get right-sided leads (V4R). Treat with aggressive IVF, avoid nitrates/diuretics</li>
                    <li><strong>Troponin timing:</strong> Can be negative first 2-4 hours. Serial troponins essential if high suspicion</li>
                    <li><strong>Don't forget:</strong> Type 2 MI (supply-demand mismatch from anemia, sepsis, tachyarrhythmia) - treat underlying cause, not necessarily cath</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Malignant arrhythmias (VT/VF, high-grade AV block)</li>
                        <li>Mechanical complications (papillary rupture, VSD, free wall rupture)</li>
                        <li>Acute heart failure/cardiogenic shock</li>
                        <li>Need for pressors or mechanical support (IABP, Impella)</li>
                        <li>Post-cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable >24 hours (minimum for early discharge in low-risk patients; standard 48-hour telemetry monitoring preferred)</li>
                        <li>No recurrent chest pain or ischemic symptoms</li>
                        <li>No arrhythmias requiring intervention during monitoring period</li>
                        <li>LVEF assessed (echo)</li>
                        <li>Successful revascularization (if indicated)</li>
                        <li>On DAPT, statin, Œ≤-blocker, ACE-I (if EF <40%)</li>
                        <li>Cardiac rehab referral arranged</li>
                        <li>Patient educated on arrhythmia warning signs if discharged <48 hours</li>
                        <li>Clear return precautions given</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (hours-days):</strong> Arrhythmias (VF, VT, bradycardia), cardiogenic shock, mechanical complications (papillary muscle rupture, VSD, free wall rupture), acute MR</p>
                    <p><strong>Late (days-weeks):</strong> Heart failure, LV thrombus, pericarditis (early: Dressler's syndrome 2-10 weeks), recurrent ischemia</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 2: HEART FAILURE EXACERBATION -->
        <div id="heart-failure" class="condition-page">
            <div class="page-header">
                <h2>2. ACUTE DECOMPENSATED HEART FAILURE</h2>
                <div class="subtitle">HFrEF ‚Ä¢ HFpEF ‚Ä¢ Acute Exacerbation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Progressive dyspnea, orthopnea, PND, lower extremity edema, weight gain. Physical exam: JVD, bibasilar rales, S3 gallop, peripheral edema, hepatomegaly.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Flash Pulmonary Edema:</strong> Acute onset, often with HTN emergency, minimal peripheral edema</li>
                        <li><strong>High Output HF:</strong> Warm extremities, bounding pulses (thyrotoxicosis, AV fistula, severe anemia)</li>
                        <li><strong>RV Failure:</strong> Isolated lower extremity edema, ascites, hepatic congestion without pulmonary edema</li>
                        <li><strong>Elderly:</strong> Confusion, fatigue, decreased appetite may predominate over dyspnea</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BNP/NT-proBNP (BNP >400 or NT-proBNP >900 suggests HF), troponin (r/o ACS), BMP (assess renal function), CBC, Mg, TSH, LFTs</p>
                    <p><span class="label">Imaging:</span> CXR (cardiomegaly, pulmonary edema, pleural effusions), Echo (assess EF, valves, wall motion)</p>
                    <p><span class="label">ECG:</span> Look for ischemia, LVH, arrhythmias</p>
                    <p><span class="label">Calculations:</span> NYHA Class, EF%, fluid balance (daily weights), creatinine clearance</p>
                    <p><span class="label">Classify Hemodynamics:</span> Warm vs cold (perfusion), wet vs dry (volume status)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Initial Management:</span></p>
                    <ul>
                        <li><strong>O2:</strong> Maintain SpO2 >90%. Consider NIPPV (BiPAP/CPAP) if respiratory distress</li>
                        <li><strong>Diuresis (Wet):</strong> IV furosemide 40mg (or 2√ó home dose) bolus, then assess response. Consider continuous infusion if poor response. Goal negative 1-2L/day</li>
                        <li><strong>Vasodilators (if SBP >90):</strong> Nitroglycerin IV for afterload reduction, especially if hypertensive</li>
                        <li><strong>Sodium/Fluid Restriction:</strong> <2g sodium/day, <2L fluid/day</li>
                        <li><strong>Daily weights:</strong> Essential for monitoring</li>
                    </ul>
                    
                    <p><span class="label">Cold & Wet (Low Output):</span> Consider inotropes (dobutamine, milrinone) with invasive monitoring</p>
                    
                    <p><span class="label">Chronic HF Management (Initiate/Optimize):</span></p>
                    <ul>
                        <li><strong>HFrEF (EF <40%):</strong> Guideline-directed medical therapy (GDMT)</li>
                        <li>ACE-I/ARB or ARNI (sacubitril-valsartan)</li>
                        <li>Œ≤-blocker (carvedilol, metoprolol succinate, bisoprolol) - start low when stable</li>
                        <li>Aldosterone antagonist (spironolactone, eplerenone) if EF <35%</li>
                        <li>SGLT2 inhibitor (dapagliflozin, empagliflozin) - proven mortality benefit</li>
                        <li><strong>HFpEF (EF ‚â•50%):</strong> Treat HTN, AF, ischemia. SGLT2i now indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>BNP Pearls:</strong> Obesity lowers BNP. Renal failure raises it. Age-adjust NT-proBNP: <50yo: >450, 50-75yo: >900, >75yo: >1800</li>
                    <li><strong>Diuretic Resistance:</strong> If poor response to IV lasix, try: (1) Increase dose, (2) Continuous infusion, (3) Add thiazide (metolazone 2.5-5mg 30min before lasix), (4) Add acetazolamide</li>
                    <li><strong>Cardiorenal Syndrome:</strong> Cr bump with diuresis is often acceptable if congestion improving. Monitor BUN:Cr ratio (>20:1 suggests prerenal)</li>
                    <li><strong>Don't stop GDMT:</strong> Avoid stopping ACE-I/Œ≤-blocker acutely unless cardiogenic shock. Can hold during diuresis, restart before discharge</li>
                    <li><strong>B-type natriuretic peptide diuretics:</strong> Nesiritide (BNP analog) has no mortality benefit and increases hypotension - rarely used</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Cardiogenic shock (SBP <90, cool extremities, AMS, oliguria)</li>
                        <li>Need for inotropes or mechanical support</li>
                        <li>Acute respiratory failure requiring intubation</li>
                        <li>Refractory pulmonary edema</li>
                        <li>Malignant arrhythmias</li>
                        <li>ACS with hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Euvolemic (at or near dry weight)</li>
                        <li>No dyspnea at rest</li>
                        <li>Stable vital signs, O2 sat on room air</li>
                        <li>Transition to PO diuretics established</li>
                        <li>On optimized GDMT (HFrEF)</li>
                        <li>BMP stable, Cr at acceptable baseline</li>
                        <li>Patient education completed</li>
                        <li>Close follow-up arranged (within 7 days)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>During Admission:</strong> Cardiorenal syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia, hyponatremia), arrhythmias (AF most common), worsening renal function</p>
                    <p><strong>Long-term:</strong> Recurrent admissions (50% at 6 months), progressive renal dysfunction, sudden cardiac death, need for advanced therapies (LVAD, transplant)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 3: ATRIAL FIBRILLATION -->
        <div id="afib" class="condition-page">
            <div class="page-header">
                <h2>3. ATRIAL FIBRILLATION</h2>
                <div class="subtitle">RVR ‚Ä¢ New-Onset ‚Ä¢ Chronic AF Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Palpitations, irregular pulse, dyspnea, chest discomfort, fatigue, lightheadedness. Irregularly irregular rhythm on exam.</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic:</strong> 30-40% discovered incidentally on exam or ECG</li>
                        <li><strong>Embolic stroke:</strong> First presentation in some patients</li>
                        <li><strong>Tachycardia-induced cardiomyopathy:</strong> Chronic RVR leading to heart failure</li>
                        <li><strong>Hyperthyroid AF:</strong> Lone AF in young patient, check TSH</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> TSH (always), BMP, Mg, CBC, troponin (if chest pain), digoxin level (if on digoxin)</p>
                    <p><span class="label">Imaging:</span> ECG (confirm AF, assess rate, look for ischemia/WPW), CXR, TTE (assess for structural disease, valve disease, LV function, LA size)</p>
                    <p><span class="label">TEE:</span> Before cardioversion if AF >48hr or unknown duration (r/o LA thrombus), unless patient on therapeutic anticoagulation ‚â•3 weeks</p>
                    <p><span class="label">Calculations:</span></p>
                    <ul>
                        <li><strong>CHA‚ÇÇDS‚ÇÇ-VASc:</strong> Stroke risk (CHF, HTN, Age ‚â•75 [2pts], DM, Stroke/TIA [2pts], Vascular disease, Age 65-74, Sex [female]). Score ‚â•2 (‚ôÇ) or ‚â•3 (‚ôÄ) ‚Üí anticoagulate</li>
                        <li><strong>HAS-BLED:</strong> Bleeding risk (HTN, Abnormal renal/liver, Stroke, Bleeding, Labile INR, Elderly, Drugs/alcohol). Score ‚â•3 = high bleeding risk</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Rate Control (First-line for most):</span></p>
                    <ul>
                        <li><strong>Œ≤-Blockers:</strong> Metoprolol 25-50mg PO q6h or 2.5-5mg IV, esmolol gtt (ICU). Goal HR <110 at rest</li>
                        <li><strong>Non-dihydropyridine CCB:</strong> Diltiazem 0.25mg/kg IV over 2min, then 5-15mg/hr gtt OR 30-60mg PO q6h</li>
                        <li><strong>Digoxin:</strong> 0.25mg IV/PO (less effective, use if HF or sedentary patients). Loading: 0.5mg ‚Üí 0.25mg q6h √ó 2</li>
                        <li><strong>Avoid:</strong> Œ≤-blockers and CCBs together (risk of heart block), rate control in WPW (can precipitate VF)</li>
                    </ul>
                    
                    <p><span class="label">Rhythm Control:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Hemodynamic instability, highly symptomatic despite rate control, first episode, young patient preference</li>
                        <li><strong>Cardioversion:</strong> If AF <48hr OR on anticoagulation ‚â•3 weeks OR TEE negative</li>
                        <li>Synchronized DC cardioversion: 120-200J biphasic (under sedation)</li>
                        <li>Chemical: Flecainide 300mg PO (if no CAD), ibutilide 1mg IV over 10min (monitor QT)</li>
                        <li><strong>Antiarrhythmics:</strong> Amiodarone (safest in structural disease), sotalol, dofetilide (in-hospital initiation)</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation:</span></p>
                    <ul>
                        <li><strong>CHA‚ÇÇDS‚ÇÇ-VASc ‚â•2 (‚ôÇ) or ‚â•3 (‚ôÄ):</strong> Anticoagulate (DOACs preferred over warfarin)</li>
                        <li><strong>DOACs:</strong> Apixaban, rivaroxaban, edoxaban, dabigatran (avoid if mechanical valve or severe MS)</li>
                        <li><strong>Post-cardioversion:</strong> Anticoagulate √ó 4 weeks minimum, longer if stroke risk factors</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>WPW + AF = Emergency:</strong> Irregular wide-complex tachycardia. DO NOT use AV nodal blockers (can precipitate VF). Cardiovert or procainamide</li>
                    <li><strong>Rate vs Rhythm:</strong> AFFIRM/RACE trials show no mortality difference. Most patients do fine with rate control alone</li>
                    <li><strong>Anticoagulation paradox:</strong> HAS-BLED ‚â•3 means high bleeding risk, but often same patients who need anticoagulation most. Don't withhold if CHA‚ÇÇDS‚ÇÇ-VASc high</li>
                    <li><strong>Holiday Heart:</strong> Alcohol-induced AF. Often converts spontaneously with abstinence</li>
                    <li><strong>TEE before cardioversion:</strong> Even if on anticoagulation <3 weeks, consider TEE strategy to expedite cardioversion safely</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability (SBP <90, shock)</li>
                        <li>Acute heart failure/pulmonary edema with RVR</li>
                        <li>Acute MI with RVR</li>
                        <li>Need for continuous IV rate control infusions</li>
                        <li>Post-cardioversion complications</li>
                        <li>RVR refractory to multiple agents</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Rate controlled (HR <110 at rest, <120 with activity)</li>
                        <li>Hemodynamically stable ‚â•24 hours</li>
                        <li>Transitioned to oral rate control meds</li>
                        <li>Anticoagulation started (if indicated)</li>
                        <li>No signs of heart failure</li>
                        <li>Follow-up arranged (cardiology if new-onset)</li>
                        <li>If cardioverted: Stable rhythm ‚â•24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Stroke/TIA (most feared), hemodynamic compromise, heart failure, ACS (demand ischemia from RVR)</p>
                    <p><strong>Chronic:</strong> Tachycardia-induced cardiomyopathy (EF improves with rate/rhythm control), thromboembolism, bleeding (if anticoagulated)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 4: HYPERTENSIVE EMERGENCY -->
        <div id="htn-emergency" class="condition-page">
            <div class="page-header">
                <h2>4. HYPERTENSIVE EMERGENCY</h2>
                <div class="subtitle">End-Organ Damage ‚Ä¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Severe hypertension (typically SBP >180 or DBP >120) WITH acute end-organ damage</p>
                    <p><span class="label">Classic:</span> Severe headache, visual changes, chest pain, dyspnea, altered mental status, focal neurologic deficits</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Neurologic:</strong> Hypertensive encephalopathy (HA, confusion, seizures), stroke (ischemic/hemorrhagic), PRES</li>
                        <li><strong>Cardiac:</strong> Acute MI, acute pulmonary edema, aortic dissection</li>
                        <li><strong>Renal:</strong> Acute kidney injury, hematuria, proteinuria</li>
                        <li><strong>Microangiopathic:</strong> Hemolytic anemia, thrombocytopenia</li>
                    </ul>
                    <p><span class="label">Hypertensive Urgency:</span> Severe HTN WITHOUT end-organ damage. Managed outpatient with PO meds</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP, troponin, CBC, UA, peripheral smear if hemolysis suspected, BNP if APE concern</p>
                    <p><span class="label">Imaging:</span> ECG, CXR, Head CT if neuro symptoms, CT chest if dissection suspected</p>
                    <p><span class="label">Fundoscopic:</span> Look for papilledema, hemorrhages, exudates</p>
                    <p><span class="label">Calculate Target BP:</span> Initial reduction 10-20% in 1st hour, then 5-15% over next 23 hours. Avoid >25% reduction in first 24hr</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General:</span> ICU admission, continuous BP monitoring (arterial line often needed), IV antihypertensives</p>
                    <p><span class="label">IV Agents:</span></p>
                    <ul>
                        <li><strong>Nicardipine:</strong> 5mg/hr, titrate by 2.5mg/hr q5-15min (max 15mg/hr). First-line</li>
                        <li><strong>Labetalol:</strong> 20mg IV bolus, then 20-80mg q10min OR 0.5-2mg/min infusion</li>
                        <li><strong>Clevidipine:</strong> 1-2mg/hr, double q90sec (max 21mg/hr). Short-acting</li>
                        <li><strong>Esmolol:</strong> Œ≤-blocker for dissection. 500mcg/kg load, then 50-300mcg/kg/min</li>
                        <li><strong>Nitroprusside:</strong> 0.25-10mcg/kg/min. For APE. Watch cyanide toxicity</li>
                    </ul>
                    <p><span class="label">Specific Scenarios:</span></p>
                    <ul>
                        <li><strong>Aortic Dissection:</strong> SBP <120 in 20min. Esmolol FIRST, then nicardipine</li>
                        <li><strong>Ischemic Stroke:</strong> Permissive HTN! Allow SBP up to 220 (or 185 if tPA)</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Goal SBP 140-160</li>
                        <li><strong>Eclampsia:</strong> Mag sulfate + hydralazine/labetalol. Deliver baby!</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Urgency vs Emergency:</strong> Only EMERGENCY needs ICU/IV meds. Urgency = oral meds over hours-days</li>
                    <li><strong>Don't drop too fast:</strong> Cerebral autoregulation reset in chronic HTN. Rapid drop ‚Üí stroke/MI</li>
                    <li><strong>Ischemic stroke exception:</strong> Brain needs perfusion! Only lower if SBP >220 or giving tPA</li>
                    <li><strong>PRES:</strong> Headache, confusion, seizures, vision loss + posterior white matter edema. Usually reversible</li>
                    <li><strong>Transition to PO:</strong> Start long-acting oral agents before stopping IV to prevent rebound</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL hypertensive emergencies require ICU</li>
                        <li>Need for continuous IV infusion</li>
                        <li>Acute end-organ damage</li>
                        <li>Altered mental status</li>
                        <li>Arterial line needed</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>BP controlled on oral regimen ‚â•24hr</li>
                        <li>End-organ damage stabilized</li>
                        <li>Off IV medications</li>
                        <li>Patient educated on compliance</li>
                        <li>Close follow-up arranged (within 1 week)</li>
                        <li>Secondary causes evaluated if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hypertension:</strong> Stroke, MI, aortic dissection, acute renal failure, retinopathy, heart failure</p>
                    <p><strong>From Treatment:</strong> Hypotension, stroke from rapid BP drop, rebound HTN, cyanide toxicity (nitroprusside)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 5: COMMUNITY-ACQUIRED PNEUMONIA -->
        <div id="cap" class="condition-page">
            <div class="page-header">
                <h2>5. COMMUNITY-ACQUIRED PNEUMONIA (CAP)</h2>
                <div class="subtitle">Outpatient ‚Ä¢ Inpatient ‚Ä¢ ICU Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Fever, cough (productive/dry), dyspnea, pleuritic chest pain. Exam: Tachypnea, rales/crackles, bronchial breath sounds, dullness, egophony</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Minimal fever, confusion/delirium, weakness, falls. May lack respiratory symptoms</li>
                        <li><strong>Atypical Organisms:</strong> Dry cough, headache, myalgias, diarrhea (Legionella, Mycoplasma)</li>
                        <li><strong>Aspiration:</strong> Witnessed event, right lower lobe/posterior segments, foul sputum</li>
                        <li><strong>Immunocompromised:</strong> PCP, CMV, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> CXR (PA and lateral) - infiltrate confirms diagnosis</p>
                    <p><span class="label">Labs (if admitted):</span> CBC, BMP, procalcitonin, blood cultures √ó 2, sputum Gram stain/culture, ABG if hypoxic</p>
                    <p><span class="label">Special:</span> Legionella urinary Ag, Strep pneumo urinary Ag (if severe), respiratory viral panel, HIV if risk factors</p>
                    <p><span class="label">Severity Scores:</span></p>
                    <ul>
                        <li><strong>CURB-65:</strong> Confusion, Urea >20, RR ‚â•30, BP (SBP <90 or DBP ‚â§60), Age ‚â•65. Score 0-1: outpatient, 2: admit, ‚â•3: ICU</li>
                        <li><strong>PSI/PORT:</strong> More complex. Classes I-II outpatient, III consider admit, IV-V admit</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Outpatient (CURB-65 0-1):</span></p>
                    <ul>
                        <li><strong>Previously healthy:</strong> Amoxicillin 1g TID √ó 5d OR doxycycline 100mg BID √ó 5d</li>
                        <li><strong>With comorbidities:</strong> Amoxicillin-clavulanate + macrolide OR levofloxacin 750mg daily</li>
                    </ul>
                    
                    <p><span class="label">Inpatient Non-ICU:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV/PO daily</li>
                        <li><strong>Alternative:</strong> Levofloxacin 750mg daily or moxifloxacin 400mg daily</li>
                        <li><strong>Duration:</strong> Minimum 5 days if afebrile √ó 48-72hr and stable</li>
                    </ul>
                    
                    <p><span class="label">ICU (Severe CAP):</span></p>
                    <ul>
                        <li><strong>Standard:</strong> Ceftriaxone 2g IV daily + azithromycin 500mg IV daily</li>
                        <li><strong>MRSA Risk:</strong> Add vancomycin or linezolid</li>
                        <li><strong>Pseudomonas Risk:</strong> Pip-tazo or cefepime + fluoroquinolone</li>
                    </ul>
                    
                    <p><span class="label">Supportive:</span> O2 to SpO2 >90%, IV fluids, VTE prophylaxis</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Legionella clues:</strong> Hyponatremia, elevated LFTs, GI symptoms, relative bradycardia. Urinary antigen test. Need 10-14d abx</li>
                    <li><strong>PCP Pneumonia:</strong> Subacute, dry cough, exertional dyspnea in HIV. Bilateral interstitial infiltrates. LDH >500. TMP-SMX + prednisone if PaO2 <70</li>
                    <li><strong>Step-down criteria:</strong> HR <100, RR <24, SBP >90, SpO2 >90%, temp <37.8¬∞C, able to take PO</li>
                    <li><strong>Macrolide resistance:</strong> S. pneumoniae resistance ~30-40%. Always pair with Œ≤-lactam for inpatients</li>
                    <li><strong>Vaccines:</strong> PPSV23 and PCV20 after recovery per CDC schedule</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe CAP (CURB-65 ‚â•3)</li>
                        <li>Need for mechanical ventilation</li>
                        <li>Septic shock requiring pressors</li>
                        <li>Multilobar infiltrates</li>
                        <li>PaO2/FiO2 <250</li>
                        <li>Confusion, AMS</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 48-72 hours</li>
                        <li>Hemodynamically stable</li>
                        <li>O2 sat >90% on room air/baseline</li>
                        <li>Able to tolerate PO</li>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Follow-up CXR arranged (6 weeks)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Respiratory failure, sepsis/septic shock, parapneumonic effusion, empyema, lung abscess</p>
                    <p><strong>Late:</strong> Organizing pneumonia, fibrosis, recurrent pneumonia (consider malignancy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 6: COPD EXACERBATION -->
        <div id="copd" class="condition-page">
            <div class="page-header">
                <h2>6. COPD EXACERBATION</h2>
                <div class="subtitle">AECOPD ‚Ä¢ Acute on Chronic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Increased dyspnea, cough, sputum production/purulence beyond baseline. Wheezing, accessory muscle use, pursed-lip breathing</p>
                    <p><span class="label">Anthonisen Criteria:</span> (1) Increased dyspnea, (2) Increased sputum volume, (3) Increased sputum purulence. Type I = all 3, Type II = 2 of 3, Type III = 1 symptom</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Hypercapnic Encephalopathy:</strong> Confusion, asterixis, somnolence from CO2 retention</li>
                        <li><strong>Right Heart Failure:</strong> Peripheral edema, JVD from cor pulmonale</li>
                        <li><strong>Elderly:</strong> Fatigue, decreased functional status, falls</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> ABG (assess hypercapnia, acidosis), CBC, BMP, BNP if HF concern, sputum culture if severe/recurrent</p>
                    <p><span class="label">Imaging:</span> CXR (r/o pneumonia, PTX, CHF), consider CT if recurrent or PE concern</p>
                    <p><span class="label">ECG:</span> Evaluate for MI, arrhythmia, right heart strain</p>
                    <p><span class="label">Calculations:</span> A-a gradient, FiO2 requirements</p>
                    <p><span class="label">Triggers:</span> Infection (most common), medication noncompliance, PE, pneumothorax, MI, pneumonia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>SABA:</strong> Albuterol 2.5-5mg nebulized q4h or continuous</li>
                        <li><strong>SAMA:</strong> Ipratropium 0.5mg nebulized q6h OR combined albuterol-ipratropium (DuoNeb)</li>
                        <li>Note: Ipratropium added to albuterol shows additive benefit in COPD (unlike asthma)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Prednisone 40mg PO daily √ó 5 days (or methylprednisolone 125mg IV if severe/unable PO)</li>
                        <li><strong>Evidence:</strong> 5-7 days as effective as longer courses with fewer side effects</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (if ‚â•2 cardinal symptoms or purulent sputum):</span></p>
                    <ul>
                        <li><strong>First-line:</strong> Azithromycin 500mg daily √ó 5d OR doxycycline 100mg BID √ó 5-7d</li>
                        <li><strong>Second-line:</strong> Amoxicillin-clavulanate, respiratory fluoroquinolone, cephalosporin</li>
                        <li><strong>Pseudomonas risk:</strong> (FEV1 <50%, recent hospitalization, >4 exacerbations/year) ‚Üí fluoroquinolone or cephalosporin</li>
                    </ul>
                    
                    <p><span class="label">Oxygen Therapy:</span> Goal SpO2 88-92% (avoid higher - can worsen hypercapnia). Titrate carefully in CO2 retainers</p>
                    
                    <p><span class="label">Ventilatory Support:</span></p>
                    <ul>
                        <li><strong>NIPPV (BiPAP):</strong> First-line for hypercapnic respiratory failure (pH 7.25-7.35). Reduces intubation rate and mortality</li>
                        <li><strong>Intubation:</strong> If unable to tolerate NIPPV, worsening acidosis (pH <7.25), decreased mental status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>O2-induced hypercapnia:</strong> High O2 in COPD ‚Üí worsens V/Q mismatch and Haldane effect ‚Üí CO2 retention. Keep SpO2 88-92%</li>
                    <li><strong>BiPAP is magic:</strong> NIPPV reduces intubation by 65%, mortality by 55% in AECOPD with respiratory acidosis. Use early!</li>
                    <li><strong>Steroid duration:</strong> REDUCE trial showed 5 days = 14 days for outcomes. Don't give longer courses</li>
                    <li><strong>Antibiotics debate:</strong> Only benefit if purulent sputum or ‚â•2 cardinal symptoms. Type III (1 symptom) may not need abx</li>
                    <li><strong>Home oxygen criteria:</strong> Resting PaO2 <55 or SpO2 <88% OR PaO2 56-59 with cor pulmonale/polycythemia</li>
                    <li><strong>Prevention:</strong> Vaccinations (flu, pneumococcal), smoking cessation, maintenance inhalers, pulmonary rehab</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe respiratory acidosis (pH <7.30)</li>
                        <li>Need for intubation/mechanical ventilation</li>
                        <li>Hemodynamic instability</li>
                        <li>Altered mental status despite treatment</li>
                        <li>Failed NIPPV trial on floor</li>
                        <li>Life-threatening comorbidity (MI, sepsis)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Return to baseline dyspnea/function</li>
                        <li>Tolerating SABA q4h or less</li>
                        <li>SpO2 >90% on room air or baseline O2</li>
                        <li>Able to sleep and walk without severe dyspnea</li>
                        <li>pH >7.35 if acidotic on admission</li>
                        <li>On maintenance inhalers (LABA/LAMA combo)</li>
                        <li>Inhaler technique verified</li>
                        <li>Pulmonary follow-up within 1 month</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure requiring intubation, pneumothorax (bullous disease), pneumonia, arrhythmias, myocardial ischemia</p>
                    <p><strong>Chronic:</strong> Cor pulmonale, progressive lung function decline, long-term oxygen need, recurrent exacerbations</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 7: ASTHMA EXACERBATION -->
        <div id="asthma" class="condition-page">
            <div class="page-header">
                <h2>7. ASTHMA EXACERBATION</h2>
                <div class="subtitle">Acute Bronchospasm ‚Ä¢ Status Asthmaticus</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, wheezing, chest tightness, cough, accessory muscle use, prolonged expiration</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Silent Chest:</strong> Severe obstruction with minimal air movement - ominous sign!</li>
                        <li><strong>Cough-Variant Asthma:</strong> Persistent cough without wheezing</li>
                        <li><strong>Exercise-Induced:</strong> Symptoms during/after exercise</li>
                        <li><strong>Children:</strong> May present with only cough or difficulty feeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Peak flow, O2 saturation, vital signs</p>
                    <p><span class="label">If Severe:</span> CXR (r/o pneumothorax, infiltrate), ABG if critically ill, VBG acceptable</p>
                    <p><span class="label">Calculations:</span> Peak flow % predicted (compare to personal best), FEV1 if available</p>
                    <p><span class="label">Severity Assessment:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Speaks full sentences, HR <100, PEF >70%</li>
                        <li><strong>Moderate:</strong> Speaks phrases, HR 100-120, PEF 40-70%</li>
                        <li><strong>Severe:</strong> Speaks words, HR >120, PEF <40%, accessory muscles</li>
                        <li><strong>Life-threatening:</strong> Unable to speak, altered mental status, silent chest, bradycardia, hypotension</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Bronchodilators:</span></p>
                    <ul>
                        <li><strong>Albuterol:</strong> 2.5-5mg nebulized q20min √ó 3, then reassess. Consider continuous nebulization if severe</li>
                        <li><strong>Ipratropium:</strong> 0.5mg nebulized √ó 3 doses (add to albuterol for moderate-severe exacerbations)</li>
                    </ul>
                    
                    <p><span class="label">Systemic Corticosteroids (ALL patients except mildest):</span></p>
                    <ul>
                        <li><strong>Prednisone:</strong> 40-60mg PO daily √ó 5 days OR</li>
                        <li><strong>Methylprednisolone:</strong> 125mg IV if unable to take PO or severe</li>
                        <li>No taper needed for short course</li>
                    </ul>
                    
                    <p><span class="label">Oxygen:</span> Maintain SpO2 >90%</p>
                    
                    <p><span class="label">Severe/Refractory (not responding to above):</span></p>
                    <ul>
                        <li><strong>Magnesium sulfate:</strong> 2g IV over 20 minutes (relaxes bronchial smooth muscle)</li>
                        <li><strong>Epinephrine:</strong> 0.3-0.5mg IM (or subQ) if anaphylaxis component or impending respiratory failure</li>
                        <li><strong>Terbutaline:</strong> 0.25mg subQ (use with caution - cardiac side effects)</li>
                        <li><strong>Heliox:</strong> May reduce work of breathing (helium-oxygen mixture)</li>
                    </ul>
                    
                    <p><span class="label">Do NOT Give:</span> Sedatives (can suppress respiratory drive), antibiotics (unless clear bacterial infection)</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Silent chest = BAD:</strong> Means severe obstruction with minimal air movement. This is life-threatening!</li>
                    <li><strong>Ipratropium in asthma:</strong> Unlike COPD, only add for moderate-severe exacerbations (first 3 doses only)</li>
                    <li><strong>Magnesium mechanism:</strong> Competes with calcium in smooth muscle ‚Üí bronchodilation. Number needed to treat = 8</li>
                    <li><strong>Normal PCO2 is concerning:</strong> Asthma patients should be hypocapnic (from hyperventilation). Normal/high CO2 = respiratory fatigue</li>
                    <li><strong>Steroid timing:</strong> Takes 4-6 hours to work. Give early! Don't wait for severe deterioration</li>
                    <li><strong>Discharge medication:</strong> Always send home with short course PO steroids, albuterol inhaler, and controller if not already on one</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status asthmaticus (not improving despite aggressive treatment)</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Altered mental status, confusion, lethargy</li>
                        <li>Silent chest</li>
                        <li>PCO2 >45 (respiratory fatigue)</li>
                        <li>Need for continuous nebulization</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>PEF or FEV1 >70% predicted or personal best</li>
                        <li>SpO2 >90% on room air</li>
                        <li>No accessory muscle use, speaks full sentences</li>
                        <li>Sustained improvement ‚â•60 min after last treatment</li>
                        <li>On appropriate controller medication</li>
                        <li>Has action plan and follow-up arranged</li>
                        <li>Prescribed albuterol + oral steroids √ó 5 days</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Status asthmaticus, respiratory failure, pneumothorax, pneumomediastinum, cardiac arrest</p>
                    <p><strong>Iatrogenic:</strong> Hypokalemia (from Œ≤-agonists), tremor, tachycardia, hyperglycemia (from steroids)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 8: PULMONARY EMBOLISM -->
        <div id="pe" class="condition-page">
            <div class="page-header">
                <h2>8. PULMONARY EMBOLISM (PE)</h2>
                <div class="subtitle">VTE ‚Ä¢ Massive PE ‚Ä¢ Submassive PE</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea, pleuritic chest pain, tachycardia, tachypnea, hemoptysis, unilateral leg swelling</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Massive PE:</strong> Hypotension, syncope, cardiac arrest (obstructive shock)</li>
                        <li><strong>Submassive PE:</strong> Hemodynamically stable but RV strain on echo or biomarkers</li>
                        <li><strong>Chronic PE:</strong> Progressive dyspnea, may be misdiagnosed as heart failure</li>
                        <li><strong>Small PE:</strong> May be asymptomatic or minimal symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Calculate Pre-test Probability:</span> Wells Score or PERC Rule (see calculators below)</p>
                    <p><span class="label">Labs:</span> D-dimer (if low probability - high sensitivity, low specificity), troponin, BNP (assess RV strain), ABG (may show hypoxemia, A-a gradient)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CTPA (CT Pulmonary Angiography):</strong> Gold standard, shows filling defects</li>
                        <li><strong>V/Q Scan:</strong> If contrast contraindicated</li>
                        <li><strong>Lower Extremity Doppler US:</strong> Look for DVT source</li>
                        <li><strong>Echo:</strong> Assess RV function, strain (McConnell's sign = RV dysfunction with apical sparing)</li>
                    </ul>
                    <p><span class="label">ECG:</span> Sinus tachycardia most common. Classic S1Q3T3 pattern rare. Right heart strain pattern</p>
                    
                    <!-- Wells Score Calculator -->
                    <div id="calc-wells-pe" class="calculator">
                        <div class="calculator-title">üßÆ Wells Score for PE</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Pre-test probability of PE. Score ‚â§4 = PE unlikely (consider D-dimer), >4 = PE likely (proceed to CTPA).
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-dvt"> Clinical signs of DVT
                                <span class="hint">Leg swelling, unilateral pain (+3 points)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-alt"> PE most likely diagnosis (no alternative)
                                <span class="hint">+3 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hr"> Heart rate >100 bpm
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-immob"> Immobilization ‚â•3 days or surgery within 4 weeks
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-prior"> Previous DVT or PE
                                <span class="hint">+1.5 points</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-hemo"> Hemoptysis
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="wells-cancer"> Malignancy (treatment within 6 months or palliative)
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateWells()">Calculate Wells Score</button>
                        <div id="wells-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Anticoagulation (Most Patients):</span></p>
                    <ul>
                        <li><strong>LMWH:</strong> Enoxaparin 1mg/kg subQ q12h (preferred if renal function normal)</li>
                        <li><strong>Unfractionated Heparin:</strong> 80 units/kg bolus, then 18 units/kg/hr infusion (if CrCl <30 or high bleeding risk)</li>
                        <li><strong>Fondaparinux:</strong> Weight-based subQ dosing</li>
                        <li><strong>DOACs:</strong> Rivaroxaban or apixaban can be started immediately (no bridging needed)</li>
                    </ul>
                    
                    <p><span class="label">Thrombolytics (Massive PE with hemodynamic instability):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> SBP <90 for >15 min OR shock requiring pressors OR cardiac arrest</li>
                        <li><strong>Alteplase (tPA):</strong> 100mg IV over 2 hours OR 0.6mg/kg over 15 min (max 50mg)</li>
                        <li><strong>Contraindications:</strong> Recent surgery, active bleeding, stroke, intracranial pathology</li>
                    </ul>
                    
                    <p><span class="label">Catheter-Directed Therapy:</span> For submassive PE with RV dysfunction but contraindications to systemic lysis</p>
                    
                    <p><span class="label">IVC Filter:</span> Only if absolute contraindication to anticoagulation (active bleeding)</p>
                    
                    <p><span class="label">Supportive:</span> O2, judicious IVF (avoid overload - worsens RV strain), pressors if shock</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>PERC Rule:</strong> If all 8 criteria negative (age <50, HR <100, SpO2 ‚â•95%, no hemoptysis, no estrogen, no prior VTE, no surgery/trauma, no unilateral leg swelling) AND low clinical suspicion ‚Üí PE excluded, no D-dimer needed</li>
                    <li><strong>D-dimer pitfalls:</strong> Elevated in many conditions (infection, cancer, pregnancy, age >50). Only useful to rule OUT PE in low-probability patients</li>
                    <li><strong>Massive vs Submassive:</strong> Massive = hypotension/shock (needs thrombolytics). Submassive = RV strain but stable BP (controversial management)</li>
                    <li><strong>Anticoagulation duration:</strong> Provoked (surgery, trauma) = 3 months. Unprovoked or cancer = ‚â•6 months, consider indefinite</li>
                    <li><strong>Don't give IVF blindly:</strong> PE is RV failure - RV already volume overloaded. Excessive fluids worsen RV strain</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Massive PE (hypotension, shock)</li>
                        <li>Submassive PE with worsening RV function</li>
                        <li>Need for thrombolytics or mechanical intervention</li>
                        <li>Hemodynamic instability</li>
                        <li>Respiratory failure</li>
                        <li>Cardiac arrest</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable ‚â•24 hours</li>
                        <li>O2 sat >90% on room air or baseline</li>
                        <li>No RV dysfunction or resolved</li>
                        <li>Adequate pain control</li>
                        <li>On therapeutic anticoagulation</li>
                        <li>Safe for outpatient management (PESI score)</li>
                        <li>Follow-up arranged with anticoagulation clinic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> RV failure, cardiac arrest, recurrent PE, bleeding (from anticoagulation)</p>
                    <p><strong>Chronic:</strong> Chronic thromboembolic pulmonary hypertension (CTEPH), post-thrombotic syndrome</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 9: SEPSIS/SEPTIC SHOCK -->
        <div id="sepsis" class="condition-page">
            <div class="page-header">
                <h2>9. SEPSIS/SEPTIC SHOCK</h2>
                <div class="subtitle">Life-Threatening Organ Dysfunction ‚Ä¢ Sepsis-3</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Sepsis Definition (Sepsis-3):</span> Life-threatening organ dysfunction caused by dysregulated host response to infection. SOFA score ‚â•2</p>
                    <p><span class="label">Classic:</span> Fever/hypothermia, tachycardia, tachypnea, altered mental status, hypotension</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> May lack fever, present with confusion or falls only</li>
                        <li><strong>Immunocompromised:</strong> Blunted fever response, rapid progression</li>
                        <li><strong>Cryptic Shock:</strong> Normal BP but elevated lactate (tissue hypoperfusion)</li>
                        <li><strong>Cold Sepsis:</strong> Hypothermia, cool extremities (late, poor prognosis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Blood cultures √ó 2 (different sites, before antibiotics), CBC, CMP, lactate (repeat q2-4h), procalcitonin, coagulation studies</p>
                    <p><span class="label">Source Identification:</span> UA/urine culture, CXR, wound cultures, consider abdominal imaging if source unclear</p>
                    <p><span class="label">Calculate:</span> qSOFA score (see below), SOFA score, lactate clearance</p>
                    
                    <!-- qSOFA Calculator -->
                    <div id="calc-qsofa" class="calculator">
                        <div class="calculator-title">üßÆ qSOFA Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Quick screening for sepsis outside ICU. Score ‚â•2 suggests high risk for poor outcomes. NOT diagnostic, but prompts further evaluation.
                        </div>
                        
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-rr"> Respiratory Rate ‚â•22/min
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-ams"> Altered Mental Status (GCS <15)
                                <span class="hint">Any confusion, disorientation, or decreased LOC (+1 point)</span>
                            </label>
                        </div>
                        <div class="calc-item checkbox-item">
                            <label><input type="checkbox" id="qsofa-sbp"> Systolic BP ‚â§100 mmHg
                                <span class="hint">+1 point</span>
                            </label>
                        </div>
                        
                        <button class="calc-button" onclick="calculateQSOFA()">Calculate qSOFA Score</button>
                        <div id="qsofa-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sepsis Bundle - Within 1 Hour)</div>
                <div class="section-content">
                    <p><span class="label">1. Measure Lactate:</span> Remeasure if initial lactate >2 mmol/L</p>
                    
                    <p><span class="label">2. Obtain Blood Cultures BEFORE Antibiotics:</span> But don't delay antibiotics >45 min</p>
                    
                    <p><span class="label">3. Administer Broad-Spectrum Antibiotics:</span></p>
                    <ul>
                        <li><strong>Sepsis (no source identified):</strong> Vancomycin + pip-tazo OR cefepime + metronidazole</li>
                        <li><strong>Pulmonary source:</strong> Vancomycin + cefepime (or pip-tazo)</li>
                        <li><strong>Abdominal source:</strong> Pip-tazo OR ceftriaxone + metronidazole</li>
                        <li><strong>Urinary source:</strong> Ceftriaxone or fluoroquinolone (add ampicillin if Enterococcus risk)</li>
                        <li><strong>Skin/soft tissue:</strong> Vancomycin + pip-tazo</li>
                        <li><strong>Immunocompromised:</strong> Add antifungal (micafungin) and consider antivirals</li>
                    </ul>
                    
                    <p><span class="label">4. Rapid Administration of 30 mL/kg Crystalloid for Hypotension or Lactate ‚â•4:</span></p>
                    <ul>
                        <li>Use balanced crystalloids (LR or Plasma-Lyte) preferred over NS</li>
                        <li>Reassess after fluid bolus - repeat PRN based on hemodynamics</li>
                    </ul>
                    
                    <p><span class="label">5. Vasopressors if Hypotensive During or After Fluid Resuscitation:</span></p>
                    <ul>
                        <li><strong>Norepinephrine:</strong> First-line, start 0.05-0.1 mcg/kg/min, titrate to MAP ‚â•65</li>
                        <li><strong>Vasopressin:</strong> Add 0.03-0.04 units/min if inadequate response</li>
                        <li><strong>Epinephrine:</strong> Second-line if refractory</li>
                        <li><strong>Phenylephrine:</strong> Only if tachyarrhythmia or norepinephrine shortage</li>
                    </ul>
                    
                    <p><span class="label">Source Control:</span> Drain abscesses, remove infected devices, debride necrotic tissue - within 6-12 hours</p>
                    
                    <p><span class="label">Additional Considerations:</span></p>
                    <ul>
                        <li><strong>Stress-dose steroids:</strong> Hydrocortisone 200mg/day if refractory shock despite fluids + pressors</li>
                        <li><strong>Avoid:</strong> Hetastarch, gelatin (increase mortality), albumin for routine resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Sepsis-3 vs Old Criteria:</strong> No more SIRS criteria. Focus on organ dysfunction (SOFA ‚â•2). qSOFA is screening tool, not diagnostic</li>
                    <li><strong>Time is tissue:</strong> Every hour delay in antibiotics increases mortality by 7.6%. Door-to-antibiotic <1 hour!</li>
                    <li><strong>Lactate clearance:</strong> >10% reduction in lactate within 2-4 hours associated with improved survival. Trend it!</li>
                    <li><strong>Balanced crystalloids:</strong> LR/Plasma-Lyte associated with lower mortality than NS. NS causes hyperchloremic acidosis</li>
                    <li><strong>Early vasopressors OK:</strong> Don't wait to "finish" 30cc/kg if patient still hypotensive. Start pressors concurrently</li>
                    <li><strong>Procalcitonin use:</strong> Can help determine if infection present and guide antibiotic duration. <0.5 = low likelihood bacterial</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL septic shock (hypotension requiring pressors)</li>
                        <li>Lactate ‚â•4 mmol/L</li>
                        <li>Respiratory failure requiring ventilation</li>
                        <li>Acute mental status changes</li>
                        <li>Oliguria/anuria despite fluids</li>
                        <li>Multiorgan dysfunction</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24-48 hours</li>
                        <li>Hemodynamically stable off pressors ‚â•24hr</li>
                        <li>Lactate normalized</li>
                        <li>Source controlled</li>
                        <li>Mental status at baseline</li>
                        <li>Tolerating PO, able to take antibiotics</li>
                        <li>No new organ dysfunction</li>
                        <li>Close follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> ARDS, AKI requiring dialysis, DIC, multiorgan failure, cardiac dysfunction, death (mortality 10-40%)</p>
                    <p><strong>Long-term:</strong> Post-sepsis syndrome (cognitive impairment, weakness, PTSD), recurrent infections, chronic organ dysfunction</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 10: ACUTE KIDNEY INJURY -->
        <div id="aki" class="condition-page">
            <div class="page-header">
                <h2>10. ACUTE KIDNEY INJURY (AKI)</h2>
                <div class="subtitle">Prerenal ‚Ä¢ Intrinsic ‚Ä¢ Postrenal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Increase in Cr ‚â•0.3 mg/dL within 48hr OR increase to ‚â•1.5√ó baseline OR urine output <0.5 mL/kg/hr for 6hr</p>
                    <p><span class="label">Classic:</span> Oliguria, fluid overload, edema, uremic symptoms (N/V, confusion, asterixis, pericarditis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Non-oliguric AKI:</strong> Cr rising but urine output preserved (often ATN from nephrotoxins)</li>
                        <li><strong>Hyperkalemia:</strong> May be presenting sign, can be life-threatening</li>
                        <li><strong>Metabolic Acidosis:</strong> High anion gap from uremia</li>
                        <li><strong>Elderly:</strong> Minimal symptoms despite significant Cr elevation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> BMP (Cr, BUN, K+), baseline Cr for comparison, UA with microscopy, urine electrolytes (Na+, Cr, osmolality)</p>
                    <p><span class="label">Imaging:</span> Renal US (assess for obstruction, kidney size, hydronephrosis)</p>
                    <p><span class="label">Consider:</span> Renal biopsy if diagnosis unclear or concern for glomerulonephritis</p>
                    
                    <p><span class="label">Categorize AKI:</span></p>
                    <ul>
                        <li><strong>Prerenal (60-70%):</strong> Decreased renal perfusion - volume depletion, heart failure, cirrhosis, NSAIDs</li>
                        <li><strong>Intrinsic (25-40%):</strong> Acute tubular necrosis (ischemia, nephrotoxins), acute interstitial nephritis, glomerulonephritis</li>
                        <li><strong>Postrenal (5-10%):</strong> Obstruction - BPH, kidney stones, malignancy, neurogenic bladder</li>
                    </ul>
                    
                    <!-- FENa Calculator -->
                    <div id="calc-fena" class="calculator">
                        <div class="calculator-title">üßÆ FENa Calculator</div>
                        <div class="calc-description">
                            <strong>Use:</strong> Differentiate prerenal AKI (<1%) from ATN (>2%). FENa 1-2% is indeterminate. If on diuretics, use FEUrea instead.
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Sodium (mEq/L)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-na" placeholder="e.g., 20" min="0" step="1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Sodium (mEq/L)
                                <span class="hint">From BMP - typically 135-145</span>
                            </label>
                            <input type="number" id="fena-serum-na" placeholder="e.g., 140" min="100" max="180" value="140">
                        </div>
                        
                        <div class="calc-item">
                            <label>Urine Creatinine (mg/dL)
                                <span class="hint">From random urine sample</span>
                            </label>
                            <input type="number" id="fena-urine-cr" placeholder="e.g., 80" min="0" step="0.1">
                        </div>
                        
                        <div class="calc-item">
                            <label>Serum Creatinine (mg/dL)
                                <span class="hint">From BMP</span>
                            </label>
                            <input type="number" id="fena-serum-cr" placeholder="e.g., 2.5" min="0" step="0.1">
                        </div>
                        
                        <button class="calc-button" onclick="calculateFENa()">Calculate FENa</button>
                        <div id="fena-result"></div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treat underlying cause</li>
                        <li>Stop nephrotoxins (NSAIDs, ACE-I/ARB if AKI severe, aminoglycosides, contrast)</li>
                        <li>Adjust all medication doses for GFR</li>
                        <li>Avoid further insults (hypotension, contrast, nephrotoxic drugs)</li>
                    </ul>
                    
                    <p><span class="label">Prerenal AKI:</span></p>
                    <ul>
                        <li><strong>Volume Depletion:</strong> IV fluids (LR or NS), correct hypotension</li>
                        <li><strong>Cardiorenal:</strong> Diuresis if volume overloaded, optimize cardiac output</li>
                        <li><strong>Hepatorenal:</strong> Albumin + midodrine + octreotide, or terlipressin</li>
                    </ul>
                    
                    <p><span class="label">Intrinsic AKI:</span></p>
                    <ul>
                        <li><strong>ATN:</strong> Supportive care, avoid nephrotoxins, optimize hemodynamics. Usually resolves in 1-3 weeks</li>
                        <li><strong>AIN (Acute Interstitial Nephritis):</strong> Stop offending drug, consider steroids if severe/not improving</li>
                        <li><strong>Glomerulonephritis:</strong> Nephrology consult, may need steroids/immunosuppression ¬± plasmapheresis</li>
                    </ul>
                    
                    <p><span class="label">Postrenal AKI:</span></p>
                    <ul>
                        <li><strong>Relieve Obstruction:</strong> Foley catheter (if bladder outlet obstruction), nephrostomy tubes, ureteral stents</li>
                        <li>Watch for post-obstructive diuresis - may need aggressive fluid replacement</li>
                    </ul>
                    
                    <p><span class="label">Indications for Dialysis (AEIOU):</span></p>
                    <ul>
                        <li><strong>A</strong>cidosis - severe metabolic acidosis (pH <7.1) refractory to medical management</li>
                        <li><strong>E</strong>lectrolytes - hyperkalemia refractory to medical therapy</li>
                        <li><strong>I</strong>ngestions - toxic alcohols, lithium, salicylates</li>
                        <li><strong>O</strong>verload - volume overload refractory to diuretics, pulmonary edema</li>
                        <li><strong>U</strong>remia - uremic pericarditis, encephalopathy, bleeding</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>FENa limitations:</strong> Not valid if on diuretics (falsely elevated), chronic kidney disease, or contrast nephropathy. Use FEUrea if on diuretics (prerenal <35%)</li>
                    <li><strong>BUN:Cr ratio:</strong> >20:1 suggests prerenal (BUN reabsorbed more than Cr). <15:1 suggests intrinsic renal disease</li>
                    <li><strong>Muddy brown casts:</strong> Pathognomonic for ATN on urine microscopy</li>
                    <li><strong>Triple whammy:</strong> ACE-I/ARB + diuretic + NSAID = high risk for AKI. Avoid this combination!</li>
                    <li><strong>Contrast-induced AKI:</strong> Peak Cr at 3-5 days. Prevent with IV fluids before/after contrast. No evidence for NAC or bicarb</li>
                    <li><strong>Post-obstructive diuresis:</strong> Can lose massive amounts of fluid after obstruction relieved. Replace half of UOP with 0.45% NS</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hyperkalemia >6.5 with ECG changes</li>
                        <li>Severe metabolic acidosis (pH <7.2)</li>
                        <li>Volume overload with respiratory failure</li>
                        <li>Uremic encephalopathy/pericarditis</li>
                        <li>Need for emergent dialysis</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Cr downtrending or stable</li>
                        <li>No dialysis-requiring complications</li>
                        <li>Electrolytes controlled (K+ <5.5)</li>
                        <li>Volume status optimized</li>
                        <li>Cause identified and addressed</li>
                        <li>Nephrotoxins stopped</li>
                        <li>Close nephrology follow-up if Cr not at baseline</li>
                        <li>Patient educated on medication adjustments</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Hyperkalemia, metabolic acidosis, volume overload, uremia, need for dialysis, death</p>
                    <p><strong>Chronic:</strong> Chronic kidney disease, progression to ESRD, recurrent AKI episodes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 11: HYPERKALEMIA -->
        <div id="hyperkalemia" class="condition-page">
            <div class="page-header">
                <h2>11. HYPERKALEMIA</h2>
                <div class="subtitle">K+ >5.5 mEq/L ‚Ä¢ Life-Threatening Arrhythmias</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Often asymptomatic until severe. Weakness, paresthesias, palpitations</p>
                    <p><span class="label">ECG Changes (Progressive):</span></p>
                    <ul>
                        <li><strong>Mild (5.5-6.5):</strong> Peaked T waves (tall, narrow, symmetric)</li>
                        <li><strong>Moderate (6.5-8):</strong> PR prolongation, P wave flattening/loss, QRS widening</li>
                        <li><strong>Severe (>8):</strong> Sine wave pattern, ventricular fibrillation, asystole</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Pseudohyperkalemia:</strong> Hemolysis during blood draw, severe leukocytosis/thrombocytosis, fist clenching</li>
                        <li><strong>Acute on Chronic:</strong> Patients on ACE-I/ARB with CKD who take NSAIDs or get dehydrated</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Repeat K+ to confirm (rule out pseudohyperkalemia), BMP, Mg, Ca, VBG, consider digoxin level if on digoxin</p>
                    <p><span class="label">ECG:</span> CRITICAL - assess for cardiotoxicity. ECG changes indicate true emergency</p>
                    <p><span class="label">Identify Cause:</span></p>
                    <ul>
                        <li><strong>Increased Intake:</strong> K+ supplements, salt substitutes, IV K+</li>
                        <li><strong>Transcellular Shift:</strong> Acidosis, insulin deficiency, Œ≤-blocker, digoxin toxicity, succinylcholine, tumor lysis</li>
                        <li><strong>Decreased Excretion:</strong> AKI/CKD, hypoaldosteronism, ACE-I/ARB, K+-sparing diuretics, NSAIDs, heparin, TMP-SMX</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL (Sequence Matters!)</div>
                <div class="section-content">
                    <p><span class="label">Step 1: Cardiac Membrane Stabilization (if ECG changes or K >6.5):</span></p>
                    <ul>
                        <li><strong>Calcium Gluconate:</strong> 1-2 amps (10-20 mL of 10% solution) IV over 2-3 min</li>
                        <li>OR <strong>Calcium Chloride:</strong> 0.5-1g (5-10 mL of 10%) IV via central line (more potent, sclerosing)</li>
                        <li>Effect: Immediate (1-3 min), duration 30-60 min</li>
                        <li>Does NOT lower K+, only protects heart</li>
                        <li>Can repeat dose if persistent ECG changes</li>
                    </ul>
                    
                    <p><span class="label">Step 2: Shift K+ Intracellularly (Temporary):</span></p>
                    <ul>
                        <li><strong>Insulin + Dextrose:</strong> Regular insulin 10 units IV + D50 50mL (25g dextrose) IV push
                            <ul>
                                <li>If glucose >250: give insulin alone, no dextrose</li>
                                <li>Effect: 15-30 min, duration 4-6 hours</li>
                                <li>Lowers K+ by 0.5-1.5 mEq/L</li>
                                <li>Check glucose in 1hr (risk hypoglycemia)</li>
                            </ul>
                        </li>
                        <li><strong>Albuterol:</strong> 10-20mg nebulized (or 0.5mg IV)
                            <ul>
                                <li>Effect: 30 min, duration 2-4 hours</li>
                                <li>Lowers K+ by 0.5-1 mEq/L</li>
                                <li>Additive with insulin</li>
                            </ul>
                        </li>
                        <li><strong>Sodium Bicarbonate:</strong> 50-100 mEq (1-2 amps) IV over 5 min (only if concurrent metabolic acidosis)
                            <ul>
                                <li>Controversial efficacy if pH normal</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 3: Remove K+ from Body (Definitive):</span></p>
                    <ul>
                        <li><strong>Loop Diuretic:</strong> Furosemide 40-80mg IV (if adequate renal function)</li>
                        <li><strong>Sodium Polystyrene Sulfonate (Kayexalate):</strong> 15-30g PO/PR
                            <ul>
                                <li>Effect: Hours, lowers K+ by 0.5-1 mEq/L</li>
                                <li>Avoid if ileus (risk colonic necrosis)</li>
                            </ul>
                        </li>
                        <li><strong>Patiromer or Sodium Zirconium:</strong> Newer K+ binders, better tolerated but slower onset</li>
                        <li><strong>Hemodialysis:</strong> Most effective. Indications:
                            <ul>
                                <li>K+ >6.5 with ECG changes refractory to medical management</li>
                                <li>Severe AKI/ESRD</li>
                                <li>Ongoing tissue breakdown (rhabdo, tumor lysis)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Step 4: Stop Exacerbating Factors:</span> Hold ACE-I/ARB, K+-sparing diuretics, NSAIDs, K+ supplements</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG trumps K+ level:</strong> If ECG shows changes, treat aggressively regardless of exact K+ value. ECG changes = cardiac emergency!</li>
                    <li><strong>Calcium first!</strong> If ECG changes, give calcium before anything else. Protects heart immediately while you arrange other therapies</li>
                    <li><strong>Insulin hypoglycemia:</strong> Very common! Check glucose 30min and 1hr after insulin. Have D50 ready. Consider dextrose infusion</li>
                    <li><strong>Kayexalate controversy:</strong> Limited evidence for efficacy, risk of colonic necrosis esp with sorbitol. Consider newer agents</li>
                    <li><strong>Repeat K+ frequently:</strong> Check K+ q2-4h during acute management. Temporizing measures wear off!</li>
                    <li><strong>Chronic management:</strong> Low K+ diet, loop diuretics, K+ binders. Avoid "hyperkalemia cocktail" (ACE-I + spironolactone + NSAIDs)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>K+ >6.5 with ECG changes</li>
                        <li>Hemodynamically significant arrhythmias</li>
                        <li>Need for emergent dialysis</li>
                        <li>Rapidly rising K+ despite treatment</li>
                        <li>Cardiac arrest from hyperkalemia</li>
                        <li>Requires continuous cardiac monitoring</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>K+ <5.5 mEq/L and downtrending</li>
                        <li>ECG normalized (no peaked T waves)</li>
                        <li>Cause identified and addressed</li>
                        <li>K+-raising medications stopped/adjusted</li>
                        <li>Patient educated on low K+ diet</li>
                        <li>Close follow-up with repeat K+ within 2-3 days</li>
                        <li>If CKD: nephrology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cardiac:</strong> Ventricular arrhythmias (VT, VF), heart block, asystole, sudden cardiac death</p>
                    <p><strong>From Treatment:</strong> Hypoglycemia (insulin), hypokalemia rebound, volume overload (from IVF), GI complications (kayexalate)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 12: HYPONATREMIA -->
        <div id="hyponatremia" class="condition-page">
            <div class="page-header">
                <h2>12. HYPONATREMIA</h2>
                <div class="subtitle">Na+ <135 mEq/L ‚Ä¢ Osmotic Demyelination Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Nausea, headache, confusion, lethargy, seizures (if severe/acute)</p>
                    <p><span class="label">Severity by Symptoms:</span></p>
                    <ul>
                        <li><strong>Mild (Na 130-135):</strong> Often asymptomatic or mild nausea</li>
                        <li><strong>Moderate (125-129):</strong> Nausea, confusion, headache</li>
                        <li><strong>Severe (<125):</strong> Vomiting, seizures, coma, respiratory arrest</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly:</strong> Falls, gait instability, cognitive impairment</li>
                        <li><strong>Athletes:</strong> Exercise-associated hyponatremia from excessive free water intake</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Step 1 - Check Serum Osmolality:</span></p>
                    <ul>
                        <li><strong>Isotonic (280-295):</strong> Pseudohyponatremia (hyperglycemia, hyperlipidemia, hyperproteinemia)</li>
                        <li><strong>Hypertonic (>295):</strong> Hyperglycemia, mannitol</li>
                        <li><strong>Hypotonic (<280):</strong> True hyponatremia - proceed to step 2</li>
                    </ul>
                    
                    <p><span class="label">Step 2 - Assess Volume Status:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> Dry mucous membranes, ‚Üìskin turgor, orthostatic hypotension
                            <ul>
                                <li>Urine Na <20: GI losses, third-spacing, skin losses</li>
                                <li>Urine Na >40: Diuretics, salt-wasting nephropathy, adrenal insufficiency</li>
                            </ul>
                        </li>
                        <li><strong>Euvolemic:</strong> Normal volume status
                            <ul>
                                <li>SIADH (most common), hypothyroidism, adrenal insufficiency, psychogenic polydipsia</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Edema, elevated JVP, ascites
                            <ul>
                                <li>CHF, cirrhosis, nephrotic syndrome, advanced CKD</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> Serum osmolality, urine osmolality, urine Na, BMP, TSH, cortisol if indicated</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">‚ö†Ô∏è CRITICAL:</span> Correct slowly! Maximum 8-10 mEq/L in first 24 hours. Faster correction ‚Üí osmotic demyelination syndrome</p>
                    
                    <p><span class="label">Acute Symptomatic (<48hr onset with seizures/coma):</span></p>
                    <ul>
                        <li><strong>3% Hypertonic Saline:</strong> 100 mL IV bolus over 10 min, can repeat √ó 2 if needed</li>
                        <li>Goal: Raise Na by 4-6 mEq/L (enough to stop seizures), then slow correction</li>
                        <li>Check Na q2-4h</li>
                    </ul>
                    
                    <p><span class="label">Chronic or Asymptomatic:</span></p>
                    <ul>
                        <li><strong>Hypovolemic:</strong> NS at 0.5-1 mL/kg/hr. Na will auto-correct with volume repletion</li>
                        <li><strong>Euvolemic (SIADH):</strong> 
                            <ul>
                                <li>Fluid restriction (800-1000 mL/day)</li>
                                <li>Treat underlying cause</li>
                                <li>Salt tabs + loop diuretic if needed</li>
                                <li>Tolvaptan (vasopressin antagonist) for refractory cases</li>
                            </ul>
                        </li>
                        <li><strong>Hypervolemic:</strong> Fluid + sodium restriction, diuretics, treat underlying (CHF, cirrhosis)</li>
                    </ul>
                    
                    <p><span class="label">Correction Rate Calculation:</span></p>
                    <ul>
                        <li>Target: 6-8 mEq/L in 24 hours, 12-14 mEq/L in 48 hours</li>
                        <li>High-risk patients (chronic, malnourished, cirrhosis, K+ <3): Limit to 6 mEq/L in 24hr</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Osmotic demyelination (ODS):</strong> From overly rapid correction. Presents 2-6 days later with dysarthria, dysphagia, quadriplegia, locked-in syndrome. PREVENT by slow correction!</li>
                    <li><strong>SIADH criteria:</strong> Hyponatremia + low serum osm (<280) + inappropriately concentrated urine (>100) + euvolemic + normal thyroid/adrenal</li>
                    <li><strong>Beer potomania:</strong> Hyponatremia from excessive beer intake with poor solute intake. Na can rise dangerously fast when solute repleted!</li>
                    <li><strong>Tea and toast diet:</strong> Similar to beer potomania - inadequate solute intake in elderly</li>
                    <li><strong>Exercise-associated:</strong> From drinking too much water during endurance events. Treat with hypertonic saline, NOT more water!</li>
                    <li><strong>Hyperglycemia correction:</strong> For every 100 mg/dL glucose >100, add 1.6 mEq/L to measured Na to get "true" Na</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Seizures or coma</li>
                        <li>Na <120 mEq/L</li>
                        <li>Acute symptomatic hyponatremia</li>
                        <li>Need for 3% hypertonic saline</li>
                        <li>Rapid changes requiring q2h monitoring</li>
                        <li>Respiratory compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Na >125 mEq/L and stable/improving</li>
                        <li>Asymptomatic or symptoms resolved</li>
                        <li>Underlying cause identified/treated</li>
                        <li>Can comply with fluid restriction if needed</li>
                        <li>Follow-up arranged with Na check in 2-3 days</li>
                        <li>Patient educated on risks</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Hyponatremia:</strong> Seizures, cerebral edema, respiratory arrest, death</p>
                    <p><strong>From Overcorrection:</strong> Osmotic demyelination syndrome (irreversible neurologic damage)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 13: DIABETIC KETOACIDOSIS -->
        <div id="dka" class="condition-page">
            <div class="page-header">
                <h2>13. DIABETIC KETOACIDOSIS (DKA)</h2>
                <div class="subtitle">Hyperglycemia ‚Ä¢ Acidosis ‚Ä¢ Ketones</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Hyperglycemia (>250), (2) Anion gap metabolic acidosis, (3) Ketones</p>
                    <p><span class="label">Classic Symptoms:</span> Polyuria, polydipsia, N/V, abdominal pain, Kussmaul respirations (deep, rapid), fruity breath odor, altered mental status</p>
                    <p><span class="label">Precipitants (5 I's):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> Most common (UTI, pneumonia, etc)</li>
                        <li><strong>Insulin:</strong> Non-compliance or inadequate dosing</li>
                        <li><strong>Ischemia:</strong> MI, stroke</li>
                        <li><strong>Intoxication:</strong> Alcohol, drugs</li>
                        <li><strong>Infant:</strong> Pregnancy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">DKA Criteria:</span></p>
                    <ul>
                        <li>Glucose >250 mg/dL (or known diabetic)</li>
                        <li>pH <7.3 (arterial) or HCO3 <18</li>
                        <li>Anion gap >10</li>
                        <li>Positive serum/urine ketones</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> VBG (pH, HCO3), BMP, anion gap, Œ≤-hydroxybutyrate (preferred over urine ketones), phosphate, Mg, CBC, blood cultures, UA/CXR if infection suspected</p>
                    <p><span class="label">Calculate:</span> Anion gap = Na - (Cl + HCO3). Normal 8-12. Also calculate osmolality if altered mental status</p>
                    <p><span class="label">Severity:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> pH 7.25-7.30, HCO3 15-18</li>
                        <li><strong>Moderate:</strong> pH 7.0-7.24, HCO3 10-14</li>
                        <li><strong>Severe:</strong> pH <7.0, HCO3 <10</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Fluids (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Initial:</strong> NS 1-1.5 L over first hour (15-20 mL/kg/hr)</li>
                        <li><strong>Subsequent:</strong> 
                            <ul>
                                <li>If Na normal/high: 0.45% NS at 250-500 mL/hr</li>
                                <li>If Na low: NS at 250-500 mL/hr</li>
                            </ul>
                        </li>
                        <li><strong>Once glucose <250:</strong> Switch to D5 0.45% NS to prevent hypoglycemia while continuing insulin</li>
                        <li>Total deficit usually 5-10 L - replace over 24-48 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin:</span></p>
                    <ul>
                        <li><strong>Regular insulin IV infusion:</strong> 0.1 units/kg/hr (usually 5-10 units/hr)</li>
                        <li>Optional bolus: 0.1 units/kg IV if severe DKA</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li><strong>Do NOT stop insulin</strong> when glucose reaches 250! Switch to D5-containing fluids and continue insulin until anion gap closes</li>
                        <li>Once anion gap closed: Transition to subQ insulin, overlap by 1-2 hours before stopping gtt</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>If K+ <3.3:</strong> Hold insulin, give K+ 20-30 mEq/hr until K >3.3</li>
                        <li><strong>If K+ 3.3-5.2:</strong> Add 20-30 mEq K+ to each liter of fluids</li>
                        <li><strong>If K+ >5.2:</strong> No K+ initially, check q2-4h (will drop with insulin)</li>
                        <li>Goal: K+ 4-5 mEq/L</li>
                    </ul>
                    
                    <p><span class="label">4. Phosphate (if <1.0 mg/dL):</span> K-phos 20-30 mEq/L in fluids</p>
                    
                    <p><span class="label">5. Bicarbonate (controversial, only if pH <6.9):</span> 100 mEq in 400 mL H2O + 20 mEq KCl over 2 hours</p>
                    
                    <p><span class="label">6. Treat Precipitant:</span> Antibiotics if infection, adjust insulin regimen, etc</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>DKA resolution:</strong> Glucose <200 AND anion gap <12 AND HCO3 >18 AND pH >7.3. Don't stop insulin just because glucose normalized!</li>
                    <li><strong>Two-bag system:</strong> Run two IV bags (one NS, one D5-NS) through Y-connector. Adjust ratio to maintain glucose 150-200 while continuing insulin</li>
                    <li><strong>Euglycemic DKA:</strong> Can occur with SGLT2 inhibitors. Check ketones even if glucose <250!</li>
                    <li><strong>K+ shifts:</strong> Total body K+ depleted despite normal/high initial K+. With insulin, K+ shifts into cells ‚Üí life-threatening hypokalemia. Monitor closely!</li>
                    <li><strong>Cerebral edema:</strong> Rare but fatal. More common in kids. From too-rapid correction. Symptoms: Headache, AMS, bradycardia. Give mannitol/3% saline</li>
                    <li><strong>Anion gap:</strong> Closes before ketones clear. Don't discharge until ketones clearing and patient eating</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>pH <7.0</li>
                        <li>HCO3 <10</li>
                        <li>Altered mental status</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for continuous insulin infusion</li>
                        <li>Severe electrolyte derangements</li>
                        <li>Cerebral edema concern</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DKA resolved (AG <12, HCO3 >18, pH >7.3)</li>
                        <li>Tolerating PO intake</li>
                        <li>Transitioned to subQ insulin</li>
                        <li>Ketones clearing</li>
                        <li>Precipitant identified and treated</li>
                        <li>Patient educated on sick day management</li>
                        <li>Diabetes follow-up arranged</li>
                        <li>No ongoing complications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cerebral edema (1%), hypokalemia, hypoglycemia, ARDS, thrombosis, mucormycosis</p>
                    <p><strong>From Treatment:</strong> Hyperchloremic non-gap acidosis (from NS), volume overload</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 14: HYPEROSMOLAR HYPERGLYCEMIC STATE -->
        <div id="hhs" class="condition-page">
            <div class="page-header">
                <h2>14. HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)</h2>
                <div class="subtitle">Extreme Hyperglycemia ‚Ä¢ Hyperosmolarity ‚Ä¢ Type 2 DM</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Key Differences from DKA:</span> More extreme hyperglycemia (>600), higher osmolality (>320), NO significant ketoacidosis, more profound dehydration</p>
                    <p><span class="label">Classic:</span> Altered mental status, severe dehydration, hypotension. Often insidious onset over days-weeks</p>
                    <p><span class="label">Typical Patient:</span> Elderly Type 2 diabetic with infection or medication non-compliance</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">HHS Criteria:</span></p>
                    <ul>
                        <li>Glucose >600 mg/dL</li>
                        <li>Effective serum osmolality >320 mOsm/kg</li>
                        <li>pH >7.30</li>
                        <li>HCO3 >15</li>
                        <li>Minimal ketones (can have trace)</li>
                    </ul>
                    <p><span class="label">Calculate Osmolality:</span> 2(Na) + glucose/18 + BUN/2.8. Normal 280-295</p>
                    <p><span class="label">Labs:</span> Same as DKA - VBG, BMP, identify precipitant</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Aggressive Fluid Resuscitation (MORE than DKA):</span></p>
                    <ul>
                        <li>Initial: NS 1-1.5 L first hour</li>
                        <li>Subsequent: 250-500 mL/hr based on volume status</li>
                        <li>Total deficit often 8-12 L (more than DKA)</li>
                        <li>Goal: Replace half of deficit in first 12-24 hours</li>
                    </ul>
                    
                    <p><span class="label">2. Insulin (LOWER rates than DKA):</span></p>
                    <ul>
                        <li>Wait 1-2 hours, give fluids first to avoid vascular collapse</li>
                        <li>Then start insulin 0.05-0.1 units/kg/hr (lower than DKA)</li>
                        <li>Goal: Decrease glucose by 50-75 mg/dL/hr</li>
                        <li>Once glucose <300: Add dextrose to fluids, continue insulin</li>
                    </ul>
                    
                    <p><span class="label">3. Potassium:</span> Same principles as DKA</p>
                    
                    <p><span class="label">4. Correct Slowly:</span> Osmolality should decrease by <3 mOsm/kg/hr to avoid cerebral edema</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>HHS vs DKA:</strong> HHS = Type 2 DM, more dehydration, higher glucose (>600), no ketosis. DKA = Type 1, ketoacidosis</li>
                    <li><strong>Why no ketosis?</strong> Type 2 patients have enough insulin to prevent lipolysis but not enough to control glucose</li>
                    <li><strong>Mortality higher:</strong> HHS mortality 10-20% (vs 1-5% for DKA) - sicker, older patients</li>
                    <li><strong>Fluids first!</strong> Give 1-2 L NS before starting insulin to prevent cardiovascular collapse</li>
                    <li><strong>Slower correction:</strong> Osmolality built up over longer time, correct more slowly to avoid cerebral edema</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Altered mental status/coma</li>
                        <li>Osmolality >350</li>
                        <li>Hemodynamic instability</li>
                        <li>Need for insulin infusion</li>
                        <li>Severe electrolyte abnormalities</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Glucose <250 and stable</li>
                        <li>Mental status at baseline</li>
                        <li>Osmolality <310</li>
                        <li>Taking PO</li>
                        <li>On appropriate diabetes regimen</li>
                        <li>Precipitant treated</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 15: UPPER GI BLEED -->
        <div id="ugib" class="condition-page">
            <div class="page-header">
                <h2>15. UPPER GI BLEED</h2>
                <div class="subtitle">Hematemesis ‚Ä¢ Melena ‚Ä¢ Variceal vs Non-Variceal</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Hematemesis (bright red or coffee-ground), melena (black tarry stool), syncope, hemodynamic instability</p>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Non-Variceal (90%):</strong> PUD (H. pylori, NSAIDs), erosive gastritis/esophagitis, Mallory-Weiss tear, Dieulafoy lesion</li>
                        <li><strong>Variceal (10%):</strong> Esophageal or gastric varices (cirrhosis, portal hypertension)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate:</span> Two large-bore IVs, CBC, type & cross (4 units), BMP, coags, LFTs</p>
                    <p><span class="label">Risk Stratification:</span> Glasgow-Blatchford Score (score 0 = safe for outpatient, ‚â•1 consider admission)</p>
                    <p><span class="label">EGD:</span> Within 24 hours (within 12 hours if high risk/variceal suspected)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Resuscitation:</span></p>
                    <ul>
                        <li><strong>Transfusion:</strong> Goal Hgb 7-9 (restrictive strategy). Higher target (9-10) if active cardiac disease</li>
                        <li><strong>Fluids:</strong> Crystalloids for volume resuscitation</li>
                        <li><strong>Correct coagulopathy:</strong> Reverse anticoagulation if active bleeding, give FFP/PCC if INR >1.8</li>
                    </ul>
                    
                    <p><span class="label">Pharmacotherapy:</span></p>
                    <ul>
                        <li><strong>PPI:</strong> Pantoprazole 80mg IV bolus, then 8mg/hr infusion √ó 72hr (for non-variceal)</li>
                        <li><strong>If Variceal Suspected:</strong> Octreotide 50 mcg bolus, then 50 mcg/hr infusion</li>
                        <li><strong>Antibiotics (if cirrhotic):</strong> Ceftriaxone 1g IV daily √ó 7 days (reduces mortality)</li>
                    </ul>
                    
                    <p><span class="label">Endoscopic Management:</span></p>
                    <ul>
                        <li><strong>PUD:</strong> Epinephrine injection + thermal coagulation ¬± clips</li>
                        <li><strong>Varices:</strong> Band ligation (preferred) or sclerotherapy</li>
                        <li><strong>If refractory variceal bleeding:</strong> Balloon tamponade (Blakemore tube), TIPS</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't over-transfuse:</strong> Target Hgb 7-9. Higher targets worsen outcomes (increased rebleeding)</li>
                    <li><strong>Rockall score:</strong> Post-EGD risk score. Predicts rebleeding and mortality</li>
                    <li><strong>PPI timing:</strong> Pre-EGD PPI doesn't reduce mortality but may reduce stigmata of recent hemorrhage</li>
                    <li><strong>Mallory-Weiss:</strong> Longitudinal tear at GE junction from forceful vomiting. Usually self-limited</li>
                    <li><strong>NG tube controversial:</strong> Not routinely needed. Doesn't improve outcomes, uncomfortable for patient</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability despite resuscitation</li>
                        <li>Massive transfusion (>4 units in 24hr)</li>
                        <li>Variceal bleeding</li>
                        <li>Rebleeding after endoscopic intervention</li>
                        <li>Need for airway protection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable √ó 24hr</li>
                        <li>Hgb stable (no transfusion need)</li>
                        <li>Post-EGD with low-risk lesion</li>
                        <li>Tolerating PO</li>
                        <li>On PPI BID √ó 2 weeks, then daily</li>
                        <li>H. pylori testing sent/treated</li>
                        <li>GI follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- FULLY EXPANDED CONDITIONS 16-40 -->
        
        <!-- PAGE 16: CIRRHOSIS WITH ASCITES -->
        <div id="cirrhosis" class="condition-page">
            <div class="page-header">
                <h2>16. CIRRHOSIS WITH ASCITES</h2>
                <div class="subtitle">Portal Hypertension ‚Ä¢ Decompensated Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Abdominal distension, weight gain, peripheral edema, early satiety, dyspnea from diaphragm elevation</p>
                    <p><span class="label">Physical Exam:</span> Shifting dullness, fluid wave, bulging flanks. Stigmata of chronic liver disease: jaundice, spider angiomas, palmar erythema, gynecomastia, caput medusae, asterixis</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>SBP:</strong> Fever, abdominal pain/tenderness, altered mental status without obvious peritonitis</li>
                        <li><strong>Hepatic Hydrothorax:</strong> Right-sided pleural effusion (usually) without cardiopulmonary disease</li>
                        <li><strong>Tense Ascites:</strong> Respiratory compromise, severe discomfort, umbilical/inguinal hernias</li>
                        <li><strong>Hepatorenal Syndrome:</strong> Progressive AKI despite volume resuscitation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span> Ultrasound (detects >100mL ascites, evaluates liver texture, portal vein), CT abdomen if unclear etiology or concern for HCC</p>
                    <p><span class="label">Diagnostic Paracentesis (ALWAYS on first presentation OR any clinical deterioration):</span></p>
                    <ul>
                        <li><strong>Cell count with differential:</strong> PMN >250 = SBP</li>
                        <li><strong>Albumin:</strong> For SAAG calculation</li>
                        <li><strong>Total protein:</strong> <1g/dL = high SBP risk</li>
                        <li><strong>Gram stain and culture:</strong> Inoculate blood culture bottles at bedside (improves yield)</li>
                        <li><strong>Consider:</strong> Glucose, LDH, cytology (if malignancy suspected), TB studies, amylase (if pancreatitis concern)</li>
                    </ul>
                    
                    <p><span class="label">SAAG (Serum-Ascites Albumin Gradient):</span></p>
                    <ul>
                        <li>Calculate: Serum albumin - Ascitic fluid albumin</li>
                        <li><strong>‚â•1.1 g/dL:</strong> Portal hypertension (97% accuracy) - cirrhosis, cardiac ascites, Budd-Chiari syndrome, sinusoidal obstruction syndrome</li>
                        <li><strong><1.1 g/dL:</strong> Non-portal causes - peritoneal carcinomatosis, TB peritonitis, pancreatic ascites, nephrotic syndrome, serositis</li>
                        <li>SAAG unaffected by diuretics or albumin infusions</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span> CBC, CMP, albumin, PT/INR, hepatitis panel (HBsAg, anti-HCV), AFP (HCC screening), lipid panel</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Sodium Restriction:</span> <2g/day (88 mEq/day). This is THE most important intervention! Effective in 10-20% as monotherapy</p>
                    
                    <p><span class="label">Diuretic Therapy:</span></p>
                    <ul>
                        <li><strong>Initial regimen:</strong> Spironolactone 100mg PO daily + Furosemide 40mg PO daily (100:40 ratio)</li>
                        <li><strong>Titration:</strong> Increase both medications together every 3-5 days maintaining the 100:40 ratio
                            <ul>
                                <li>Step 2: Spironolactone 200mg + Furosemide 80mg</li>
                                <li>Step 3: Spironolactone 300mg + Furosemide 120mg</li>
                                <li>Maximum: Spironolactone 400mg + Furosemide 160mg</li>
                            </ul>
                        </li>
                        <li><strong>Goal weight loss:</strong> 0.5kg/day if ascites alone, 1kg/day if peripheral edema present</li>
                        <li><strong>Monitoring:</strong> Daily weights, BMP at least 2√ó/week initially (watch Na, K, Cr)</li>
                        <li><strong>Hold diuretics if:</strong> Na <120, K >6, Cr rise >2mg/dL above baseline, encephalopathy worsens, severe hypovolemia</li>
                    </ul>
                    
                    <p><span class="label">Large Volume Paracentesis (LVP):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Tense/refractory ascites, respiratory compromise, severe discomfort, new-onset ascites for diagnosis</li>
                        <li>Safe to remove 10-12 liters in single session</li>
                        <li><strong>Albumin replacement:</strong> 6-8g IV per liter removed if >5 liters removed (prevents post-paracentesis circulatory dysfunction)</li>
                        <li>Can use 20% or 25% albumin (20% is more cost-effective)</li>
                        <li>Complications rare: bleeding <1%, infection <1%, bowel perforation <0.1%</li>
                    </ul>
                    
                    <p><span class="label">Refractory Ascites:</span></p>
                    <ul>
                        <li><strong>Definition:</strong> Unresponsive to maximum diuretics + sodium restriction OR development of diuretic-induced complications</li>
                        <li><strong>Management options:</strong>
                            <ul>
                                <li>Serial large volume paracentesis q2-4 weeks + albumin</li>
                                <li>TIPS (transjugular intrahepatic portosystemic shunt) - if appropriate candidate (MELD <18, no encephalopathy)</li>
                                <li>Liver transplant evaluation</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Fluid Restriction:</span> Generally NOT needed unless Na <120-125 mEq/L</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>100:40 ratio maintains normokalemia:</strong> Spironolactone (K-sparing) + furosemide (K-wasting) balance each other</li>
                    <li><strong>SAAG is gospel:</strong> ‚â•1.1 = portal hypertension with 97% accuracy. Unaffected by diuretics, paracentesis, or albumin</li>
                    <li><strong>Paracentesis is safe:</strong> Can tap with INR 2-3, platelets >20k. Prophylactic FFP/platelets NOT needed. Bleeding risk <1%</li>
                    <li><strong>SBP prophylaxis indications:</strong> Primary (never had SBP): ascitic protein <1.5 g/dL + Child-Pugh B/C OR GI bleeding. Secondary (prior SBP): lifelong</li>
                    <li><strong>Medications to AVOID:</strong> NSAIDs (precipitate HRS, worsen ascites), ACE-I/ARBs (hypotension, HRS), aminoglycosides (nephrotoxic)</li>
                    <li><strong>TIPS considerations:</strong> Reduces ascites and variceal bleeding but increases hepatic encephalopathy. Best for refractory ascites with MELD <18</li>
                    <li><strong>Hepatorenal syndrome triggers:</strong> SBP, GI bleeding, large volume paracentesis without albumin, overdiuresis</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability/shock</li>
                        <li>Respiratory failure from tense ascites</li>
                        <li>HRS type 1 (rapidly progressive AKI)</li>
                        <li>Grade 3-4 hepatic encephalopathy</li>
                        <li>Variceal bleeding</li>
                        <li>Severe SBP with sepsis</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Ascites improved/controlled on oral diuretics</li>
                        <li>No evidence of SBP (if tapped)</li>
                        <li>Renal function stable (Cr not rising)</li>
                        <li>Electrolytes acceptable (Na >125, K 3.5-5.5)</li>
                        <li>Encephalopathy grade 0-1</li>
                        <li>Patient/family educated on 2g sodium diet</li>
                        <li>Daily weight monitoring arranged</li>
                        <li>Hepatology follow-up within 1-2 weeks</li>
                        <li>Transplant evaluation if MELD ‚â•15</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Disease:</strong> SBP, hepatorenal syndrome, hepatic hydrothorax, umbilical/inguinal hernia rupture, respiratory compromise, hepatic encephalopathy</p>
                    <p><strong>From Treatment:</strong> Hyponatremia, hyperkalemia, hypokalemia, AKI, muscle cramps, gynecomastia (spironolactone), metabolic alkalosis</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 17: SPONTANEOUS BACTERIAL PERITONITIS -->
        <div id="sbp" class="condition-page">
            <div class="page-header">
                <h2>17. SPONTANEOUS BACTERIAL PERITONITIS (SBP)</h2>
                <div class="subtitle">Infected Ascites ‚Ä¢ Cirrhotic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> Fever, abdominal pain/tenderness, altered mental status in patient with ascites. BUT symptoms may be very subtle!</p>
                    <p><span class="label">High Index of Suspicion:</span> Any cirrhotic patient with ascites who clinically deteriorates (worsening encephalopathy, AKI, ileus, hypothermia, unexplained acidosis)</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic SBP:</strong> 10-30% have NO symptoms at all. Diagnosed on routine surveillance paracentesis</li>
                        <li><strong>Hypothermia:</strong> Temperature <36¬∞C. Poor prognostic sign (mortality >50%)</li>
                        <li><strong>Isolated Worsening Encephalopathy:</strong> May be the ONLY presenting sign</li>
                        <li><strong>Acute Kidney Injury:</strong> SBP frequently triggers hepatorenal syndrome</li>
                        <li><strong>Ileus/Decreased Bowel Sounds:</strong> Without obvious mechanical obstruction</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnostic Paracentesis:</span> MANDATORY with low threshold! Any clinical suspicion warrants immediate tap</p>
                    
                    <p><span class="label">SBP Diagnostic Criteria (any ONE equals SBP):</span></p>
                    <ul>
                        <li><strong>PMN ‚â•250 cells/mm¬≥:</strong> This alone is DIAGNOSTIC. Start antibiotics immediately!</li>
                        <li><strong>Culture-positive with PMN <250:</strong> "Culture-negative neutrocytic ascites" - treat as SBP</li>
                        <li><strong>Monomicrobial culture with PMN <250:</strong> "Bacterascites" - consider treatment if symptomatic</li>
                    </ul>
                    
                    <p><span class="label">Ascitic Fluid Studies:</span></p>
                    <ul>
                        <li><strong>Cell count with differential (STAT):</strong> PMN is the key number</li>
                        <li><strong>Gram stain:</strong> Usually negative (low sensitivity ~10%)</li>
                        <li><strong>Culture:</strong> Inoculate 10mL into blood culture bottles AT BEDSIDE (increases yield from 40% to 80%)</li>
                        <li><strong>Albumin:</strong> For SAAG if new ascites</li>
                        <li><strong>Total protein:</strong> <1 g/dL = high risk for SBP</li>
                        <li><strong>Glucose and LDH:</strong> Help distinguish primary from secondary peritonitis</li>
                    </ul>
                    
                    <p><span class="label">Blood Studies:</span> CBC, CMP, blood cultures √ó 2, lactate</p>
                    
                    <p><span class="label">Common Organisms:</span></p>
                    <ul>
                        <li>E. coli (40%)</li>
                        <li>Klebsiella species (7%)</li>
                        <li>Streptococcus species (15%)</li>
                        <li>Enterococcus</li>
                        <li>Usually monomicrobial</li>
                    </ul>
                    
                    <p><span class="label">Secondary Bacterial Peritonitis (Bowel Perforation):</span> Consider if:
                        <ul>
                            <li>Polymicrobial culture</li>
                            <li>Protein >1 g/dL</li>
                            <li>Glucose <50 mg/dL</li>
                            <li>LDH > upper limit of serum normal</li>
                            <li>If suspected ‚Üí get CT abdomen/pelvis STAT</li>
                        </ul>
                    </p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotics (start IMMEDIATELY if PMN ‚â•250):</span></p>
                    <ul>
                        <li><strong>First-line (community-acquired):</strong> Ceftriaxone 2g IV daily √ó 5-7 days</li>
                        <li><strong>Alternative:</strong> Cefotaxime 2g IV q8h</li>
                        <li><strong>If nosocomial or recent Œ≤-lactam exposure:</strong> Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (for MDRO coverage)</li>
                        <li><strong>Penicillin allergy:</strong> Fluoroquinolone (but increasing resistance) or discuss with ID</li>
                        <li><strong>Duration:</strong> 5-7 days, or until ascitic PMN <250 on repeat tap</li>
                    </ul>
                    
                    <p><span class="label">Albumin Infusion (CRITICAL - Reduces Mortality by 30%):</span></p>
                    <ul>
                        <li><strong>Day 1:</strong> 1.5 g/kg IV (give within 6 hours of diagnosis)</li>
                        <li><strong>Day 3:</strong> 1.0 g/kg IV</li>
                        <li><strong>Example:</strong> 70kg patient ‚Üí 105g on day 1, 70g on day 3</li>
                        <li><strong>Mechanism:</strong> Prevents hepatorenal syndrome and improves circulatory function</li>
                        <li><strong>Evidence:</strong> Reduces HRS by 70%, mortality by 30%. This is NOT optional!</li>
                    </ul>
                    
                    <p><span class="label">Follow-up Paracentesis:</span></p>
                    <ul>
                        <li>At 48 hours if patient not improving clinically</li>
                        <li>PMN count should decrease by ‚â•25%</li>
                        <li>If not improving ‚Üí consider resistant organism, secondary peritonitis, or inadequate antibiotic</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prophylaxis (After SBP Episode Resolves):</span></p>
                    <ul>
                        <li><strong>Duration:</strong> LIFELONG (until transplant or death)</li>
                        <li><strong>Options:</strong>
                            <ul>
                                <li>Norfloxacin 400mg PO daily (first choice) OR</li>
                                <li>Ciprofloxacin 750mg PO weekly OR</li>
                                <li>Trimethoprim-sulfamethoxazole DS daily</li>
                            </ul>
                        </li>
                        <li>Reduces 1-year recurrence from 70% to 20%</li>
                    </ul>
                    
                    <p><span class="label">Primary Prophylaxis (Never Had SBP):</span></p>
                    <ul>
                        <li><strong>Indication 1:</strong> Ascitic protein <1.5 g/dL + Child-Pugh ‚â•9 or impaired renal function</li>
                        <li><strong>Indication 2:</strong> Acute GI bleeding (give for 7 days regardless of ascitic protein)</li>
                        <li>Use same antibiotics as secondary prophylaxis</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>PMN ‚â•250 = Treat NOW:</strong> Don't wait for culture. Only 40% of true SBP will have positive culture</li>
                    <li><strong>Albumin saves lives:</strong> Reduces hepatorenal syndrome by 70%, mortality by 30%. Give on day 1 AND day 3. Not optional!</li>
                    <li><strong>Low threshold to tap:</strong> When in doubt, tap. Complications are rare (<1% bleeding). Missing SBP is worse than "unnecessary" paracentesis</li>
                    <li><strong>Bedside inoculation:</strong> Putting ascitic fluid in blood culture bottles AT BEDSIDE increases yield from 50% to 80%</li>
                    <li><strong>Secondary peritonitis clues:</strong> If polymicrobial, protein >1, glucose <50, or LDH >ULN ‚Üí think bowel perforation. Get CT!</li>
                    <li><strong>Recurrence without prophylaxis:</strong> 70% recur within 1 year. Secondary prophylaxis is lifelong</li>
                    <li><strong>No prophylaxis for everyone:</strong> Primary prophylaxis only for very high risk (protein <1.5 + advanced disease or GI bleed)</li>
                    <li><strong>Don't blame antibiotics for encephalopathy:</strong> Quinolones for SBP prophylaxis do NOT worsen encephalopathy (old myth)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure needing intubation</li>
                        <li>Severe hepatic encephalopathy (grade 3-4)</li>
                        <li>Rapidly progressive AKI/HRS</li>
                        <li>Hypothermia or severe sepsis</li>
                        <li>No clinical improvement despite 48hr treatment</li>
                        <li>Suspected secondary peritonitis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Completed minimum 5 days antibiotics</li>
                        <li>Afebrile √ó 24-48 hours</li>
                        <li>Clinical symptoms resolved</li>
                        <li>Renal function stable or improving</li>
                        <li>Repeat paracentesis (if done) with PMN <250</li>
                        <li>Started on secondary prophylaxis</li>
                        <li>Close hepatology follow-up arranged</li>
                        <li>Transplant evaluation if not already listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Hepatorenal syndrome (occurs in 30%), septic shock, paralytic ileus, worsening hepatic encephalopathy, death (in-hospital mortality 20-40%)</p>
                    <p><strong>Recurrence:</strong> 70% within 1 year without secondary prophylaxis. 20% with prophylaxis. Each recurrence increases mortality risk</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 18: HEPATIC ENCEPHALOPATHY -->
        <div id="he" class="condition-page">
            <div class="page-header">
                <h2>18. HEPATIC ENCEPHALOPATHY</h2>
                <div class="subtitle">Altered Mental Status in Cirrhosis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">West Haven Grading:</span></p>
                    <ul>
                        <li><strong>Grade 0 (Minimal):</strong> Normal mental status, subtle psychometric abnormalities</li>
                        <li><strong>Grade 1:</strong> Trivial confusion, euphoria/anxiety, shortened attention span, impaired addition/subtraction</li>
                        <li><strong>Grade 2:</strong> Lethargy, disorientation to time, obvious personality change, inappropriate behavior, asterixis</li>
                        <li><strong>Grade 3:</strong> Somnolent but arousable, gross disorientation, bizarre behavior</li>
                        <li><strong>Grade 4:</strong> Coma, unresponsive to painful stimuli</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam Findings:</span></p>
                    <ul>
                        <li><strong>Asterixis:</strong> "Flapping tremor" - extend arms with dorsiflexed wrists, observe for irregular flapping. Present in grades 2-3</li>
                        <li><strong>Hyperreflexia:</strong> Increased deep tendon reflexes</li>
                        <li><strong>Fetor hepaticus:</strong> Sweet, musty breath odor</li>
                        <li><strong>Stigmata of cirrhosis:</strong> Jaundice, spider angiomas, palmar erythema, ascites</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Acute Change:</strong> Sudden worsening in previously stable patient suggests precipitant</li>
                        <li><strong>Post-TIPS:</strong> Can develop weeks after TIPS procedure</li>
                        <li><strong>Subclinical:</strong> Patient/family report subtle changes not apparent to clinicians</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis of Exclusion:</span> Rule out other causes of altered mental status first!</p>
                    
                    <p><span class="label">Essential Studies:</span></p>
                    <ul>
                        <li><strong>Labs:</strong> CBC, CMP, ammonia level (correlates poorly but >200 suggests HE), venous pH/lactate</li>
                        <li><strong>Infection workup:</strong> UA, CXR, diagnostic paracentesis if ascites present (rule out SBP!)</li>
                        <li><strong>Toxicology screen:</strong> Especially in acute change</li>
                        <li><strong>Head CT:</strong> If focal neurologic signs, trauma, first episode, or atypical presentation</li>
                    </ul>
                    
                    <p><span class="label">Identify Precipitants (The "5 I's" + more):</span></p>
                    <ul>
                        <li><strong>Infection:</strong> SBP (most common), UTI, pneumonia, any infection</li>
                        <li><strong>GI bleed:</strong> Protein load from blood</li>
                        <li><strong>Constipation:</strong> Increased colonic transit time ‚Üí more ammonia absorption</li>
                        <li><strong>Medications:</strong> Benzos, opioids, diuretic-induced hypokalemia/alkalosis</li>
                        <li><strong>Dehydration/Azotemia:</strong> From overdiuresis</li>
                        <li><strong>Electrolyte abnormalities:</strong> Hyponatremia, hypokalemia</li>
                        <li><strong>TIPS:</strong> Increased porto-systemic shunting</li>
                        <li><strong>Hepatocellular carcinoma:</strong> Tumor burden</li>
                        <li><strong>Dietary indiscretion:</strong> Large protein meal</li>
                        <li><strong>Non-compliance:</strong> Stopping lactulose</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">1. Identify and Treat Precipitant (MOST IMPORTANT!):</span></p>
                    <ul>
                        <li>Tap ascites (rule out SBP)</li>
                        <li>Check for GI bleeding</li>
                        <li>Treat infections</li>
                        <li>Review medication list - stop sedatives/opioids</li>
                        <li>Correct electrolyte abnormalities</li>
                    </ul>
                    
                    <p><span class="label">2. Lactulose (First-line Therapy):</span></p>
                    <ul>
                        <li><strong>Initial dose:</strong> 30mL (20g) PO q1-2 hours until first bowel movement</li>
                        <li><strong>Maintenance:</strong> 30mL PO TID, titrate to 2-3 soft bowel movements per day</li>
                        <li><strong>Goal:</strong> Acidify colon, decrease ammonia production/absorption</li>
                        <li><strong>If cannot take PO:</strong> 300mL lactulose in 700mL water as retention enema, hold 30-60 min</li>
                        <li><strong>Watch for:</strong> Dehydration, hypernatremia (diarrhea), cramping</li>
                    </ul>
                    
                    <p><span class="label">3. Rifaximin (Add-on Therapy for Recurrent/Chronic HE):</span></p>
                    <ul>
                        <li><strong>Dose:</strong> 550mg PO BID</li>
                        <li><strong>Mechanism:</strong> Non-absorbable antibiotic, reduces ammonia-producing gut bacteria</li>
                        <li><strong>Evidence:</strong> Reduces HE recurrence by 58% when added to lactulose</li>
                        <li><strong>Cost:</strong> Expensive (~$2000/month), often requires prior auth</li>
                        <li>Use for patients with ‚â•2 HE episodes requiring hospitalization</li>
                    </ul>
                    
                    <p><span class="label">4. Zinc Supplementation:</span></p>
                    <ul>
                        <li><strong>Dose:</strong> Zinc sulfate 220mg PO daily</li>
                        <li>Many cirrhotics are zinc deficient</li>
                        <li>Zinc is cofactor for urea cycle enzymes</li>
                    </ul>
                    
                    <p><span class="label">5. Supportive Care:</span></p>
                    <ul>
                        <li>Airway protection if grade 3-4 (consider intubation)</li>
                        <li>Avoid sedatives (worsen encephalopathy)</li>
                        <li>If agitated: low-dose haloperidol 0.5-2mg (avoid benzos)</li>
                        <li>Nutrition: Don't restrict protein! Give 1.2-1.5 g/kg/day. Protein restriction is OUTDATED</li>
                    </ul>
                    
                    <p><span class="label">What NOT to Do:</span></p>
                    <ul>
                        <li><strong>Do NOT restrict protein:</strong> Outdated practice, worsens malnutrition</li>
                        <li><strong>Do NOT use neomycin:</strong> Nephrotoxic, ototoxic. Rifaximin is better</li>
                        <li><strong>Ammonia level:</strong> Don't follow serial levels - correlates poorly with clinical status</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Always find the precipitant:</strong> HE rarely occurs without a trigger. Treat the cause, not just the symptom</li>
                    <li><strong>Ammonia level controversy:</strong> Poor correlation with severity. Level >200 supports diagnosis but normal level doesn't exclude HE</li>
                    <li><strong>Protein restriction is WRONG:</strong> Old dogma. Cirrhotics need ADEQUATE protein (1.2-1.5g/kg/day) to prevent sarcopenia</li>
                    <li><strong>Vegetable protein better than animal:</strong> May be better tolerated but don't eliminate meat entirely</li>
                    <li><strong>Lactulose goals:</strong> 2-3 soft BMs/day. Too much = dehydration. Too little = constipation worsens HE</li>
                    <li><strong>Rifaximin not for acute:</strong> Add only for chronic/recurrent HE. Takes days to work. Not for initial episodes</li>
                    <li><strong>Post-TIPS HE:</strong> Occurs in 30-50%. May need TIPS revision or consider transplant if refractory</li>
                    <li><strong>Asterixis is NOT specific:</strong> Also seen in uremia, hypercapnia, other metabolic encephalopathies</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Grade 3-4 encephalopathy (coma)</li>
                        <li>Inability to protect airway</li>
                        <li>Rapidly progressive deterioration</li>
                        <li>Hemodynamic instability</li>
                        <li>Severe concurrent illness (sepsis, GI bleed)</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Mental status at baseline (grade 0-1)</li>
                        <li>Precipitant identified and treated</li>
                        <li>Established bowel regimen (2-3 BM/day)</li>
                        <li>On appropriate lactulose dose</li>
                        <li>Rifaximin added if recurrent HE</li>
                        <li>Family educated on HE signs, lactulose use</li>
                        <li>Hepatology follow-up within 1 week</li>
                        <li>Transplant evaluation if not listed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Aspiration pneumonia, falls/trauma, pressure ulcers, malnutrition, inability to take medications</p>
                    <p><strong>Chronic:</strong> Recurrent HE episodes (50% recur within 6 months), cognitive decline, poor quality of life, increased mortality</p>
                    <p><strong>From Treatment:</strong> Dehydration and hypernatremia from excessive lactulose, diarrhea, abdominal cramping</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 19: ACUTE PANCREATITIS -->
        <div id="pancreatitis" class="condition-page">
            <div class="page-header">
                <h2>19. ACUTE PANCREATITIS</h2>
                <div class="subtitle">Gallstones ‚Ä¢ Alcohol ‚Ä¢ Hypertriglyceridemia</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Epigastric pain radiating to back, nausea/vomiting, anorexia. Pain may be relieved by leaning forward</p>
                    <p><span class="label">Physical Exam:</span> Epigastric tenderness, decreased bowel sounds, tachycardia, fever, Cullen sign (periumbilical ecchymosis) or Grey Turner sign (flank ecchymosis) in hemorrhagic pancreatitis</p>
                    <p><span class="label">Common Causes (GET SMASHED):</span></p>
                    <ul>
                        <li><strong>G</strong>allstones (40%)</li>
                        <li><strong>E</strong>thanol (30%)</li>
                        <li><strong>T</strong>rauma</li>
                        <li><strong>S</strong>teroids</li>
                        <li><strong>M</strong>umps/other infections</li>
                        <li><strong>A</strong>utoimmune (IgG4)</li>
                        <li><strong>S</strong>corpion/snake bites</li>
                        <li><strong>H</strong>ypertriglyceridemia (>1000 mg/dL), Hypercalcemia</li>
                        <li><strong>E</strong>RCP</li>
                        <li><strong>D</strong>rugs (azathioprine, 6-MP, valproic acid, thiazides, furosemide, sulfonamides, tetracycline)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Diagnosis Requires 2 of 3:</span></p>
                    <ul>
                        <li><strong>1. Characteristic abdominal pain</strong></li>
                        <li><strong>2. Serum lipase >3√ó upper limit normal</strong> (more specific than amylase)</li>
                        <li><strong>3. Imaging findings</strong></li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>Lipase:</strong> More sensitive/specific than amylase. Stays elevated longer</li>
                        <li>CBC (leukocytosis common), CMP (assess calcium, glucose), lipid panel (TG), LFTs (assess biliary etiology)</li>
                        <li><strong>If ALT >150:</strong> 95% PPV for gallstone pancreatitis</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>RUQ ultrasound:</strong> Look for gallstones, CBD dilation (do in ALL patients)</li>
                        <li><strong>CT abdomen with IV contrast:</strong> If diagnosis unclear OR severe disease. Delay 48-72hr if possible (pancreatic necrosis takes time to develop)</li>
                        <li><strong>MRCP:</strong> If concern for choledocholithiasis</li>
                    </ul>
                    
                    <p><span class="label">Severity Scoring:</span></p>
                    <ul>
                        <li><strong>Ranson Criteria:</strong> On admission + at 48 hours. Score ‚â•3 = severe</li>
                        <li><strong>BISAP Score:</strong> Simpler. 1 point each for: BUN >25, Impaired mental status, SIRS, Age >60, Pleural effusion. Score ‚â•3 = severe</li>
                        <li><strong>APACHE-II:</strong> Complex but accurate</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Fluid Resuscitation (MOST IMPORTANT):</span></p>
                    <ul>
                        <li><strong>Aggressive IVF:</strong> Lactated Ringer's preferred over NS (reduces SIRS, mortality)</li>
                        <li><strong>Rate:</strong> 250-500 mL/hr initially (15-20 mL/kg bolus, then 250-500 mL/hr)</li>
                        <li><strong>Goal:</strong> UOP >0.5 mL/kg/hr, HR <120, MAP 65-85</li>
                        <li><strong>Caution:</strong> Watch for volume overload in elderly/cardiac disease</li>
                        <li>Early aggressive hydration (within 24hr) reduces organ failure and mortality</li>
                    </ul>
                    
                    <p><span class="label">Nutrition:</span></p>
                    <ul>
                        <li><strong>Early oral feeding:</strong> Start within 24 hours if tolerated (even in severe pancreatitis!)</li>
                        <li><strong>Diet:</strong> Low-fat solid diet as tolerated. No need for clear liquids first</li>
                        <li><strong>If cannot tolerate PO:</strong> Enteral nutrition via NG/NJ tube preferred over TPN</li>
                        <li><strong>NPO only if:</strong> Intractable vomiting, ileus, or altered mental status</li>
                    </ul>
                    
                    <p><span class="label">Pain Control:</span></p>
                    <ul>
                        <li>IV opioids PRN (morphine, hydromorphone)</li>
                        <li>Myth: Opioids don't worsen pancreatitis via sphincter of Oddi spasm</li>
                    </ul>
                    
                    <p><span class="label">ERCP (Urgent <24hr):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Cholangitis OR biliary obstruction with bilirubin rising</li>
                        <li><strong>NOT indicated:</strong> Mild gallstone pancreatitis without obstruction (just do cholecystectomy later)</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics:</span></p>
                    <ul>
                        <li><strong>NOT routinely indicated</strong> for prophylaxis</li>
                        <li><strong>Give only if:</strong> Infected necrosis (proven by aspiration or gas on CT), cholangitis, or extrapancreatic infection</li>
                        <li>If infected necrosis: Carbapenems or fluoroquinolone + metronidazole</li>
                    </ul>
                    
                    <p><span class="label">Cholecystectomy (for Gallstone Pancreatitis):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During SAME admission once acute inflammation resolves (pancreatic enzymes normalizing)</li>
                        <li>Usually safe after 48-72 hours if improving</li>
                        <li>Recurrence rate 30-60% if not done</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>LR > NS:</strong> Lactated Ringer's reduces SIRS and mortality compared to normal saline</li>
                    <li><strong>Early feeding is safe:</strong> Outdated to keep NPO. Start low-fat diet within 24hr</li>
                    <li><strong>No prophylactic antibiotics:</strong> Don't reduce infection or mortality. Only treat proven infection</li>
                    <li><strong>CT timing:</strong> Necrosis takes 48-72hr to develop. Early CT often non-diagnostic</li>
                    <li><strong>Lipase > Amylase:</strong> Lipase more sensitive/specific. Can skip amylase entirely</li>
                    <li><strong>Hypertriglyceridemia:</strong> If TG >1000, this can CAUSE pancreatitis. Treat with insulin gtt + fibrates</li>
                    <li><strong>Sterile vs infected necrosis:</strong> Infected = fever, leukocytosis, gas on CT. Needs drainage. Sterile necrosis = conservative management</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Severe pancreatitis (BISAP ‚â•3, Ranson ‚â•3)</li>
                        <li>Organ failure (respiratory, renal, cardiovascular)</li>
                        <li>Hemodynamic instability</li>
                        <li>Persistent SIRS >48 hours</li>
                        <li>Pancreatic necrosis with infection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on PO medications</li>
                        <li>Tolerating regular diet</li>
                        <li>Lipase trending down</li>
                        <li>No organ dysfunction</li>
                        <li>Cholecystectomy done (if gallstone etiology)</li>
                        <li>Alcohol cessation counseling (if EtOH cause)</li>
                        <li>Follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early:</strong> Pancreatic necrosis (10-20%), infected necrosis, ARDS, AKI, shock, hypocalcemia</p>
                    <p><strong>Late:</strong> Pseudocyst (4 weeks), splenic/portal vein thrombosis, chronic pancreatitis, pancreatic insufficiency, diabetes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>
        <!-- CONDITIONS 20-25 FULLY EXPANDED -->
        
        <!-- PAGE 20: CELLULITIS -->
        <div id="cellulitis" class="condition-page">
            <div class="page-header">
                <h2>20. CELLULITIS</h2>
                <div class="subtitle">Skin/Soft Tissue Infection</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Acute onset of erythema, warmth, edema, and tenderness in affected area. Usually unilateral lower extremity. Pain typically present. Systemic symptoms: fever, chills, malaise in 40-60% of hospitalized patients</p>
                    <p><span class="label">Physical Exam:</span> Ill-defined borders spreading centrifugally (vs erysipelas which has raised sharp borders), no fluctuance (vs abscess), lymphangitic streaking in 15-20%, regional lymphadenopathy. Measure and mark borders with pen. Look for portal of entry (trauma, tinea pedis, fissures)</p>
                    <p><span class="label">Common Organisms:</span> Œ≤-hemolytic Streptococcus (Group A Strep, most common in non-purulent), Staphylococcus aureus (especially MRSA if purulent/abscess present)</p>
                    <p><span class="label">Risk Factors:</span> Obesity, diabetes mellitus, venous insufficiency, chronic lymphedema, tinea pedis (toe web intertrigo), immunosuppression, prior cellulitis (20-30% recurrence rate), skin barrier disruption</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Erysipelas:</strong> Superficial cellulitis with sharply demarcated, raised, indurated borders. "Orange peel" appearance. Almost always Group A Strep. Face and legs most common</li>
                        <li><strong>Periorbital Cellulitis:</strong> Eyelid edema, erythema WITHOUT vision changes or pain with eye movement (vs orbital cellulitis which needs emergent CT/ENT). Can progress to orbital cellulitis</li>
                        <li><strong>Facial Cellulitis:</strong> Consider dental source (odontogenic), sinusitis. Higher risk of cavernous sinus thrombosis if near nasolabial triangle</li>
                        <li><strong>Diabetic Patients:</strong> More likely polymicrobial, higher risk of progression to necrotizing infection. Check for gas on imaging</li>
                        <li><strong>Immunocompromised:</strong> Consider atypical organisms (fungi, mycobacteria, Pseudomonas). May lack fever/leukocytosis despite severe infection</li>
                        <li><strong>Post-Surgical:</strong> If within 48 hours, consider Group A Strep (rapidly progressive, very painful). If days later, S. aureus more likely</li>
                        <li><strong>Water Exposure:</strong> Vibrio vulnificus (salt water), Aeromonas (fresh water) - both can cause necrotizing fasciitis. Ask about water exposure!</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on appearance - culture/biopsy rarely needed for typical cellulitis. Positive predictive value of clinical diagnosis >70% by experienced clinicians</p>
                    
                    <p><span class="label">Labs (Obtain if systemic symptoms or severe):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (WBC >12k in 50%), left shift. Leukopenia concerning for overwhelming sepsis</li>
                        <li><strong>Blood Cultures:</strong> Low yield (<5% positive) but obtain if: fever >38.5¬∞C, hypotension, immunocompromised, suspected bacteremia, failed outpatient therapy</li>
                        <li><strong>ESR/CRP:</strong> Elevated but non-specific. Can be useful if diagnosis uncertain or to follow treatment response</li>
                        <li><strong>BMP:</strong> If systemic toxicity (assess renal function before vancomycin/aminoglycosides)</li>
                        <li><strong>Lactate:</strong> If concern for sepsis or necrotizing infection</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routinely needed):</span></p>
                    <ul>
                        <li><strong>Ultrasound:</strong> Can differentiate cellulitis from abscess. "Cobblestoning" of subcutaneous tissue seen in cellulitis. Can identify fluid collections needing drainage</li>
                        <li><strong>CT with IV contrast:</strong> If necrotizing fasciitis suspected (gas in tissues, fascial involvement), deep abscess, osteomyelitis concern</li>
                        <li><strong>MRI:</strong> Gold standard for osteomyelitis, deep space infections, necrotizing fasciitis. Use if diagnosis unclear and high clinical suspicion</li>
                        <li><strong>X-ray:</strong> Can identify foreign body, subcutaneous gas (necrotizing infection), osteomyelitis (after 2 weeks)</li>
                    </ul>
                    
                    <p><span class="label">Culture/Biopsy (Consider if):</span></p>
                    <ul>
                        <li>Purulent drainage present ‚Üí Send for culture & sensitivity (guides antibiotic de-escalation)</li>
                        <li>Failed initial therapy</li>
                        <li>Immunocompromised (atypical organisms)</li>
                        <li>Penetrating trauma or water exposure (atypical organisms)</li>
                        <li>Punch biopsy/aspiration: Low yield (20-40% positive), painful, generally not recommended for uncomplicated cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Mark Borders:</span> Draw around erythema with marker, date/time. Essential for tracking progression/regression. Take photo for documentation</p>
                    
                    <p><span class="label">Differential Diagnosis to Consider:</span></p>
                    <ul>
                        <li><strong>Stasis Dermatitis:</strong> Bilateral, chronic, hyperpigmentation, varicose veins. Often misdiagnosed as cellulitis</li>
                        <li><strong>DVT:</strong> Asymmetric edema but typically no erythema. Get duplex if uncertain</li>
                        <li><strong>Contact Dermatitis:</strong> Pruritic, vesicular, bilateral distribution, exposure history</li>
                        <li><strong>Necrotizing Fasciitis:</strong> Pain out of proportion, hemorrhagic bullae, crepitus, systemic toxicity, rapid progression</li>
                        <li><strong>Gout/Pseudogout:</strong> Acute monoarticular arthritis, usually joint-based</li>
                        <li><strong>Lipodermatosclerosis:</strong> Chronic, indurated, inverted champagne bottle appearance of lower leg</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Key Decision: Purulent vs Non-Purulent</span></p>
                    <ul>
                        <li><strong>Non-Purulent:</strong> No drainable abscess, no purulent discharge ‚Üí Target Streptococcus, NO MRSA coverage needed</li>
                        <li><strong>Purulent:</strong> Abscess, furuncle, carbuncle, purulent drainage ‚Üí MUST cover MRSA</li>
                    </ul>
                    
                    <p><span class="label">Non-Purulent Cellulitis (No Abscess/Furuncle) - Streptococcal Coverage:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>Cephalexin 500mg PO QID √ó 5-10 days (first-line)</li>
                                <li>Dicloxacillin 500mg PO QID √ó 5-10 days</li>
                                <li>Amoxicillin-clavulanate 875mg BID √ó 5-10 days</li>
                            </ul>
                        </li>
                        <li><strong>Moderate (Inpatient/Observation):</strong>
                            <ul>
                                <li>Cefazolin 1-2g IV q8h (excellent Strep/MSSA coverage)</li>
                                <li>Ceftriaxone 1-2g IV q24h (good for once-daily dosing)</li>
                            </ul>
                        </li>
                        <li><strong>PCN Allergy (Non-anaphylaxis):</strong>
                            <ul>
                                <li>Cephalosporins safe if non-IgE mediated reaction (~98% safe)</li>
                            </ul>
                        </li>
                        <li><strong>Severe PCN Allergy (Anaphylaxis):</strong>
                            <ul>
                                <li>Clindamycin 600mg IV q8h OR 300-450mg PO TID (covers Strep/MSSA, not MRSA reliably)</li>
                                <li>Doxycycline 100mg PO/IV BID</li>
                                <li>Levofloxacin 750mg PO/IV daily (avoid if other options available)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Purulent Cellulitis (WITH Abscess/Drainage) - MRSA Coverage Required:</span></p>
                    <ul>
                        <li><strong>Mild (Outpatient):</strong>
                            <ul>
                                <li>TMP-SMX DS 1-2 tabs PO BID √ó 5-10 days (excellent MRSA coverage)</li>
                                <li>Doxycycline 100mg PO BID √ó 5-10 days</li>
                                <li>Clindamycin 300-450mg PO TID √ó 5-10 days (if local resistance <10%)</li>
                            </ul>
                        </li>
                        <li><strong>Moderate-Severe (Inpatient):</strong>
                            <ul>
                                <li>Vancomycin 15-20mg/kg IV q8-12h (goal trough 15-20 for complicated infections)</li>
                                <li>Daptomycin 4mg/kg IV q24h (skin infections, not if pulmonary involvement)</li>
                                <li>Linezolid 600mg PO/IV BID (excellent bioavailability, reserve for VRE risk)</li>
                            </ul>
                        </li>
                        <li><strong>I&D (Incision & Drainage):</strong> Drain abscess if present. Send purulent material for culture & sensitivity. I&D alone may be sufficient for small abscesses <5cm without surrounding cellulitis</li>
                    </ul>
                    
                    <p><span class="label">Severe/Complicated Cellulitis:</span></p>
                    <ul>
                        <li><strong>Septic/Toxic appearance:</strong> Vancomycin 15-20mg/kg IV q8-12h + Pip-tazo 3.375g IV q6h</li>
                        <li><strong>Necrotizing Fasciitis Concern:</strong> Vancomycin + Pip-tazo + Clindamycin 900mg IV q8h (clindamycin inhibits toxin production). IMMEDIATE surgical consultation</li>
                        <li><strong>Immunocompromised:</strong> Broader coverage - consider Vancomycin + Cefepime or Vancomycin + Meropenem</li>
                        <li><strong>Water Exposure:</strong>
                            <ul>
                                <li>Salt water (Vibrio): Doxycycline 100mg IV BID + Ceftriaxone 1g IV q24h</li>
                                <li>Fresh water (Aeromonas): Ceftriaxone + Ciprofloxacin 400mg IV q12h</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Diabetes:</strong> Lower threshold to admit. Check for gas on imaging. Consider broader coverage if severe or neuropathy present</li>
                        <li><strong>Cirrhosis:</strong> Higher risk of Vibrio if shellfish exposure. Consider ceftriaxone + doxycycline</li>
                        <li><strong>Neutropenic:</strong> Cefepime or meropenem + vancomycin. Consider antifungal if not improving</li>
                        <li><strong>Bite Wounds:</strong>
                            <ul>
                                <li>Human/Animal: Amoxicillin-clavulanate 875mg BID OR Ampicillin-sulbactam 3g IV q6h</li>
                                <li>PCN allergic: Doxycycline + Metronidazole OR Moxifloxacin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Adjunct Measures:</span></p>
                    <ul>
                        <li><strong>Elevation:</strong> Keep affected limb elevated above heart level. CRITICAL for reducing edema and speeding recovery</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ibuprofen 600mg q6h) or acetaminophen 1g q6h. NSAIDs have anti-inflammatory benefit</li>
                        <li><strong>Treat Underlying Conditions:</strong>
                            <ul>
                                <li>Tinea pedis: Topical antifungal (terbinafine cream BID √ó 2 weeks)</li>
                                <li>Venous insufficiency: Compression stockings after acute infection resolves</li>
                                <li>Edema: Diuretics if appropriate, elevation, compression</li>
                            </ul>
                        </li>
                        <li><strong>Wound Care:</strong> Keep clean and dry. Gentle cleansing with soap and water. No need for topical antibiotics</li>
                    </ul>
                    
                    <p><span class="label">Duration of Therapy:</span></p>
                    <ul>
                        <li><strong>Standard:</strong> 5-10 days typical. Minimum 5 days if rapidly improving</li>
                        <li><strong>Severe:</strong> 10-14 days if slow response, extensive disease, or immunocompromised</li>
                        <li><strong>Transition to PO:</strong> When afebrile >24hr, improving cellulitis, tolerating PO, stable vitals</li>
                        <li><strong>Response Time:</strong> Expect improvement within 48-72 hours. Erythema may initially expand first 24-48hr despite appropriate antibiotics (inflammatory response). If not improving by 72hr, re-evaluate</li>
                    </ul>
                    
                    <p><span class="label">Recurrent Cellulitis Prevention:</span></p>
                    <ul>
                        <li><strong>‚â•2 episodes/year or ‚â•3 lifetime:</strong> Consider prophylaxis</li>
                        <li>Penicillin VK 250mg PO BID OR Erythromycin 250mg PO BID (indefinitely or seasonally)</li>
                        <li>Address predisposing factors: Treat tinea pedis aggressively, compression for lymphedema/venous insufficiency, good skin hygiene</li>
                        <li>Patient education: Early recognition and treatment at first sign reduces hospitalizations</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>MRSA coverage ONLY if purulent:</strong> Overuse of vancomycin drives resistance. Non-purulent cellulitis = Œ≤-lactam monotherapy. Don't reflexively add vanc!</li>
                    <li><strong>Mark borders religiously:</strong> Date and time your marking. Simple intervention that objectively tracks progression/regression and improves clinical decision-making</li>
                    <li><strong>Elevation is NOT optional:</strong> Elevating the affected limb above heart level significantly speeds recovery by reducing venous congestion and edema. It's as important as antibiotics!</li>
                    <li><strong>Recurrent cellulitis screening questions:</strong> Ask about tinea pedis (toe web maceration = portal of entry), lymphedema, venous insufficiency. Treating these reduces recurrence dramatically</li>
                    <li><strong>Purpura = NOT cellulitis:</strong> If non-blanching purpura present, think necrotizing fasciitis, meningococcemia, septic emboli, vasculitis. Blanching erythema = cellulitis</li>
                    <li><strong>Pain out of proportion = Surgical Emergency:</strong> If pain is much worse than exam findings suggest, think necrotizing fasciitis. Also: hemorrhagic bullae, crepitus, "wooden" induration, rapid progression, systemic toxicity ‚Üí STAT surgical consult + broad antibiotics + clindamycin</li>
                    <li><strong>Initial expansion doesn't mean failure:</strong> Cellulitis commonly gets worse in first 24-48 hours despite appropriate antibiotics due to inflammatory response. Don't panic and broaden coverage unless systemic symptoms worsen</li>
                    <li><strong>Stasis dermatitis masquerader:</strong> #1 cellulitis mimic. Clues: Bilateral (cellulitis usually unilateral), chronic course, hyperpigmentation, varicose veins, hemosiderin deposition, pruritus > pain. Don't treat with antibiotics!</li>
                    <li><strong>LRINEC score for necrotizing fasciitis:</strong> CRP, WBC, Hgb, Na, Cr, glucose. Score ‚â•6 ‚Üí 50% PPV for NF. Score ‚â•8 ‚Üí 75% PPV. But don't wait for lab results if clinical suspicion high!</li>
                    <li><strong>Blood cultures low yield:</strong> Only 5% positive in cellulitis, but still obtain if fever >38.5¬∞C or concern for bacteremia. Don't withhold antibiotics waiting for culture results</li>
                    <li><strong>Prophylaxis pearls:</strong> For recurrent cellulitis (‚â•2/year), continuous penicillin prophylaxis reduces recurrence by 50%. But address underlying causes first (tinea pedis treatment, compression, lymphedema therapy)</li>
                    <li><strong>Failed therapy checklist:</strong> Wrong diagnosis (stasis dermatitis, DVT)? Inadequate coverage (MRSA not covered)? Abscess needing drainage? Underlying osteomyelitis? Deep space infection? Non-infectious cause?</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Necrotizing fasciitis suspected or confirmed (pain out of proportion, crepitus, bullae, "wooden" feel)</li>
                        <li>Septic shock (SBP <90 despite fluids, lactate >4)</li>
                        <li>Rapidly progressive cellulitis despite IV antibiotics (expanding >5cm/hr)</li>
                        <li>Compartment syndrome (tense compartment, pain with passive stretch, paresthesias, pulselessness)</li>
                        <li>Streptococcal toxic shock syndrome (hypotension + multi-organ dysfunction)</li>
                        <li>Airway compromise (facial/neck cellulitis, Ludwig's angina)</li>
                        <li>Need for vasopressors or aggressive resuscitation</li>
                        <li>Hemodynamic instability with failed floor management</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24 hours (Temp <38¬∞C)</li>
                        <li>Hemodynamically stable (SBP >90, HR <110)</li>
                        <li>Erythema/edema clearly improving (borders regressing)</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Tolerating PO intake and oral antibiotics</li>
                        <li>No evidence of abscess requiring drainage</li>
                        <li>No concern for necrotizing infection</li>
                        <li>Adequate home support for elevation/wound care</li>
                        <li>Close follow-up arranged within 2-3 days</li>
                        <li>Patient educated on: limb elevation, signs of worsening, medication adherence</li>
                        <li>If diabetes: glucose controlled, good perfusion to affected area</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Local Complications:</strong> Abscess formation (fluctuance, purulent drainage - needs I&D), necrotizing fasciitis (pain out of proportion, bullae, crepitus, rapid progression), compartment syndrome (increased pressure in fascial compartment - surgical emergency), lymphangitis (red streaking), chronic lymphedema (after repeated episodes), post-infectious scarring/hyperpigmentation</p>
                    <p><strong>Systemic Complications:</strong> Bacteremia/sepsis (5-10% of hospitalized patients), septic shock, endocarditis (especially MRSA bacteremia), osteomyelitis (if bone involvement), septic arthritis (if joint nearby), glomerulonephritis (post-Streptococcal), toxic shock syndrome (Strep or Staph toxins)</p>
                    <p><strong>Treatment-Related:</strong> Antibiotic-associated diarrhea, C. difficile infection, drug allergy/rash, nephrotoxicity (vancomycin, aminoglycosides), red man syndrome (vancomycin infusion reaction), thrombophlebitis (IV site)</p>
                    <p><strong>Recurrence:</strong> 20-30% recurrence rate, higher with lymphedema. Monitor for: inadequately treated portal of entry (tinea pedis), unaddressed edema/venous insufficiency, immunosuppression</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGE 21: UTI/PYELONEPHRITIS -->
        <div id="uti" class="condition-page">
            <div class="page-header">
                <h2>21. URINARY TRACT INFECTION / PYELONEPHRITIS</h2>
                <div class="subtitle">Cystitis ‚Ä¢ Pyelonephritis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Cystitis (Lower UTI):</span> Acute onset of dysuria, urinary frequency, urgency, suprapubic pain/pressure, hematuria (gross or microscopic). NO fever (Temp <38¬∞C) or flank pain. Symptoms typically develop over hours to 1-2 days</p>
                    <p><span class="label">Pyelonephritis (Upper UTI):</span> Fever >38.5¬∞C, rigors, unilateral flank/back pain, costovertebral angle (CVA) tenderness on exam, nausea/vomiting. Often accompanied by dysuria and frequency. Can progress to sepsis</p>
                    <p><span class="label">Complicated UTI Definition:</span> Structural/functional abnormality of GU tract, instrumentation, immunosuppression, pregnancy, males, indwelling catheter, recent antimicrobial use, diabetes, renal transplant, hospital-acquired. Higher risk of treatment failure and complications</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly Patients:</strong> May present with altered mental status, confusion, falls, functional decline, or generalized weakness WITHOUT classic UTI symptoms. Fever often absent or blunted. Dysuria may not be reported. High index of suspicion needed</li>
                        <li><strong>Diabetic Patients:</strong> Higher risk of emphysematous pyelonephritis (gas-forming infection - E. coli, Klebsiella), papillary necrosis, perinephric abscess. Worse outcomes, longer treatment needed. May have poor glucose control as only manifestation</li>
                        <li><strong>Pregnancy:</strong> 20-30% of untreated asymptomatic bacteriuria progresses to pyelonephritis. Pyelonephritis can trigger preterm labor, low birth weight. Must screen ALL pregnant women and treat asymptomatic bacteriuria. Higher risk of recurrence during pregnancy</li>
                        <li><strong>Men (Any Age):</strong> Almost always complicated UTI. Assume prostatic involvement until proven otherwise. Need 7-14 days of treatment. Evaluate for structural abnormalities, BPH, prostatitis. First UTI in young man = red flag for anatomic defect</li>
                        <li><strong>Catheter-Associated (CAUTI):</strong> New fever, flank pain, suprapubic pain, altered mental status in catheterized patient. Often polymicrobial. Pyuria alone is NOT diagnostic (50% of catheterized patients have asymptomatic pyuria). Need symptoms to treat</li>
                        <li><strong>Perinephric/Renal Abscess:</strong> Persistent fever despite 48-72 hours appropriate antibiotics. Unilateral flank pain, palpable flank mass. Risk factors: diabetes, IV drug use, renal stones, obstruction. CT diagnostic. May need percutaneous or surgical drainage</li>
                        <li><strong>Xanthogranulomatous Pyelonephritis:</strong> Rare chronic infection causing granulomatous destruction of kidney. Mimics renal mass on imaging. Presents with persistent flank pain, fever, weight loss. Kidney non-functional, requires nephrectomy</li>
                        <li><strong>Emphysematous Pyelonephritis:</strong> Life-threatening gas-forming infection. 90% diabetics. Presents with severe sepsis, CVA tenderness. CT shows gas in renal parenchyma. High mortality (20-40%). Requires IV antibiotics + possible nephrectomy</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urinalysis (Essential for ALL):</span></p>
                    <ul>
                        <li><strong>Pyuria:</strong> >10 WBC/hpf highly suggestive. >5 WBC/hpf = abnormal. Absence of pyuria makes UTI unlikely (95% NPV)</li>
                        <li><strong>Bacteriuria:</strong> Any bacteria on unspun urine microscopy = ‚â•10^5 CFU/mL</li>
                        <li><strong>Leukocyte Esterase:</strong> Sensitive (75-96%) but less specific. Produced by WBCs. Can be false positive with contamination</li>
                        <li><strong>Nitrites:</strong> Highly specific (90-100%) but only 50% sensitive. Many uropathogens (Enterococcus, Staph saprophyticus, Pseudomonas) don't produce nitrites. Requires bacteria in bladder ‚â•4 hours</li>
                        <li><strong>Hematuria:</strong> Present in 40-60% of UTIs but non-specific</li>
                        <li><strong>WBC Casts:</strong> Pathognomonic for pyelonephritis (indicates renal parenchymal involvement). Differentiates from cystitis</li>
                    </ul>
                    
                    <p><span class="label">Urine Culture & Sensitivity (When to Send):</span></p>
                    <ul>
                        <li><strong>ALWAYS send before antibiotics if:</strong> Pyelonephritis, complicated UTI, pregnant, recent antibiotic use, healthcare-associated, symptoms >7 days, recurrent UTI, immunocompromised</li>
                        <li><strong>NOT needed for:</strong> Uncomplicated cystitis in young women (treat empirically)</li>
                        <li><strong>Collection:</strong> Mid-stream clean catch (not catheter unless catheter present <2 hours). First morning void best</li>
                        <li><strong>Interpretation:</strong>
                            <ul>
                                <li>‚â•10^5 CFU/mL = diagnostic for cystitis</li>
                                <li>‚â•10^4 CFU/mL = diagnostic for pyelonephritis</li>
                                <li>‚â•10^2 CFU/mL = diagnostic if catheter specimen</li>
                                <li>Multiple organisms = contamination (repeat culture)</li>
                            </ul>
                        </li>
                        <li><strong>Common Organisms:</strong> E. coli (75-95%), Klebsiella pneumoniae (5-10%), Proteus mirabilis (5%), Enterococcus (5%), Staphylococcus saprophyticus (5-15% in young women)</li>
                    </ul>
                    
                    <p><span class="label">Blood Cultures:</span></p>
                    <ul>
                        <li><strong>Obtain if:</strong> Pyelonephritis with sepsis/hemodynamic instability, immunocompromised, persistent fever despite 48-72hr of antibiotics, concern for bacteremia</li>
                        <li>Positive in 15-25% of hospitalized pyelonephritis patients</li>
                        <li>Usually same organism as urine culture</li>
                    </ul>
                    
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common in pyelonephritis (WBC often 12-20k with left shift). Leukopenia suggests severe sepsis</li>
                        <li><strong>BMP:</strong> Assess renal function (baseline Cr), check for AKI. Evaluate electrolytes</li>
                        <li><strong>Pregnancy test:</strong> ALL women of childbearing age (ectopic can present as flank pain, UTI changes management in pregnancy)</li>
                        <li><strong>Lactate:</strong> If sepsis suspected (goal <2, elevated suggests tissue hypoperfusion)</li>
                    </ul>
                    
                    <p><span class="label">Imaging (NOT routine, but obtain if):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast (Test of Choice):</strong>
                            <ul>
                                <li>No clinical improvement after 48-72 hours of appropriate antibiotics</li>
                                <li>Sepsis/septic shock</li>
                                <li>Immunocompromised (evaluate for abscess)</li>
                                <li>Concern for urinary obstruction (hydronephrosis, stones)</li>
                                <li>Recurrent pyelonephritis (>2 episodes)</li>
                                <li>Men with pyelonephritis (evaluate for anatomic abnormality)</li>
                                <li>Suspected emphysematous pyelonephritis (gas in tissues)</li>
                                <li>Suspected perinephric/renal abscess</li>
                            </ul>
                        </li>
                        <li><strong>Renal Ultrasound:</strong> First-line if pregnant or contraindication to IV contrast. Can detect hydronephrosis (obstruction) but less sensitive for abscess than CT. Good for assessing kidney size/echogenicity</li>
                        <li><strong>KUB X-ray:</strong> Limited utility. Can identify radiopaque stones (calcium) but misses 10-20% of stones</li>
                    </ul>
                    
                    <p><span class="label">Special Diagnostic Considerations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic Bacteriuria (ASB):</strong> Positive culture (‚â•10^5 CFU/mL) WITHOUT symptoms. Very common in elderly, catheterized patients. <strong>DO NOT TREAT</strong> except in pregnancy or before urologic procedures. Treatment causes antibiotic resistance without benefit</li>
                        <li><strong>Sterile Pyuria:</strong> WBCs in urine but negative culture. Differential: TB (send AFB culture √ó 3), fungal infection, interstitial nephritis, appendicitis, recent antibiotic use, urethritis (chlamydia, gonorrhea), kidney stones</li>
                        <li><strong>Catheter-Associated UTI Diagnosis:</strong> Catheterized patient with fever (>38¬∞C) OR new onset suprapubic pain OR flank pain OR altered mental status WITHOUT other source PLUS positive culture ‚â•10^3 CFU/mL. Pyuria alone is NOT diagnostic</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Uncomplicated Cystitis (Healthy Non-Pregnant Women):</span></p>
                    <ul>
                        <li><strong>First-Line Options:</strong>
                            <ul>
                                <li>Nitrofurantoin monohydrate/macrocrystals 100mg PO BID √ó 5 days (preferred)</li>
                                <li>TMP-SMX DS (160/800mg) PO BID √ó 3 days (only if local E. coli resistance <20%)</li>
                            </ul>
                        </li>
                        <li><strong>Second-Line Options:</strong>
                            <ul>
                                <li>Fosfomycin 3g PO √ó single dose (convenient but slightly lower cure rate ~90%)</li>
                                <li>Pivmecillinam 400mg PO TID √ó 3-5 days (not available in US)</li>
                            </ul>
                        </li>
                        <li><strong>When Œ≤-lactams Necessary:</strong>
                            <ul>
                                <li>Amoxicillin-clavulanate 875/125mg PO BID √ó 5-7 days</li>
                                <li>Cefpodoxime 100mg PO BID √ó 5-7 days</li>
                                <li>Less effective than nitrofurantoin/TMP-SMX - use only if alternatives unavailable</li>
                            </ul>
                        </li>
                        <li><strong>AVOID Fluoroquinolones:</strong> Reserve for pyelonephritis due to serious adverse effects (C. diff, tendon rupture, neuropathy) and resistance concerns</li>
                        <li><strong>Contraindications:</strong>
                            <ul>
                                <li>Nitrofurantoin: CrCl <30 mL/min, pregnancy at term (risk of hemolytic anemia in newborn), G6PD deficiency</li>
                                <li>TMP-SMX: Pregnancy (especially 1st trimester - neural tube defects), severe sulfa allergy, CrCl <15</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Outpatient (Mild, Tolerates PO, Reliable):</span></p>
                    <ul>
                        <li><strong>Fluoroquinolone (if local resistance <10%):</strong>
                            <ul>
                                <li>Ciprofloxacin 500mg PO BID √ó 7 days OR 1000mg XR daily √ó 7 days</li>
                                <li>Levofloxacin 750mg PO daily √ó 5 days</li>
                                <li>Can give single dose ceftriaxone 1g IM in ED before starting oral quinolone</li>
                            </ul>
                        </li>
                        <li><strong>If Fluoroquinolone Resistance or Contraindicated:</strong>
                            <ul>
                                <li>Ceftriaxone 1g IM/IV √ó 1 dose, THEN oral step-down based on culture susceptibility</li>
                                <li>If susceptible: TMP-SMX DS BID √ó 14 days OR Amoxicillin-clavulanate 875mg BID √ó 10-14 days</li>
                                <li>Cefpodoxime 200mg PO BID √ó 10-14 days (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Duration:</strong> 7-14 days depending on agent and clinical response. Fluoroquinolones 5-7 days, Œ≤-lactams 10-14 days</li>
                    </ul>
                    
                    <p><span class="label">Acute Pyelonephritis - Inpatient (Toxic, Septic, Unable to Tolerate PO):</span></p>
                    <ul>
                        <li><strong>Moderate Severity:</strong>
                            <ul>
                                <li>Ceftriaxone 1-2g IV q24h (excellent E. coli, Klebsiella, Proteus coverage)</li>
                                <li>Ciprofloxacin 400mg IV q12h OR Levofloxacin 750mg IV q24h</li>
                            </ul>
                        </li>
                        <li><strong>Severe/Septic/Complicated:</strong>
                            <ul>
                                <li>Cefepime 2g IV q8h (broader than ceftriaxone, covers Pseudomonas)</li>
                                <li>Piperacillin-tazobactam 3.375g IV q6h or 4.5g IV q8h</li>
                            </ul>
                        </li>
                        <li><strong>If Gram-Positive Cocci on Culture:</strong> Add Ampicillin 2g IV q4h (for Enterococcus - VRE risk if amp-resistant)</li>
                        <li><strong>ESBL Risk Factors Present:</strong> Previous ESBL infection, recent hospitalization, healthcare exposure, international travel, chronic care facility resident
                            <ul>
                                <li>Ertapenem 1g IV q24h OR Meropenem 1g IV q8h</li>
                                <li>Avoid cephalosporins/fluoroquinolones if ESBL confirmed</li>
                            </ul>
                        </li>
                        <li><strong>Transition to Oral:</strong> When afebrile √ó 24 hours, improved symptoms, tolerating PO, hemodynamically stable
                            <ul>
                                <li>Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>TMP-SMX DS BID (if susceptible)</li>
                                <li>Amoxicillin-clavulanate 875mg BID (if susceptible)</li>
                            </ul>
                        </li>
                        <li><strong>Total Duration:</strong> 7-14 days
                            <ul>
                                <li>7 days if uncomplicated, rapid response to treatment</li>
                                <li>10-14 days if complicated, bacteremia, slow response, immunocompromised, male</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Complicated UTI/Urosepsis:</span></p>
                    <ul>
                        <li><strong>Broad-Spectrum Initial Coverage:</strong>
                            <ul>
                                <li>Pip-tazo 4.5g IV q6h OR Cefepime 2g IV q8h</li>
                                <li>If MRSA suspected (skin breakdown, recent healthcare): ADD Vancomycin 15-20mg/kg IV q8-12h</li>
                                <li>If critically ill: Meropenem 1g IV q8h (covers ESBL, Pseudomonas)</li>
                            </ul>
                        </li>
                        <li><strong>De-escalate Based on Cultures:</strong> Narrow to organism-specific therapy once susceptibilities available</li>
                        <li><strong>Duration:</strong> 10-14 days minimum. Extend if slow response, abscess, obstruction</li>
                        <li><strong>Source Control:</strong> Remove catheters if possible. Drain abscesses. Relieve obstruction (nephrostomy, stent)</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li><strong>Screen ALL pregnant women</strong> for ASB at 12-16 weeks (treat if positive)</li>
                                <li>Cystitis: Nitrofurantoin 100mg BID √ó 5-7 days (avoid at term) OR Amoxicillin-clavulanate 875mg BID √ó 5-7 days OR Cephalexin 500mg QID √ó 5-7 days</li>
                                <li>Pyelonephritis: <strong>ADMIT</strong> - Ceftriaxone 1-2g IV q24h until afebrile √ó 24-48hr, then Cephalexin 500mg QID √ó 10-14 days total</li>
                                <li><strong>AVOID:</strong> Fluoroquinolones (cartilage toxicity), TMP in 1st trimester (neural tube defects), nitrofurantoin at term</li>
                            </ul>
                        </li>
                        <li><strong>Men (Always Complicated):</strong>
                            <ul>
                                <li>Assume prostatic involvement</li>
                                <li>Fluoroquinolone √ó 10-14 days (penetrates prostate): Ciprofloxacin 500mg BID or Levofloxacin 750mg daily</li>
                                <li>Alternative: TMP-SMX DS BID √ó 14 days (if susceptible)</li>
                                <li>If severe: Start IV (ceftriaxone, cefepime), transition to PO quinolone</li>
                                <li>Urology referral for: recurrent UTI, first UTI in young man, concern for obstruction</li>
                            </ul>
                        </li>
                        <li><strong>Catheter-Associated UTI (CAUTI):</strong>
                            <ul>
                                <li><strong>Remove or replace catheter</strong> if possible before starting antibiotics</li>
                                <li>Often polymicrobial, resistant organisms (Pseudomonas, Enterococcus, Candida)</li>
                                <li>Empiric: Ceftriaxone 1g IV daily OR Ciprofloxacin 400mg IV q12h</li>
                                <li>If severe: Cefepime or Pip-tazo (Pseudomonas coverage)</li>
                                <li>Duration: 7 days if catheter removed, 10-14 days if catheter remains in place</li>
                                <li>De-escalate based on cultures</li>
                            </ul>
                        </li>
                        <li><strong>Renal Impairment:</strong>
                            <ul>
                                <li>Avoid nitrofurantoin if CrCl <30 (inadequate levels)</li>
                                <li>Dose-adjust fluoroquinolones, Œ≤-lactams based on CrCl</li>
                                <li>TMP-SMX: Avoid if CrCl <15</li>
                            </ul>
                        </li>
                        <li><strong>Elderly/Nursing Home:</strong>
                            <ul>
                                <li>Do NOT treat asymptomatic bacteriuria</li>
                                <li>If symptomatic: Consider atypical presentations (AMS, falls)</li>
                                <li>Higher resistance rates - obtain culture before treating</li>
                                <li>Lower threshold to admit (dehydration, frailty, poor PO intake)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Recurrent UTI Management (‚â•2 in 6 months or ‚â•3 in 12 months):</span></p>
                    <ul>
                        <li><strong>Non-Antibiotic Strategies:</strong>
                            <ul>
                                <li>Increase fluid intake (2-3 L/day)</li>
                                <li>Void after intercourse</li>
                                <li>Avoid spermicides, diaphragms</li>
                                <li>Cranberry products (modest benefit - 500-1500mg proanthocyanidins daily)</li>
                                <li>D-mannose 2g daily (prevents E. coli adhesion)</li>
                                <li>Vaginal estrogen cream (post-menopausal women) - Estradiol 0.5g intravaginally 2x/week</li>
                            </ul>
                        </li>
                        <li><strong>Antibiotic Prophylaxis:</strong>
                            <ul>
                                <li><strong>Continuous:</strong> TMP-SMX SS (40/200mg) daily OR Nitrofurantoin 50-100mg daily at bedtime</li>
                                <li><strong>Post-coital:</strong> Single dose TMP-SMX SS or nitrofurantoin 50-100mg within 2 hours of intercourse</li>
                                <li><strong>Self-start therapy:</strong> Patient-initiated 3-day course at first symptom if reliable patient</li>
                            </ul>
                        </li>
                        <li><strong>Further Workup:</strong> Consider urologic evaluation (cystoscopy, renal US) if: recurrent pyelonephritis, hematuria, men, young children, suspicion of anatomic abnormality</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pyuria alone is NOT infection:</strong> 30-50% of catheterized patients have asymptomatic pyuria. Need SYMPTOMS to diagnose and treat CAUTI. Don't treat labs, treat patients!</li>
                    <li><strong>Asymptomatic bacteriuria - DON'T treat (with 2 exceptions):</strong> Treating ASB in elderly, catheterized, or diabetic patients drives resistance without benefit. ONLY treat in pregnancy or before urologic procedures. This is one of the most common antibiotic stewardship errors</li>
                    <li><strong>E. coli is the usual suspect:</strong> Causes 75-95% of community-acquired UTIs. Klebsiella, Proteus, Enterococcus are next. If unusual organism (Pseudomonas, Staph aureus), think catheter, recent healthcare exposure, or structural abnormality</li>
                    <li><strong>Men = complicated until proven otherwise:</strong> Almost all UTIs in men involve prostate. Need 10-14 days treatment (vs 3-5 days women). First UTI in young man = red flag for anatomic abnormality (posterior urethral valves, etc) - needs urologic workup</li>
                    <li><strong>Nitrofurantoin doesn't work for pyelonephritis:</strong> Doesn't achieve therapeutic levels in renal parenchyma or blood. Excellent for cystitis only. Using for pyelo = treatment failure</li>
                    <li><strong>Emphysematous pyelonephritis = life-threatening:</strong> Gas in kidney on CT. 90% in diabetics. E. coli or Klebsiella ferment glucose ‚Üí gas production. High mortality (20-40%). Needs IV antibiotics ¬± nephrectomy if refractory. Never miss this on imaging!</li>
                    <li><strong>WBC casts are pathognomonic for pyelonephritis:</strong> If WBC casts on UA = renal parenchymal involvement (vs cystitis which is bladder only). This finding confirms pyelonephritis diagnosis</li>
                    <li><strong>Post-treatment UA not needed:</strong> If symptoms resolve, don't recheck UA/culture. Pyuria can persist for weeks after successful treatment. Only reculture if persistent symptoms. "Test of cure" is symptom resolution, not negative UA</li>
                    <li><strong>Pregnancy ASB MUST be treated:</strong> 30% of untreated ASB in pregnancy progresses to pyelonephritis ‚Üí preterm labor. Screen ALL pregnant women at 12-16 weeks and treat positive cultures even if asymptomatic. This is the ONLY population where ASB treatment is indicated</li>
                    <li><strong>Fluoroquinolone resistance is rising:</strong> E. coli resistance now 20-30% in many areas. Check local antibiogram. If resistance >10%, avoid empiric quinolones for pyelonephritis - use ceftriaxone instead</li>
                    <li><strong>Perinephric abscess if fever persists despite antibiotics:</strong> Still febrile after 48-72 hours of appropriate antibiotics? Get CT - look for abscess. Abscess >3cm usually needs percutaneous drainage. Antibiotics alone often insufficient</li>
                    <li><strong>Recurrent UTI red flags needing urologic evaluation:</strong> Recurrent pyelonephritis, men, young children, painless hematuria, suspicion of stones/obstruction/anatomic defect. These need cystoscopy and/or imaging to find underlying cause</li>
                    <li><strong>Sterile pyuria differential:</strong> WBCs but negative culture = TB (get AFB culture √ó 3), partially treated UTI, urethritis (STI - test for chlamydia/gonorrhea), interstitial nephritis (NSAIDs, antibiotics), kidney stones, appendicitis, fungal infection (Candida in catheterized/diabetics)</li>
                    <li><strong>Nitrites are specific but not sensitive:</strong> If positive = infection. But 50% of UTIs are nitrite-negative because many organisms (Enterococcus, Staph saprophyticus, Pseudomonas, Acinetobacter) don't convert nitrate to nitrite. Don't rule out UTI based on negative nitrites alone</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Urosepsis with septic shock (SBP <90 despite fluids, lactate >4, requiring pressors)</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Severe sepsis with multi-organ dysfunction (AKI, AMS, coagulopathy)</li>
                        <li>Obstructive uropathy with sepsis (needs emergent decompression)</li>
                        <li>Perinephric or renal abscess with hemodynamic instability</li>
                        <li>Emphysematous pyelonephritis with shock (may need nephrectomy)</li>
                        <li>Papillary necrosis with obstruction and sepsis</li>
                        <li>Fournier's gangrene (necrotizing perineal infection - surgical emergency)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile √ó 24-48 hours (temperature <38¬∞C)</li>
                        <li>Hemodynamically stable (SBP >100, HR <100)</li>
                        <li>Tolerating PO intake without nausea/vomiting</li>
                        <li>Pain controlled on oral analgesics</li>
                        <li>Able to take oral antibiotics and reliable for adherence</li>
                        <li>Improving leukocytosis (if initially elevated, downtrending WBC)</li>
                        <li>Stable or improving renal function (if AKI, Cr trending toward baseline)</li>
                        <li>No evidence of obstruction requiring intervention (if imaging done)</li>
                        <li>No abscess, or abscess drained and improving</li>
                        <li>Urine culture results available and organism susceptible to oral agent</li>
                        <li>Patient educated on: completing full antibiotic course, adequate hydration (2-3 L/day), return precautions</li>
                        <li>PCP follow-up arranged within 1 week (urology if recurrent, male, or anatomic concern)</li>
                        <li>Plan for repeat culture if: pregnant, recurrent infection, initial blood culture positive</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early Complications (Hours-Days):</strong> Sepsis/septic shock (15-25% of hospitalized pyelonephritis), bacteremia with metastatic seeding (endocarditis, vertebral osteomyelitis, septic arthritis), acute kidney injury (from sepsis, obstruction, or bilateral pyelonephritis), urinary retention (from UTI-induced detrusor dysfunction), severe hematuria (can cause clot retention requiring continuous bladder irrigation)</p>
                    <p><strong>Late Complications (Days-Weeks):</strong> Perinephric abscess (persistent fever >72hr despite antibiotics, needs CT diagnosis and drainage), intrarenal abscess, emphysematous pyelonephritis (diabetics - gas-forming infection, 20-40% mortality, may need nephrectomy), renal papillary necrosis (diabetics, sickle cell disease, analgesic abuse - presents with flank pain, hematuria, AKI), chronic pyelonephritis with renal scarring (recurrent infections ‚Üí CKD), xanthogranulomatous pyelonephritis (rare chronic granulomatous destruction of kidney)</p>
                    <p><strong>Treatment-Related Complications:</strong> C. difficile infection (fluoroquinolones highest risk), antibiotic-associated diarrhea, allergic reactions (rash, anaphylaxis), tendon rupture (fluoroquinolones - Achilles tendon), peripheral neuropathy (fluoroquinolones - can be irreversible), QT prolongation (fluoroquinolones, especially if other QT drugs), photosensitivity (fluoroquinolones), pulmonary fibrosis (nitrofurantoin with chronic use >6 months), hemolytic anemia (nitrofurantoin in G6PD deficiency)</p>
                    <p><strong>Pregnancy-Related:</strong> Preterm labor and delivery (pyelonephritis), low birth weight, intrauterine growth restriction, maternal sepsis, respiratory failure (ARDS from pyelonephritis in pregnancy)</p>
                    <p><strong>Recurrence:</strong> 25-30% recurrence within 6 months if underlying factors not addressed (kidney stones, obstruction, vesicoureteral reflux, anatomic abnormality, poor hygiene, sexual activity with spermicide use, post-menopausal atrophic vaginitis, BPH in men, neurogenic bladder, immunosuppression)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- PAGES 22-25 streamlined to fit tokens, can expand later -->
        
        <div id="cdiff" class="condition-page">
            <div class="page-header">
                <h2>22. C. DIFFICILE INFECTION (CDI)</h2>
                <div class="subtitle">Clostridioides difficile ‚Ä¢ Antibiotic-Associated Diarrhea ‚Ä¢ Pseudomembranous Colitis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> ‚â•3 unformed (loose or watery) stools in 24 hours in setting of recent antibiotic exposure (typically within past 3 months). Crampy abdominal pain, low-grade fever. Diarrhea is NOT bloody in most cases. Leukocytosis often pronounced (WBC 15-30k)</p>
                    <p><span class="label">Physical Exam:</span> Diffuse abdominal tenderness (worse in left lower quadrant), abdominal distension, hyperactive bowel sounds. If peritoneal signs present ‚Üí concerning for toxic megacolon or perforation</p>
                    
                    <p><span class="label">Risk Factors:</span></p>
                    <ul>
                        <li><strong>Antibiotic exposure:</strong> #1 risk factor. Highest risk: clindamycin, fluoroquinolones, cephalosporins, carbapenems. Even single dose can trigger. Usually within 3 months but can be up to 3 years</li>
                        <li><strong>Healthcare exposure:</strong> Hospitalization, nursing home, recent admission</li>
                        <li><strong>Advanced age:</strong> >65 years (decreased immunity, increased exposure)</li>
                        <li><strong>Medications:</strong> PPIs (impair gastric acid barrier), H2 blockers, chemotherapy</li>
                        <li><strong>Immunosuppression:</strong> IBD, transplant, malignancy, HIV</li>
                        <li><strong>GI surgery/manipulation:</strong> Recent abdominal surgery, NG tube, PEG tube</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Severe CDI:</strong> WBC ‚â•15k, Cr ‚â•1.5√ó baseline. Presents with high fever (>38.5¬∞C), severe abdominal pain, hypotension. May have minimal diarrhea (ileus develops)</li>
                        <li><strong>Fulminant CDI (2-3% of cases):</strong> Hypotension requiring pressors, shock, ileus, megacolon, perforation, multi-organ failure. WBC >35k or <2k (leukemoid reaction or leukopenia both bad signs). High mortality (30-50%)</li>
                        <li><strong>Toxic Megacolon:</strong> Abdominal distension, absent bowel sounds, peritoneal signs. Colon >6cm on imaging. Life-threatening - requires surgical evaluation</li>
                        <li><strong>Elderly Patients:</strong> May present with only altered mental status, functional decline, or minimal diarrhea. Lower threshold for testing</li>
                        <li><strong>IBD Patients:</strong> Difficult to distinguish from IBD flare. C. diff superinfection in 5-10% of IBD hospitalizations. Always test IBD patients with worsening symptoms</li>
                        <li><strong>Community-Acquired CDI:</strong> No recent healthcare or antibiotic exposure (15-25% of cases). Often younger, healthier patients. Associated with PPI use, outpatient antibiotics</li>
                        <li><strong>Asymptomatic Carriage:</strong> 3-15% of healthy adults, 20-40% of hospitalized patients colonized without symptoms. Do NOT test or treat asymptomatic patients (even if formed stool sent for testing comes back positive)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">When to Test:</span> ONLY test patients with ‚â•3 unformed stools in 24 hours. Do NOT test formed stools or asymptomatic patients (high false positive rate from colonization)</p>
                    
                    <p><span class="label">Diagnostic Testing (Multi-Step Algorithm Preferred):</span></p>
                    <ul>
                        <li><strong>NAAT (Nucleic Acid Amplification Test/PCR):</strong>
                            <ul>
                                <li>Detects toxin genes (tcdB). Most sensitive test (>95%)</li>
                                <li>Problem: Can't distinguish active infection from colonization</li>
                                <li>If positive ‚Üí need clinical correlation (symptoms + risk factors)</li>
                            </ul>
                        </li>
                        <li><strong>EIA for Toxins A/B:</strong>
                            <ul>
                                <li>Detects actual toxins in stool. High specificity (>95%) but poor sensitivity (60-80%)</li>
                                <li>If positive ‚Üí definite infection (can start treatment)</li>
                                <li>If negative ‚Üí doesn't rule out (may need NAAT or repeat testing)</li>
                            </ul>
                        </li>
                        <li><strong>GDH (Glutamate Dehydrogenase) Antigen:</strong>
                            <ul>
                                <li>Screening test. Sensitive but not specific (detects organism, not toxin)</li>
                                <li>If negative ‚Üí C. diff ruled out</li>
                                <li>If positive ‚Üí need confirmatory toxin testing</li>
                            </ul>
                        </li>
                        <li><strong>Recommended 2-Step Algorithm:</strong>
                            <ul>
                                <li>Step 1: GDH + Toxin EIA</li>
                                <li>If both positive ‚Üí Treat</li>
                                <li>If GDH positive but Toxin negative ‚Üí Send NAAT (if high suspicion, can empirically treat while awaiting)</li>
                                <li>If both negative ‚Üí C. diff excluded</li>
                            </ul>
                        </li>
                        <li><strong>Do NOT send repeat testing:</strong> If initially negative but high clinical suspicion persists, can repeat once after 24-48 hours. More than 2 tests in 7 days is excessive</li>
                        <li><strong>Test of cure NOT recommended:</strong> Patients can shed toxin for weeks. Treat symptoms, not test results</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess Severity):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis common (15-30k). WBC >15k = severe. WBC >35k or <2k = very high risk for complications/death</li>
                        <li><strong>BMP:</strong> Cr >1.5√ó baseline = severe. Check for AKI, electrolyte abnormalities (hypokalemia from diarrhea)</li>
                        <li><strong>Albumin:</strong> Hypoalbuminemia from protein-losing enteropathy</li>
                        <li><strong>Lactate:</strong> Elevated if sepsis/shock</li>
                    </ul>
                    
                    <p><span class="label">Imaging (If Severe or Complications Suspected):</span></p>
                    <ul>
                        <li><strong>CT Abdomen/Pelvis WITH IV Contrast:</strong>
                            <ul>
                                <li>Indications: Severe CDI, fulminant presentation, concern for megacolon/perforation, ileus, peritoneal signs</li>
                                <li>Findings: Colonic wall thickening (>4mm), pericolonic stranding, "accordion sign" (contrast trapped in thickened colonic folds), ascites, megacolon (>6cm), pneumatosis</li>
                                <li>Helps determine need for surgery</li>
                            </ul>
                        </li>
                        <li><strong>KUB X-ray:</strong> Can identify megacolon, free air (perforation), but CT preferred if available</li>
                        <li><strong>Colonoscopy:</strong> Generally NOT needed. Consider if diagnosis uncertain or refractory to treatment. Pseudomembranes (yellow-white plaques) are pathognomonic but only present in 50% of cases. Risk of perforation - avoid if severe colitis</li>
                    </ul>
                    
                    <p><span class="label">Severity Classification (Guides Treatment):</span></p>
                    <ul>
                        <li><strong>Non-Severe (Mild-Moderate):</strong> WBC <15k, Cr <1.5 mg/dL</li>
                        <li><strong>Severe:</strong> WBC ‚â•15k OR Cr ‚â•1.5√ó baseline</li>
                        <li><strong>Fulminant:</strong> Hypotension, shock, ileus, megacolon, perforation, ICU admission, WBC >35k or <2k</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Stop offending antibiotics immediately</strong> if medically possible (single most important intervention)</li>
                        <li><strong>Discontinue PPIs/H2 blockers</strong> if possible</li>
                        <li><strong>Contact isolation:</strong> Private room, gloves and gown for all contact. Soap and water hand hygiene (alcohol doesn't kill spores)</li>
                        <li><strong>Avoid anti-motility agents:</strong> Loperamide, opiates can precipitate toxic megacolon. Contraindicated</li>
                        <li><strong>Avoid unnecessary antibiotics:</strong> But continue life-saving antibiotics if needed (C. diff treatment will work alongside)</li>
                    </ul>
                    
                    <p><span class="label">Initial Episode - Non-Severe/Severe:</span></p>
                    <ul>
                        <li><strong>FIRST-LINE: Oral Vancomycin 125mg PO QID √ó 10 days</strong>
                            <ul>
                                <li>Preferred for both non-severe AND severe CDI (2021 IDSA guidelines changed recommendation)</li>
                                <li>Acts locally in gut (not absorbed systemically)</li>
                                <li>Higher doses (500mg QID) do NOT improve outcomes for non-fulminant disease</li>
                            </ul>
                        </li>
                        <li><strong>ALTERNATIVE: Fidaxomicin 200mg PO BID √ó 10 days</strong>
                            <ul>
                                <li>Narrow-spectrum, preserves gut flora better</li>
                                <li>Lower recurrence rate than vancomycin (15% vs 25%)</li>
                                <li>Very expensive - reserve for: recurrent CDI, high risk for recurrence, immunocompromised</li>
                            </ul>
                        </li>
                        <li><strong>If Oral Vanc/Fidaxomicin Unavailable: Metronidazole 500mg PO TID √ó 10 days</strong>
                            <ul>
                                <li>No longer first-line (inferior to vancomycin)</li>
                                <li>Only use if vanc/fidaxomicin not available</li>
                                <li>Systemic side effects (neuropathy with prolonged use)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Severe CDI (WBC ‚â•15k OR Cr ‚â•1.5√ó baseline):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 125mg PO QID √ó 10 days</strong> (same dose as non-severe)</li>
                        <li>Some experts use 500mg QID for severe, but 125mg QID likely equivalent</li>
                        <li>Monitor closely for progression to fulminant</li>
                    </ul>
                    
                    <p><span class="label">Fulminant CDI (Shock, Ileus, Megacolon, ICU):</span></p>
                    <ul>
                        <li><strong>Oral Vancomycin 500mg PO/NG QID</strong></li>
                        <li><strong>PLUS IV Metronidazole 500mg IV q8h</strong> (for systemic absorption since gut may not absorb oral meds)</li>
                        <li><strong>If Ileus Present: ADD Vancomycin 500mg in 500mL NS PR q6h</strong> (rectal enema to reach colon)</li>
                        <li><strong>Surgery consult immediately:</strong> Subtotal colectomy with end ileostomy if:
                            <ul>
                                <li>Refractory shock despite pressors</li>
                                <li>Perforation or peritonitis</li>
                                <li>Worsening lactate despite treatment</li>
                                <li>WBC >50k or <2k with clinical deterioration</li>
                                <li>Mental status decline</li>
                            </ul>
                        </li>
                        <li><strong>Mortality without surgery:</strong> 80% if meet criteria. With surgery: 40-50%</li>
                    </ul>
                    
                    <p><span class="label">Recurrent CDI (Most Challenging Aspect):</span></p>
                    <ul>
                        <li><strong>First Recurrence (20-30% of patients):</strong>
                            <ul>
                                <li>If metronidazole used initially ‚Üí Switch to Vancomycin 125mg QID √ó 10 days</li>
                                <li>If vancomycin used initially ‚Üí Repeat Vancomycin 125mg QID √ó 10 days OR Fidaxomicin 200mg BID √ó 10 days (preferred - lower re-recurrence)</li>
                            </ul>
                        </li>
                        <li><strong>Second or Later Recurrence (40-60% after 2nd episode):</strong>
                            <ul>
                                <li><strong>Option 1: Vancomycin Taper/Pulse</strong>
                                    <ul>
                                        <li>125mg QID √ó 10-14 days</li>
                                        <li>Then 125mg BID √ó 7 days</li>
                                        <li>Then 125mg daily √ó 7 days</li>
                                        <li>Then 125mg every 2-3 days √ó 2-8 weeks</li>
                                    </ul>
                                </li>
                                <li><strong>Option 2: Fidaxomicin 200mg BID √ó 10 days</strong> (preferred if available - 13% re-recurrence vs 25% with vanc)</li>
                                <li><strong>Option 3: Fecal Microbiota Transplant (FMT)</strong>
                                    <ul>
                                        <li>90% cure rate after ‚â•2 recurrences</li>
                                        <li>Restores normal gut flora</li>
                                        <li>Usually via colonoscopy (can also do via capsules, NG tube)</li>
                                        <li>Screening of donor required</li>
                                    </ul>
                                </li>
                                <li><strong>Option 4: Bezlotoxumab (Zinplava)</strong>
                                    <ul>
                                        <li>Monoclonal antibody against C. diff toxin B</li>
                                        <li>Given as single 10mg/kg IV infusion during antibiotic treatment</li>
                                        <li>Reduces recurrence from 26% to 17%</li>
                                        <li>Expensive - reserve for high-risk recurrent patients</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Unable to Take PO:</strong> Vancomycin via NG/OG tube + IV metronidazole + consider vanc enemas</li>
                        <li><strong>Pregnancy/Breastfeeding:</strong> Vancomycin safe (not absorbed). Avoid metronidazole in 1st trimester</li>
                        <li><strong>Renal Failure:</strong> Vancomycin dose unchanged (not absorbed). Metronidazole - monitor for neuropathy</li>
                        <li><strong>Concomitant Antibiotics Needed:</strong> Continue C. diff treatment alongside. Stop offending antibiotics if possible, but don't withhold life-saving antibiotics</li>
                        <li><strong>Prevention in High-Risk:</strong> Antibiotic stewardship (limit unnecessary antibiotics), avoid PPIs, probiotics NOT recommended for prevention</li>
                    </ul>
                    
                    <p><span class="label">Duration and Monitoring:</span></p>
                    <ul>
                        <li><strong>Standard duration:</strong> 10 days for initial/first recurrence</li>
                        <li><strong>Expect improvement:</strong> Within 3-5 days (decreased diarrhea, resolution of fever). If no improvement by day 5-7 ‚Üí re-evaluate</li>
                        <li><strong>Do NOT retest stool:</strong> Can remain PCR positive for 6 weeks. Treat symptoms, not tests</li>
                        <li><strong>Resolution defined as:</strong> ‚â§3 formed stools per day OR return to baseline bowel pattern</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Test ONLY liquid stool:</strong> If stool takes shape of container = test. If stool holds its own shape = don't test. Testing formed stool leads to false positives from asymptomatic colonization (10-15% of hospitalized patients colonized)</li>
                    <li><strong>PCR can't distinguish infection from colonization:</strong> NAAT detects toxin genes, not actual toxins. Positive PCR + no symptoms = colonization, not infection. Need clinical correlation always</li>
                    <li><strong>One antibiotic dose can trigger CDI:</strong> Even single perioperative dose. Symptoms typically 5-10 days after starting antibiotics but can be up to 3 months (or longer). Any antibiotic can cause it, but clinda/FQ/cephalosporins are worst</li>
                    <li><strong>Vancomycin 125mg = 500mg for non-fulminant:</strong> Higher doses don't improve outcomes. Save 500mg QID for fulminant only. This saves money and prevents unnecessary dose escalation</li>
                    <li><strong>Metronidazole is NOT first-line anymore:</strong> 2021 IDSA guidelines downgraded metronidazole. Vancomycin superior and should be used for initial treatment. Metronidazole only if vanc unavailable</li>
                    <li><strong>Fidaxomicin costs 100√ó more than vancomycin:</strong> ~$3,000 vs $30 for 10-day course. Lower recurrence (15% vs 25%) but reserve for recurrent CDI or high-risk patients due to cost</li>
                    <li><strong>FMT is incredibly effective for recurrent CDI:</strong> 85-90% cure rate after ‚â•2 recurrences. Should be offered to all patients with multiple recurrences. Colonoscopy method preferred (highest success)</li>
                    <li><strong>Never use anti-diarrheal agents:</strong> Loperamide and opiates retain toxin in colon ‚Üí toxic megacolon. Absolutely contraindicated. Let the diarrhea clear the toxin</li>
                    <li><strong>Soap and water, not alcohol:</strong> Alcohol hand sanitizer doesn't kill C. diff spores. Healthcare workers must use soap and water + contact precautions (gown and gloves)</li>
                    <li><strong>WBC >35k or <2k = bad prognostic sign:</strong> Leukemoid reaction (>35k) or leukopenia (<2k) both associated with fulminant disease and high mortality. These patients need ICU + surgery consult</li>
                    <li><strong>Stop PPIs in CDI patients:</strong> PPIs increase CDI risk and recurrence. Discontinue unless absolutely necessary (active bleeding ulcer). Gastric acid is natural defense</li>
                    <li><strong>Bezlotoxumab for recurrent disease prevention:</strong> Single IV dose during antibiotic treatment reduces recurrence from 26% to 17%. Expensive but worth considering for patients with ‚â•2 recurrences or high risk (age >65, immunocompromised, severe disease)</li>
                    <li><strong>Surgery for fulminant = life-saving:</strong> Subtotal colectomy with ileostomy. Mortality 80% without surgery vs 40-50% with surgery if meet criteria. Don't delay if indicated</li>
                    <li><strong>Probiotics NOT recommended:</strong> No evidence for prevention or treatment. Don't use routinely. May increase infection risk in immunocompromised</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Fulminant CDI: hypotension requiring pressors, shock, lactate >4</li>
                        <li>WBC >35k or <2k (leukemoid reaction or leukopenia)</li>
                        <li>Toxic megacolon (colon >6cm, peritoneal signs)</li>
                        <li>Perforation or peritonitis</li>
                        <li>Ileus with severe abdominal distension</li>
                        <li>AKI with Cr >2√ó baseline or requiring dialysis</li>
                        <li>Mental status decline despite treatment</li>
                        <li>Worsening lactate despite resuscitation</li>
                        <li>Need for mechanical ventilation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Diarrhea significantly improved (‚â§3 unformed stools/day or return to baseline)</li>
                        <li>Afebrile √ó 24 hours (temperature <38¬∞C)</li>
                        <li>Hemodynamically stable (no tachycardia, normotensive)</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Abdominal pain resolved or minimal</li>
                        <li>WBC downtrending (if initially elevated)</li>
                        <li>No signs of complications (megacolon, perforation, ileus)</li>
                        <li>Able to complete antibiotic course as outpatient</li>
                        <li>Prescription for remaining vancomycin provided</li>
                        <li>Patient/family educated on: completing full course, hand hygiene, contact precautions at home if immunocompromised household members</li>
                        <li>PCP follow-up arranged within 1-2 weeks</li>
                        <li>Patient instructed on recurrence symptoms and when to return</li>
                        <li>If recurrent CDI: discussed prevention strategies (avoid unnecessary antibiotics/PPIs, FMT referral if multiple recurrences)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications (During Treatment):</strong> Toxic megacolon (colon dilation >6cm - 3-8% of cases, high mortality), colonic perforation (peritonitis, free air, requires emergency colectomy), fulminant colitis with shock (hypotension, multi-organ failure, 2-3% of cases), ileus (paradoxical decrease in diarrhea with worsening distension), sepsis/septic shock, acute kidney injury (from hypovolemia or sepsis)</p>
                    <p><strong>Metabolic/Nutritional:</strong> Severe dehydration and electrolyte imbalances (hypokalemia, hypomagnesemia from diarrhea), protein-losing enteropathy with hypoalbuminemia (<2.5 g/dL), malnutrition from prolonged illness</p>
                    <p><strong>Recurrence (Most Common Complication):</strong> First recurrence 20-30%, second recurrence 40-60% (cumulative). Usually within 2-8 weeks of completing treatment. Risk factors: age >65, continued antibiotics, PPI use, immunosuppression, initial severe infection, hospitalization. Each recurrence increases risk of subsequent recurrence</p>
                    <p><strong>Post-Infection:</strong> Post-infectious IBS (10-25% develop chronic diarrhea/abdominal pain even after CDI cured), chronic diarrhea from dysbiosis, small intestinal bacterial overgrowth (SIBO) from gut flora disruption</p>
                    <p><strong>Treatment-Related:</strong> Metronidazole peripheral neuropathy (with prolonged use >2 weeks - can be irreversible), disulfiram-like reaction with alcohol (metronidazole), vancomycin-resistant Enterococcus (VRE) colonization (prolonged oral vanc), microbiome disruption from prolonged treatment</p>
                    <p><strong>Surgical:</strong> Need for colectomy (1-3% of cases - fulminant colitis, perforation, toxic megacolon), post-surgical complications (wound infection, ileus, short bowel syndrome), high mortality with surgery (30-50%) but higher without surgery if indicated (80%)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="dvt" class="condition-page">
            <div class="page-header">
                <h2>23. DEEP VEIN THROMBOSIS (DVT)</h2>
                <div class="subtitle">Venous Thromboembolism ‚Ä¢ Lower Extremity ‚Ä¢ Pulmonary Embolism Risk</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Unilateral leg swelling, pain, warmth, erythema. Calf tenderness, palpable cord. Swelling typically involves entire leg if proximal DVT (iliofemoral), calf only if distal DVT</p>
                    <p><span class="label">Physical Exam:</span> Measure calf/thigh circumference (>3cm difference = significant), assess for pitting edema, erythema, warmth. Homan's sign (calf pain with dorsiflexion) is unreliable - do NOT use for diagnosis</p>
                    
                    <p><span class="label">Anatomic Classification:</span></p>
                    <ul>
                        <li><strong>Proximal DVT:</strong> Popliteal vein or above (femoral, iliofemoral). High PE risk (50% if untreated). ALWAYS requires anticoagulation</li>
                        <li><strong>Distal DVT:</strong> Calf veins only (peroneal, tibial, gastrocnemius). Lower PE risk (10%). May monitor without anticoagulation if low risk</li>
                        <li><strong>Upper Extremity DVT:</strong> Axillary, subclavian, internal jugular. 10% of DVTs. Often catheter-related</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Asymptomatic DVT:</strong> 50% of DVTs have minimal symptoms. May present as PE. Screen high-risk hospitalized patients</li>
                        <li><strong>Phlegmasia Alba Dolens:</strong> "Milk leg" - pale, swollen leg from extensive iliofemoral DVT with spasm. Painful but pulses intact</li>
                        <li><strong>Phlegmasia Cerulea Dolens:</strong> Blue, painful, massively swollen leg from complete venous occlusion. Arterial compromise, gangrene risk. Surgical emergency</li>
                        <li><strong>May-Thurner Syndrome:</strong> Left common iliac vein compression by right common iliac artery. Young women with left leg DVT</li>
                        <li><strong>Upper Extremity DVT:</strong> Arm swelling, pain. Paget-Schroetter syndrome (effort thrombosis) in athletes. Central line-associated in hospitalized</li>
                        <li><strong>Superficial Thrombophlebitis:</strong> Palpable tender cord, erythema along superficial vein. Low PE risk but can extend to deep system. If >5cm or near saphenofemoral junction, consider anticoagulation</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Decision Rule - Wells Score for DVT:</span></p>
                    <ul>
                        <li>Active cancer (treatment within 6 months or palliative): +1</li>
                        <li>Paralysis, paresis, or recent immobilization of lower extremity: +1</li>
                        <li>Recently bedridden >3 days or major surgery within 4 weeks: +1</li>
                        <li>Localized tenderness along deep venous system: +1</li>
                        <li>Entire leg swollen: +1</li>
                        <li>Calf swelling >3cm compared to other leg (10cm below tibial tuberosity): +1</li>
                        <li>Pitting edema (greater in symptomatic leg): +1</li>
                        <li>Collateral superficial veins (non-varicose): +1</li>
                        <li>Alternative diagnosis as likely or more likely than DVT: -2</li>
                        <li><strong>Score interpretation:</strong> ‚â§0 = Low probability (5% DVT), 1-2 = Moderate (17%), ‚â•3 = High (53%)</li>
                    </ul>
                    
                    <p><span class="label">Diagnostic Algorithm:</span></p>
                    <ul>
                        <li><strong>Low Probability (Wells ‚â§0):</strong> D-dimer first. If negative ‚Üí DVT excluded (99% NPV). If positive ‚Üí Ultrasound</li>
                        <li><strong>Moderate-High Probability (Wells ‚â•1):</strong> Proceed directly to ultrasound (don't wait for D-dimer)</li>
                    </ul>
                    
                    <p><span class="label">D-Dimer:</span></p>
                    <ul>
                        <li><strong>High sensitivity (95-98%), low specificity (40-50%)</strong></li>
                        <li>Excellent negative predictive value - if negative, DVT/PE ruled out in low-risk patients</li>
                        <li>Many false positives: infection, malignancy, pregnancy, post-op, elderly, hospitalization</li>
                        <li><strong>Age-adjusted D-dimer:</strong> Age √ó 10 mcg/L if age >50 (improves specificity in elderly)</li>
                        <li><strong>When NOT to use:</strong> High pretest probability, active cancer, recent surgery, pregnancy (always elevated)</li>
                    </ul>
                    
                    <p><span class="label">Compression Ultrasonography (Test of Choice):</span></p>
                    <ul>
                        <li><strong>Technique:</strong> 2-point compression (common femoral vein, popliteal vein). Add full duplex if high suspicion</li>
                        <li><strong>Positive = Non-compressibility of vein</strong> (vein doesn't collapse with probe pressure)</li>
                        <li><strong>Sensitivity/Specificity:</strong> >95% for proximal DVT, 50-70% for distal (calf) DVT</li>
                        <li><strong>If negative but high suspicion:</strong> Repeat ultrasound in 1 week (5-10% of distal DVTs extend proximally)</li>
                        <li><strong>Limitations:</strong> Operator-dependent, difficult with edema/obesity, poor for iliac veins and calf veins</li>
                    </ul>
                    
                    <p><span class="label">Additional Imaging (Special Situations):</span></p>
                    <ul>
                        <li><strong>CT/MR Venography:</strong> If ultrasound non-diagnostic and high suspicion. Better for pelvic/IVC thrombus</li>
                        <li><strong>Contrast Venography:</strong> Gold standard but invasive, rarely used now. Reserved for cases where diagnosis remains uncertain</li>
                    </ul>
                    
                    <p><span class="label">Labs (Assess for Complications and Etiology):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Baseline hemoglobin (before anticoagulation), platelet count (baseline for HIT monitoring)</li>
                        <li><strong>PT/INR, aPTT:</strong> Baseline coagulation studies</li>
                        <li><strong>BMP, Cr:</strong> Renal function (affects anticoagulant dosing)</li>
                        <li><strong>Hypercoagulability Workup:</strong> Generally NOT needed for provoked DVT. Consider if: age <50, recurrent VTE, strong family history, unusual sites
                            <ul>
                                <li>Factor V Leiden, Prothrombin G20210A mutation, Protein C/S deficiency, Antithrombin deficiency</li>
                                <li>Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-Œ≤2-glycoprotein)</li>
                                <li>Test AFTER acute phase and OFF anticoagulation (if possible) - results unreliable during acute DVT</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Anticoagulation (Start Immediately if High Suspicion - Don't Wait for Imaging):</span></p>
                    
                    <p><span class="label">Direct Oral Anticoagulants (DOACs) - FIRST-LINE for Most Patients:</span></p>
                    <ul>
                        <li><strong>Rivaroxaban (Xarelto):</strong> 15mg PO BID √ó 21 days, then 20mg PO daily
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, BID dosing only first 3 weeks</li>
                            </ul>
                        </li>
                        <li><strong>Apixaban (Eliquis):</strong> 10mg PO BID √ó 7 days, then 5mg PO BID
                            <ul>
                                <li>Advantages: Single drug, no LMWH bridge, lowest bleeding risk of DOACs</li>
                                <li>Preferred if high bleeding risk</li>
                            </ul>
                        </li>
                        <li><strong>Edoxaban (Savaysa):</strong> LMWH √ó 5-10 days FIRST, then Edoxaban 60mg PO daily
                            <ul>
                                <li>Requires bridge - less convenient</li>
                            </ul>
                        </li>
                        <li><strong>Dabigatran (Pradaxa):</strong> LMWH √ó 5-10 days FIRST, then Dabigatran 150mg PO BID
                            <ul>
                                <li>Requires bridge - less convenient</li>
                                <li>Advantage: Reversible with idarucizumab (Praxbind)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">DOAC Contraindications (Use LMWH/Warfarin Instead):</span></p>
                    <ul>
                        <li>Severe renal impairment (CrCl <30 mL/min for most DOACs, <25 for apixaban)</li>
                        <li>Mechanical heart valves</li>
                        <li>Antiphospholipid syndrome (high recurrence with DOACs - use warfarin)</li>
                        <li>Active malignancy (LMWH preferred - see below)</li>
                        <li>Extremes of body weight (<50kg or >120kg - limited data)</li>
                    </ul>
                    
                    <p><span class="label">Low Molecular Weight Heparin (LMWH):</span></p>
                    <ul>
                        <li><strong>Enoxaparin (Lovenox):</strong> 1mg/kg SC q12h OR 1.5mg/kg SC q24h
                            <ul>
                                <li>Bridge to warfarin √ó 5-10 days (until INR 2-3 √ó 2 consecutive days)</li>
                                <li>Or continue as monotherapy (especially cancer patients)</li>
                            </ul>
                        </li>
                        <li><strong>Dalteparin:</strong> 200 units/kg SC daily (max 18,000 units) √ó 1 month, then 150 units/kg daily</li>
                        <li><strong>Advantages:</strong> No monitoring needed, predictable dosing, safe in renal impairment (CrCl >30)</li>
                        <li><strong>Dosing adjustments:</strong>
                            <ul>
                                <li>Obesity (>150kg): Consider anti-Xa levels</li>
                                <li>Renal impairment (CrCl 15-30): Reduce dose by 50% or switch to UFH</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Unfractionated Heparin (UFH):</span></p>
                    <ul>
                        <li><strong>Use when:</strong> Severe renal failure (CrCl <15), high bleeding risk (short half-life, reversible), possible need for procedure, massive PE</li>
                        <li><strong>Dosing:</strong> 80 units/kg IV bolus, then 18 units/kg/hr infusion</li>
                        <li><strong>Goal aPTT:</strong> 1.5-2.5√ó control (60-80 seconds typically)</li>
                        <li><strong>Monitor:</strong> aPTT q6h until therapeutic, then daily. Platelet count q2-3 days (HIT risk)</li>
                    </ul>
                    
                    <p><span class="label">Warfarin (Coumadin):</span></p>
                    <ul>
                        <li><strong>Start 5mg PO daily</strong> (overlap with LMWH/UFH √ó 5-10 days)</li>
                        <li><strong>Goal INR:</strong> 2-3 (2.5-3.5 for antiphospholipid syndrome)</li>
                        <li><strong>Monitor:</strong> INR daily until stable, then weekly, then monthly</li>
                        <li><strong>Advantages:</strong> Cheapest option, long track record, reversible with vitamin K/FFP/PCC</li>
                        <li><strong>Disadvantages:</strong> Requires monitoring, drug-food interactions, narrow therapeutic window</li>
                    </ul>
                    
                    <p><span class="label">Special Populations:</span></p>
                    <ul>
                        <li><strong>Cancer-Associated VTE:</strong>
                            <ul>
                                <li><strong>LMWH preferred over warfarin/DOACs</strong> (lower recurrence rate)</li>
                                <li>Enoxaparin 1mg/kg SC BID √ó 3-6 months minimum, often lifelong</li>
                                <li>Alternative: Apixaban or rivaroxaban if LMWH not tolerated (recent trials show non-inferiority)</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy:</strong>
                            <ul>
                                <li>LMWH throughout pregnancy (enoxaparin 1mg/kg SC q12h)</li>
                                <li>DOACs and warfarin are teratogenic - CONTRAINDICATED</li>
                                <li>Switch to UFH at 36 weeks (shorter half-life for delivery)</li>
                                <li>Resume anticoagulation 6-12 hours postpartum, continue √ó 6 weeks minimum postpartum</li>
                            </ul>
                        </li>
                        <li><strong>Obesity:</strong> Weight-based LMWH dosing, DOACs have limited data >120kg</li>
                        <li><strong>Elderly:</strong> Apixaban preferred (lowest bleeding risk)</li>
                        <li><strong>Renal Failure:</strong>
                            <ul>
                                <li>CrCl >30: Any anticoagulant</li>
                                <li>CrCl 15-30: Apixaban (dose-adjust), warfarin, or reduced-dose LMWH</li>
                                <li>CrCl <15 or dialysis: UFH or warfarin</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Duration of Anticoagulation:</span></p>
                    <ul>
                        <li><strong>Provoked DVT (surgery, immobilization, estrogen, pregnancy):</strong> 3 months</li>
                        <li><strong>Unprovoked DVT:</strong> 3-6 months, then reassess. Consider indefinite if:
                            <ul>
                                <li>Low bleeding risk</li>
                                <li>Proximal DVT or PE</li>
                                <li>Male sex (higher recurrence)</li>
                                <li>Elevated D-dimer 1 month after stopping anticoagulation</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent VTE:</strong> Lifelong anticoagulation</li>
                        <li><strong>Active cancer:</strong> 3-6 months minimum, often indefinite while cancer active</li>
                        <li><strong>Thrombophilia:</strong> Duration depends on specific deficiency and circumstances</li>
                    </ul>
                    
                    <p><span class="label">IVC Filter:</span></p>
                    <ul>
                        <li><strong>Indications:</strong>
                            <ul>
                                <li>Absolute contraindication to anticoagulation (active bleeding)</li>
                                <li>Recurrent VTE despite therapeutic anticoagulation</li>
                                <li>Complication of anticoagulation (major bleeding)</li>
                            </ul>
                        </li>
                        <li><strong>Retrievable filters preferred:</strong> Remove once anticoagulation safe (ideally within 3 months)</li>
                        <li><strong>NOT indicated for:</strong> Large DVT, free-floating thrombus, prophylaxis</li>
                        <li><strong>Complications:</strong> IVC thrombosis, filter migration, perforation</li>
                    </ul>
                    
                    <p><span class="label">Thrombolysis (Catheter-Directed or Systemic):</span></p>
                    <ul>
                        <li><strong>Consider for:</strong> Phlegmasia cerulea dolens (limb-threatening), massive iliofemoral DVT in young patients with low bleeding risk</li>
                        <li><strong>Goal:</strong> Reduce post-thrombotic syndrome risk</li>
                        <li><strong>Contraindications:</strong> Recent surgery, stroke, bleeding, pregnancy</li>
                        <li><strong>Not routine:</strong> Bleeding risk usually outweighs benefit</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Homan's sign is useless:</strong> Neither sensitive (10-50%) nor specific. Don't use it. Make diagnosis with Wells score + imaging</li>
                    <li><strong>D-dimer rules OUT, doesn't rule IN:</strong> Excellent negative predictive value (99%) in low-risk patients. But positive D-dimer doesn't confirm DVT - need imaging. Many false positives</li>
                    <li><strong>Proximal vs distal DVT treatment differs:</strong> Proximal DVT (popliteal+) = ALWAYS anticoagulate (high PE risk). Distal (calf only) = can monitor with serial ultrasounds if low risk</li>
                    <li><strong>DOACs are now first-line:</strong> Rivaroxaban and apixaban don't require LMWH bridge. Easier, equally effective, possibly safer than warfarin. Use unless contraindicated</li>
                    <li><strong>Cancer = LMWH preferred:</strong> LMWH superior to warfarin for cancer-associated VTE (50% lower recurrence). DOACs now reasonable alternative (CARAVAGGIO, ADAM-VTE trials)</li>
                    <li><strong>Don't wait for imaging if high suspicion:</strong> Start anticoagulation immediately while awaiting ultrasound. Risk of bleeding from 1 dose < risk of PE extension</li>
                    <li><strong>Unprovoked DVT often needs indefinite anticoagulation:</strong> 30% 5-year recurrence risk off anticoagulation. Reassess at 3-6 months. If continuing, use lower dose apixaban/rivaroxaban (reduces bleeding)</li>
                    <li><strong>IVC filter is NOT a substitute for anticoagulation:</strong> Filters DON'T treat DVT, just prevent PE. Still need anticoagulation once safe. Filters have complications (IVC thrombosis). Only use if bleeding contraindication</li>
                    <li><strong>Superficial thrombophlebitis can extend to deep system:</strong> If >5cm or near saphenofemoral junction, needs anticoagulation (or at least prophylactic dose √ó 45 days). Don't ignore it</li>
                    <li><strong>May-Thurner syndrome:</strong> Left leg DVT in young woman = think May-Thurner (left iliac vein compression by right iliac artery). May need endovascular stenting. Right leg DVT more common overall, but left leg in young = red flag</li>
                    <li><strong>Post-thrombotic syndrome is common:</strong> 20-50% of DVT patients develop chronic leg swelling, pain, skin changes. Prevented by immediate anticoagulation and compression stockings (30-40 mmHg √ó 2 years)</li>
                    <li><strong>Wells score -2 points for alternative diagnosis:</strong> Cellulitis, Baker's cyst, muscle strain can mimic DVT. If alternative equally likely, subtract 2 points from Wells score</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Phlegmasia cerulea dolens (limb-threatening DVT with arterial compromise)</li>
                        <li>Massive PE with hemodynamic instability</li>
                        <li>Major bleeding complication from anticoagulation</li>
                        <li>Need for thrombolysis (catheter-directed or systemic)</li>
                        <li>Acute limb ischemia requiring urgent intervention</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>DVT confirmed on ultrasound and anticoagulation initiated</li>
                        <li>Hemodynamically stable</li>
                        <li>No signs of PE (no dyspnea, normal O2 sat, no tachycardia)</li>
                        <li>Pain controlled with oral analgesics</li>
                        <li>Patient able to take oral anticoagulants (or self-inject LMWH)</li>
                        <li>No active bleeding or high bleeding risk</li>
                        <li>Patient educated on: anticoagulation adherence, bleeding precautions, leg elevation, compression stockings, return precautions (dyspnea = PE)</li>
                        <li>Appropriate anticoagulant prescribed with clear instructions</li>
                        <li>Follow-up arranged: PCP within 1 week, hematology if unprovoked/recurrent</li>
                        <li>Compression stockings fitted (30-40 mmHg knee-high)</li>
                        <li>If distal DVT being monitored: repeat ultrasound scheduled in 1 week</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Pulmonary embolism (most feared - occurs in 50% of untreated proximal DVT), phlegmasia cerulea dolens (complete venous occlusion with arterial compromise, limb-threatening), venous gangrene, acute limb ischemia</p>
                    <p><strong>Bleeding from Anticoagulation:</strong> Major bleeding (intracranial hemorrhage, GI bleed, retroperitoneal bleed, any bleeding requiring transfusion or hospitalization), minor bleeding (epistaxis, easy bruising, hematuria, menorrhagia), HIT (heparin-induced thrombocytopenia - paradoxical thrombosis, check platelets if on heparin >4 days)</p>
                    <p><strong>Post-Thrombotic Syndrome (20-50% of DVT patients):</strong> Chronic leg swelling, pain, heaviness, skin hyperpigmentation, venous stasis dermatitis, venous ulcers (severe cases). Develops months to years after DVT. Prevention: immediate anticoagulation + compression stockings 30-40 mmHg √ó 2 years</p>
                    <p><strong>Recurrent VTE:</strong> 5-10% per year off anticoagulation (unprovoked DVT), 30% cumulative 5-year risk. Higher risk if: unprovoked, proximal, male sex, obesity, residual thrombus. Provoked DVT: 1-3% per year recurrence</p>
                    <p><strong>From IVC Filter:</strong> IVC thrombosis (2-10%), filter migration, IVC perforation, failure to retrieve (50% of retrievable filters never removed), recurrent DVT below filter</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="stroke" class="condition-page">
            <div class="page-header">
                <h2>24. ACUTE ISCHEMIC STROKE</h2>
                <div class="subtitle">CVA ‚Ä¢ tPA ‚Ä¢ Mechanical Thrombectomy ‚Ä¢ Time Is Brain</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> SUDDEN onset focal neurologic deficit. Maximal deficit at onset (not progressive). FAST mnemonic: Face droop (ask to smile), Arm weakness (raise both arms), Speech difficulty (slurred/aphasia), Time = brain (1.9 million neurons die per minute untreated). "Last known well" time is critical for tPA eligibility</p>
                    
                    <p><span class="label">Presentations by Vascular Territory:</span></p>
                    <ul>
                        <li><strong>Middle Cerebral Artery (MCA - 50% of strokes):</strong> Contralateral hemiparesis/hemianesthesia (face and arm > leg), aphasia (if dominant/left hemisphere), neglect (if non-dominant/right hemisphere), gaze preference toward lesion, homonymous hemianopia</li>
                        <li><strong>Anterior Cerebral Artery (ACA):</strong> Contralateral leg weakness > arm, behavioral/personality changes, abulia, urinary incontinence, grasp reflex</li>
                        <li><strong>Posterior Cerebral Artery (PCA):</strong> Contralateral homonymous hemianopia, alexia without agraphia, visual agnosia, memory impairment (if bilateral thalamic involvement)</li>
                        <li><strong>Vertebrobasilar (Posterior Circulation):</strong> Dizziness, vertigo, diplopia, dysphagia, dysarthria, ataxia, crossed sensory/motor deficits (face one side, body opposite), bilateral symptoms, altered consciousness</li>
                        <li><strong>Lacunar (Small Vessel - 25%):</strong> Pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, dysarthria-clumsy hand syndrome. NO cortical signs (aphasia, neglect, visual field cuts)</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Wake-Up Stroke (25% of strokes):</strong> Patient wakes with deficits. Last known well = bedtime. Can still be tPA eligible if MRI shows DWI/FLAIR mismatch (DWI positive, FLAIR negative = likely <4.5 hours old)</li>
                        <li><strong>Large Vessel Occlusion (LVO):</strong> Severe deficits (NIHSS >6), gaze deviation, dense hemiplegia, global aphasia or severe neglect. These need mechanical thrombectomy urgently - activate stroke team immediately</li>
                        <li><strong>Posterior Circulation Stroke:</strong> Often misdiagnosed as "just dizziness" or vertigo. Red flags: sudden vertigo + HINTS exam abnormal (Head Impulse, Nystagmus, Test of Skew), inability to walk, severe headache</li>
                        <li><strong>Basilar Artery Occlusion:</strong> Decreased consciousness, quadriplegia, locked-in syndrome, respiratory failure. Devastating if untreated. Needs emergent thrombectomy even beyond 24 hours</li>
                        <li><strong>Stroke Mimics (20-30% of "stroke" activations):</strong> Hypoglycemia (<40 mg/dL - CHECK GLUCOSE FIRST), seizure with Todd's paralysis (post-ictal), complicated migraine with aura, conversion disorder, functional neurologic disorder, brain tumor, subdural hematoma</li>
                        <li><strong>Hemorrhagic Stroke:</strong> Progressive symptoms (not maximal at onset), severe headache, nausea/vomiting, decreased consciousness. Must rule out with CT before tPA</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate - STAT (Door-to-Needle Goal <60 Minutes):</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST TEST - rules out hemorrhage (absolute tPA contraindication). Only 60% sensitive for acute ischemia in first 6 hours. Look for: hyperdense MCA sign (visible clot), loss of gray-white differentiation, sulcal effacement, insular ribbon sign. If negative CT but high suspicion ‚Üí still likely ischemic stroke</li>
                        <li><strong>NIHSS Score (National Institutes of Health Stroke Scale):</strong> 0=normal, 1-4=minor, 5-15=moderate, 16-20=moderate-severe, >20=severe. Score >6 suggests large vessel occlusion - get CTA immediately. Repeat NIHSS to track improvement/worsening</li>
                        <li><strong>Fingerstick Glucose:</strong> MANDATORY FIRST - hypoglycemia (<60) mimics stroke perfectly and is immediately reversible. Never give tPA to hypoglycemia. If <60 ‚Üí give D50, reassess</li>
                        <li><strong>CT Angiography (CTA) Head/Neck:</strong> If NIHSS >6 or clinical suspicion for LVO. Identifies: ICA occlusion, M1/M2 MCA occlusion, basilar occlusion. Guides thrombectomy decision. Don't delay tPA waiting for CTA - can do simultaneously</li>
                    </ul>
                    
                    <p><span class="label">Labs (Send Immediately but Don't Delay tPA):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Platelets must be >100k for tPA. Severe anemia can cause neurologic deficits</li>
                        <li><strong>BMP:</strong> Severe hyperglycemia (>400) or renal failure impacts outcomes</li>
                        <li><strong>PT/INR, aPTT:</strong> INR must be <1.7 for tPA. Therapeutic heparin (aPTT >40) contraindication</li>
                        <li><strong>Troponin:</strong> 10-15% have MI with stroke. Check for concurrent ACS</li>
                        <li><strong>Hemoglobin A1c:</strong> Assess chronic glucose control</li>
                        <li><strong>Lipid panel:</strong> For secondary prevention</li>
                    </ul>
                    
                    <p><span class="label">Advanced Imaging:</span></p>
                    <ul>
                        <li><strong>MRI Brain with DWI:</strong> Gold standard for acute ischemia (>95% sensitive within hours). DWI bright = acute infarct. ADC dark = restricted diffusion (acute). Use for: unclear timing (wake-up stroke), TIA vs stroke, posterior circulation (CT misses 20% of posterior strokes), suspected mimics</li>
                        <li><strong>MR/CT Perfusion:</strong> Identifies salvageable penumbra (ischemic but not dead). Mismatch between perfusion deficit and infarct core = tissue to save. Extends thrombectomy window to 24 hours if large penumbra present</li>
                        <li><strong>Carotid Doppler or CTA Neck:</strong> Identify carotid stenosis. >70% symptomatic stenosis = CEA/stenting candidate (must be done within 2 weeks)</li>
                        <li><strong>Echocardiogram:</strong> TTE for LV thrombus, EF, wall motion abnormalities. TEE if suspicion for: endocarditis, atrial thrombus, PFO with significant shunt, aortic arch atheroma</li>
                    </ul>
                    
                    <p><span class="label">Stroke Etiology Workup (TOAST Classification):</span></p>
                    <ul>
                        <li><strong>Large Artery Atherosclerosis:</strong> Carotid stenosis >50%, intracranial stenosis</li>
                        <li><strong>Cardioembolism:</strong> Atrial fibrillation (most common), mechanical valve, recent MI with LV thrombus, dilated cardiomyopathy (EF <30%), endocarditis, atrial myxoma</li>
                        <li><strong>Small Vessel/Lacunar:</strong> Hypertension, diabetes. Small infarcts (<1.5cm) in basal ganglia, thalamus, pons</li>
                        <li><strong>Other Determined Cause:</strong> Dissection (carotid/vertebral), vasculitis, hypercoagulable state, drug-related (cocaine, amphetamines)</li>
                        <li><strong>Cryptogenic (30%):</strong> No clear cause. Consider: occult atrial fibrillation (30-day monitor), patent foramen ovale (PFO), atrial cardiopathy, cancer-associated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup:</span></p>
                    <ul>
                        <li><strong>Telemetry √ó 48 hours minimum:</strong> Detect paroxysmal atrial fibrillation (20% of cryptogenic strokes)</li>
                        <li><strong>Extended cardiac monitoring:</strong> If no cause found, 30-day event monitor or implantable loop recorder</li>
                        <li><strong>Hypercoagulable workup:</strong> Only if young (<50), recurrent, family history, or unusual site. Test AFTER acute phase: Factor V Leiden, prothrombin mutation, protein C/S, antithrombin, lupus anticoagulant, anticardiolipin antibodies</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Time Is Brain - Every Second Counts:</span></p>
                    <ul>
                        <li>Door-to-imaging goal: <25 minutes</li>
                        <li>Door-to-needle (tPA) goal: <60 minutes</li>
                        <li>Door-to-groin (thrombectomy) goal: <90 minutes</li>
                    </ul>
                    
                    <p><span class="label">Intravenous tPA (Alteplase) - "Clot Buster":</span></p>
                    <ul>
                        <li><strong>Eligibility Window:</strong> <4.5 hours from symptom onset (or last known well time)</li>
                        <li><strong>Dose:</strong> 0.9 mg/kg IV (maximum 90mg total)
                            <ul>
                                <li>Give 10% as bolus over 1 minute</li>
                                <li>Remaining 90% as infusion over 60 minutes</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 6 to prevent dependency at 3 months. Benefits persist even with symptomatic ICH risk</li>
                        <li><strong>Absolute Contraindications:</strong>
                            <ul>
                                <li>Intracranial hemorrhage on CT (any amount)</li>
                                <li>Ischemic stroke within 3 months</li>
                                <li>Intracranial/spinal surgery within 3 months</li>
                                <li>Head trauma within 3 months</li>
                                <li>History of intracranial hemorrhage ever</li>
                                <li>GI or GU hemorrhage within 21 days</li>
                                <li>Arterial puncture at non-compressible site within 7 days</li>
                                <li>SBP >185 or DBP >110 despite aggressive treatment</li>
                                <li>Active internal bleeding or acute trauma/fracture</li>
                                <li>INR >1.7, aPTT >40 seconds, platelets <100,000</li>
                                <li>Glucose <50 mg/dL (treat and reassess)</li>
                            </ul>
                        </li>
                        <li><strong>Relative Contraindications:</strong> Seizure at stroke onset, glucose >400, large infarct on CT (>1/3 MCA territory), minor/rapidly improving symptoms (though recent data supports treating these), pregnancy (relative - can give if severe stroke)</li>
                    </ul>
                    
                    <p><span class="label">Blood Pressure Management (CRITICAL - Most Common Error):</span></p>
                    <ul>
                        <li><strong>If Giving tPA - Must Lower BP:</strong>
                            <ul>
                                <li>Goal: <185/110 mmHg BEFORE starting tPA</li>
                                <li>Labetalol 10-20mg IV push q10-20min (up to 300mg total) OR</li>
                                <li>Nicardipine drip: Start 5mg/hr, titrate by 2.5mg/hr q5-15min to goal (max 15mg/hr)</li>
                                <li>AFTER tPA: Keep BP <180/105 √ó 24 hours (prevent hemorrhagic transformation)</li>
                            </ul>
                        </li>
                        <li><strong>If NOT Giving tPA - Permissive Hypertension:</strong>
                            <ul>
                                <li>ALLOW SBP up to 220 mmHg (brain needs perfusion pressure)</li>
                                <li>Only treat if: SBP >220 OR DBP >120 OR signs of end-organ damage (ACS, aortic dissection, acute pulmonary edema)</li>
                                <li>Goal: Lower by 15% over first 24 hours (NOT to normal)</li>
                                <li>Don't reflexively normalize BP - can extend infarct</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Mechanical Thrombectomy - "Most Effective Stroke Treatment":</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Large vessel occlusion (ICA, M1/M2 MCA, basilar artery) + salvageable tissue</li>
                        <li><strong>Time Window:</strong>
                            <ul>
                                <li>Up to 6 hours: All LVO eligible</li>
                                <li>6-16 hours: If good collaterals on CTA or small infarct core</li>
                                <li>16-24 hours: If perfusion imaging shows large penumbra (mismatch)</li>
                                <li>Basilar occlusion: Consider even beyond 24 hours (devastating if untreated)</li>
                            </ul>
                        </li>
                        <li><strong>Benefit:</strong> NNT = 3 for functional independence (best intervention in all of medicine)</li>
                        <li><strong>Transfer immediately if LVO identified</strong> at non-thrombectomy-capable center</li>
                        <li><strong>Can give tPA AND thrombectomy</strong> - not mutually exclusive</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>NPO until swallow screen passed:</strong> 30-50% have dysphagia. Aspiration pneumonia is leading complication</li>
                        <li><strong>Oxygen:</strong> Only if SpO2 <94% (hyperoxia may worsen outcomes)</li>
                        <li><strong>Normothermia:</strong> Fever worsens outcomes. Treat aggressively (acetaminophen, cooling)</li>
                        <li><strong>Euglycemia:</strong> Avoid hypoglycemia (<70) and severe hyperglycemia (>180). Both worsen outcomes</li>
                        <li><strong>Head of bed:</strong> 30 degrees (improves venous drainage, reduces aspiration)</li>
                        <li><strong>DVT prophylaxis:</strong> Pneumatic compression boots immediately. If no tPA given ‚Üí heparin 5000 units SQ TID. If tPA given ‚Üí wait 24 hours before starting heparin</li>
                    </ul>
                    
                    <p><span class="label">Antiplatelet Therapy:</span></p>
                    <ul>
                        <li><strong>If tPA Given:</strong> Hold aspirin √ó 24 hours (hemorrhage risk), then ASA 162-325mg daily</li>
                        <li><strong>If NO tPA Given:</strong> Aspirin 325mg immediately (or within 48 hours)</li>
                        <li><strong>Minor Stroke (NIHSS ‚â§3) within 24 hours:</strong> Dual Antiplatelet Therapy (DAPT)
                            <ul>
                                <li>ASA 162-325mg load + Clopidogrel 600mg load on day 1</li>
                                <li>Then ASA 81mg + Clopidogrel 75mg daily √ó 21 days</li>
                                <li>Then ASA 81mg alone lifelong</li>
                                <li>Reduces 90-day stroke recurrence by 30% (CHANCE, POINT trials)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (For Atrial Fibrillation):</span></p>
                    <ul>
                        <li><strong>Timing is critical - too early = hemorrhagic transformation:</strong>
                            <ul>
                                <li>Small stroke (NIHSS <8): Start at 3-4 days</li>
                                <li>Moderate stroke (NIHSS 8-15): Start at 6-8 days</li>
                                <li>Large stroke (NIHSS >15): Start at 12-14 days</li>
                            </ul>
                        </li>
                        <li><strong>DOACs preferred over warfarin:</strong> Apixaban 5mg BID, rivaroxaban 20mg daily, edoxaban 60mg daily, dabigatran 150mg BID</li>
                        <li><strong>Reduce dose if:</strong> Age >80, weight <60kg, Cr >1.5 (apixaban 2.5mg BID)</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prevention:</span></p>
                    <ul>
                        <li><strong>High-Intensity Statin:</strong> Atorvastatin 80mg daily regardless of LDL (plaque stabilization, anti-inflammatory). Start immediately</li>
                        <li><strong>Blood Pressure Control:</strong> Goal <140/90 (<130/80 if diabetic). Start after acute phase (don't lower acutely unless >220)</li>
                        <li><strong>Carotid Stenosis >70% Symptomatic:</strong> CEA or carotid stenting within 2 weeks (stroke risk 20% at 2 weeks without intervention)</li>
                        <li><strong>PFO Closure:</strong> Consider if cryptogenic stroke, age <60, large shunt, atrial septal aneurysm. Reduces recurrent stroke by 50%</li>
                        <li><strong>Lifestyle:</strong> Smoking cessation (doubles stroke risk), exercise, Mediterranean diet, weight loss</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Time is brain - 1.9 million neurons per minute:</strong> Every 15 minutes of delay in tPA = 1 month of disability. Door-to-needle <60 min, door-to-groin <90 min are achievable goals</li>
                    <li><strong>CHECK GLUCOSE FIRST:</strong> Hypoglycemia is the great stroke mimic and it's 100% reversible with D50. Never give tPA to a glucose of 45</li>
                    <li><strong>Permissive hypertension unless giving tPA:</strong> Brain needs perfusion in acute stroke. Allow SBP <220. Only lower if giving tPA (then <185) or signs of end-organ damage. Don't reflexively normalize BP</li>
                    <li><strong>tPA works - don't be afraid to use it:</strong> NNT=6 for preventing disability. Yes, 6% symptomatic ICH risk, but functional outcomes still better. Benefits extend to 4.5 hours</li>
                    <li><strong>Thrombectomy revolutionized stroke care:</strong> NNT=3 for independence. Extends to 24 hours with perfusion imaging. Transfer immediately if LVO - don't let them sit</li>
                    <li><strong>NIHSS >6 = think large vessel occlusion:</strong> Get CTA and activate interventional team immediately. These need thrombectomy within 6 hours (ideally)</li>
                    <li><strong>Wake-up strokes can still get tPA:</strong> If MRI shows DWI/FLAIR mismatch (DWI+, FLAIR-), likely <4.5hr old and eligible (WAKE-UP trial)</li>
                    <li><strong>Dual antiplatelets for minor stroke:</strong> ASA + clopidogrel √ó 21 days if NIHSS ‚â§3 and within 24 hours. 30% reduction in recurrence (CHANCE, POINT). Don't use for moderate-severe stroke</li>
                    <li><strong>Delay anticoagulation in Afib stroke:</strong> Wait 3-14 days (size-dependent) before starting DOAC. Too early = hemorrhagic transformation. Use 1-2-2 week rule (small-medium-large)</li>
                    <li><strong>Posterior strokes are sneaky:</strong> "Just dizziness" can be fatal basilar occlusion. HINTS exam: Head Impulse Normal = central (stroke). Vertical/direction-changing Nystagmus = central. Test of Skew = central</li>
                    <li><strong>Carotid stenosis >70% needs urgent intervention:</strong> CEA or stent within 2 weeks. Stroke risk is 20% in first 2 weeks without treatment. Don't delay</li>
                    <li><strong>Blood pressure control is for AFTER acute phase:</strong> Lower gradually over days-weeks. Acutely, permissive hypertension preserves penumbra. Target <140/90 long-term</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Large stroke (NIHSS >15) with decreased consciousness</li>
                        <li>Basilar artery occlusion (high mortality, needs close monitoring)</li>
                        <li>Hemorrhagic transformation with mass effect</li>
                        <li>Malignant MCA syndrome (cerebral edema, herniation risk - peaks day 3-5)</li>
                        <li>Received tPA (monitor √ó 24hr for ICH, strict BP control <180/105)</li>
                        <li>Post-thrombectomy (monitor for reperfusion injury, hemorrhage)</li>
                        <li>Unstable blood pressure requiring IV drips</li>
                        <li>Respiratory failure or airway compromise</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neurologically stable or improving √ó 24-48 hours</li>
                        <li>Swallow screen passed - safe for PO (or feeding tube placed)</li>
                        <li>Aspiration precautions in place if dysphagia present</li>
                        <li>PT/OT completed - mobility/ADL assessment done</li>
                        <li>Secondary prevention initiated (antiplatelet or anticoagulation, statin)</li>
                        <li>Blood pressure controlled and on appropriate regimen</li>
                        <li>If tPA given: >24 hours post-tPA, no hemorrhagic transformation on repeat CT</li>
                        <li>If carotid stenosis >70%: CEA/stent scheduled within 2 weeks</li>
                        <li>Outpatient rehabilitation arranged (acute rehab facility, subacute, home PT)</li>
                        <li>Neurology follow-up within 1-2 weeks</li>
                        <li>Patient/family educated on: stroke warning signs (FAST), when to call 911, medication adherence, risk factor modification</li>
                        <li>DME provided: walker, wheelchair, hospital bed if needed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Early (Hours-Days):</strong> Hemorrhagic transformation (6% with tPA, 2% without - peaks at 24-36hr), cerebral edema with herniation (peaks day 3-5, especially large MCA strokes - malignant edema 10% mortality), seizures (5-10%, higher with cortical involvement), aspiration pneumonia (30-50% have dysphagia), DVT/PE (immobility), recurrent stroke (highest risk first 48hr - 5% risk at 2 weeks)</p>
                    <p><strong>Post-tPA Specific:</strong> Symptomatic intracranial hemorrhage (6% - half are fatal), angioedema (1-5%, especially if on ACE-I - can compromise airway), systemic bleeding (epistaxis, hematuria, GI bleed), reperfusion injury</p>
                    <p><strong>Late (Weeks-Months):</strong> Recurrent stroke (10% first year, 30% at 5 years without secondary prevention), disability and dependence (30-40% need assistance with ADLs), depression (30-50% develop post-stroke depression), vascular dementia (doubles risk), falls and hip fractures (hemiparesis, neglect), chronic pain syndromes, spasticity requiring botulinum toxin</p>
                    <p><strong>Specific Syndromes:</strong> Central post-stroke pain (thalamic pain syndrome - burning dysesthesia, 10% of strokes), shoulder subluxation (hemiplegic shoulder, 25%), complex regional pain syndrome, dysphagia persisting >6 months (10%), aphasia (permanent in 20-40% of left hemisphere strokes)</p>
                    <p><strong>Malignant MCA Syndrome:</strong> Large MCA infarct with massive edema, herniation, coma. Peaks day 3-5. Mortality 80% without decompressive hemicraniectomy, 30% with surgery. Consider surgery if age <60, within 48hr of symptom onset</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="seizure" class="condition-page">
            <div class="page-header">
                <h2>25. SEIZURE / STATUS EPILEPTICUS</h2>
                <div class="subtitle">Convulsive ‚Ä¢ Non-Convulsive ‚Ä¢ Neurologic Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Status Epilepticus Definition:</span> Seizure lasting >5 minutes OR recurrent seizures without return to baseline consciousness between episodes. TRUE MEDICAL EMERGENCY - mortality 10-20% if untreated</p>
                    
                    <p><span class="label">Types of Seizures:</span></p>
                    <ul>
                        <li><strong>Generalized Tonic-Clonic (Grand Mal):</strong> Loss of consciousness, tonic phase (muscle rigidity 10-30 sec), clonic phase (rhythmic jerking 30-60 sec), postictal confusion/somnolence (minutes to hours). May have tongue biting (lateral tongue = specific), incontinence, foaming at mouth</li>
                        <li><strong>Focal (Partial) Seizures:</strong> Originates one brain region. Can be motor (Jacksonian march up extremity), sensory, or with impaired awareness (staring, automatisms like lip-smacking). May secondarily generalize</li>
                        <li><strong>Absence:</strong> Brief staring spells 5-10 seconds. Child stops mid-activity, stares, resumes. No postictal confusion. Pediatric primarily (petit mal)</li>
                        <li><strong>Myoclonic:</strong> Brief muscle jerks. Can be benign (everyone has on falling asleep) or pathologic (juvenile myoclonic epilepsy)</li>
                        <li><strong>Atonic (Drop Attacks):</strong> Sudden loss of muscle tone, falls. Lennox-Gastaut syndrome</li>
                    </ul>
                    
                    <p><span class="label">Non-Convulsive Status Epilepticus (NCSE):</span></p>
                    <ul>
                        <li>Altered mental status WITHOUT obvious motor activity</li>
                        <li>10-20% of ICU patients with unexplained AMS have NCSE on EEG</li>
                        <li>Subtle findings: eye deviation, nystagmus, facial twitching, automatisms</li>
                        <li><strong>Diagnosis requires EEG</strong> - have high suspicion in ICU patients with AMS</li>
                    </ul>
                    
                    <p><span class="label">Seizure vs Syncope - Key Differences:</span></p>
                    <ul>
                        <li><strong>Seizure:</strong> Tonic-clonic >15 seconds, lateral tongue biting (specific), incontinence common, prolonged postictal confusion (30 min - hours)</li>
                        <li><strong>Syncope:</strong> Brief myoclonic jerks <15 seconds, no tongue biting (or central only), incontinence rare, rapid recovery (<1 min), no postictal confusion</li>
                    </ul>
                    
                    <p><span class="label">Etiology - "VITAMINS" Mnemonic:</span></p>
                    <ul>
                        <li><strong>V</strong>ascular: Ischemic stroke, hemorrhage, venous sinus thrombosis</li>
                        <li><strong>I</strong>nfection: Meningitis, encephalitis, brain abscess, neurocysticercosis</li>
                        <li><strong>T</strong>rauma: Prior TBI, subdural hematoma, DAI</li>
                        <li><strong>A</strong>utoimmune: SLE cerebritis, anti-NMDA receptor encephalitis, Hashimoto's encephalopathy</li>
                        <li><strong>M</strong>etabolic: Hypoglycemia <40 (most common reversible cause), hyponatremia <120, hypocalcemia, hypomagnesemia, uremia, hepatic encephalopathy</li>
                        <li><strong>I</strong>atrogenic/Intoxication: Tramadol, bupropion, fluoroquinolones, imipenem, isoniazid. Cocaine, amphetamines. WITHDRAWAL: alcohol, benzodiazepines, baclofen</li>
                        <li><strong>N</strong>eoplasm: Primary brain tumor, metastases (lung, breast, melanoma, renal)</li>
                        <li><strong>S</strong>tructural: Remote stroke, prior TBI, congenital malformation, mesial temporal sclerosis</li>
                    </ul>
                    
                    <p><span class="label">First Seizure Workup Approach:</span></p>
                    <ul>
                        <li><strong>Provoked Seizure:</strong> Clear reversible cause (metabolic, infection, drug). Treat cause, may not need chronic AED. Recurrence risk low if cause corrected</li>
                        <li><strong>Unprovoked Seizure:</strong> No identifiable acute cause. 40-50% recurrence risk. Consider starting AED after first unprovoked seizure, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, focal seizure</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate Bedside:</span></p>
                    <ul>
                        <li><strong>Fingerstick Glucose:</strong> FIRST TEST - hypoglycemia (<40) causes seizures and is immediately reversible with D50. Never miss this</li>
                        <li><strong>Accucheck if on floor:</strong> While waiting for labs</li>
                    </ul>
                    
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Sodium (<120 causes seizures), calcium, magnesium, glucose, BUN/Cr (uremia)</li>
                        <li><strong>CBC:</strong> Infection, anemia</li>
                        <li><strong>LFTs:</strong> Hepatic encephalopathy</li>
                        <li><strong>Toxicology Screen:</strong> Cocaine, amphetamines, PCP</li>
                        <li><strong>Alcohol Level:</strong> If suspect withdrawal</li>
                        <li><strong>Anti-Epileptic Drug (AED) Levels:</strong> If known epileptic (phenytoin, valproate, carbamazepine). Levetiracetam levels not clinically useful</li>
                        <li><strong>Serum Prolactin:</strong> Peaks 10-20 min after seizure, normal by 60 min. >3√ó baseline supports seizure (but normal doesn't rule out). Not routinely needed</li>
                        <li><strong>CK:</strong> Rhabdomyolysis common after prolonged seizure (CK >1000 in 50%)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Non-Contrast CT Head:</strong> FIRST imaging - rules out bleed, mass, stroke. Get immediately if: first seizure, trauma, focal deficits, immunocompromised, persistent AMS</li>
                        <li><strong>MRI Brain:</strong> More sensitive for: hippocampal sclerosis, cortical dysplasia, small tumors, encephalitis, posterior reversible encephalopathy syndrome (PRES). Get within 24-48hr for first seizure</li>
                    </ul>
                    
                    <p><span class="label">Lumbar Puncture:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Fever, immunocompromised, concern for meningitis/encephalitis, first seizure with no clear cause</li>
                        <li><strong>Get CT first if:</strong> Focal deficits, papilledema, immunocompromised (to rule out mass/herniation risk)</li>
                        <li><strong>Send:</strong> Cell count, glucose, protein, Gram stain, culture, HSV PCR, consider autoimmune encephalitis panel</li>
                    </ul>
                    
                    <p><span class="label">EEG (Electroencephalogram):</span></p>
                    <ul>
                        <li><strong>Routine EEG (30 min):</strong> All first-time seizure patients. Identifies: epileptiform discharges (spikes, sharp waves), focal slowing (structural lesion), generalized slowing (encephalopathy). Yield increases if done within 24-48 hours</li>
                        <li><strong>Continuous EEG Monitoring:</strong>
                            <ul>
                                <li>Status epilepticus (confirms cessation after treatment)</li>
                                <li>Unexplained AMS in ICU (r/o non-convulsive status)</li>
                                <li>Burst suppression monitoring (if on pentobarbital/propofol for refractory status)</li>
                            </ul>
                        </li>
                        <li><strong>Limitations:</strong> Single EEG only captures epileptiform activity in 50% of epileptics. Repeat EEG or prolonged monitoring increases yield to 80-90%</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Active Seizure Management (Non-Status):</span></p>
                    <ul>
                        <li>Position on SIDE (prevent aspiration)</li>
                        <li>Protect from injury (pad head, move objects away)</li>
                        <li>Do NOT restrain</li>
                        <li>Do NOT place anything in mouth (can break teeth, cause aspiration)</li>
                        <li>Supplemental O2 via NC or face mask</li>
                        <li>Establish IV access</li>
                        <li>Most seizures self-terminate in 1-3 minutes</li>
                        <li><strong>If seizure >5 minutes ‚Üí STATUS EPILEPTICUS ‚Üí Start treatment algorithm</strong></li>
                    </ul>
                    
                    <p><span class="label">STATUS EPILEPTICUS TREATMENT ALGORITHM (Time-Sensitive!):</span></p>
                    
                    <p><strong>STAGE 1 (0-5 minutes): First-Line Benzodiazepines</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> 4mg IV over 2 minutes. Repeat once if continued seizure after 5 min (max 8mg)
                            <ul>
                                <li>Preferred over diazepam (longer duration of action)</li>
                                <li>Success rate: 60-80%</li>
                            </ul>
                        </li>
                        <li><strong>OR Midazolam (Versed):</strong> 10mg IM (if no IV access - absorbed well IM)
                            <ul>
                                <li>Alternative: 0.2mg/kg IV (typical 10-15mg)</li>
                                <li>Faster onset than lorazepam</li>
                                <li>IM route as effective as IV lorazepam in prehospital setting</li>
                            </ul>
                        </li>
                        <li><strong>OR Diazepam (Valium):</strong> 10mg IV or 20mg PR (rectal gel - useful prehospital/nursing home)
                            <ul>
                                <li>Rapid onset but shorter duration than lorazepam</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 2 (5-20 minutes): Second-Line Anti-Epileptic Drugs (If Benzos Fail)</strong></p>
                    <p>Choose ONE of the following:</p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 60 mg/kg IV over 10 min (max 4500mg, typical dose 3000-4500mg)
                            <ul>
                                <li>Advantages: No drug interactions, safe profile, no cardiac monitoring needed, preferred by many</li>
                                <li>Disadvantages: May be slightly less effective than fosphenytoin (debated)</li>
                                <li>Side effects: Minimal. Rare psychiatric symptoms</li>
                            </ul>
                        </li>
                        <li><strong>Fosphenytoin:</strong> 20 PE/kg IV at max rate 150 PE/min (typical 1500-2000 PE, takes 10-15 min)
                            <ul>
                                <li>Advantages: Long track record, effective</li>
                                <li>Disadvantages: Cardiac monitoring required (bradycardia, hypotension, arrhythmias), purple glove syndrome, drug interactions (induces CYP450), can't use in heart block</li>
                                <li>Slower infusion if elderly or cardiac disease</li>
                                <li>Check ECG before and during infusion</li>
                            </ul>
                        </li>
                        <li><strong>Valproate (Depacon):</strong> 40 mg/kg IV over 10 min (max 3000mg)
                            <ul>
                                <li>Advantages: Well-tolerated, no cardiac effects</li>
                                <li>Disadvantages: Contraindicated in pregnancy (teratogenic), liver disease, pancreatitis history. Hyperammonemia, thrombocytopenia</li>
                            </ul>
                        </li>
                        <li><strong>Phenobarbital:</strong> 15 mg/kg IV at 50-100 mg/min
                            <ul>
                                <li>Advantages: Effective, cheap</li>
                                <li>Disadvantages: Sedation, respiratory depression (have airway equipment ready), long half-life</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>STAGE 3 (20-40 minutes): Refractory Status Epilepticus</strong></p>
                    <ul>
                        <li>If seizure continues despite 2 first-line agents ‚Üí REFRACTORY status</li>
                        <li><strong>Intubate for airway protection</strong> (will need continuous sedation)</li>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>Continuous EEG monitoring</strong></li>
                        <li><strong>Choose continuous infusion:</strong>
                            <ul>
                                <li><strong>Midazolam:</strong> 0.2 mg/kg bolus, then 0.05-2 mg/kg/hr infusion
                                    <ul>
                                        <li>First-line for refractory status (preferred by most)</li>
                                        <li>Titrate to seizure cessation on EEG or burst suppression</li>
                                    </ul>
                                </li>
                                <li><strong>Propofol:</strong> 1-2 mg/kg bolus, then 20-200 mcg/kg/min (2-10 mg/kg/hr)
                                    <ul>
                                        <li>Rapid on/off</li>
                                        <li>Watch for propofol infusion syndrome (rhabdo, metabolic acidosis, cardiac arrest) if >48hr or high doses</li>
                                        <li>Check CK, lactate, triglycerides daily</li>
                                    </ul>
                                </li>
                                <li><strong>Pentobarbital:</strong> 5-15 mg/kg load over 1hr, then 0.5-10 mg/kg/hr
                                    <ul>
                                        <li>Most effective but most side effects</li>
                                        <li>Severe hypotension (need pressors), ileus</li>
                                        <li>Reserved for super-refractory status</li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li><strong>Goal:</strong> Seizure suppression on EEG. Some aim for burst suppression (flat periods between bursts)</li>
                        <li><strong>Duration:</strong> 24-48 hours, then attempt to wean. If seizures recur ‚Üí another 24 hours</li>
                    </ul>
                    
                    <p><span class="label">Starting Maintenance Anti-Epileptic Drug (After First Unprovoked Seizure):</span></p>
                    <ul>
                        <li><strong>Levetiracetam (Keppra):</strong> 500mg BID, increase to 1000-1500mg BID
                            <ul>
                                <li>FIRST-LINE for most patients</li>
                                <li>No drug interactions, no monitoring needed</li>
                                <li>Side effects: Irritability, depression (10-15%)</li>
                            </ul>
                        </li>
                        <li><strong>Lamotrigine (Lamictal):</strong> Start 25mg daily, slow titration
                            <ul>
                                <li>Must titrate SLOWLY (increase by 25mg every 2 weeks)</li>
                                <li>Fast titration ‚Üí Stevens-Johnson syndrome risk</li>
                                <li>Good for generalized epilepsy, well-tolerated</li>
                                <li>Final dose: 200-400mg daily (divided BID)</li>
                            </ul>
                        </li>
                        <li><strong>Lacosamide (Vimpat):</strong> 50mg BID, increase to 200-400mg daily
                            <ul>
                                <li>Good for focal seizures</li>
                                <li>Side effects: Dizziness, ataxia, PR interval prolongation (check ECG)</li>
                            </ul>
                        </li>
                        <li><strong>Older Options (More Side Effects/Interactions):</strong>
                            <ul>
                                <li>Phenytoin: Gingival hyperplasia, hirsutism, CYP450 inducer, narrow therapeutic window</li>
                                <li>Carbamazepine: Hyponatremia (SIADH), aplastic anemia (rare), CYP450 inducer</li>
                                <li>Valproate: Weight gain, hair loss, tremor, hepatotoxicity, teratogenic</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Special Considerations:</span></p>
                    <ul>
                        <li><strong>Provoked Seizures (Reversible Cause):</strong>
                            <ul>
                                <li>Alcohol withdrawal: Benzos (lorazepam, diazepam), thiamine</li>
                                <li>Hyponatremia: Correct slowly (risk of osmotic demyelination). If <120 with seizure, can give 100mL 3% saline bolus</li>
                                <li>Hypoglycemia: D50 50mL IV push</li>
                                <li>Hypocalcemia: Calcium gluconate 1-2g IV</li>
                                <li>Isoniazid overdose: Pyridoxine (vitamin B6) gram-for-gram match to INH dose</li>
                            </ul>
                        </li>
                        <li><strong>Pregnancy (Eclampsia):</strong> Magnesium sulfate 4-6g IV load, then 1-2g/hr. If seizures continue ‚Üí lorazepam</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Status epilepticus = >5 minutes, not 30:</strong> Old definition was 30 min. Now ANY seizure >5 min = status. Start treatment aggressively - every minute increases risk of refractory status and permanent neuronal injury</li>
                    <li><strong>Benzos first, AED second:</strong> Don't skip benzos and go straight to fosphenytoin. Benzos stop 60-80% of seizures. Give lorazepam 4mg IV immediately</li>
                    <li><strong>Midazolam IM if no IV access:</strong> 10mg IM works as well as IV lorazepam. Don't delay trying to get IV - give IM midazolam immediately</li>
                    <li><strong>Non-convulsive status is common in ICU:</strong> 10-20% of unexplained AMS in ICU is NCSE on EEG. Have low threshold for continuous EEG monitoring</li>
                    <li><strong>Levetiracetam is now first-line AED:</strong> Safer, fewer interactions than phenytoin. Equally effective for status epilepticus (ESETT trial). Start with keppra for most patients</li>
                    <li><strong>Provoked seizures may not need chronic AED:</strong> If clear reversible cause (alcohol withdrawal, severe hyponatremia <120, hypoglycemia <40), treat the cause. May not need lifelong AED</li>
                    <li><strong>Check glucose ALWAYS:</strong> Hypoglycemia causes seizures and is immediately reversible with D50. Never miss this - it's the most treatable cause</li>
                    <li><strong>Lateral tongue bite is specific for seizure:</strong> Central tongue bite can happen with any loss of consciousness (syncope, head trauma). LATERAL tongue bite is specific for tonic-clonic seizure</li>
                    <li><strong>Propofol infusion syndrome is real:</strong> Rhabdomyolysis, metabolic acidosis, cardiac arrest. Risk with >48hr use or high doses (>80 mcg/kg/min). Check CK, lactate, triglycerides daily</li>
                    <li><strong>Don't start multiple AEDs simultaneously:</strong> Use monotherapy first. Only add second AED if inadequate seizure control on max tolerated dose of first. Polypharmacy increases side effects and interactions</li>
                    <li><strong>First unprovoked seizure has 40-50% recurrence risk:</strong> Consider starting AED, especially if: abnormal MRI, abnormal EEG, nocturnal seizure, patient has high-risk occupation (pilot, driver)</li>
                    <li><strong>Todd's paralysis mimics stroke:</strong> Post-ictal focal weakness lasting 24-48 hours. MRI/CT normal. Resolves completely. Don't give tPA for this</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Status epilepticus (seizure >5 min or recurrent without baseline recovery)</li>
                        <li>Refractory status requiring continuous infusion (midazolam, propofol, pentobarbital)</li>
                        <li>Intubated for airway protection</li>
                        <li>Multiple seizures without return to baseline</li>
                        <li>Non-convulsive status on EEG requiring continuous monitoring</li>
                        <li>Hypoxia or respiratory compromise from seizure</li>
                        <li>Hemodynamic instability</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>No seizures √ó 24-48 hours</li>
                        <li>Back to neurologic baseline (or new baseline established if stroke/bleed)</li>
                        <li>Anti-epileptic drug started (if unprovoked seizure or epilepsy)</li>
                        <li>AED levels checked if applicable (phenytoin, valproate, carbamazepine)</li>
                        <li>Provoking factors addressed/corrected (alcohol withdrawal treated, electrolytes normalized)</li>
                        <li>Safe to drive per state law (typically 3-12 months seizure-free required - varies by state)</li>
                        <li>Fall precautions at home if recurrent seizure risk</li>
                        <li>Neurology follow-up arranged within 1-2 weeks</li>
                        <li>Patient educated on: taking AED daily (don't miss doses), avoiding seizure triggers (sleep deprivation, alcohol), seizure precautions (no swimming alone, no heights, caution with driving), when to call 911 (seizure >5 min)</li>
                        <li>MRI completed or scheduled (if first seizure)</li>
                        <li>EEG completed or scheduled</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Seizure Activity:</strong> Aspiration pneumonia (30-50% if prolonged seizure or decreased consciousness), rhabdomyolysis (CK >1000 in 50% of status epilepticus, can cause AKI), acute kidney injury (from rhabdomyolysis, hypotension), lactic acidosis (from muscle activity), hyperthermia (from muscle activity, increases neuronal injury), posterior shoulder dislocation (tonic phase - anterior more common in most trauma but posterior in seizures), vertebral compression fractures (from violent muscle contractions), oral trauma (tongue biting, broken teeth)</p>
                    <p><strong>From Status Epilepticus:</strong> Permanent neuronal injury if >30 minutes (excitotoxicity from glutamate), cerebral edema, Todd's paralysis (post-ictal focal weakness lasting 24-48hr, mimics stroke), cognitive impairment, development of refractory epilepsy, death (10-20% mortality for status epilepticus)</p>
                    <p><strong>From Treatment:</strong> Respiratory depression (benzodiazepines, barbiturates - have airway equipment ready), hypotension (propofol, phenytoin, barbiturates), propofol infusion syndrome (rhabdo, acidosis, cardiac arrest after >48hr high-dose propofol), cardiac arrhythmias (phenytoin - especially if infused too fast), purple glove syndrome (phenytoin extravasation causing limb ischemia), hepatotoxicity (valproate), thrombocytopenia (valproate), hyponatremia (carbamazepine causing SIADH), Steven-Johnson syndrome (lamotrigine if titrated too fast, carbamazepine)</p>
                    <p><strong>Psychosocial:</strong> Loss of driving privileges (state-dependent, typically 3-12 months seizure-free required), job limitations (can't be pilot, commercial driver, work at heights), stigma, depression (30% of epileptics), medication non-adherence (leading cause of breakthrough seizures)</p>
                    <p><strong>SUDEP (Sudden Unexpected Death in Epilepsy):</strong> 1 in 1000 epilepsy patients per year. Higher risk if: poorly controlled seizures, generalized tonic-clonic, young age, non-adherence to AEDs, nocturnal seizures. Mechanism: likely cardiac arrhythmia or respiratory arrest during seizure</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <!-- CONDITIONS 26-40 - Complete but streamlined for token efficiency -->
        
        <!-- CONDITION 26: BACTERIAL MENINGITIS - EXPANDED -->
        <div id="meningitis" class="condition-page">
            <div class="page-header">
                <h2>26. BACTERIAL MENINGITIS</h2>
                <div class="subtitle">CNS Emergency ‚Ä¢ Give Antibiotics BEFORE LP ‚Ä¢ Dexamethasone</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad (44% have all 3):</span> Fever + headache + nuchal rigidity. 95% have ‚â•2 of: fever, headache, stiff neck, altered mental status</p>
                    <p><span class="label">Physical Exam:</span> Nuchal rigidity (passive neck flexion causes resistance), Kernig sign (hip flexed 90¬∞ then extend knee ‚Üí pain/resistance), Brudzinski sign (neck flexion ‚Üí involuntary hip flexion), jolt accentuation (turning head worsens HA). Altered MS 69%, focal deficits 10-30%, seizures 20-30%, papilledema rare (<1%). Petechial/purpuric rash = N. meningitidis</p>
                    
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Elderly/Immunocompromised:</strong> Subtle - only AMS, weakness, falls. May lack fever/meningismus. Low threshold for LP</li>
                        <li><strong>Listeria (>50yo, pregnant, immunocompromised):</strong> More indolent. May have rhombencephalitis (brainstem - ataxia, CN palsies). Unpasteurized dairy/deli meats</li>
                        <li><strong>Meningococcemia:</strong> Fulminant - petechiae/purpura, shock, DIC, multi-organ failure. Health-to-death <24hr. Waterhouse-Friderichsen (adrenal hemorrhage)</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Healthcare-associated (S. aureus, coag-neg Staph, Pseudomonas). Fever + HA = shunt infection until proven otherwise</li>
                        <li><strong>Partially treated:</strong> Prior antibiotics (even 1-2 doses oral) sterilize CSF culture but leave inflammatory profile. Use PCR. Treat as bacterial</li>
                        <li><strong>Chronic meningitis (>4 weeks):</strong> TB, fungal (Cryptococcus in HIV), Lyme, syphilis, malignancy. Lymphocytic CSF</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">CRITICAL PRINCIPLE:</span> <strong>DO NOT DELAY ANTIBIOTICS for LP or CT!</strong> Door-to-antibiotic <1 hour improves outcomes. Antibiotics before LP don't affect yield if LP within 2-4 hours</p>
                    
                    <p><span class="label">CT Head BEFORE LP if:</span> Immunocompromised, history CNS disease, new seizure (<1 week), papilledema, GCS ‚â§10, focal deficit. Algorithm: Give antibiotics ‚Üí CT ‚Üí LP. If mass effect on CT, discuss LP with neurology</p>
                    
                    <p><span class="label">LP Procedure:</span> Lateral (measure OP) or sitting. L3-L4 or L4-L5. Opening pressure with manometer (normal 10-20 cm H2O, bacterial >25). Collect 4 tubes: (1) Gram/culture/PCR, (2) glucose/protein, (3) cell count/diff, (4) hold for extras. Traumatic tap: subtract 1 WBC per 700 RBCs</p>
                    
                    <p><span class="label">CSF Interpretation - Bacterial vs Viral:</span></p>
                    <ul>
                        <li><strong>Bacterial:</strong> WBC >1000 (often >5000), PMN >80%, glucose <40 or <50% serum, protein >200 (often >1000), opening pressure >25</li>
                        <li><strong>Viral:</strong> WBC 10-500, lymphs >50%, glucose normal (>45), protein 50-100</li>
                        <li><strong>Normal:</strong> WBC 0-5, glucose 50-80, protein 15-45</li>
                    </ul>
                    
                    <p><span class="label">CSF Studies:</span> Cell count/diff, glucose (+ simultaneous serum glucose for ratio), protein, Gram stain (60-90% positive depending on organism), culture (gold standard, 24-48hr), PCR/BioFire FilmArray (rapid ~1hr, detects S. pneumo, N. meningitidis, H. flu, Listeria, viruses - helpful when antibiotics given before LP), CSF lactate (>4 mmol/L = bacterial, 95% sens/spec). Add AFB/TB PCR, fungal culture, Crypto Ag, VDRL, Lyme if chronic presentation</p>
                    
                    <p><span class="label">Blood Studies:</span> Cultures √ó 2 (positive 50-80%), CBC (leukocytosis, bands, thrombocytopenia if DIC), BMP (hyponatremia from SIADH common), coags if DIC suspected, lactate, serum glucose (for CSF ratio), procalcitonin (>0.5 suggests bacterial)</p>
                    
                    <p><span class="label">Common Pathogens by Age:</span></p>
                    <ul>
                        <li><strong>Adults <50yo:</strong> S. pneumoniae (50%), N. meningitidis (25%), rarely H. influenzae</li>
                        <li><strong>Adults ‚â•50yo:</strong> S. pneumoniae, Listeria, gram-negatives (E. coli, Klebsiella)</li>
                        <li><strong>Post-neurosurgery/shunt:</strong> S. aureus/epidermidis, Pseudomonas, Acinetobacter</li>
                        <li><strong>Immunocompromised:</strong> Listeria, gram-negatives, Cryptococcus, TB</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START IMMEDIATELY, Within 1 Hour):</span></p>
                    <ul>
                        <li><strong>Adults <50yo, immunocompetent:</strong> Vancomycin 15-20 mg/kg IV q8-12h + Ceftriaxone 2g IV q12h (or Cefotaxime 2g q4-6h). Covers S. pneumo (including resistant), N. meningitidis, H. flu</li>
                        <li><strong>Adults ‚â•50yo OR immunocompromised OR alcoholism:</strong> Add Ampicillin 2g IV q4h for Listeria coverage. Triple therapy: Vanc + Ceftriaxone + Ampicillin</li>
                        <li><strong>Post-neurosurgery/VP shunt:</strong> Vancomycin + Cefepime 2g IV q8h (or Meropenem 2g q8h) for Pseudomonas coverage</li>
                        <li><strong>Severe PCN allergy:</strong> Vancomycin + Moxifloxacin 400mg IV daily. Can use Aztreonam + Moxifloxacin if needed</li>
                    </ul>
                    
                    <p><span class="label">DEXAMETHASONE:</span> 10mg IV q6h √ó 4 days. MUST give BEFORE or WITH first antibiotic dose (not after). Reduces mortality/hearing loss in pneumococcal meningitis. Discontinue if organism not S. pneumoniae</p>
                    
                    <p><span class="label">Targeted Therapy (once organism/sensitivities known):</span></p>
                    <ul>
                        <li><strong>S. pneumoniae PCN-sensitive (MIC <0.06):</strong> Penicillin G 4 million units IV q4h. If resistant: continue Vanc + Ceftriaxone. Duration 10-14 days. Continue dexamethasone √ó 4d</li>
                        <li><strong>N. meningitidis:</strong> Ceftriaxone 2g IV q12h √ó 7 days (or Penicillin G if sensitive). Droplet precautions √ó 24hr after antibiotics. Chemoprophylaxis close contacts: Cipro 500mg PO √ó 1 or Ceftriaxone 250mg IM √ó 1</li>
                        <li><strong>Listeria:</strong> Ampicillin 2g IV q4h + Gentamicin 5-7 mg/kg IV daily √ó 21 days (synergy). TMP-SMX 5 mg/kg IV q8h if PCN allergy. Don't use ceftriaxone (no Listeria coverage)</li>
                        <li><strong>H. influenzae:</strong> Ceftriaxone 2g IV q12h √ó 7-10 days</li>
                        <li><strong>Pseudomonas:</strong> Cefepime 2g IV q8h or Meropenem 2g IV q8h √ó 21 days. Consider intrathecal/intraventricular aminoglycoside if refractory</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>ICP management:</strong> Elevate HOB 30¬∞, avoid hypotonic fluids, treat fever/pain aggressively. If severe ‚ÜëICP: Mannitol 0.25-1 g/kg IV or 3% saline bolus. Neurosurgery for ventriculostomy if hydrocephalus</li>
                        <li><strong>Seizures:</strong> Treat acutely (lorazepam 2-4mg IV). Prophylactic AEDs not recommended unless seizure occurred. Load levetiracetam if recurrent</li>
                        <li><strong>SIADH (common):</strong> Fluid restrict 1-1.5 L/day. Hypertonic saline if severe symptomatic hyponatremia (Na <120, seizures, severe AMS)</li>
                        <li><strong>Isolation:</strong> Droplet precautions for N. meningitidis until 24hr after antibiotics. Standard precautions for other organisms</li>
                    </ul>
                    
                    <p><span class="label">Repeat LP at 48hr if:</span> Persistent fever, worsening neurologic status, concern for resistant organism. Should see ‚ÜìWBC, ‚Üìprotein, sterile cultures</p>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Antibiotics before LP saves lives:</strong> Every hour delay increases mortality. If high suspicion, give empiric antibiotics immediately - don't wait. Diagnostic yield minimally affected if LP within 2-4 hours</li>
                    <li><strong>Classic triad is the minority:</strong> Only 44% have fever + HA + stiff neck. 95% have ‚â•2 of: fever, HA, stiff neck, AMS. Don't wait for "classic" presentation</li>
                    <li><strong>Dexamethasone timing critical:</strong> BEFORE or WITH first antibiotic (not after). Reduces mortality/hearing loss in pneumococcal. Don't forget it!</li>
                    <li><strong>Low CSF glucose = bacterial:</strong> CSF glucose <40 or <50% serum highly specific for bacterial meningitis. Viral/aseptic has normal glucose</li>
                    <li><strong>PCR is game-changer:</strong> BioFire results ~1hr vs 24-48hr culture. Helpful when antibiotics given before LP. High sensitivity/specificity</li>
                    <li><strong>Listeria loves extremes:</strong> Neonates, elderly >50, pregnant, immunocompromised. MUST add ampicillin empirically - ceftriaxone doesn't cover Listeria</li>
                    <li><strong>Meningococcus kills fast:</strong> Petechial rash + shock = urgent antibiotics + ICU + prophylaxis contacts (Cipro 500mg √ó 1). Health-to-death <24hr</li>
                    <li><strong>Shunt infection = neurosurgery consult:</strong> Fever + HA in VP shunt = infection until proven otherwise. Often coag-neg Staph. Needs vancomycin + shunt removal/externalization</li>
                    <li><strong>Hearing screen everyone:</strong> 30% get hearing loss with pneumococcal meningitis. Audiology screening before discharge + follow-up mandatory</li>
                    <li><strong>Normal CT doesn't rule out ‚ÜëICP:</strong> CT may be normal even with elevated ICP from meningitis. Only delays LP if mass effect/shift. Give antibiotics first!</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>GCS <12 or rapidly declining mental status</li>
                        <li>Hemodynamic instability requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Refractory or recurrent seizures</li>
                        <li>Signs of increased ICP (Cushing triad, papilledema)</li>
                        <li>Need for ICP monitoring or ventriculostomy</li>
                        <li>Meningococcemia with septic shock/DIC</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics</li>
                        <li>Clinical improvement (HA resolving, AMS cleared, ambulating)</li>
                        <li>Tolerating PO intake</li>
                        <li>Neurologic exam stable or improved</li>
                        <li>Completed appropriate IV antibiotic duration (7-21d depending on organism)</li>
                        <li>CSF sterilized if repeat LP performed</li>
                        <li>Hearing screen performed (audiology follow-up arranged)</li>
                        <li>Close outpatient follow-up with ID/neurology</li>
                        <li>No complications requiring ongoing inpatient management</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Neurologic:</strong> Seizures (20-30% - treat acutely, consider prophylaxis if recurrent), stroke (15% from vasculitis/venous thrombosis), brain abscess, subdural empyema, ventriculitis, cerebral edema with herniation, hydrocephalus (communicating or obstructive requiring VP shunt), cranial nerve palsies (CN VI, VII, VIII most common - especially hearing loss)</p>
                    <p><strong>Systemic Complications:</strong> Septic shock (especially meningococcemia), DIC with bleeding, ARDS requiring mechanical ventilation, multi-organ failure, adrenal crisis (Waterhouse-Friderichsen syndrome in meningococcemia), SIADH with severe hyponatremia</p>
                    <p><strong>Long-term Sequelae:</strong> Sensorineural hearing loss (30% with S. pneumoniae - permanent, requires hearing aids/cochlear implants), cognitive impairment (memory, executive function), motor deficits/hemiparesis, post-infectious epilepsy, hydrocephalus requiring permanent shunt</p>
                    <p><strong>Mortality:</strong> Overall 15-20%. S. pneumoniae 20-30%, N. meningitidis 5-10%, Listeria 20-30%, gram-negatives 20-40%. Poor prognostic factors: elderly, delayed treatment, GCS <10, seizures, shock, focal deficits</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 27: ANEMIA - EXPANDED -->
        <div id="anemia" class="condition-page">
            <div class="page-header">
                <h2>27. ANEMIA</h2>
                <div class="subtitle">Microcytic ‚Ä¢ Normocytic ‚Ä¢ Macrocytic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">General Symptoms (severity depends on acuity and degree):</span> Fatigue, weakness, dyspnea on exertion, dizziness, headache, tinnitus, palpitations, chest pain (angina if severe anemia + CAD). Pallor (conjunctivae, palmar creases), tachycardia, systolic flow murmur, orthostatic hypotension if acute blood loss</p>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Iron Deficiency:</strong> Koilonychia (spoon nails), glossitis, angular cheilitis, pica (ice chips/starch/dirt craving), restless leg syndrome, dysphagia (Plummer-Vinson syndrome with esophageal webs)</li>
                        <li><strong>B12 Deficiency:</strong> Neurologic symptoms - paresthesias (glove-stocking), ataxia, decreased proprioception/vibratory sense, dementia, psychiatric changes. Glossitis (beefy red tongue). Subacute combined degeneration of spinal cord (dorsal columns + lateral corticospinal tracts)</li>
                        <li><strong>Folate Deficiency:</strong> Similar to B12 but NO neurologic symptoms. Glossitis, diarrhea. Often in alcoholics, malnutrition</li>
                        <li><strong>Hemolysis:</strong> Jaundice (‚Üëunconjugated bilirubin), dark urine (hemoglobinuria), splenomegaly. If intravascular: hemoglobinuria, hemosiderinuria. If extravascular: splenomegaly, gallstones (pigmented)</li>
                        <li><strong>Acute Blood Loss:</strong> Tachycardia, hypotension, orthostatic changes, melena/hematochezia (GI bleed), hematemesis, vaginal bleeding. Hgb may be normal initially (takes hours for equilibration)</li>
                        <li><strong>Anemia of Chronic Disease:</strong> Underlying inflammatory condition (RA, IBD, malignancy, CKD). Usually mild-moderate anemia (Hgb 9-11)</li>
                        <li><strong>Thalassemia:</strong> Mild microcytic anemia often asymptomatic. Family history Mediterranean/Asian descent. Splenomegaly if thalassemia major</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Initial Labs:</span> CBC with differential, reticulocyte count (assess bone marrow response), peripheral smear, iron studies, B12/folate, LDH/haptoglobin/bilirubin (if hemolysis suspected)</p>
                    
                    <p><span class="label">Approach by MCV (Mean Corpuscular Volume):</span></p>
                    
                    <p><strong>MICROCYTIC (MCV <80 fL) - "TAILS":</strong></p>
                    <ul>
                        <li><strong>Thalassemia:</strong> Hgb electrophoresis (‚ÜëHbA2 in Œ≤-thal trait), family hx, ethnicity. MCV often <75, RBC count elevated despite low Hgb (RBC >5 million). RDW normal. Mentzer index (MCV/RBC count) <13 suggests thalassemia</li>
                        <li><strong>Anemia of chronic disease:</strong> Ferritin elevated (>100) or normal, TIBC low, transferrin saturation low-normal. Inflammatory markers elevated (CRP, ESR). Look for underlying chronic condition</li>
                        <li><strong>Iron deficiency:</strong> Ferritin <30 ng/mL (most specific). Serum iron low, TIBC elevated, transferrin saturation <20%. RDW elevated. Peripheral smear: hypochromic microcytic cells, pencil cells. Investigate source of blood loss (GI workup if no obvious source)</li>
                        <li><strong>Lead poisoning:</strong> Basophilic stippling on smear, elevated blood lead level. Occupational exposure, pica</li>
                        <li><strong>Sideroblastic anemia:</strong> Ring sideroblasts on bone marrow. Elevated ferritin, normal/high iron. Causes: alcohol, isoniazid, lead, copper deficiency, myelodysplasia</li>
                    </ul>
                    
                    <p><strong>NORMOCYTIC (MCV 80-100 fL):</strong></p>
                    <ul>
                        <li><strong>Check reticulocyte count to distinguish:</strong></li>
                        <li><strong>Elevated reticulocyte count (>2-3%) = Appropriate Response:</strong>
                            <ul>
                                <li><strong>Acute blood loss:</strong> Obvious source (GI bleed, trauma, surgery, menorrhagia). Hgb may be normal initially</li>
                                <li><strong>Hemolysis:</strong> Elevated LDH, low haptoglobin, elevated indirect bilirubin, +/- hemoglobinuria. Smear: schistocytes (TTP, HUS, DIC, mechanical valves), spherocytes (autoimmune, hereditary spherocytosis), sickle cells, bite cells (G6PD). Coombs test for autoimmune hemolytic anemia</li>
                            </ul>
                        </li>
                        <li><strong>Low reticulocyte count (<2%) = Inadequate Response:</strong>
                            <ul>
                                <li><strong>Anemia of chronic disease/inflammation:</strong> Ferritin normal/high, low TIBC. Underlying chronic illness (CKD, cancer, infection, autoimmune)</li>
                                <li><strong>CKD:</strong> Low EPO production. Cr elevated, usually Hgb 9-11. Start EPO if Hgb <10</li>
                                <li><strong>Bone marrow failure:</strong> Pancytopenia (‚ÜìWBC, ‚Üìplatelets, ‚ÜìRBC). Aplastic anemia, myelodysplasia, leukemia, myelofibrosis. Needs bone marrow biopsy</li>
                                <li><strong>Early iron/B12/folate deficiency:</strong> May be normocytic before becoming micro/macrocytic. Check iron studies, B12, folate</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>MACROCYTIC (MCV >100 fL):</strong></p>
                    <ul>
                        <li><strong>B12 deficiency:</strong> B12 <200 pg/mL (or <300 if high clinical suspicion). Elevated methylmalonic acid and homocysteine (more sensitive). Hypersegmented neutrophils on smear. Causes: pernicious anemia (anti-IF antibodies), malabsorption (Crohn's, celiac, gastric bypass), strict vegan diet, metformin</li>
                        <li><strong>Folate deficiency:</strong> Folate <2 ng/mL. Elevated homocysteine but normal methylmalonic acid. No neurologic symptoms (vs B12). Causes: poor diet (alcoholics, elderly), malabsorption, medications (methotrexate, phenytoin, TMP-SMX), pregnancy/lactation (increased demand)</li>
                        <li><strong>Alcohol:</strong> Direct marrow suppression. Often with folate deficiency. MCV 100-110. Elevated GGT, AST>ALT</li>
                        <li><strong>Hypothyroidism:</strong> Check TSH. MCV usually 100-110</li>
                        <li><strong>Medications:</strong> Hydroxyurea, zidovudine (AZT), azathioprine, 5-FU, methotrexate</li>
                        <li><strong>Myelodysplastic syndrome (MDS):</strong> Elderly, refractory anemia, dysplastic cells on smear, cytopenias. Bone marrow biopsy shows dysplasia. Risk of transformation to AML</li>
                        <li><strong>Reticulocytosis:</strong> Young RBCs are larger. If brisk hemolysis/blood loss with appropriate reticulocyte response, MCV may be elevated</li>
                    </ul>
                    
                    <p><span class="label">Additional Workup for Specific Situations:</span></p>
                    <ul>
                        <li><strong>GI workup if iron deficiency with no obvious source:</strong> EGD + colonoscopy to evaluate for occult GI bleeding (gastritis, ulcer, colon cancer, AVM). Celiac serologies. H. pylori testing</li>
                        <li><strong>Hemolysis workup:</strong> Coombs (direct antiglobulin test) for autoimmune hemolytic anemia. G6PD level (if bite cells, acute hemolysis after oxidative stress). Osmotic fragility (hereditary spherocytosis). PNH flow cytometry if intravascular hemolysis</li>
                        <li><strong>Bone marrow biopsy if:</strong> Pancytopenia, suspected malignancy (leukemia, lymphoma, myeloma), unexplained anemia, MDS suspected</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Transfusion Thresholds:</span></p>
                    <ul>
                        <li><strong>Stable, no CAD:</strong> Transfuse if Hgb <7 g/dL (restrictive strategy)</li>
                        <li><strong>CAD or high cardiac risk:</strong> Transfuse if Hgb <8 g/dL</li>
                        <li><strong>Acute MI/ACS:</strong> Transfuse if Hgb <10 g/dL (some say <8, controversial - individualize)</li>
                        <li><strong>Symptomatic (dyspnea, angina, orthostasis):</strong> Transfuse regardless of Hgb if symptomatic</li>
                        <li><strong>Chronic anemia:</strong> Often tolerate lower Hgb (compensatory mechanisms). Treat underlying cause, transfuse only if symptomatic or Hgb <7</li>
                        <li><strong>Each unit pRBC raises Hgb by ~1 g/dL</strong> (or Hct by ~3%)</li>
                    </ul>
                    
                    <p><span class="label">Specific Treatments by Etiology:</span></p>
                    
                    <p><strong>Iron Deficiency:</strong></p>
                    <ul>
                        <li><strong>Oral iron (first-line):</strong> Ferrous sulfate 325mg PO TID (65mg elemental iron per tablet). Take on empty stomach with vitamin C (enhances absorption). Common SE: constipation, dark stools, nausea. Response in 2-4 weeks (‚Üëreticulocytes), full repletion 3-6 months. Continue 3 months after Hgb normalized to replete stores</li>
                        <li><strong>IV iron (if oral intolerance, malabsorption, CKD, need rapid repletion):</strong> Iron sucrose 200mg IV √ó 5 doses or Ferric carboxymaltose 750mg IV √ó 2 doses or Iron dextran (test dose required). Risk: anaphylaxis (rare with newer formulations), hypophosphatemia</li>
                        <li><strong>Treat underlying cause:</strong> GI bleeding (PPI for ulcer, colonoscopy for polyp/cancer removal), menorrhagia (NSAIDs, OCPs, IUD, ablation)</li>
                    </ul>
                    
                    <p><strong>B12 Deficiency:</strong></p>
                    <ul>
                        <li><strong>Cyanocobalamin 1000 mcg IM daily √ó 7 days, then weekly √ó 4 weeks, then monthly lifelong</strong> (if pernicious anemia or malabsorption)</li>
                        <li><strong>Oral B12 1000-2000 mcg daily:</strong> Alternative if dietary deficiency or mild malabsorption (compliance issue - less reliable)</li>
                        <li><strong>Neurologic symptoms may be irreversible if prolonged deficiency:</strong> Treat urgently</li>
                        <li><strong>NEVER give folate without B12</strong> in macrocytic anemia - can worsen B12 neuropathy!</li>
                    </ul>
                    
                    <p><strong>Folate Deficiency:</strong></p>
                    <ul>
                        <li><strong>Folic acid 1mg PO daily √ó 1-4 months</strong> until replete</li>
                        <li><strong>Treat underlying cause:</strong> Alcohol cessation, improve diet</li>
                        <li><strong>Pregnancy:</strong> All women of childbearing age should take 400-800 mcg daily (prevent neural tube defects)</li>
                    </ul>
                    
                    <p><strong>Anemia of Chronic Disease:</strong></p>
                    <ul>
                        <li><strong>Treat underlying condition</strong> (control inflammation, treat cancer, manage CKD)</li>
                        <li><strong>If concurrent iron deficiency</strong> (ferritin <100 in setting of inflammation): IV iron (oral poorly absorbed)</li>
                        <li><strong>EPO (erythropoietin):</strong> If CKD with Hgb <10, or cancer-related anemia. Epoetin alfa 50-100 units/kg SC 3√ó/week. Target Hgb 10-11 (don't overcorrect - ‚Üëthrombosis risk). Requires adequate iron stores</li>
                    </ul>
                    
                    <p><strong>Hemolytic Anemia:</strong></p>
                    <ul>
                        <li><strong>Autoimmune (warm AIHA):</strong> Prednisone 1mg/kg daily, taper over weeks-months. If refractory: Rituximab, IVIG, splenectomy. Folic acid 1mg daily (increased RBC turnover)</li>
                        <li><strong>Cold agglutinin disease:</strong> Avoid cold exposure. Rituximab. Don't transfuse unless life-threatening (can worsen hemolysis)</li>
                        <li><strong>G6PD deficiency:</strong> Avoid oxidative triggers (sulfa drugs, dapsone, antimalarials, fava beans). Supportive care, transfuse if severe</li>
                        <li><strong>TTP:</strong> URGENT plasmapheresis (see TTP section)</li>
                    </ul>
                    
                    <p><strong>Thalassemia:</strong></p>
                    <ul>
                        <li><strong>Trait (minor):</strong> No treatment needed. Avoid unnecessary iron supplementation. Genetic counseling</li>
                        <li><strong>Major:</strong> Chronic transfusions (maintain Hgb >9-10), iron chelation (deferoxamine, deferasirox) to prevent iron overload. Splenectomy if hypersplenism. Bone marrow transplant curative</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>MCV is your roadmap:</strong> Microcytic ‚Üí think iron/thalassemia/chronic disease. Normocytic ‚Üí check retic count (high = bleeding/hemolysis, low = bone marrow problem). Macrocytic ‚Üí B12/folate/alcohol/hypothyroid</li>
                    <li><strong>Ferritin <30 = iron deficiency:</strong> Most specific test. But ferritin is acute phase reactant - may be falsely normal/elevated with inflammation. If ferritin 30-100 with chronic disease, still suspect iron deficiency</li>
                    <li><strong>RDW helps distinguish:</strong> High RDW = iron deficiency (mixed cell sizes). Normal RDW = thalassemia, chronic disease (uniform small cells)</li>
                    <li><strong>Thalassemia has HIGH RBC count:</strong> Despite low Hgb/MCV, RBC count often >5 million (vs iron deficiency with low RBC count). Mentzer index <13 suggests thalassemia</li>
                    <li><strong>B12 deficiency causes neuro symptoms, folate doesn't:</strong> Paresthesias, ataxia, dementia = B12. Never give folate without checking B12 first in macrocytic anemia - can worsen neuropathy!</li>
                    <li><strong>Acute blood loss: Hgb lags:</strong> Initial Hgb may be normal because both RBCs and plasma lost equally. Takes hours for equilibration. Treat based on clinical status (hypotension, tachycardia)</li>
                    <li><strong>Hemolysis triad:</strong> Elevated LDH + low haptoglobin + elevated indirect bilirubin. If all three present, hemolysis confirmed. Then figure out cause (Coombs, smear)</li>
                    <li><strong>Restrictive transfusion saves lives:</strong> Transfuse <7 in stable patients (or <8 if CAD). Overtransfusion increases mortality, volume overload, immunosuppression</li>
                    <li><strong>Each unit pRBC raises Hgb ~1 g/dL:</strong> Don't transfuse more than needed. Reassess after each unit</li>
                    <li><strong>Iron pills cause constipation/GI upset:</strong> Take with food if intolerant (absorption slightly decreased but better than not taking). Try every-other-day dosing (absorption actually better). Black stools are expected</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Hemodynamic instability (hypotension, tachycardia unresponsive to fluids/transfusion)</li>
                        <li>Active massive hemorrhage requiring massive transfusion protocol</li>
                        <li>Severe symptomatic anemia (Hgb <5-6) with angina, AMS, respiratory distress</li>
                        <li>TTP/HUS with neurologic changes or renal failure</li>
                        <li>Severe autoimmune hemolytic anemia with rapid decompensation</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable</li>
                        <li>Hgb stable or improving</li>
                        <li>No active bleeding</li>
                        <li>Tolerating PO intake (including iron/B12 if applicable)</li>
                        <li>Underlying cause identified and treated (or plan in place)</li>
                        <li>Appropriate outpatient follow-up arranged (PCP, hematology, GI)</li>
                        <li>Patient educated on medications, dietary recommendations</li>
                        <li>Transfusion reactions ruled out if transfused</li>
                        <li>Safe for discharge from functional standpoint</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> High-output heart failure (severe chronic anemia - Hgb <6-7 with inadequate compensation), angina/MI (demand ischemia from anemia in patient with CAD), syncope, falls (orthostasis, weakness), transfusion reactions (see transfusion section)</p>
                    <p><strong>From Iron Deficiency:</strong> Restless leg syndrome (improves with iron repletion), cognitive impairment (especially children), increased risk infection (impaired immune function), pica complications (lead poisoning from paint chips, bowel obstruction)</p>
                    <p><strong>From B12 Deficiency:</strong> Irreversible neurologic damage (subacute combined degeneration - ataxia, spasticity, paresthesias), dementia, depression, increased homocysteine ‚Üí thrombosis risk</p>
                    <p><strong>From Treatment:</strong> Iron overload (chronic transfusions - hemochromatosis, cardiac/liver damage, requires chelation), transfusion reactions, infection from immunosuppression (rituximab, steroids for AIHA)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 28: NEUTROPENIC FEVER - EXPANDED -->
        <div id="neutropenic-fever" class="condition-page">
            <div class="page-header">
                <h2>28. NEUTROPENIC FEVER</h2>
                <div class="subtitle">Oncologic Emergency ‚Ä¢ Empiric Antibiotics Within 1 Hour</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Single oral temperature ‚â•38.3¬∞C (101¬∞F) OR temperature ‚â•38¬∞C (100.4¬∞F) for ‚â•1 hour WITH absolute neutrophil count (ANC) <500 cells/¬µL OR ANC expected to decline to <500 within 48 hours</p>
                    <p><span class="label">Calculation:</span> ANC = WBC √ó (% neutrophils + % bands) / 100</p>
                    
                    <p><span class="label">Typical Presentation:</span> Fever may be ONLY sign of infection (neutropenic patients lack inflammatory response - no pus, minimal symptoms). Subtle findings: mild hypotension, tachycardia, confusion. Absence of fever does NOT rule out infection</p>
                    
                    <p><span class="label">Common Sources (often no clear source found 50-60%):</span></p>
                    <ul>
                        <li><strong>GI tract (most common):</strong> Oral mucositis, esophagitis, typhlitis (cecal inflammation), C. diff, perirectal abscess</li>
                        <li><strong>Lungs:</strong> Pneumonia (bacterial, fungal - Aspergillus, PCP)</li>
                        <li><strong>Skin/soft tissue:</strong> Cellulitis, catheter site infection, perirectal abscess</li>
                        <li><strong>Bloodstream:</strong> Catheter-related bloodstream infection (CRBSI - coag-neg Staph, S. aureus)</li>
                        <li><strong>Urinary tract:</strong> Less common (neutrophils needed for pyuria - may have negative UA despite UTI)</li>
                        <li><strong>Sinusitis:</strong> Especially if prolonged neutropenia (fungal - Mucor, Aspergillus)</li>
                    </ul>
                    
                    <p><span class="label">Alternate/High-Risk Presentations:</span></p>
                    <ul>
                        <li><strong>Septic shock:</strong> Hypotension, tachycardia, AMS, lactate elevation. Requires urgent resuscitation + antibiotics</li>
                        <li><strong>Typhlitis (neutropenic enterocolitis):</strong> RLQ pain, diarrhea, distension. CT shows bowel wall thickening cecum/ascending colon. High mortality if perforation. Needs surgical consult</li>
                        <li><strong>Perirectal abscess:</strong> Severe perianal pain, tenderness. Often NO fluctuance (neutropenic - can't form pus). Needs exam under anesthesia + drainage + antibiotics</li>
                        <li><strong>Invasive fungal infection (if prolonged neutropenia >7-10 days):</strong> Persistent fever despite antibiotics. Aspergillus (pulmonary nodules, halo sign on CT), Candida (bloodstream, hepatosplenic candidiasis), Mucormycosis (sinusitis, black eschar)</li>
                        <li><strong>Atypical pneumonia:</strong> PCP (HIV/lymphoma), CMV, viral (RSV, influenza)</li>
                        <li><strong>CNS infection:</strong> Headache, AMS, focal deficits. Listeria, Aspergillus, Toxoplasma, Cryptococcus</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs (STAT):</span></p>
                    <ul>
                        <li><strong>CBC with differential:</strong> Confirm ANC. Trend daily. Platelets (thrombocytopenia common)</li>
                        <li><strong>Blood cultures √ó 2 sets:</strong> One from EACH lumen of central line (if present) + peripheral. Label which lumen. Positive in 20-30%</li>
                        <li><strong>CMP:</strong> Renal function (for antibiotic dosing), electrolytes, LFTs</li>
                        <li><strong>Lactate:</strong> If concern for sepsis</li>
                        <li><strong>UA with culture:</strong> Even if UA negative (neutropenia ‚Üí may not have WBCs in urine despite UTI)</li>
                        <li><strong>Stool culture, C. diff if diarrhea</strong></li>
                        <li><strong>Procalcitonin:</strong> May help distinguish bacterial vs non-bacterial (not routinely recommended)</li>
                        <li><strong>Fungal markers if prolonged fever (>4-7 days) or high risk:</strong> Serum (1‚Üí3)-Œ≤-D-glucan (Candida, Aspergillus, PCP), Galactomannan (Aspergillus), Cryptococcal antigen</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Chest X-ray:</strong> All patients. But CXR may be normal early (neutropenia ‚Üí no infiltrate). If negative but respiratory symptoms, get CT chest</li>
                        <li><strong>CT Chest (if respiratory symptoms, hypoxia, or persistent fever):</strong> More sensitive for pneumonia, fungal nodules. Look for: infiltrates, nodules, halo sign (Aspergillus), cavitation</li>
                        <li><strong>CT Abdomen/Pelvis (if abdominal pain or no clear source):</strong> Evaluate for typhlitis, abscess, colitis</li>
                        <li><strong>CT Sinuses (if sinus symptoms, especially prolonged neutropenia):</strong> Rule out invasive fungal sinusitis</li>
                    </ul>
                    
                    <p><span class="label">Other Studies:</span></p>
                    <ul>
                        <li><strong>Respiratory viral panel (if respiratory symptoms):</strong> Influenza, RSV, COVID</li>
                        <li><strong>Lumbar puncture (if CNS symptoms):</strong> After platelets >50k. CSF for cell count, protein, glucose, Gram stain, culture, Crypto Ag, fungal culture</li>
                        <li><strong>Skin biopsy (if skin lesions):</strong> Culture and histology. Rule out disseminated fungal (Fusarium, Mucor)</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification (MASCC Score - guides inpatient vs outpatient, intensity):</span></p>
                    <ul>
                        <li><strong>MASCC Score ‚â•21:</strong> Low risk (mortality <5%). May consider outpatient management in select patients</li>
                        <li><strong>MASCC Score <21:</strong> High risk (mortality >20%). Requires inpatient management + aggressive treatment</li>
                        <li><strong>High-risk features:</strong> Prolonged neutropenia (>7 days expected), ANC <100, hemodynamic instability, pneumonia, mucositis grade 3-4, neurologic changes, abdominal pain, renal/liver dysfunction, age >60</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">EMPIRIC ANTIBIOTICS (START WITHIN 1 HOUR):</span></p>
                    
                    <p><strong>Initial Monotherapy (Preferred):</strong></p>
                    <ul>
                        <li><strong>Cefepime 2g IV q8h</strong> (antipseudomonal cephalosporin, preferred)</li>
                        <li><strong>OR Piperacillin-Tazobactam 4.5g IV q6h</strong> (broader spectrum)</li>
                        <li><strong>OR Meropenem 1g IV q8h</strong> (if PCN allergy or resistant organisms suspected)</li>
                        <li>Monotherapy covers: Pseudomonas, E. coli, Klebsiella, Enterobacter, Proteus, Staph (not MRSA), Strep</li>
                    </ul>
                    
                    <p><strong>ADD Vancomycin 15-20 mg/kg IV q8-12h if:</strong></p>
                    <ul>
                        <li>Central line/catheter infection suspected (erythema, tenderness at site)</li>
                        <li>Severe mucositis (oral, esophageal, GI - ‚ÜëStrep viridans, Enterococcus risk)</li>
                        <li>Hemodynamic instability/septic shock</li>
                        <li>Skin/soft tissue infection</li>
                        <li>Known MRSA colonization</li>
                        <li>Pneumonia (cover MRSA)</li>
                    </ul>
                    
                    <p><strong>ADD Antifungal Coverage if:</strong></p>
                    <ul>
                        <li><strong>Persistent fever >4-7 days despite broad-spectrum antibiotics</strong> (empiric antifungal)</li>
                        <li><strong>Clinical/radiographic evidence of invasive fungal infection:</strong> Pulmonary nodules, halo sign, sinusitis</li>
                        <li><strong>Positive fungal markers:</strong> Œ≤-D-glucan, galactomannan</li>
                        <li><strong>Options:</strong> Micafungin 100mg IV daily (Candida), Voriconazole 6mg/kg q12h √ó 2 then 4mg/kg q12h (Aspergillus), Liposomal Amphotericin B 3-5mg/kg IV daily (broad spectrum, if refractory)</li>
                    </ul>
                    
                    <p><strong>Special Situations:</strong></p>
                    <ul>
                        <li><strong>Perirectal abscess/typhlitis:</strong> Pip-tazo + Vancomycin (or Meropenem + Vanc). Metronidazole 500mg IV q8h if extensive bowel involvement. Surgical consult</li>
                        <li><strong>PCP suspected (HIV, lymphoma):</strong> TMP-SMX 5mg/kg IV q8h. Prednisone if severe (PaO2 <70 or A-a gradient >35)</li>
                        <li><strong>Viral respiratory infection (influenza):</strong> Oseltamivir 75mg PO BID √ó 5d if within 48hr symptom onset (or longer if immunocompromised)</li>
                        <li><strong>HSV/VZV (mucositis, vesicular rash):</strong> Acyclovir 5-10mg/kg IV q8h</li>
                    </ul>
                    
                    <p><span class="label">Duration of Antibiotics:</span></p>
                    <ul>
                        <li><strong>If source identified:</strong> Treat for appropriate duration (7-14 days typical)</li>
                        <li><strong>If NO source, clinically improving, afebrile >48hr:</strong> Continue until ANC >500 (at least 7 days total)</li>
                        <li><strong>If persistent fever but stable:</strong> Continue antibiotics until ANC >500 or until fungal workup complete</li>
                        <li><strong>Do NOT stop antibiotics just because fever persists</strong> - fever may persist due to tumor, drugs, blood products, non-bacterial causes</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>G-CSF (filgrastim 5 mcg/kg SC daily):</strong> Consider if high-risk (MASCC <21, pneumonia, septic shock, invasive fungal, prolonged neutropenia expected >7-10 days). Shortens duration neutropenia. NOT needed routinely low-risk patients</li>
                        <li><strong>Fluid resuscitation:</strong> NS boluses if hypotensive. Early aggressive hydration improves outcomes</li>
                        <li><strong>Avoid rectal temps/exams, suppositories, enemas:</strong> Risk of bacteremia from mucosal trauma</li>
                        <li><strong>Transfusion support:</strong> pRBCs if Hgb <7-8, platelets if <10k (or <50k if bleeding/procedure)</li>
                        <li><strong>Oral care:</strong> Chlorhexidine or salt/soda rinses QID. Pain control (opiates if severe mucositis)</li>
                        <li><strong>Isolate patient:</strong> Private room, hand hygiene, avoid fresh flowers/plants (fungal spores), low-microbial diet controversial</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Door-to-antibiotic <1 hour saves lives:</strong> Mortality increases 18% for each hour delay. Don't wait for cultures - empiric antibiotics immediately</li>
                    <li><strong>Fever may be only sign:</strong> Neutropenic patients can't mount inflammatory response. No pus, minimal symptoms despite severe infection. Low threshold to treat</li>
                    <li><strong>ANC <100 is very high risk:</strong> "Profound neutropenia." Mortality >20%. Need aggressive treatment, GCSF, close monitoring</li>
                    <li><strong>Persistent fever >4-7 days ‚Üí add antifungal:</strong> Empiric coverage for invasive fungal (Aspergillus, Candida). Don't wait for positive cultures/markers</li>
                    <li><strong>Don't forget perirectal exam:</strong> But be gentle! Perirectal abscess common, may not have fluctuance. Severe tenderness = likely abscess. Needs drainage</li>
                    <li><strong>CXR can be falsely negative:</strong> Neutropenia ‚Üí no infiltrate despite pneumonia. If respiratory symptoms, get CT chest even if CXR normal</li>
                    <li><strong>Mucositis = add vancomycin:</strong> Oral/GI mucositis ‚Üërisk Strep viridans bacteremia. Must add vancomycin to empiric regimen</li>
                    <li><strong>Typhlitis is surgical emergency:</strong> RLQ pain + fever + neutropenia = typhlitis until proven otherwise. CT shows cecal wall thickening. High mortality if perforation. Surgical consult urgently</li>
                    <li><strong>Don't remove central line unless CRBSI confirmed:</strong> Lines are precious in chemo patients. Can treat through line unless Staph aureus, Candida, or persistent bacteremia</li>
                    <li><strong>GCSF shortens duration:</strong> Use if high-risk (MASCC <21). Shortens neutropenia by ~2-3 days, reduces infection complications. NOT needed routinely</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation</li>
                        <li>Multi-organ dysfunction (renal failure, hepatic failure)</li>
                        <li>Hemodynamic instability despite fluid resuscitation</li>
                        <li>Profound neutropenia (ANC <100) with sepsis</li>
                        <li>Typhlitis with concern for perforation</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile >24-48 hours off antibiotics (or on PO antibiotics if continued)</li>
                        <li>Hemodynamically stable</li>
                        <li>ANC recovering (>200-500 and rising)</li>
                        <li>No evidence of active infection requiring IV therapy</li>
                        <li>Able to tolerate PO intake</li>
                        <li>Close outpatient follow-up arranged (oncology within 48-72hr)</li>
                        <li>Patient education on infection precautions, when to return</li>
                        <li>Low-risk by MASCC score if outpatient management planned</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Infectious Complications:</strong> Septic shock (mortality 30-50%), invasive fungal infection (Aspergillus pneumonia, disseminated candidiasis - high mortality), typhlitis with perforation (requires surgery, high mortality), perirectal abscess with necrotizing fasciitis, catheter-related bloodstream infection (S. aureus, Candida - may require line removal), PCP pneumonia with respiratory failure</p>
                    <p><strong>Non-Infectious:</strong> Tumor lysis syndrome (especially with treatment of hematologic malignancies), mucositis (severe pain, inability to eat/swallow, TPN required), bleeding (thrombocytopenia), VTE (hypercoagulable from cancer), drug toxicity (nephrotoxicity, hepatotoxicity from antibiotics/antifungals)</p>
                    <p><strong>Mortality:</strong> Overall 5-20% depending on risk factors. Low-risk (MASCC ‚â•21) <5%, High-risk (MASCC <21) >20%. Mortality higher if: ANC <100, septic shock, pneumonia, invasive fungal infection, age >60</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 29: ALCOHOL WITHDRAWAL - EXPANDED -->
        <div id="etoh-withdrawal" class="condition-page">
            <div class="page-header">
                <h2>29. ALCOHOL WITHDRAWAL</h2>
                <div class="subtitle">CIWA-Ar Protocol ‚Ä¢ Delirium Tremens ‚Ä¢ Thiamine BEFORE Glucose</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Timeline of Symptoms:</span></p>
                    <ul>
                        <li><strong>Minor withdrawal (6-12 hours after last drink):</strong> Tremor, anxiety, agitation, diaphoresis, nausea/vomiting, headache, insomnia, mild tachycard ia, mild hypertension</li>
                        <li><strong>Withdrawal seizures (12-48 hours):</strong> Generalized tonic-clonic, typically brief (<2 min), single or clustered (2-4 seizures), self-limited. If prolonged or focal ‚Üí think other cause (structural lesion, infection)</li>
                        <li><strong>Alcoholic hallucinosis (12-24 hours):</strong> Visual, auditory, or tactile hallucinations WITH intact orientation (patient knows hallucinations aren't real). No autonomic instability. Benign, self-limited</li>
                        <li><strong>Delirium Tremens/DTs (48-72 hours, can be up to 7-10 days):</strong> Life-threatening. Severe autonomic instability (tachycardia >120, hypertension, hyperthermia >38.5¬∞C, profound diaphoresis), delirium (disoriented, agitated, hallucinations), tremor. Mortality 5-15% if untreated, <1-5% with treatment</li>
                    </ul>
                    
                    <p><span class="label">Risk Factors for Severe Withdrawal/DTs:</span> History of DTs/severe withdrawal, concurrent illness (pneumonia, pancreatitis, trauma), advanced age, multiple prior detoxifications (kindling phenomenon), prolonged heavy drinking, abrupt cessation, metabolic abnormalities (‚ÜìK, ‚ÜìMg, ‚ÜìPO4)</p>
                    
                    <p><span class="label">Alternate/Complicated Presentations:</span></p>
                    <ul>
                        <li><strong>Occult withdrawal in hospitalized patients:</strong> Admitted for other reason (trauma, surgery, infection), develops withdrawal 24-72hr into admission. High suspicion if unexplained tachycardia, hypertension, agitation</li>
                        <li><strong>Concurrent Wernicke encephalopathy:</strong> Acute thiamine deficiency. Triad: confusion, ataxia, ophthalmoplegia (nystagmus, gaze palsy). Often only 1-2 of triad present. Needs urgent IV thiamine BEFORE glucose</li>
                        <li><strong>Co-ingestion:</strong> Benzodiazepines (may mask withdrawal initially then rebound), opioids (can have concurrent withdrawal), stimulants (confound tachycardia/hypertension assessment)</li>
                        <li><strong>Hepatic encephalopathy mimicking DTs:</strong> Both have AMS, but HE has asterixis, elevated ammonia, slower onset. Can coexist</li>
                        <li><strong>Seizure complications:</strong> Status epilepticus (rare but life-threatening), aspiration pneumonia, traumatic injury from fall</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis:</span> Based on history, timeline, CIWA-Ar score. No specific diagnostic test</p>
                    
                    <p><span class="label">CIWA-Ar Score (Clinical Institute Withdrawal Assessment - Alcohol, revised):</span></p>
                    <p>10-item scale, max score 67. Assess q1-2h initially:</p>
                    <ul>
                        <li>Nausea/vomiting (0-7)</li>
                        <li>Tremor (0-7)</li>
                        <li>Paroxysmal sweats (0-7)</li>
                        <li>Anxiety (0-7)</li>
                        <li>Agitation (0-7)</li>
                        <li>Tactile disturbances (0-7)</li>
                        <li>Auditory disturbances (0-7)</li>
                        <li>Visual disturbances (0-7)</li>
                        <li>Headache (0-7)</li>
                        <li>Orientation/clouding of sensorium (0-4)</li>
                    </ul>
                    <p><strong>Interpretation:</strong> <8 = minimal withdrawal, 8-15 = moderate, >15 = severe, >20 = very severe (high DT risk)</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>BMP:</strong> Hypokalemia, hypomagnesemia, hypophosphatemia common. Anion gap metabolic acidosis (lactic acidosis, ketoacidosis). Renal function</li>
                        <li><strong>CBC:</strong> Macrocytosis (MCV >100), thrombocytopenia. Leukocytosis if infection</li>
                        <li><strong>LFTs:</strong> Elevated AST>ALT (2:1 ratio), GGT elevated. Assess for cirrhosis, hepatitis</li>
                        <li><strong>Albumin, INR:</strong> Synthetic liver function (low albumin, elevated INR = advanced liver disease)</li>
                        <li><strong>Magnesium, phosphate:</strong> Correct deficiencies (affect seizure threshold, cardiac arrhythmias)</li>
                        <li><strong>Thiamine level:</strong> Usually not sent (takes days, unreliable). Just give empiric thiamine</li>
                        <li><strong>Ethanol level:</strong> Helpful to know if still intoxicated vs pure withdrawal. But low/negative ethanol doesn't rule out withdrawal</li>
                        <li><strong>Lipase, troponin if abdominal pain/chest pain:</strong> Pancreatitis and ACS common in alcoholics</li>
                        <li><strong>Ammonia if concern for hepatic encephalopathy</strong></li>
                        <li><strong>Blood cultures if fever:</strong> Rule out infection (pneumonia, SBP, bacteremia)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT Head (if first seizure, focal seizure, persistent AMS, focal neurologic deficit, head trauma):</strong> Rule out ICH, subdural, stroke, mass</li>
                        <li><strong>CXR:</strong> Aspiration pneumonia common (especially post-seizure), eval for other pulmonary pathology</li>
                        <li><strong>EEG (if prolonged seizure or concern for non-convulsive status):</strong> Withdrawal seizures are brief, self-limited. If prolonged ‚Üí other etiology</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Benzodiazepines (Cornerstone of Treatment):</span></p>
                    
                    <p><strong>CIWA-Ar Protocol (Symptom-Triggered):</strong></p>
                    <ul>
                        <li><strong>Assess CIWA-Ar q1-2h (or q4h if stable/asleep)</strong></li>
                        <li><strong>If CIWA ‚â•8:</strong> Lorazepam 2-4mg IV/PO OR Diazepam 10-20mg IV/PO OR Chlordiazepoxide 50-100mg PO</li>
                        <li><strong>Reassess 1 hour after dose, repeat if CIWA still ‚â•8</strong></li>
                        <li><strong>Goal:</strong> CIWA <8, patient calm but arousable</li>
                        <li><strong>IV preferred if severe withdrawal, NPO, vomiting, or poor absorption</strong></li>
                    </ul>
                    
                    <p><strong>Fixed-Dose Protocol (if CIWA not feasible - ICU, intubated):</strong></p>
                    <ul>
                        <li><strong>Lorazepam 2mg IV q6h scheduled + 2mg q1h PRN breakthrough</strong></li>
                        <li><strong>OR Diazepam 10mg IV q6h scheduled + 10mg q1h PRN</strong></li>
                        <li><strong>Taper over 3-5 days once stable</strong></li>
                    </ul>
                    
                    <p><strong>Choice of Benzodiazepine:</strong></p>
                    <ul>
                        <li><strong>Lorazepam (Ativan):</strong> Intermediate-acting. No active metabolites. Safe in liver disease. Predictable IM absorption. PREFERRED if: liver disease, elderly, need IM route</li>
                        <li><strong>Diazepam (Valium):</strong> Long-acting, active metabolites (smoother withdrawal, less breakthrough). Preferred by some for DTs. Accumulates in liver disease. PREFERRED if: normal liver function, severe withdrawal/DTs</li>
                        <li><strong>Chlordiazepoxide (Librium):</strong> Long-acting, PO only. Good for mild-moderate withdrawal outpatient. NOT for severe/DTs</li>
                    </ul>
                    
                    <p><span class="label">Delirium Tremens (DTs) - Aggressive Management:</span></p>
                    <ul>
                        <li><strong>ICU admission</strong></li>
                        <li><strong>High-dose benzodiazepines:</strong> Lorazepam 2-4mg IV q10-15min or Diazepam 10-20mg IV q10-15min until symptoms controlled. May need 100s of mg/day</li>
                        <li><strong>Phenobarbital (if refractory to benzos):</strong> Phenobarbital 130-260mg IV q15-20min (max 10-15 mg/kg loading dose) then 30-60mg IV q6-8h maintenance. Synergistic with benzos, works on different GABA receptor</li>
                        <li><strong>Propofol/dexmedetomidine infusion (if refractory, intubated):</strong> Propofol 20-80 mcg/kg/min, Dexmedetomidine 0.2-1.5 mcg/kg/hr. Adjuncts, not replacements for benzos</li>
                        <li><strong>Avoid antipsychotics (haloperidol) as monotherapy:</strong> Lower seizure threshold, don't treat withdrawal. Can use low-dose as adjunct for hallucinations if needed (haloperidol 0.5-2mg)</li>
                        <li><strong>Aggressive supportive care:</strong> IVF, cooling for hyperthermia, electrolyte repletion</li>
                    </ul>
                    
                    <p><span class="label">Thiamine & Nutritional Repletion (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Thiamine 100mg IV daily √ó 3-5 days, then 100mg PO daily</strong></li>
                        <li><strong>MUST give thiamine BEFORE glucose</strong> (glucose depletes thiamine, can precipitate Wernicke encephalopathy)</li>
                        <li><strong>If concern for Wernicke:</strong> Thiamine 500mg IV TID √ó 3 days (higher dose)</li>
                        <li><strong>Folic acid 1mg PO daily</strong></li>
                        <li><strong>Multivitamin daily</strong></li>
                        <li><strong>Magnesium repletion:</strong> Mag sulfate 2-4g IV (or Mag oxide 400-800mg PO TID). Recheck and replete until >2 mg/dL. Hypomagnesemia ‚Üìefficacy of benzos, ‚Üëseizure risk</li>
                        <li><strong>Phosphate repletion:</strong> K-phos or NaPhos based on K level. Goal >2.5 mg/dL</li>
                        <li><strong>Potassium repletion:</strong> 40-80 mEq IV (if <3.5). Recheck q4-6h until >3.5</li>
                    </ul>
                    
                    <p><span class="label">Seizure Management:</span></p>
                    <ul>
                        <li><strong>Acute seizure:</strong> Lorazepam 2-4mg IV (treat seizure + withdrawal). Usually self-limited</li>
                        <li><strong>NO prophylactic AEDs:</strong> Benzodiazepines prevent seizures. AEDs (phenytoin, levetiracetam) don't prevent withdrawal seizures</li>
                        <li><strong>If status epilepticus or prolonged seizure:</strong> Standard status protocol (lorazepam, then phenytoin/fosphenytoin or levetiracetam loading)</li>
                        <li><strong>Replete magnesium aggressively</strong> (low Mg lowers seizure threshold)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Hydration:</strong> NS 100-150 mL/hr (many patients volume depleted). Monitor for volume overload if cirrhosis/cardiomyopathy</li>
                        <li><strong>Cooling for hyperthermia:</strong> Ice packs, cooling blanket. Acetaminophen (avoid NSAIDs if cirrhosis/varices)</li>
                        <li><strong>Aspiration precautions:</strong> NPO if AMS, HOB elevated, monitor for pneumonia</li>
                        <li><strong>Restraints only if necessary:</strong> Can worsen agitation, rhabdomyolysis. Verbal de-escalation, sitter, adequate sedation preferred</li>
                        <li><strong>Treat concurrent conditions:</strong> Pancreatitis, pneumonia, GI bleed common</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Thiamine BEFORE glucose:</strong> Glucose depletes thiamine stores, can precipitate Wernicke encephalopathy (irreversible). Always give thiamine first in alcoholic patients</li>
                    <li><strong>Withdrawal seizures are 12-48hr, self-limited:</strong> If seizure <12hr (still intoxicated?) or >48hr (other cause?), broaden differential. No need for AED prophylaxis - benzos prevent withdrawal seizures</li>
                    <li><strong>DTs peak 48-72hr:</strong> Life-threatening. Autonomic storm (tachy, HTN, fever, diaphoresis) + delirium. Needs ICU, massive doses of benzos. Mortality 5-15% if untreated</li>
                    <li><strong>Magnesium is key:</strong> Hypomagnesemia lowers seizure threshold, reduces benzo efficacy. Aggressively replete Mg until >2 mg/dL</li>
                    <li><strong>CIWA doesn't work if intubated/ICU:</strong> Need fixed-dose protocol. CIWA requires patient cooperation</li>
                    <li><strong>Phenobarbital for refractory DTs:</strong> If benzos failing (which is rare), add phenobarbital. Different GABA receptor, synergistic. Works when benzos don't</li>
                    <li><strong>Don't confuse with hepatic encephalopathy:</strong> Both have AMS in alcoholic. HE has asterixis, elevated ammonia, responds to lactulose/rifaximin. Can coexist. If unsure, treat both</li>
                    <li><strong>Occult withdrawal in hospital:</strong> Patient admitted for trauma/surgery/infection, becomes unexplained tachy/HTN/agitated 24-72hr later. Think withdrawal, check alcohol history</li>
                    <li><strong>Restraints worsen outcomes:</strong> Increase agitation, rhabdomyolysis, aspiration. Use adequate sedation instead. Chemical > physical restraint</li>
                    <li><strong>Can't oversedatewith benzos in withdrawal:</strong> Respiratory drive preserved until massive doses. Goal is calm but arousable. Don't underdose - prevents DTs</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Delirium tremens (autonomic instability + delirium)</li>
                        <li>Refractory withdrawal requiring high-dose benzos or phenobarbital</li>
                        <li>Seizures (especially if recurrent or status epilepticus)</li>
                        <li>Severe agitation requiring intubation for airway protection</li>
                        <li>Hemodynamic instability, severe hypertension</li>
                        <li>Concurrent critical illness (sepsis, GI bleed, pancreatitis)</li>
                    </ul>
                </div>
                
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>CIWA <8-10 for >24 hours</li>
                        <li>Stable vital signs off benzodiazepines</li>
                        <li>No seizure activity</li>
                        <li>Tolerating PO intake</li>
                        <li>Ambulating safely</li>
                        <li>Completed thiamine/vitamin repletion (or on PO regimen)</li>
                        <li>Substance use treatment/counseling initiated or arranged</li>
                        <li>Outpatient follow-up arranged (PCP, addiction medicine)</li>
                        <li>Safe discharge environment</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute Complications:</strong> Delirium tremens (mortality 5-15% if untreated), seizures (aspiration, trauma, status epilepticus), Wernicke encephalopathy (irreversible if not treated - ataxia, confusion, ophthalmoplegia ‚Üí Korsakoff syndrome with permanent memory impairment), aspiration pneumonia, rhabdomyolysis (from agitation, seizures, restraints - can cause AKI)</p>
                    <p><strong>Cardiovascular:</strong> Arrhythmias (especially if hypokalemia/hypomagnesemia), cardiomyopathy exacerbation (alcoholic CMP), hypertensive crisis, MI (demand ischemia from tachycardia)</p>
                    <p><strong>From Underlying Alcoholism:</strong> GI bleed (varices, gastritis, Mallory-Weiss), pancreatitis, hepatic encephalopathy, hepatorenal syndrome, coagulopathy (low platelets, elevated INR), infections (pneumonia, SBP)</p>
                    <p><strong>From Treatment:</strong> Over-sedation with respiratory depression (rare with benzos alone), paradoxical agitation, delirium from benzodiazepines</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITIONS 30-39: COMPREHENSIVE BUT STREAMLINED -->

<!-- CONDITION 30: DELIRIUM -->
        <div id="delirium" class="condition-page">
            <div class="page-header">
                <h2>30. DELIRIUM</h2>
                <div class="subtitle">Acute Confusional State ‚Ä¢ CAM Criteria ‚Ä¢ Treat Underlying Cause</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION & DIAGNOSIS</div>
                <div class="section-content">
                    <p><span class="label">CAM Criteria (Confusion Assessment Method) - ALL required:</span></p>
                    <ul>
                        <li><strong>(1) Acute onset + fluctuating course:</strong> Symptoms developed acutely (hours-days), wax/wane throughout day</li>
                        <li><strong>(2) Inattention:</strong> Difficulty focusing, easily distracted, can't follow conversation</li>
                        <li><strong>PLUS EITHER:</strong> (3) Disorganized thinking (rambling, illogical) OR (4) Altered level of consciousness (hyperalert, lethargic, stuporous)</li>
                    </ul>
                    
                    <p><span class="label">Types:</span> Hyperactive (25% - agitated, combative, hallucinations), Hypoactive (25% - lethargic, withdrawn, often missed), Mixed (50%)</p>
                    
                    <p><span class="label">Common Causes - "I WATCH DEATH":</span> Infections, Withdrawal, Acute metabolic, Trauma/CNS, Hypoxia, Deficiencies (B12, thiamine), Endocrine, Acute vascular, Toxins/drugs, Heavy metals</p>
                    
                    <p><span class="label">High-Risk Medications (Avoid):</span> Anticholinergics (diphenhydramine, TCAs), benzodiazepines (paradoxical), opioids, H2 blockers, corticosteroids, dopamine agonists</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">WORKUP & TREATMENT</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> CBC, CMP, UA/culture, blood cultures if fever, TSH, B12, drug screen, ammonia if liver disease, ABG if hypoxia</p>
                    <p><span class="label">Imaging:</span> CT head if focal signs, fall, anticoagulated, new-onset</p>
                    <p><span class="label">LP if:</span> Fever + AMS with no clear source (meningitis/encephalitis)</p>
                    
                    <p><span class="label">Non-Pharmacologic (FIRST-LINE):</span></p>
                    <ul>
                        <li>Reorient frequently (clocks, calendars, familiar objects)</li>
                        <li>Normalize sleep-wake cycle (lights on during day, dark/quiet at night)</li>
                        <li>Early mobilization (PT/OT daily)</li>
                        <li>Sensory aids (glasses, hearing aids)</li>
                        <li>Avoid restraints (worsen delirium)</li>
                        <li>Family/sitter presence</li>
                    </ul>
                    
                    <p><span class="label">Pharmacologic (ONLY if severe agitation, danger to self/others):</span></p>
                    <ul>
                        <li><strong>Haloperidol 0.5-2mg IV/PO q4-6h PRN</strong> (low-dose). Avoid if QTc >500, Parkinson's, Lewy body dementia</li>
                        <li><strong>Quetiapine 25-50mg PO q12h</strong> (if hyperactive, sundowning). Better for elderly</li>
                        <li><strong>Avoid benzodiazepines</strong> (except alcohol/benzo withdrawal)</li>
                    </ul>
                </div>
            </div>
            
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Delirium vs Dementia:</strong> Delirium = acute onset (hours-days), fluctuating, inattention. Dementia = chronic (months-years), stable throughout day, memory loss predominates</li>
                    <li><strong>Hypoactive delirium often missed:</strong> Quiet, withdrawn, "pleasantly confused." Worse outcomes than hyperactive. Screen all elderly admissions with CAM</li>
                    <li><strong>Anticholinergics are enemy #1:</strong> Diphenhydramine, TCAs, scopolamine, first-gen antihistamines. Avoid in elderly</li>
                    <li><strong>Restraints worsen delirium:</strong> Increase agitation, prolong delirium, cause injury. Use sitters, reorientation instead</li>
                    <li><strong>Every delirious patient needs infection workup:</strong> UTI, pneumonia, bacteremia most common. Even if afebrile</li>
                </ul>
            </div>
            
            <div class="two-column-container">
                <div class="risk-box">
                    <div class="box-title">‚ö†Ô∏è ICU TRANSFER CRITERIA</div>
                    <ul>
                        <li>Severe agitation refractory to medications</li>
                        <li>Respiratory compromise requiring intubation for airway protection</li>
                        <li>Hemodynamic instability</li>
                        <li>Concern for life-threatening cause (meningitis, severe sepsis)</li>
                    </ul>
                </div>
                <div class="risk-box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Delirium resolved or significantly improved</li>
                        <li>Underlying cause identified and treated</li>
                        <li>Safe functional status (ambulation, ADLs)</li>
                        <li>Medication reconciliation (d/c deliriogenic meds)</li>
                        <li>Adequate support at discharge (may need rehab/SNF)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Falls, aspiration, pressure ulcers, prolonged hospitalization (‚ÜëLOS by 5-10 days), functional decline</p>
                    <p><strong>Long-term:</strong> Persistent cognitive impairment (30-40%), increased mortality (11% at 1 month), institutionalization, progression to dementia</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITION 31-35: ENDOCRINE EMERGENCIES (Condensed) -->
        
        <div id="hyperthyroid" class="condition-page">
            <div class="page-header">
                <h2>31. HYPERTHYROIDISM / THYROID STORM</h2>
                <div class="subtitle">Graves ‚Ä¢ Toxic Adenoma ‚Ä¢ Storm = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Weight loss despite ‚Üëappetite, tremor, palpitations/AFib, heat intolerance, diarrhea, anxiety, proximal weakness. Graves: exophthalmos, pretibial myxedema, diffuse goiter</p>
                    <p><span class="label">Storm (Life-Threatening):</span> Fever >40¬∞C (104¬∞F), severe tachycardia (>140), AMS, agitation/psychosis, heart failure, vomiting/diarrhea. Burch-Wartofsky score ‚â•45 = storm. Mortality 10-20%</p>
                    <p><span class="label">Labs:</span> TSH suppressed (<0.01), Free T4 elevated (>1.8), Free T3 elevated. TSI/TRAb positive (Graves). Radioiodine uptake scan if etiology unclear</p>
                    
                    <p><span class="label">Storm Treatment (Order Matters!):</span></p>
                    <ol>
                        <li><strong>Œ≤-blocker FIRST:</strong> Propranolol 60-80mg PO q4-6h (or 1mg IV q10min) OR Esmolol infusion. Blocks peripheral T4‚ÜíT3 conversion + controls symptoms</li>
                        <li><strong>Thionamide (1hr after Œ≤-blocker):</strong> PTU 600mg PO load then 200mg q6h OR Methimazole 20mg q6h. PTU preferred (blocks T4‚ÜíT3 conversion)</li>
                        <li><strong>Iodine (1hr AFTER thionamide):</strong> SSKI 5 drops PO q6h OR Lugol's solution 10 drops q8h. Blocks thyroid hormone release. Must give after thionamide (prevents iodine from being used for hormone synthesis)</li>
                        <li><strong>Steroid:</strong> Hydrocortisone 100mg IV q8h (blocks T4‚ÜíT3, treats possible adrenal insufficiency)</li>
                        <li><strong>Supportive:</strong> Cooling (acetaminophen, cooling blanket - NOT aspirin, displaces T4 from binding proteins), IVF, treat precipitant</li>
                    </ol>
                    
                    <p><span class="label">Outpatient Hyperthyroidism:</span> Methimazole 10-20mg daily (first-line) OR PTU 50mg TID (if pregnant 1st trimester, intolerant to methimazole). Propranolol 20-40mg TID for symptoms. Definitive: Radioiodine ablation or thyroidectomy after euthyroid</p>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Order matters in storm:</strong> Œ≤-blocker first, thionamide 1hr later, iodine 1hr after that. Wrong order = worsened storm</li>
                    <li><strong>Iodine without thionamide = bad:</strong> Provides substrate for more hormone synthesis. Always give thionamide first</li>
                    <li><strong>PTU in pregnancy 1st trimester:</strong> Methimazole causes aplasia cutis. Switch to methimazole 2nd/3rd trimester</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypothyroid" class="condition-page">
            <div class="page-header">
                <h2>32. HYPOTHYROIDISM / MYXEDEMA COMA</h2>
                <div class="subtitle">Severe Hypothyroidism ‚Ä¢ Rare but Lethal</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic Hypothyroidism:</span> Fatigue, weight gain, cold intolerance, constipation, hair loss, dry skin, bradycardia, delayed DTRs, periorbital edema. Labs: TSH elevated (>10), Free T4 low (<0.8)</p>
                    <p><span class="label">Treatment Outpatient:</span> Levothyroxine 1.6 mcg/kg/day PO (typical 75-125 mcg daily). Start 25-50 mcg if elderly/>65yo or CAD (risk MI from increased demand). Recheck TSH 6-8 weeks, titrate to normal TSH</p>
                    
                    <p><span class="label">Myxedema Coma (Emergency, Mortality 30-60%):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Profound hypothermia (<95¬∞F), severe bradycardia (<50), hypoventilation (‚ÜìCO2 drive, respiratory failure), hyponatremia, hypoglycemia, AMS‚Üícoma, non-pitting edema, pericardial/pleural effusions</li>
                        <li><strong>Precipitants:</strong> Infection, MI, stroke, hypothermia, sedatives/narcotics, surgery</li>
                        <li><strong>Diagnosis:</strong> Clinical + TSH elevated (>20), Free T4 very low. Don't wait for labs - treat empirically if high suspicion</li>
                    </ul>
                    
                    <p><span class="label">Myxedema Coma Treatment:</span></p>
                    <ul>
                        <li><strong>T4 (levothyroxine) 200-400 mcg IV load</strong> then 100 mcg IV daily. Larger, slower onset but safer</li>
                        <li><strong>PLUS T3 (liothyronine) 10 mcg IV q8h:</strong> Faster onset (hours vs days). Use both T4+T3</li>
                        <li><strong>Hydrocortisone 100mg IV q8h:</strong> Rule out adrenal insufficiency (can coexist). Give steroids BEFORE thyroid hormone (thyroid hormone can precipitate crisis if AI present)</li>
                        <li><strong>Supportive:</strong> Passive rewarming (NOT active - can cause vascular collapse), mechanical ventilation if respiratory failure, hypertonic saline if severe hyponatremia (usually improves with treatment), treat precipitant (infection)</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Steroid BEFORE thyroid hormone in crisis:</strong> Prevents adrenal crisis from increased cortisol metabolism</li>
                    <li><strong>Passive rewarming only:</strong> Active rewarming (warm blankets, heating) causes peripheral vasodilation ‚Üí cardiovascular collapse</li>
                    <li><strong>Hyponatremia improves with treatment:</strong> Due to SIADH from hypothyroidism. Don't over correct</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="adrenal" class="condition-page">
            <div class="page-header">
                <h2>33. ADRENAL INSUFFICIENCY / CRISIS</h2>
                <div class="subtitle">Primary (Addison's) ‚Ä¢ Secondary ‚Ä¢ Crisis = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Chronic AI Presentation:</span> Fatigue, weight loss, hypotension, hyponatremia, hypoglycemia. PRIMARY (Addison's) ALSO has: hyperkalemia, hyperpigmentation (‚ÜëACTH stimulates melanocytes), salt craving. SECONDARY: no hyperK/hyperpigmentation</p>
                    
                    <p><span class="label">Adrenal Crisis (Emergency):</span> Shock (refractory hypotension), abdominal pain/vomiting (mimics acute abdomen), fever, severe dehydration, AMS/confusion. Precipitants: Infection, surgery, trauma, stopping steroids abruptly</p>
                    
                    <p><span class="label">Diagnosis:</span></p>
                    <ul>
                        <li><strong>Random cortisol:</strong> <3 mcg/dL = AI, >18 = excludes, 3-18 = indeterminate (do stim test)</li>
                        <li><strong>Cosyntropin stimulation test:</strong> Give cosyntropin 250 mcg IV, check cortisol at 30 and 60 min. Normal: cortisol >18-20. Abnormal: <18 = AI</li>
                        <li><strong>DON'T WAIT for test in crisis - treat empirically!</strong> Can do test later</li>
                        <li><strong>Distinguish primary vs secondary:</strong> ACTH level. Primary: ACTH >100 (pituitary trying to stimulate failed adrenals). Secondary: ACTH <10 (pituitary failure)</li>
                    </ul>
                    
                    <p><span class="label">Crisis Treatment (DON'T DELAY):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 100mg IV bolus immediately,</strong> then 50-100mg IV q6-8h (or 200mg/24hr continuous infusion)</li>
                        <li><strong>Aggressive IVF:</strong> NS 1-2L rapidly, then 200-300 mL/hr. Patients profoundly volume depleted</li>
                        <li><strong>Dextrose if hypoglycemic:</strong> D50 1-2 amps IV</li>
                        <li><strong>Treat precipitant:</strong> Antibiotics if infection, stress-dose steroids perioperatively</li>
                        <li><strong>NO fludrocortisone initially:</strong> High-dose hydrocortisone has mineralocorticoid activity. Add fludrocortisone once stable on oral therapy</li>
                    </ul>
                    
                    <p><span class="label">Chronic Replacement (After Crisis):</span></p>
                    <ul>
                        <li><strong>Hydrocortisone 15-25mg/day divided BID-TID</strong> (give 2/3 AM, 1/3 afternoon - mimic diurnal rhythm)</li>
                        <li><strong>Fludrocortisone 0.1mg PO daily if PRIMARY</strong> (mineralocorticoid replacement). Not needed if secondary</li>
                        <li><strong>Stress dosing:</strong> Double-triple dose for illness, surgery. Fever/infection: double dose. Major surgery: hydrocortisone 100mg IV q8h √ó 24-48hr</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Don't wait to treat crisis:</strong> If suspected, give hydrocortisone 100mg IV immediately. Can do cosyntropin test after (use dexamethasone 4mg if need test, doesn't interfere)</li>
                    <li><strong>Hyperkalemia + hyponatremia = PRIMARY:</strong> Aldosterone deficiency. Secondary AI has normal K (aldosterone intact)</li>
                    <li><strong>Hyperpigmentation = PRIMARY:</strong> ‚ÜëACTH stimulates melanocytes. Look: knuckles, palmar creases, scars, mucous membranes</li>
                    <li><strong>Most common cause chronic AI:</strong> Iatrogenic (stopping steroids abruptly after chronic use). Need slow taper</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypercalcemia" class="condition-page">
            <div class="page-header">
                <h2>34. HYPERCALCEMIA</h2>
                <div class="subtitle">"Stones, Bones, Groans, Psychiatric Overtones"</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Symptoms:</span> Mild (Ca 10.5-12): Often asymptomatic. Moderate-Severe (Ca >12): Polyuria/polydipsia (nephrogenic DI), constipation, nausea/vomiting, weakness, confusion, lethargy, shortened QT interval. Very severe (>14): AMS, coma, arrhythmias</p>
                    
                    <p><span class="label">Causes (90% are these 2):</span></p>
                    <ul>
                        <li><strong>Primary hyperparathyroidism:</strong> Outpatient, mild-moderate (Ca 10.5-11.5). PTH elevated or "inappropriately normal" with high Ca. Adenoma usually. Treatment: Parathyroidectomy if symptomatic</li>
                        <li><strong>Malignancy:</strong> Inpatient, moderate-severe (Ca >12). PTH suppressed (<20). Mechanisms: PTHrP (squamous cell, renal, breast), osteolytic mets (multiple myeloma, breast), calcitriol production (lymphoma). Treatment: Treat cancer, aggressive hydration, bisphosphonates</li>
                        <li><strong>Other:</strong> Granulomatous disease (sarcoid, TB - ‚Üëcalcitriol), meds (thiazides, lithium, vitamin D intoxication), immobilization</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Severe Hypercalcemia Ca >12-14):</span></p>
                    <ol>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (goal UOP 100-150 mL/hr). Rehydrate (hypercalcemia causes dehydration from nephrogenic DI). Works in hours, lowers Ca 1-3 mg/dL. FIRST-LINE</li>
                        <li><strong>Calcitonin 4 units/kg subQ or IM q12h:</strong> Rapid onset (4-6hr), modest effect (‚ÜìCa 1-2 mg/dL). Tachyphylaxis in 48-72hr. Use as bridge while waiting for bisphosphonate</li>
                        <li><strong>Bisphosphonates (MOST effective):</strong> Pamidronate 60-90mg IV over 2-4hr OR Zoledronic acid 4mg IV over 15min. Onset 2-4 days, peak 5-7 days, lasts weeks. Lowers Ca 2-3 mg/dL. Dose-adjust if CrCl <30</li>
                        <li><strong>Dialysis:</strong> If refractory, severe renal failure, or Ca >18. Rapidly effective</li>
                        <li><strong>Avoid thiazides, lithium, vitamin D/calcium supplements</strong></li>
                    </ol>
                    
                    <p><span class="label">Special Cases:</span></p>
                    <ul>
                        <li><strong>Granulomatous (sarcoid):</strong> Prednisone 20-40mg daily (‚Üìcalcitriol production)</li>
                        <li><strong>Lymphoma:</strong> Treat malignancy, steroids help</li>
                        <li><strong>Vitamin D intoxication:</strong> Stop vitamin D, steroids, fluids, bisphosphonates</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>PTH tells you the cause:</strong> PTH elevated/normal = hyperparathyroidism. PTH suppressed = malignancy or other</li>
                    <li><strong>Outpatient vs inpatient:</strong> Outpatient mild hypercalcemia = hyperparathyroidism. Inpatient severe = malignancy</li>
                    <li><strong>Calcitonin is bridge:</strong> Works fast (hours) but tachyphylaxis (stops working after 2-3 days). Use while waiting for bisphosphonate to kick in</li>
                    <li><strong>Bisphosphonates most effective:</strong> But slow (2-4 days). Lasts weeks. Don't give if AKI (wait for rehydration)</li>
                    <li><strong>Furosemide does NOT help:</strong> Old teaching. Causes dehydration, worsens. Only if volume overload</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="hypomag" class="condition-page">
            <div class="page-header">
                <h2>35. HYPOMAGNESEMIA</h2>
                <div class="subtitle">Mg <1.5 ‚Ä¢ Often With HypoK/HypoCa</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes:</span> GI losses (diarrhea, malabsorption), renal losses (diuretics - loops/thiazides, PPIs, aminoglycosides, cisplatin, amphotericin), alcohol, DKA, refeeding syndrome, chronic PPI use</p>
                    <p><span class="label">Symptoms:</span> Often asymptomatic until Mg <1. Tremor, muscle fasciculations, weakness, tetany (Trousseau/Chvostek signs), seizures, arrhythmias (torsades de pointes, afib, PVCs), personality changes. Refractory hypokalemia/hypocalcemia (Mg needed for K/Ca homeostasis)</p>
                    <p><span class="label">ECG:</span> Prolonged QT, widened QRS, peaked T waves, torsades de pointes</p>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Asymptomatic/Mild (Mg >1):</strong> Magnesium oxide 400-800mg PO BID-TID (poorly absorbed, causes diarrhea). OR Mag glycinate/citrate better tolerated</li>
                        <li><strong>Moderate (Mg <1) or Symptomatic:</strong> Magnesium sulfate 2g IV over 15-30min, repeat q6h until Mg >1.5. Then transition to PO</li>
                        <li><strong>Severe/Life-Threatening (Torsades, seizure, tetany):</strong> Magnesium sulfate 2-4g IV over 10-15min, then continuous infusion 1-2g/hr. Monitor DTRs (loss = hypermagnesemia). Cardiac monitor</li>
                        <li><strong>Replete K and Ca simultaneously:</strong> Won't normalize until Mg corrected. Check all three, replete together</li>
                        <li><strong>Monitor serum Mg q6-12h</strong> during repletion. Goal >1.5-2 mg/dL</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Refractory hypokalemia = check Mg:</strong> Can't fix K until Mg replete. Mg needed for K channel function</li>
                    <li><strong>Hypocalcemia with Mg deficiency:</strong> Mg needed for PTH secretion/action. Replete Mg first, Ca will follow</li>
                    <li><strong>Torsades de pointes:</strong> 2g Mg IV over 1-2min (even if Mg normal). First-line treatment</li>
                    <li><strong>Monitor DTRs:</strong> Loss of reflexes = hypermagnesemia (>4-5). Stop infusion if DTRs lost</li>
                    <li><strong>PPI-induced hypomagnesemia:</strong> Chronic PPI use (months-years) ‚Üí severe hypomagnesemia. Stop PPI, switch to H2 blocker</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- CONDITIONS 36-39: Final Four -->

        <div id="rhabdo" class="condition-page">
            <div class="page-header">
                <h2>36. RHABDOMYOLYSIS</h2>
                <div class="subtitle">CK >1000 ‚Ä¢ Myoglobinuria ‚Ä¢ AKI Risk</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Causes - "CRAMPS":</span> Crush injury/trauma, Recreational drugs (cocaine, PCP, MDMA, amphetamines), Alcohol/Anesthetics (malignant hyperthermia, NMS), Meds (statins, fibrates, colchicine), Prolonged immobilization/seizures, Strenuous exercise, Heat stroke, Infections (influenza, HIV)</p>
                    <p><span class="label">Classic Triad (only 10% have all 3):</span> Myalgias, weakness, dark urine (tea/cola-colored from myoglobinuria)</p>
                    <p><span class="label">Presentation:</strong> Muscle pain/tenderness/swelling, weakness, dark urine. May have compartment syndrome (tense compartments, pain out of proportion, 5 P's). Severe: AKI, hyperkalemia, arrhythmias</p>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CK (creatine kinase):</strong> >1000 (often >5000, can be >100,000). Peak 24-36hr, normalize in 3-5 days. Trend daily</li>
                        <li><strong>Urine:</strong> Dipstick positive for blood (myoglobin cross-reacts) but NO RBCs on microscopy. Urine myoglobin (rarely sent, not needed)</li>
                        <li><strong>BMP:</strong> AKI (Cr rising), hyperkalemia (released from muscle - LIFE-THREATENING), hypocalcemia early (Ca deposits in necrotic muscle), hypercalcemia late (resorption), hyperphosphatemia (released from muscle), elevated anion gap (lactate)</li>
                        <li><strong>ABG:</strong> Metabolic acidosis</li>
                        <li><strong>Check:</strong> LDH, AST/ALT (elevated from muscle, not liver), uric acid (elevated)</li>
                    </ul>
                    
                    <p><span class="label">Treatment (Aggressive IVF is Key):</span></p>
                    <ul>
                        <li><strong>IV Fluids:</strong> NS 200-300 mL/hr (or 1-1.5 L/hr if severe). Goal: UOP >200-300 mL/hr (flush myoglobin before it precipitates in tubules). Continue until CK downtrending <5000 AND Cr improving</li>
                        <li><strong>Monitor:</strong> Strict I/Os, UOP hourly, daily CK/BMP/Ca/Phos, cardiac telemetry (hyperK risk)</li>
                        <li><strong>Alkalinize urine (controversial, not routinely recommended):</strong> Some add NaHCO3 to IVF (3 amps in 1L D5W at 200 mL/hr) to maintain urine pH >6.5 (prevents myoglobin precipitation). But no proven benefit, risks volume overload/alkalosis</li>
                        <li><strong>Avoid:</strong> NSAIDs, nephrotoxins</li>
                        <li><strong>Hyperkalemia:</strong> Treat aggressively (insulin/dextrose, calcium, kayexalate, dialysis if severe)</li>
                        <li><strong>Hypocalcemia (early):</strong> DO NOT treat unless symptomatic (seizures, tetany, long QT). Repleting Ca can worsen later hypercalcemia</li>
                        <li><strong>Dialysis if:</strong> Severe AKI (oliguric, Cr >5-6), refractory hyperkalemia, severe acidosis, volume overload</li>
                        <li><strong>Compartment syndrome:</strong> Ortho/surgery consult URGENTLY. Fasciotomy if pressures >30 mmHg</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>IVF, IVF, IVF:</strong> Aggressive volume expansion is treatment. Prevents AKI by flushing myoglobin. Goal UOP >200 mL/hr</li>
                    <li><strong>Hyperkalemia kills:</strong> Released from necrotic muscle. Check K q6-12h initially. Cardiac monitor. Treat aggressively</li>
                    <li><strong>Don't treat early hypocalcemia:</strong> Ca deposits in muscle. Later, gets resorbed ‚Üí hypercalcemia. Treating early worsens late</li>
                    <li><strong>Dipstick + but no RBCs = myoglobinuria:</strong> Myoglobin cross-reacts with hemoglobin on dipstick. Microscopy negative for RBCs</li>
                    <li><strong>Statin-induced rhabdo:</strong> Risk factors: Asian, elderly, CKD, drug interactions (gemfibrozil, azoles, macrolides). Check CK before starting if high risk</li>
                    <li><strong>Compartment syndrome:</strong> Tense compartment, pain out of proportion, pain with passive stretch. Pressures >30 mmHg. SURGICAL EMERGENCY - fasciotomy</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="transfusion" class="condition-page">
            <div class="page-header">
                <h2>37. TRANSFUSION REACTIONS</h2>
                <div class="subtitle">Acute Hemolytic ‚Ä¢ TRALI ‚Ä¢ TACO ‚Ä¢ Febrile</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Acute Hemolytic (ABO Incompatibility) - WORST:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within minutes of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever, chills, back/chest/flank pain, dyspnea, hypotension, hemoglobinuria (red/dark urine), DIC, AKI. IF INTUBATED: unexplained fever, hypotension, hemoglobinuria, oozing from surgical sites</li>
                        <li><strong>Cause:</strong> Clerical error (wrong blood to wrong patient). ABO antibodies lyse donor RBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion immediately! Maintain UOP >100 mL/hr (IVF, diuretics, alkalinize urine). Pressors if shock. Check: Coombs (DAT), LDH, haptoglobin, bilirubin, coags (DIC screen). Send blood bag + patient blood back to blood bank</li>
                    </ul>
                    
                    <p><span class="label">Febrile Non-Hemolytic (FNHTR) - Most Common:</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 4hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Fever (>1¬∞C rise or >38¬∞C), chills, rigors. No hemolysis</li>
                        <li><strong>Cause:</strong> Recipient antibodies against donor WBCs/platelets, or cytokines released from donor WBCs</li>
                        <li><strong>Treatment:</strong> STOP transfusion. Check hemolysis labs (rule out hemolytic). If negative, give acetaminophen, can cautiously resume transfusion slowly. Prevent: Leukoreduced blood for future transfusions, pre-med with acetaminophen</li>
                    </ul>
                    
                    <p><span class="label">TRALI (Transfusion-Related Acute Lung Injury):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> Within 6hr of transfusion</li>
                        <li><strong>Symptoms:</strong> Acute hypoxemia, dyspnea, bilateral infiltrates on CXR (looks like ARDS), fever, hypotension. Normal CVP/PCWP (vs TACO)</li>
                        <li><strong>Cause:</strong> Donor antibodies against recipient WBCs ‚Üí capillary leak, non-cardiogenic pulmonary edema</li>
                        <li><strong>Treatment:</strong> Supportive - O2, may need intubation/mechanical ventilation. Diuretics NOT helpful (not volume overload). Usually resolves 48-96hr</li>
                    </ul>
                    
                    <p><span class="label">TACO (Transfusion-Associated Circulatory Overload):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> During or within 6hr</li>
                        <li><strong>Symptoms:</strong> Dyspnea, tachycardia, hypertension, JVD, pulmonary edema, bilateral crackles. Elevated BNP/NT-proBNP</li>
                        <li><strong>Cause:</strong> Volume overload (especially in CHF, renal failure, elderly)</li>
                        <li><strong>Treatment:</strong> Slow/stop transfusion. Diuretics (furosemide 20-40mg IV). O2, upright position. Prevent: Slow transfusion rate (<1 unit per 2-4hr), furosemide between units if high risk</li>
                    </ul>
                    
                    <p><span class="label">Allergic:</span></p>
                    <ul>
                        <li><strong>Mild (urticaria):</strong> Stop transfusion, antihistamine (diphenhydramine 25-50mg). Can resume if improves. Pre-med with antihistamine for future</li>
                        <li><strong>Severe (anaphylaxis):</strong> Angioedema, bronchospasm, hypotension. STOP transfusion. Epinephrine 0.3-0.5mg IM, antihistamines, steroids, IVF, pressors. Washed RBCs for future (removes plasma proteins)</li>
                    </ul>
                    
                    <p><span class="label">Delayed Hemolytic (Days to Weeks):</span></p>
                    <ul>
                        <li><strong>Timing:</strong> 3-10 days post-transfusion</li>
                        <li><strong>Symptoms:</strong> Unexplained fever, jaundice, falling Hgb, dark urine. Less severe than acute hemolytic</li>
                        <li><strong>Cause:</strong> Anamnestic antibody response (patient previously sensitized, antibody level low ‚Üí transfusion boosts antibody production)</li>
                        <li><strong>Labs:</strong> Positive DAT, elevated bilirubin, LDH, low haptoglobin</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>STOP transfusion first:</strong> For ANY reaction (except very mild urticaria). Check vitals, send hemolysis labs, notify blood bank</li>
                    <li><strong>Acute hemolytic is clerical error:</strong> Wrong blood to wrong patient. Double-check patient ID before transfusion. Devastating complication</li>
                    <li><strong>TRALI vs TACO:</strong> Both have pulmonary edema within 6hr. TRALI = hypotension, normal CVP. TACO = hypertension, JVD, elevated BNP. TRALI = supportive, TACO = diuretics</li>
                    <li><strong>Febrile reaction most common:</strong> Benign. Rule out hemolysis (check labs), then acetaminophen, resume transfusion. Prevent with leukoreduced blood</li>
                    <li><strong>Pre-med selectively:</strong> Acetaminophen if prior febrile reactions. Diphenhydramine if prior allergic. NOT routinely for everyone</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="pleural-effusion" class="condition-page">
            <div class="page-header">
                <h2>38. PLEURAL EFFUSION</h2>
                <div class="subtitle">Transudate vs Exudate ‚Ä¢ Light's Criteria</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Presentation:</span> Dyspnea, pleuritic chest pain, cough. Exam: Decreased breath sounds, dullness to percussion, decreased tactile fremitus</p>
                    <p><span class="label">CXR:</span> Blunted costophrenic angle (requires ~200 mL). Lateral decubitus view (layering confirms free-flowing fluid). If loculated, doesn't layer</p>
                    <p><span class="label">Ultrasound:</span> More sensitive than CXR (detects 50 mL). Guides thoracentesis</p>
                    
                    <p><span class="label">Light's Criteria (Exudate if ‚â•1 of 3):</span></p>
                    <ul>
                        <li>Pleural fluid protein / Serum protein >0.5</li>
                        <li>Pleural fluid LDH / Serum LDH >0.6</li>
                        <li>Pleural fluid LDH >2/3 upper limit of normal serum LDH</li>
                    </ul>
                    <p><strong>Sensitivity 98%, Specificity 80%.</strong> Misclassifies ~20% transudates as exudates (especially if on diuretics). If clinically transudate but meets Light's, calculate serum-albumin gradient: Serum albumin - Pleural albumin >1.2 = transudate</p>
                    
                    <p><span class="label">Transudate (‚ÜìCapillary Hydrostatic Pressure or ‚ÜìOncotic Pressure):</span></p>
                    <ul>
                        <li><strong>CHF (most common):</strong> Bilateral, symmetric. Treat CHF (diuretics). Thoracentesis only if asymmetric, fever, or not responding to diuresis</li>
                        <li><strong>Cirrhosis/Hepatic hydrothorax:</strong> Usually right-sided. Treat ascites (diuretics, TIPS if refractory)</li>
                        <li><strong>Nephrotic syndrome:</strong> Hypoalbuminemia (<2.5), proteinuria >3.5 g/day</li>
                        <li><strong>PE:</strong> Can be transudate OR exudate. If high suspicion, get CTPA</li>
                    </ul>
                    
                    <p><span class="label">Exudate (Inflammation, Infection, Malignancy):</span></p>
                    <ul>
                        <li><strong>Pneumonia/Parapneumonic:</strong> Most common exudate. Thoracentesis if fluid >10mm on lateral decubitus or loculated. Simple parapneumonic: pH >7.2, glucose >60, LDH <1000, negative Gram/culture ‚Üí antibiotics alone. Complicated: pH <7.2, glucose <60, LDH >1000, or positive Gram/culture ‚Üí chest tube drainage</li>
                        <li><strong>Empyema:</strong> Pus in pleural space. Frank pus, positive Gram stain/culture, pH <7.2, glucose <40. Needs chest tube + antibiotics +/- VATS/surgery</li>
                        <li><strong>Malignancy:</strong> Lung cancer, breast, lymphoma, ovarian. Often bloody, exudative. Cytology positive in 60%. Thoracentesis for diagnosis + symptom relief. Pleurodesis if recurrent</li>
                        <li><strong>TB:</strong> Lymphocytic predominance (>50%), elevated ADA (>40 U/L), positive AFB culture (50-80% if also send pleural biopsy). Pleural biopsy for culture + histology (granulomas)</li>
                        <li><strong>PE:</strong> 1/3 transudates, 2/3 exudates. Often bloody. If suspected, get CTPA</li>
                        <li><strong>Pancreatitis:</strong> Left-sided, elevated pleural fluid amylase (>serum)</li>
                    </ul>
                    
                    <p><span class="label">Send Pleural Fluid for:</span></p>
                    <ul>
                        <li><strong>Always:</strong> pH, protein, LDH, cell count/diff, Gram stain, culture (aerobic/anaerobic)</li>
                        <li><strong>If concern for malignancy:</strong> Cytology (3 samples ‚Üëyield)</li>
                        <li><strong>If suspect TB:</strong> AFB smear/culture, ADA, pleural biopsy</li>
                        <li><strong>If bloody:</strong> Hematocrit (Hct >50% of serum Hct = hemothorax)</li>
                        <li><strong>If concern for pancreatitis, esophageal rupture:</strong> Amylase</li>
                        <li><strong>If milky appearance:</strong> Triglycerides (>110 = chylothorax)</li>
                    </ul>
                    
                    <p><span class="label">Treatment:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause</strong></li>
                        <li><strong>Therapeutic thoracentesis:</strong> If symptomatic (dyspnea). Remove 1-1.5L max at a time (risk re-expansion pulmonary edema if >1.5L). Repeatthorax as needed</li>
                        <li><strong>Chest tube:</strong> If empyema, complicated parapneumonic, hemothorax</li>
                        <li><strong>Pleurodesis:</strong> If recurrent malignant effusion (talc, doxycycline, bleomycin). Prevents reaccumulation</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé PEARLS</div>
                <ul>
                    <li><strong>Light's Criteria rules in exudate:</strong> Sens 98%, but 20% false positives (transudate called exudate). Use serum-albumin gradient if doesn't fit clinically</li>
                    <li><strong>CHF effusions are bilateral/symmetric:</strong> If unilateral or asymmetric, tap it (could be empyema, malignancy, PE)</li>
                    <li><strong>pH <7.2 or glucose <60 = drain it:</strong> Complicated parapneumonic/empyema. Won't resolve with antibiotics alone. Needs chest tube</li>
                    <li><strong>TB effusion is lymphocytic:</strong> >50% lymphs. ADA >40 suggestive. Pleural biopsy ‚Üëyield (culture + granulomas)</li>
                    <li><strong>Don't remove >1.5L at once:</strong> Risk re-expansion pulmonary edema (chest pain, cough, hypoxia after thoracentesis). Stop if patient develops symptoms or pressure drops >20 cm H2O</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

        <div id="pneumothorax" class="condition-page">
            <div class="page-header">
                <h2>39. PNEUMOTHORAX</h2>
                <div class="subtitle">Primary ‚Ä¢ Secondary ‚Ä¢ Iatrogenic ‚Ä¢ TENSION = Emergency</div>
            </div>
            
            <div class="section">
                <div class="section-content">
                    <p><span class="label">Types:</span></p>
                    <ul>
                        <li><strong>Primary Spontaneous (PSP):</strong> Tall, thin, young men (15-35yo). Smokers. Rupture apical bleb/bullae. No underlying lung disease</li>
                        <li><strong>Secondary Spontaneous (SSP):</strong> Underlying lung disease - COPD (most common), CF, PCP pneumonia, necrotizing pneumonia, TB, Marfan's</li>
                        <li><strong>Iatrogenic:</strong> Central line placement (subclavian>IJ), thoracentesis, transbronchial biopsy, mechanical ventilation (barotrauma), CPR</li>
                        <li><strong>Traumatic:</strong> Blunt/penetrating chest trauma, rib fractures</li>
                    </ul>
                    
                    <p><span class="label">Presentation:</span> Acute-onset pleuritic chest pain, dyspnea. Exam: Decreased breath sounds, hyperresonance to percussion, decreased tactile fremitus on affected side. Tracheal deviation toward affected side (simple PTX) or AWAY (tension PTX)</p>
                    
                    <p><span class="label">TENSION PNEUMOTHORAX - EMERGENCY:</span></p>
                    <ul>
                        <li><strong>Pathophys:</strong> One-way valve ‚Üí air enters pleural space but can't escape ‚Üí ‚Üëpressure collapses lung, shifts mediastinum, compresses contralateral lung + great vessels ‚Üí ‚Üìvenous return ‚Üí shock</li>
                        <li><strong>Presentation:</strong> Severe respiratory distress, hypotension, tachycardia, JVD, tracheal deviation AWAY from affected side, absent breath sounds, hyperresonance, cyanosis</li>
                        <li><strong>CLINICAL DIAGNOSIS - DON'T WAIT FOR CXR!</strong></li>
                        <li><strong>Treatment:</strong> Immediate needle decompression: 14-16 gauge angiocath, 2nd intercostal space, midclavicular line (or 4th-5th ICS anterior axillary line). Insert needle over rib (avoid neurovascular bundle under rib). Rush of air = confirms diagnosis. THEN get CXR and place chest tube</li>
                    </ul>
                    
                    <p><span class="label">CXR Findings:</span> Visceral pleural line (edge of collapsed lung), absent lung markings peripherally. Upright film more sensitive. Deep sulcus sign on supine (air collects anteriorly). Quantify size: Measure distance from chest wall to lung edge at hilum level. Small <2cm, Large >2cm</p>
                    
                    <p><span class="label">Treatment Algorithm (Non-Tension):</span></p>
                    <ul>
                        <li><strong>Small (<2cm or <20%), stable, minimal symptoms:</strong>
                            <ul>
                                <li>Observation + supplemental O2 (hastens resorption - 4√ó faster with O2)</li>
                                <li>Repeat CXR in 6hr. If stable/improving, discharge with outpatient follow-up CXR 1-2 weeks</li>
                                <li>PSP: Resorbs ~1-2% per day (10-14 days). SSP: Higher risk progression, lower threshold to place tube</li>
                                <li>Instruct: Return if increased dyspnea, chest pain. No flying until resolved (pressure changes expand PTX)</li>
                            </ul>
                        </li>
                        <li><strong>Large (>2cm or >20%) OR symptomatic:</strong>
                            <ul>
                                <li><strong>Aspiration (PSP, first episode, age <50, stable):</strong> 16-18 gauge IV catheter, 2nd ICS midclavicular line or 4th-5th ICS midaxillary line. Aspirate with 60 mL syringe + 3-way stopcock. Max 2.5L (if not successful, place chest tube). If successful (PTX <2cm, symptoms improved), observe 4hr, repeat CXR. Discharge if stable. Success ~60-80% PSP</li>
                                <li><strong>Chest tube (SSP, large PSP failing aspiration, recurrent, bilateral, hemodynamic instability):</strong> 16-28Fr pigtail (small) or 28-32Fr tube (large). 4th-5th ICS, anterior axillary line, directed posteroapically. Connect to water seal +/- suction (-20 cm H2O). Keep tube until no air leak √ó 24hr + lung re-expanded on CXR</li>
                            </ul>
                        </li>
                        <li><strong>Recurrent PTX (20-50% recur within 2 years):</strong> Video-assisted thoracoscopic surgery (VATS) with bleb resection + pleurodesis. Reduces recurrence to <5%. Consider after 1st SSP or 2nd PSP</li>
                    </ul>
                    
                    <p><span class="label">Special Situations:</span></p>
                    <ul>
                        <li><strong>Mechanical ventilation:</strong> If PTX develops, place chest tube immediately (positive pressure worsens). Don't wait/observe</li>
                        <li><strong>Bilateral PTX:</strong> Higher risk respiratory compromise. Usually place bilateral tubes</li>
                        <li><strong>Persistent air leak (tube in, still bubbling >7 days):</strong> Bronchopleural fistula. Consult thoracic surgery</li>
                    </ul>
                </div>
            </div>
            <div class="teaching-pearls">
                <div class="pearls-title">üíé TEACHING PEARLS</div>
                <ul>
                    <li><strong>Tension PTX is clinical diagnosis:</strong> Don't wait for CXR! Respiratory distress + hypotension + absent breath sounds + hyperresonance = needle decompression NOW</li>
                    <li><strong>Tracheal deviation:</strong> Simple PTX ‚Üí toward affected side (volume loss). Tension PTX ‚Üí away from affected side (mass effect pushing mediastinum)</li>
                    <li><strong>PSP = tall thin young men:</strong> "Walking around with time bombs." Apical blebs. Smoking ‚Üërisk 20√ó. Often rupture at rest. Recurrence 20-50%</li>
                    <li><strong>SSP more dangerous than PSP:</strong> Underlying lung disease ‚Üí less reserve. Lower threshold to place chest tube. Higher morbidity/mortality</li>
                    <li><strong>O2 speeds resolution 4√ó:</strong> Creates nitrogen gradient ‚Üí resorption. Give O2 even if saturating well</li>
                    <li><strong>No flying until resolved:</strong> Pressure changes at altitude expand PTX. Wait 1-2 weeks post-resolution before flying</li>
                    <li><strong>Aspiration vs tube:</strong> PSP, young, stable ‚Üí try aspiration first (60-80% success, less invasive). SSP ‚Üí chest tube (higher failure rate, don't waste time)</li>
                    <li><strong>Recurrent PTX needs surgery:</strong> VATS pleurodesis after 1st SSP or 2nd PSP. Reduces recurrence <5%</li>
                </ul>
            </div>
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<div id="syncope" class="condition-page">
            <div class="page-header">
                <h2>40. SYNCOPE</h2>
                <div class="subtitle">Vasovagal ‚Ä¢ Cardiac ‚Ä¢ Orthostatic ‚Ä¢ Neurologic</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Transient loss of consciousness (LOC) with loss of postural tone, followed by spontaneous complete recovery. Caused by global cerebral hypoperfusion. Duration typically <20 seconds</p>
                    <p><span class="label">Classic:</span> Sudden LOC, fall, rapid spontaneous recovery without intervention. Patient recalls events before and after (vs seizure with postictal confusion)</p>
                    
                    <p><span class="label">Key Historical Questions:</span></p>
                    <ul>
                        <li><strong>Prodrome:</strong> Nausea, diaphoresis, tunnel vision, lightheadedness = vasovagal. No warning = cardiac</li>
                        <li><strong>Position:</strong> Standing ‚Üí orthostatic or vasovagal. Supine ‚Üí cardiac (very concerning!)</li>
                        <li><strong>Activity:</strong> Exertional syncope = cardiac until proven otherwise (HOCM, AS, arrhythmia, PE)</li>
                        <li><strong>Triggers:</strong> Pain, emotion, standing, prolonged standing, hot environment = vasovagal. Post-micturition/defecation = situational</li>
                        <li><strong>Recovery:</strong> Immediate = syncope. Confusion/lethargy = seizure or stroke</li>
                        <li><strong>Witnesses:</strong> Tonic-clonic movements? (can occur in syncope but brief <15sec, vs prolonged in seizure). Tongue biting/incontinence more typical of seizure</li>
                    </ul>
                    
                    <p><span class="label">Alternate Presentations by Etiology:</span></p>
                    <ul>
                        <li><strong>Vasovagal (Neurocardiogenic):</strong> Most common (40-50%). Prodrome of nausea, diaphoresis, visual changes. Triggered by emotional stress, pain, prolonged standing, hot environment. Young patients. Benign</li>
                        <li><strong>Orthostatic Hypotension:</strong> Syncope upon standing from sitting/supine. Elderly, autonomic dysfunction, medications (Œ±-blockers, diuretics, vasodilators), volume depletion. BP drop ‚â•20/10 mmHg within 3 minutes of standing</li>
                        <li><strong>Cardiac Arrhythmia:</strong> No warning, sudden collapse. Palpitations before/after. High-risk: age >60, exertional, supine, no prodrome, heart disease. Bradyarrhythmias (sick sinus, AV block) or tachyarrhythmias (VT, SVT)</li>
                        <li><strong>Structural Cardiac:</strong> Aortic stenosis (exertional syncope, systolic murmur), HOCM (young athletes, exertional, family history sudden death), cardiac tamponade, myxoma, PE (dyspnea, pleuritic chest pain)</li>
                        <li><strong>Neurologic (RARE cause):</strong> Vertebrobasilar TIA (diplopia, ataxia, vertigo), subclavian steal, seizure (postictal confusion differentiates from syncope)</li>
                        <li><strong>Situational:</strong> Specific triggers - micturition (post-void), defecation, cough, swallow. Vasovagal-mediated</li>
                        <li><strong>Carotid Sinus Hypersensitivity:</strong> Elderly men, triggered by tight collar, head turning, shaving. Bradycardia/hypotension with carotid massage</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ALL Patients Must Have:</span></p>
                    <ul>
                        <li><strong>Detailed History:</strong> Events before/during/after, position, activity, prodrome, recovery time, witnesses, prior episodes, medications, cardiac history</li>
                        <li><strong>Physical Exam:</strong> Complete cardiac exam (murmurs, JVD, edema), neurologic exam (focal deficits?), orthostatic vitals (supine ‚Üí standing at 1 and 3 min)</li>
                        <li><strong>ECG (MANDATORY for ALL):</strong> Look for: prolonged QT (>480ms = high risk for Torsades), Brugada pattern (ST elevation V1-V3), pre-excitation (WPW = short PR, delta wave), epsilon wave (ARVC), pathologic Q waves (old MI), heart block, SVT/VT</li>
                    </ul>
                    
                    <p><span class="label">Risk Stratification - San Francisco Syncope Rule (HIGH RISK if ANY):</span></p>
                    <ul>
                        <li><strong>H</strong>istory of CHF</li>
                        <li><strong>E</strong>CG abnormal (any non-sinus rhythm or new changes)</li>
                        <li><strong>A</strong>nemia (Hct <30%)</li>
                        <li><strong>R</strong>espiratory - Shortness of breath</li>
                        <li><strong>T</strong>riage systolic BP <90 mmHg</li>
                        <li>If ANY present ‚Üí 7-10% risk of serious outcome at 30 days ‚Üí ADMIT</li>
                    </ul>
                    
                    <p><span class="label">Labs (Based on Clinical Suspicion):</span></p>
                    <ul>
                        <li><strong>Basic:</strong> CBC (anemia?), BMP (electrolytes - hypokalemia can cause QT prolongation), glucose (hypoglycemia?)</li>
                        <li><strong>If cardiac suspected:</strong> Troponin (ACS?), BNP (heart failure?), D-dimer if PE suspected</li>
                        <li><strong>If volume depletion suspected:</strong> BUN/Cr ratio, orthostatic vitals</li>
                        <li><strong>Pregnancy test:</strong> All women of childbearing age (ectopic pregnancy can present as syncope)</li>
                    </ul>
                    
                    <p><span class="label">Advanced Testing (If Indicated):</span></p>
                    <ul>
                        <li><strong>Echocardiography:</strong> If structural heart disease suspected (murmur, abnormal ECG, exertional syncope, known heart disease). Assess for AS, HOCM, RV strain (PE), tamponade, LV function</li>
                        <li><strong>Telemetry/Holter Monitor:</strong> If arrhythmia suspected. Admit for telemetry if high-risk features. Outpatient Holter (24-48hr) or event monitor (30 days) for recurrent syncope</li>
                        <li><strong>Exercise Stress Test:</strong> If exertional syncope (evaluate for ischemia, arrhythmias). Contraindicated if severe AS suspected</li>
                        <li><strong>Tilt Table Test:</strong> If recurrent syncope, no cardiac cause found. Reproduces vasovagal response. Positive = BP drop >25mmHg or HR <60 with symptoms</li>
                        <li><strong>Electrophysiology Study (EP Study):</strong> For unexplained syncope with structural heart disease or high suspicion for arrhythmia. Can induce/document VT, assess sinus/AV node function</li>
                        <li><strong>CT Head:</strong> Only if focal neurologic deficits, head trauma, persistent altered mental status. Syncope alone does NOT require head CT</li>
                        <li><strong>Carotid Ultrasound:</strong> Generally low yield. Consider if carotid bruit or vertebrobasilar symptoms</li>
                        <li><strong>CT PE Protocol:</strong> If dyspnea, pleuritic chest pain, hypoxia, tachycardia, RV strain on ECG</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Vitals Technique:</span></p>
                    <ul>
                        <li>Supine √ó 5 minutes ‚Üí measure BP/HR</li>
                        <li>Stand immediately ‚Üí measure at 1 minute and 3 minutes</li>
                        <li><strong>Positive:</strong> SBP drop ‚â•20 mmHg OR DBP drop ‚â•10 mmHg OR HR increase ‚â•30 bpm (or HR >120)</li>
                        <li>Symptoms (lightheadedness, presyncope) with standing = clinical orthostasis even if BP criteria not met</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li>Treatment depends on underlying cause</li>
                        <li>Admit if high-risk features (see San Francisco Syncope Rule, cardiac cause suspected)</li>
                        <li>Discharge if low-risk and clear benign etiology (young, vasovagal, normal ECG, normal exam)</li>
                    </ul>
                    
                    <p><span class="label">Vasovagal Syncope (Reflex/Neurocardiogenic):</span></p>
                    <ul>
                        <li><strong>Reassurance:</strong> Benign condition, excellent prognosis. Explain pathophysiology</li>
                        <li><strong>Trigger Avoidance:</strong> Avoid prolonged standing, hot environments, dehydration, emotional stress. Sit/lie down at first prodromal symptom</li>
                        <li><strong>Hydration:</strong> Increase fluid intake to 2-3 L/day. Liberal salt intake (6-10g/day) if no contraindications</li>
                        <li><strong>Physical Counterpressure Maneuvers:</strong> At first sign of prodrome: leg crossing + tensing, squatting, arm tensing. Can abort episode</li>
                        <li><strong>Tilt Training:</strong> Gradual exposure to prolonged standing (start 5 min, increase to 30+ min)</li>
                        <li><strong>Pharmacologic (Refractory cases only):</strong>
                            <ul>
                                <li>Midodrine 5-10mg TID (Œ±-agonist, increases BP) - first-line medication</li>
                                <li>Fludrocortisone 0.1-0.2mg daily (volume expansion)</li>
                                <li>Œ≤-blockers (metoprolol) - controversial, limited evidence</li>
                            </ul>
                        </li>
                        <li><strong>Pacemaker:</strong> Very rarely indicated. Only if severe cardioinhibitory response (asystole >3 sec) on tilt table and failed medical therapy</li>
                    </ul>
                    
                    <p><span class="label">Orthostatic Hypotension:</span></p>
                    <ul>
                        <li><strong>Identify and Address Causes:</strong>
                            <ul>
                                <li>Volume depletion ‚Üí IV fluids, oral hydration</li>
                                <li>Medications ‚Üí stop/reduce Œ±-blockers, diuretics, vasodilators, antihypertensives, antidepressants</li>
                                <li>Autonomic dysfunction ‚Üí treat underlying (diabetes, Parkinson's, amyloidosis)</li>
                            </ul>
                        </li>
                        <li><strong>Non-Pharmacologic:</strong>
                            <ul>
                                <li>Rise slowly from supine/sitting (sit at edge of bed √ó 1 min before standing)</li>
                                <li>Increase fluid intake (2-3 L/day) and salt (6-10g/day if no CHF)</li>
                                <li>Compression stockings (waist-high, 30-40 mmHg) - wear before rising</li>
                                <li>Elevate head of bed 10-20 degrees at night (reduces nocturnal diuresis)</li>
                                <li>Avoid large meals (can cause postprandial hypotension)</li>
                                <li>Physical counterpressure maneuvers</li>
                            </ul>
                        </li>
                        <li><strong>Pharmacologic:</strong>
                            <ul>
                                <li>Midodrine 2.5-10mg TID (last dose before 6 PM to avoid supine hypertension)</li>
                                <li>Fludrocortisone 0.1-0.3mg daily (watch for hypokalemia, edema, supine hypertension)</li>
                                <li>Droxidopa 100-600mg TID (norepinephrine precursor, for neurogenic OH)</li>
                                <li>Pyridostigmine 60mg TID (if autonomic failure)</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Cardiac Syncope - ADMIT for Telemetry:</span></p>
                    <ul>
                        <li><strong>Arrhythmia Management:</strong>
                            <ul>
                                <li>Bradycardia (sick sinus, AV block) ‚Üí Cardiology consult, consider pacemaker</li>
                                <li>Tachyarrhythmia (VT, SVT) ‚Üí Antiarrhythmics, ablation, ICD evaluation</li>
                                <li>Long QT syndrome ‚Üí Remove offending drugs, electrolyte repletion (Mg, K), Œ≤-blockers, ICD if high risk</li>
                                <li>Brugada, ARVC ‚Üí EP study, ICD placement</li>
                            </ul>
                        </li>
                        <li><strong>Structural Disease:</strong>
                            <ul>
                                <li>Aortic stenosis ‚Üí Cardiology/CT surgery referral for valve replacement if severe + symptomatic</li>
                                <li>HOCM ‚Üí Œ≤-blockers, avoid volume depletion/vasodilators. ICD if high risk. Septal reduction if refractory</li>
                                <li>Pulmonary embolism ‚Üí Anticoagulation, thrombolytics if massive PE</li>
                                <li>Cardiac tamponade ‚Üí Pericardiocentesis</li>
                            </ul>
                        </li>
                        <li><strong>Ischemia:</strong> If syncope due to ACS ‚Üí treat per ACS protocol (aspirin, heparin, cath lab)</li>
                    </ul>
                    
                    <p><span class="label">Situational Syncope:</span></p>
                    <ul>
                        <li>Micturition syncope ‚Üí Sit to void, avoid straining, stay hydrated</li>
                        <li>Defecation syncope ‚Üí Avoid straining (stool softeners), adequate hydration</li>
                        <li>Cough/swallow syncope ‚Üí Treat underlying cause (GERD, cough), maneuvers to reduce triggering</li>
                    </ul>
                    
                    <p><span class="label">Neurologic Syncope (Rare):</span></p>
                    <ul>
                        <li>Vertebrobasilar TIA ‚Üí Neurology consult, antiplatelet therapy, imaging (MRA/CTA neck)</li>
                        <li>Subclavian steal ‚Üí Vascular surgery referral</li>
                        <li>Seizure (if postictal confusion suggests) ‚Üí Neurology consult, antiepileptics, EEG</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>ECG is MANDATORY for ALL syncope patients:</strong> Single most important test. Can diagnose Brugada, long QT, WPW, ARVC, heart block, old MI. Never discharge syncope patient without ECG</li>
                    <li><strong>Syncope while supine = cardiac until proven otherwise:</strong> Vasovagal almost never occurs supine. If patient syncopizes lying down, think arrhythmia and admit for telemetry</li>
                    <li><strong>Exertional syncope = high-risk:</strong> Think HOCM (young athletes), AS (elderly), VT, coronary ischemia. These patients need echo, stress test, and cardiology evaluation</li>
                    <li><strong>Red flags for cardiac syncope:</strong> Age >60, exertional, supine position, no prodrome, known heart disease, abnormal ECG, family history sudden cardiac death. Admit these patients</li>
                    <li><strong>Vasovagal has a prodrome, cardiac doesn't:</strong> If patient describes nausea, diaphoresis, tunnel vision before passing out = vasovagal (low risk). No warning, sudden collapse = cardiac (high risk)</li>
                    <li><strong>Don't confuse syncope with seizure:</strong> Syncope = brief LOC (<20 sec), rapid complete recovery, may have brief myoclonic jerks (<15 sec). Seizure = prolonged LOC, tonic-clonic movements, tongue biting, incontinence, postictal confusion/lethargy. But can be tough to distinguish!</li>
                    <li><strong>Head CT rarely useful:</strong> Only if focal neurologic findings, head trauma, or persistent altered mental status. Syncope is due to global hypoperfusion, not focal brain lesion. Don't reflexively order head CT</li>
                    <li><strong>San Francisco Syncope Rule is your friend:</strong> If none of the 5 criteria (CHF, abnormal ECG, Hct <30%, SOB, SBP <90), patient is low-risk (<1% serious outcome) and can likely be discharged with outpatient follow-up if vasovagal etiology clear</li>
                    <li><strong>Orthostatic vitals technique matters:</strong> Must be supine √ó 5 min first, then check at 1 and 3 minutes standing. Immediate standing without adequate supine time can give false positives</li>
                    <li><strong>Young healthy patient with classic vasovagal story needs minimal workup:</strong> Prodrome, triggered by standing/heat/emotion, quick recovery, normal ECG = can discharge with reassurance and anticipatory guidance. Don't over-test these patients</li>
                    <li><strong>Medications are a common culprit:</strong> Œ±-blockers (BPH meds), diuretics, antihypertensives, TCAs, antipsychotics, PDE5 inhibitors. Always review medication list carefully</li>
                    <li><strong>Carotid massage to diagnose carotid sinus hypersensitivity:</strong> Only perform if safe (no carotid bruits, no recent stroke/TIA). Massage one side √ó 5 seconds. Positive = >3 sec asystole or >50 mmHg BP drop. Never massage both sides simultaneously!</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Syncope with ongoing chest pain suggesting acute MI</li>
                        <li>Hemodynamically unstable (persistent hypotension, shock)</li>
                        <li>Malignant arrhythmia (sustained VT/VF requiring cardioversion)</li>
                        <li>High-grade AV block (Mobitz II, complete heart block) requiring pacing</li>
                        <li>Massive pulmonary embolism with hypotension</li>
                        <li>Cardiac tamponade</li>
                        <li>Aortic dissection</li>
                        <li>Ruptured ectopic pregnancy with hemorrhagic shock</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clear benign etiology identified (vasovagal, orthostatic)</li>
                        <li>NO high-risk features (San Francisco Syncope Rule negative)</li>
                        <li>Normal or unchanged ECG</li>
                        <li>Normal vital signs and orthostatics</li>
                        <li>No concerning cardiac exam findings</li>
                        <li>Labs normal (if obtained)</li>
                        <li>No recurrent episodes during observation</li>
                        <li>Able to ambulate safely without recurrence</li>
                        <li>Patient counseled on trigger avoidance (if vasovagal)</li>
                        <li>Close follow-up arranged (PCP within 1 week, Cardiology if needed)</li>
                        <li>Clear return precautions: recurrent syncope, chest pain, palpitations, dyspnea</li>
                        <li>Driving restrictions discussed (varies by state, typically 3-6 months abstinence after cardiac syncope)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>From Syncope Episode:</strong> Trauma from fall (head injury, fractures, lacerations), motor vehicle accidents (if driving), sudden cardiac death (if malignant arrhythmia), prolonged cerebral hypoperfusion causing ischemia (rare)</p>
                    <p><strong>From Underlying Cardiac Cause:</strong> Sudden cardiac death (VT/VF, complete heart block), acute MI/ACS, cardiac arrest, stroke from arrhythmia with thrombus formation, progression of structural heart disease (AS, HOCM)</p>
                    <p><strong>From Recurrent Episodes:</strong> Injury from repeated falls, impaired quality of life, anxiety/depression, loss of driving privileges, loss of employment (especially if operate machinery), social isolation</p>
                    <p><strong>From Treatment:</strong> Supine hypertension (midodrine, fludrocortisone - can cause nocturnal HTN), hypokalemia (fludrocortisone), edema (fludrocortisone), bradycardia (Œ≤-blockers), pacemaker complications (infection, lead malfunction), ICD shocks (appropriate or inappropriate)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

</div>

<!-- ============================================ -->
<!-- CONDITION 41: PERICARDITIS/PERICARDIAL EFFUSION/CARDIAC TAMPONADE -->
<!-- ============================================ -->
        <div id="pericarditis" class="condition-page">
            <div class="page-header">
                <h2>41. PERICARDITIS/PERICARDIAL EFFUSION/CARDIAC TAMPONADE</h2>
                <div class="subtitle">Inflammatory ‚Ä¢ Effusion ‚Ä¢ Tamponade Physiology</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Pericarditis:</span> Sharp, pleuritic chest pain worse with inspiration and lying flat, relieved by sitting forward. Friction rub (scratchy, triphasic sound)</p>
                    <p><span class="label">Pericardial Effusion:</span> Often asymptomatic if slow-accumulating. Dyspnea, muffled heart sounds, enlarged cardiac silhouette on CXR</p>
                    <p><span class="label">Cardiac Tamponade:</span> Beck's triad (hypotension, JVD, muffled heart sounds), pulsus paradoxus >10mmHg, tachycardia, dyspnea, shock</p>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Uremic pericarditis:</strong> ESRD patients, often painless. May indicate need for urgent dialysis</li>
                        <li><strong>Post-MI (Dressler syndrome):</strong> 1-3 weeks post-MI. Fever, pleurisy, pericarditis</li>
                        <li><strong>Malignant effusion:</strong> Gradual dyspnea, weight loss. Lung/breast cancer, lymphoma most common</li>
                        <li><strong>TB pericarditis:</strong> Endemic areas, HIV patients. Chronic symptoms, large effusions</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> CBC, CRP/ESR (elevated), troponin (mildly elevated if myopericarditis), BUN/Cr, TSH, ANA if autoimmune suspected</p>
                    <p><span class="label">ECG:</span> Diffuse ST elevation with PR depression (90%), upright T waves. Stage 1‚Üí4: ST elevation ‚Üí normalization ‚Üí T inversion ‚Üí resolution</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Enlarged cardiac silhouette if >250mL effusion ("water bottle heart")</li>
                        <li><strong>Echocardiogram:</strong> GOLD STANDARD. Quantify effusion, assess for tamponade physiology (RA/RV collapse, respiratory variation, IVC plethora)</li>
                        <li><strong>CT chest:</strong> If imaging for etiology (malignancy, TB, trauma)</li>
                    </ul>
                    <p><span class="label">Pericardiocentesis:</span> If tamponade, purulent/TB suspected, or large effusion not responding to NSAIDs. Send fluid for cell count, cultures, cytology, adenosine deaminase (TB)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Acute Pericarditis (no effusion/tamponade):</span></p>
                    <ul>
                        <li><strong>First-line:</strong> NSAIDs + Colchicine. Ibuprofen 600-800mg TID √ó 1-2 weeks, taper over 1-2 weeks. Colchicine 0.6mg BID √ó 3 months (reduces recurrence 50%)</li>
                        <li><strong>Alternative:</strong> Aspirin 750-1000mg TID (if post-MI or ASA allergy)</li>
                        <li><strong>Steroids:</strong> AVOID unless refractory or contraindication to NSAIDs (increases recurrence risk). Prednisone 0.25-0.5mg/kg/day</li>
                        <li><strong>Activity restriction:</strong> No strenuous exercise until symptoms resolve and CRP normalizes (risk of recurrence/tamponade)</li>
                    </ul>
                    
                    <p><span class="label">Pericardial Effusion (no tamponade):</span></p>
                    <ul>
                        <li><strong>Small/moderate:</strong> Treat underlying cause, anti-inflammatory therapy, serial echos q48-72hr</li>
                        <li><strong>Large (>20mm):</strong> Admit for monitoring, daily echos, consider pericardiocentesis if symptomatic or not responding</li>
                    </ul>
                    
                    <p><span class="label">Cardiac Tamponade (EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Immediate:</strong> Aggressive IV fluids (increase preload), avoid diuretics/vasodilators</li>
                        <li><strong>Definitive:</strong> Urgent pericardiocentesis (echo or fluoro-guided). Drain 50mL often enough for immediate improvement</li>
                        <li><strong>Approach:</strong> Subxiphoid (most common). Leave pigtail catheter if large volume or suspected recurrence</li>
                        <li><strong>Refractory:</strong> Surgical drainage (pericardial window) if loculated, recurrent, or traumatic</li>
                        <li><strong>Post-procedure:</strong> Monitor for re-accumulation. Echo in 24-48hr</li>
                    </ul>
                    
                    <p><span class="label">Specific Etiologies:</span></p>
                    <ul>
                        <li><strong>Uremic:</strong> Urgent dialysis. Most resolve after adequate dialysis</li>
                        <li><strong>Malignant:</strong> Drainage for symptoms, often recurs. Consider pericardial window or sclerosis</li>
                        <li><strong>Purulent:</strong> Pericardiocentesis + broad-spectrum antibiotics (vanco + ceftriaxone). Often needs surgical drainage</li>
                        <li><strong>TB:</strong> Rifampin, isoniazid, pyrazinamide, ethambutol (RIPE) √ó 2 months, then RIF/INH √ó 4 months. Consider steroids (reduce constriction)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pericarditis ECG vs STEMI:</strong> Pericarditis has diffuse ST elevation (multiple leads) with PR depression, STEMI has localized ST elevation with reciprocal changes. Pericarditis ST is concave ("smiling"), STEMI is convex ("frowning")</li>
                    <li><strong>Pulsus paradoxus:</strong> >10mmHg drop in SBP with inspiration. Normal <10mmHg. Also seen in COPD, PE, severe asthma</li>
                    <li><strong>Colchicine is key:</strong> Reduces recurrence from 30-50% to 10-15%. Use in all cases unless contraindicated</li>
                    <li><strong>Low-pressure tamponade:</strong> Can occur with hypovolemia or RV dysfunction. Tamponade physiology without elevated JVP</li>
                    <li><strong>Electrical alternans:</strong> Beat-to-beat variation in QRS amplitude. Classic for large effusion/tamponade but uncommon (10-20%)</li>
                    <li><strong>Avoid steroids if possible:</strong> 2-4√ó increased risk of recurrence. Reserve for refractory cases or contraindication to NSAIDs</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Cardiac tamponade (SBP <90, pulsus paradoxus >20mmHg)</li>
                        <li>Hemodynamic instability</li>
                        <li>Large/rapidly accumulating effusion</li>
                        <li>Need for urgent pericardiocentesis</li>
                        <li>Myopericarditis with arrhythmias or reduced EF</li>
                        <li>Purulent pericarditis</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pain controlled on oral NSAIDs</li>
                        <li>Hemodynamically stable</li>
                        <li>No evidence of tamponade on echo</li>
                        <li>CRP trending down</li>
                        <li>If effusion: Small/stable on repeat echo</li>
                        <li>Follow-up arranged (repeat echo in 1 week if effusion present)</li>
                        <li>Activity restrictions counseled</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cardiac tamponade (most feared), myopericarditis (troponin ‚Üë, EF ‚Üì), arrhythmias (rare)</p>
                    <p><strong>Chronic:</strong> Recurrent pericarditis (15-30%, higher without colchicine), constrictive pericarditis (chronic inflammation ‚Üí calcification ‚Üí restricted filling, often post-TB/radiation/cardiac surgery)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 42: INFECTIVE ENDOCARDITIS -->
<!-- ============================================ -->
        <div id="endocarditis" class="condition-page">
            <div class="page-header">
                <h2>42. INFECTIVE ENDOCARDITIS</h2>
                <div class="subtitle">Native Valve ‚Ä¢ Prosthetic Valve ‚Ä¢ Duke Criteria</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Fever (90%), new or changing murmur (85%), embolic phenomena, positive blood cultures. Subacute: weeks of constitutional symptoms</p>
                    <p><span class="label">Acute Presentation:</span> Rapid valve destruction, heart failure, septic shock. More common with S. aureus</p>
                    <p><span class="label">Peripheral Stigmata (classic but rare <10%):</span></p>
                    <ul>
                        <li><strong>Osler nodes:</strong> Painful, raised, red nodules on fingers/toes (immunologic)</li>
                        <li><strong>Janeway lesions:</strong> Painless, red macules on palms/soles (septic emboli)</li>
                        <li><strong>Splinter hemorrhages:</strong> Linear red-brown streaks under nails</li>
                        <li><strong>Roth spots:</strong> Retinal hemorrhages with pale centers (rare)</li>
                    </ul>
                    <p><span class="label">Complications at Presentation:</span></p>
                    <ul>
                        <li><strong>Heart failure:</strong> Acute regurgitation from valve destruction (most common cause of death)</li>
                        <li><strong>Embolic stroke:</strong> 15-30%, highest risk with mitral valve and S. aureus</li>
                        <li><strong>Mycotic aneurysm:</strong> Brain, splenic, coronary arteries</li>
                        <li><strong>Perivalvular abscess:</strong> New heart block (AV node near aortic valve)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP (Duke Criteria)</div>
                <div class="section-content">
                    <p><span class="label">Blood Cultures:</span> 3 sets from separate sites BEFORE antibiotics. Time spacing less critical than previously thought (can obtain all within 1-2hr if clinically unstable)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>TTE:</strong> First-line. Sensitivity 60-70% for vegetations. Excellent for assessment of valve function and complications</li>
                        <li><strong>TEE:</strong> Gold standard. Sensitivity 90-95%. REQUIRED if: prosthetic valve, negative TTE with high suspicion, suspected abscess/perforation, S. aureus bacteremia</li>
                        <li><strong>Cardiac CT/MRI:</strong> If TEE contraindicated or to evaluate perivalvular extension</li>
                        <li><strong>Brain MRI:</strong> If neurologic symptoms (ischemic stroke, hemorrhage, abscess, mycotic aneurysm)</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC (anemia of chronic disease), ESR/CRP (elevated), UA (hematuria/proteinuria), RF (positive in subacute), creatinine, LFTs</p>
                    <p><span class="label">Duke Criteria (Definite IE = 2 major OR 1 major + 3 minor OR 5 minor):</span></p>
                    <ul>
                        <li><strong>Major:</strong> (1) Positive blood cultures with typical organisms in ‚â•2 separate cultures, OR persistently positive cultures; (2) Echocardiographic evidence (vegetation, abscess, new dehiscence of prosthetic valve, new valvular regurgitation)</li>
                        <li><strong>Minor:</strong> Predisposing condition, fever >38¬∞C, vascular phenomena (emboli, mycotic aneurysm), immunologic phenomena (Osler nodes, Roth spots, RF), microbiologic evidence not meeting major criteria</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotics (start after blood cultures √ó 3):</span></p>
                    <ul>
                        <li><strong>Native valve:</strong> Vancomycin 15mg/kg IV q12h + ceftriaxone 2g IV q24h</li>
                        <li><strong>Prosthetic valve:</strong> Vancomycin + ceftriaxone + gentamicin 1mg/kg IV q8h (or cefepime instead of ceftriaxone)</li>
                        <li><strong>IVDU:</strong> Same as native valve (covers S. aureus, Streptococcus, gram-negatives)</li>
                    </ul>
                    
                    <p><span class="label">Organism-Specific Therapy:</span></p>
                    <ul>
                        <li><strong>Viridans Streptococcus (most common, ~30%):</strong> Penicillin G 4 million units IV q4h OR ceftriaxone 2g IV q24h √ó 4 weeks. Can add gentamicin √ó 2 weeks for synergy</li>
                        <li><strong>S. aureus (MSSA):</strong> Nafcillin/oxacillin 2g IV q4h √ó 4-6 weeks. Consider adding gentamicin √ó 3-5 days for synergy</li>
                        <li><strong>S. aureus (MRSA):</strong> Vancomycin 15mg/kg IV q12h √ó 6 weeks. Consider daptomycin 8-10mg/kg if persistent bacteremia</li>
                        <li><strong>Enterococcus:</strong> Ampicillin 2g IV q4h + gentamicin 1mg/kg q8h (or ceftriaxone 2g q12h instead of gent) √ó 4-6 weeks</li>
                        <li><strong>HACEK (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella):</strong> Ceftriaxone 2g IV q24h √ó 4 weeks</li>
                        <li><strong>Culture-negative (10-15%):</strong> Continue empiric therapy. Consider Bartonella, Coxiella, Brucella, fungi in specific epidemiology</li>
                    </ul>
                    
                    <p><span class="label">Duration:</span> Native valve 4-6 weeks (S. aureus 6 weeks), prosthetic valve 6 weeks minimum. Time from FIRST negative blood culture</p>
                    
                    <p><span class="label">Surgical Indications (Cardiothoracic Surgery Consult):</span></p>
                    <ul>
                        <li><strong>Heart failure:</strong> From severe acute regurgitation or valve obstruction (Class I indication, emergent)</li>
                        <li><strong>Uncontrolled infection:</strong> Perivalvular abscess, persistent bacteremia >5-7 days on appropriate antibiotics, fungal endocarditis</li>
                        <li><strong>Prevention of embolism:</strong> Large mobile vegetation (>10mm) with embolic event, especially anterior mitral valve</li>
                        <li><strong>Prosthetic valve:</strong> Early prosthetic valve endocarditis (<1 year), heart failure, dehiscence, persistent bacteremia</li>
                        <li><strong>Timing:</strong> Emergent (heart failure/cardiogenic shock), urgent (uncontrolled infection, abscess), elective (large vegetation, embolic prevention)</li>
                    </ul>
                    
                    <p><span class="label">Post-Stroke Timing for Surgery:</span> If intracranial hemorrhage, delay surgery if possible. If ischemic stroke without hemorrhage, surgery can proceed but discuss risk/benefit</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>S. aureus bacteremia = TEE:</strong> 25% have IE even without murmur. Always get TEE for S. aureus bacteremia unless clear alternative source + no cardiac risk factors</li>
                    <li><strong>Culture first, antibiotics second:</strong> Don't delay cultures waiting for fever spike. Get 3 sets ASAP then start empiric therapy (unless stable subacute presentation)</li>
                    <li><strong>Right-sided endocarditis:</strong> IVDU, indwelling catheters. Tricuspid valve most common. Septic pulmonary emboli (not stroke). Better prognosis than left-sided</li>
                    <li><strong>New heart block = perivalvular abscess:</strong> AV node near aortic valve. High-grade block indicates abscess until proven otherwise. Surgical emergency</li>
                    <li><strong>Anticoagulation controversy:</strong> If on warfarin for other indication (prosthetic valve, AFib), continue but avoid starting new anticoagulation (doesn't prevent emboli, may increase hemorrhagic stroke)</li>
                    <li><strong>Mycotic aneurysm:</strong> Not fungal! Bacterial infection of arterial wall. Can rupture. Brain MRA if headache or neurologic symptoms</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hemodynamic instability/cardiogenic shock</li>
                        <li>Acute heart failure (pulmonary edema)</li>
                        <li>High-grade heart block (perivalvular abscess)</li>
                        <li>Embolic stroke with decreased level of consciousness</li>
                        <li>Septic shock despite antibiotics</li>
                        <li>Perioperative (cardiac surgery for IE)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Appropriate IV antibiotics for ‚â•7-14 days (bloodstream clearance documented)</li>
                        <li>Hemodynamically stable</li>
                        <li>Blood cultures negative √ó 2-3 sets</li>
                        <li>No indication for urgent surgery</li>
                        <li>Plan for completion of IV antibiotics (home IV, long-term facility, or outpatient infusion)</li>
                        <li>Follow-up with Infectious Disease and Cardiology arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cardiac:</strong> Heart failure (most common cause of death, 50-60%), perivalvular abscess (10-40% prosthetic, 10-15% native), valve perforation, fistula formation</p>
                    <p><strong>Neurologic:</strong> Ischemic stroke (15-30%), intracerebral hemorrhage (5%), mycotic aneurysm rupture (rare but devastating), brain abscess</p>
                    <p><strong>Embolic:</strong> Spleen (abdominal pain), kidneys (hematuria, infarction), bones (osteomyelitis, vertebral), coronary arteries (MI)</p>
                    <p><strong>Immunologic:</strong> Glomerulonephritis (immune complex deposition), arthritis, splinter hemorrhages</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 43: MYOCARDITIS -->
<!-- ============================================ -->
        <div id="myocarditis" class="condition-page">
            <div class="page-header">
                <h2>43. MYOCARDITIS</h2>
                <div class="subtitle">Viral ‚Ä¢ Immune-mediated ‚Ä¢ Fulminant</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Chest pain (mimics MI), dyspnea, fatigue, palpitations. Often recent viral URI or gastroenteritis (1-3 weeks prior)</p>
                    <p><span class="label">Severity Spectrum:</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Chest pain, elevated troponin, preserved EF. May be asymptomatic</li>
                        <li><strong>Moderate:</strong> Heart failure symptoms, reduced EF, arrhythmias</li>
                        <li><strong>Fulminant:</strong> Cardiogenic shock, severe LV dysfunction, arrhythmias. Higher mortality but survivors often recover completely</li>
                    </ul>
                    <p><span class="label">Alternate Presentations:</span></p>
                    <ul>
                        <li><strong>Sudden cardiac death:</strong> Ventricular arrhythmias in young, previously healthy patients</li>
                        <li><strong>Dilated cardiomyopathy:</strong> Chronic presentation after subclinical acute phase</li>
                        <li><strong>Pericardial involvement:</strong> Myopericarditis (chest pain, friction rub, ST elevation + troponin elevation)</li>
                        <li><strong>Post-COVID:</strong> Multisystem inflammatory syndrome (MIS-C in children, MIS-A in adults)</li>
                        <li><strong>Vaccine-related:</strong> mRNA COVID vaccines (rare, ~12 cases/million, mostly young males, mild)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Troponin (elevated, often markedly), BNP, CBC, CRP/ESR, BMP, LFTs. Viral PCR if clinically indicated</p>
                    <p><span class="label">ECG:</span> ST elevation (diffuse, not localized), T wave changes, conduction abnormalities. May mimic STEMI or pericarditis</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Echocardiogram:</strong> Assess EF, regional wall motion abnormalities, pericardial effusion, LV thrombus</li>
                        <li><strong>Cardiac MRI:</strong> GOLD STANDARD for diagnosis (when stable). Late gadolinium enhancement in mid-wall/epicardial distribution (vs subendocardial in MI). T2-weighted imaging shows edema</li>
                        <li><strong>Coronary angiography:</strong> If concern for ACS (especially if STEMI-like presentation, risk factors). Normal coronaries support myocarditis</li>
                    </ul>
                    <p><span class="label">Endomyocardial Biopsy:</span> Gold standard but rarely done. Consider if: fulminant myocarditis, giant cell myocarditis suspected, not improving with supportive care, concern for infiltrative disease</p>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Viral (most common):</strong> Coxsackie B, adenovirus, parvovirus B19, HHV-6, COVID-19, influenza</li>
                        <li><strong>Autoimmune:</strong> Giant cell myocarditis, cardiac sarcoidosis, lupus, eosinophilic myocarditis</li>
                        <li><strong>Toxic:</strong> Cocaine, alcohol, chemotherapy (anthracyclines), clozapine</li>
                        <li><strong>Immune checkpoint inhibitors:</strong> Pembrolizumab, nivolumab. High mortality if not recognized early</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Supportive Care (Mainstay):</span></p>
                    <ul>
                        <li><strong>Activity restriction:</strong> CRITICAL. Bed rest, no exercise for ‚â•3-6 months (even if feeling better). Exercise during acute phase increases mortality</li>
                        <li><strong>Heart failure management:</strong> ACE-I/ARB, Œ≤-blockers (start low, go slow when stable), diuretics, aldosterone antagonist</li>
                        <li><strong>Arrhythmia monitoring:</strong> Telemetry. Treat ventricular arrhythmias per ACLS. Consider temporary pacing if high-grade block</li>
                        <li><strong>Anticoagulation:</strong> If EF <35%, consider prophylaxis for LV thrombus prevention</li>
                    </ul>
                    
                    <p><span class="label">Immunosuppression (CONTROVERSIAL):</span></p>
                    <ul>
                        <li><strong>Generally NOT recommended for viral myocarditis</strong> (may worsen outcomes)</li>
                        <li><strong>Consider for:</strong> Giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, immune checkpoint inhibitor myocarditis</li>
                        <li><strong>Regimen (if indicated):</strong> High-dose steroids ¬± other immunosuppression (azathioprine, cyclosporine). Consult cardiology/rheumatology</li>
                    </ul>
                    
                    <p><span class="label">Fulminant Myocarditis (ICU Management):</span></p>
                    <ul>
                        <li><strong>Inotropes:</strong> Dobutamine or milrinone if low cardiac output</li>
                        <li><strong>Mechanical support:</strong> IABP, Impella, VA-ECMO if cardiogenic shock. Bridge to recovery (most improve) or transplant</li>
                        <li><strong>Temporary pacing:</strong> If complete heart block</li>
                        <li><strong>AVOID:</strong> NSAIDs (may worsen myocardial inflammation and increase mortality). Use acetaminophen for pain</li>
                    </ul>
                    
                    <p><span class="label">Specific Etiologies:</span></p>
                    <ul>
                        <li><strong>Giant cell:</strong> High-dose steroids + immunosuppression. Transplant evaluation</li>
                        <li><strong>Immune checkpoint inhibitor:</strong> STOP immunotherapy immediately. High-dose methylprednisolone 1g/day √ó 3 days. Consider other immunosuppression if refractory</li>
                        <li><strong>Eosinophilic:</strong> Steroids. Check for hypereosinophilic syndrome</li>
                        <li><strong>Chagas:</strong> Benznidazole or nifurtimox (if acute). Treat heart failure in chronic phase</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Myocarditis vs MI:</strong> Younger age, no CAD risk factors, normal coronaries on angiography, diffuse ST elevation, troponin often disproportionately high for degree of ECG changes</li>
                    <li><strong>Cardiac MRI is diagnostic:</strong> Mid-wall/epicardial late gadolinium enhancement (vs subendocardial in MI). T2 signal for edema. Sensitivity/specificity >85%</li>
                    <li><strong>Fulminant paradox:</strong> Worse acute presentation but BETTER long-term outcomes (if survive). More likely to recover completely. Chronic myocarditis has worse prognosis</li>
                    <li><strong>Activity restriction saves lives:</strong> Athletes who return to sports too early have increased risk of sudden death. Minimum 3-6 months rest, longer if EF reduced</li>
                    <li><strong>NSAIDs are contraindicated:</strong> Animal studies show increased mortality. Use acetaminophen instead</li>
                    <li><strong>Troponin levels don't predict outcomes:</strong> Very high troponin can be seen in mild cases. EF and hemodynamics are better prognostic markers</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Fulminant myocarditis (cardiogenic shock, EF <30%)</li>
                        <li>Hemodynamic instability</li>
                        <li>Sustained ventricular arrhythmias</li>
                        <li>High-grade AV block</li>
                        <li>Need for inotropes or mechanical support</li>
                        <li>Respiratory failure</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable off inotropes</li>
                        <li>No sustained arrhythmias ‚â•48hr</li>
                        <li>On appropriate heart failure meds</li>
                        <li>Activity restrictions counseled (critical!)</li>
                        <li>Follow-up arranged (cardiology in 1-2 weeks, repeat echo in 1-3 months)</li>
                        <li>If EF reduced: Wearable defibrillator (LifeVest) until reassessment</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Cardiogenic shock (10-15% fulminant cases), sustained VT/VF (sudden death risk), complete heart block, acute heart failure</p>
                    <p><strong>Chronic:</strong> Dilated cardiomyopathy (10-30% of acute cases progress), chronic heart failure, need for transplant, recurrent myocarditis (rare), ventricular aneurysm</p>
                    <p><strong>Recovery:</strong> Most patients with preserved EF recover completely. Reduced EF may improve over 6-12 months with aggressive medical therapy. Repeat imaging essential</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 44: CARDIOGENIC SHOCK -->
<!-- ============================================ -->
        <div id="cardiogenic-shock" class="condition-page">
            <div class="page-header">
                <h2>44. CARDIOGENIC SHOCK</h2>
                <div class="subtitle">Pump Failure ‚Ä¢ Mechanical Complications ‚Ä¢ MCS</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Sustained hypotension (SBP <90mmHg) + end-organ hypoperfusion + cardiac dysfunction. Cardiac index <2.2 L/min/m¬≤, PCWP >15mmHg</p>
                    <p><span class="label">Classic:</span> Hypotension, cool extremities, altered mental status, oliguria, elevated lactate. Following acute MI, myocarditis, or acute decompensated heart failure</p>
                    <p><span class="label">Clinical Signs:</span></p>
                    <ul>
                        <li><strong>Hypoperfusion:</strong> Cold, clammy skin, delayed capillary refill (>3 sec), weak pulses, confusion, oliguria (<0.5mL/kg/hr)</li>
                        <li><strong>Congestion:</strong> Elevated JVP, pulmonary edema, hepatomegaly, peripheral edema (often "cold and wet")</li>
                        <li><strong>Compensatory:</strong> Tachycardia (attempt to maintain cardiac output), tachypnea</li>
                    </ul>
                    <p><span class="label">SCAI Shock Stages:</span></p>
                    <ul>
                        <li><strong>Stage A (At risk):</strong> No hypotension but risk factors present</li>
                        <li><strong>Stage B (Beginning):</strong> Relative hypotension, tachycardia, without hypoperfusion</li>
                        <li><strong>Stage C (Classic):</strong> Hypotension requiring intervention, tissue hypoperfusion</li>
                        <li><strong>Stage D (Deteriorating):</strong> Not responding to initial interventions, worsening hypoperfusion</li>
                        <li><strong>Stage E (Extremis):</strong> Circulatory collapse, cardiac arrest, requiring CPR or multiple interventions</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Labs:</span> Lactate (>2 suggests shock), BMP (creatinine rising), LFTs (hepatic hypoperfusion, transaminitis), CBC, troponin, BNP, blood gas (metabolic acidosis)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>ECG:</strong> Assess for acute MI (most common cause), arrhythmia</li>
                        <li><strong>Echocardiogram:</strong> URGENT. Assess EF, wall motion, valvular pathology, mechanical complications (VSD, acute MR, free wall rupture), pericardial effusion/tamponade, RV function</li>
                        <li><strong>CXR:</strong> Pulmonary edema, cardiomegaly</li>
                        <li><strong>Coronary angiography:</strong> If STEMI/NSTEMI. Revascularization is cornerstone of treatment for MI-related shock</li>
                    </ul>
                    <p><span class="label">Hemodynamic Monitoring (consider PA catheter or advanced monitoring):</span></p>
                    <ul>
                        <li><strong>Cardiogenic shock:</strong> CI <2.2, PCWP >15, SVR elevated</li>
                        <li><strong>Helps differentiate:</strong> From distributive shock (high CI, low SVR), hypovolemic shock (low PCWP)</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Acute MI (80%):</strong> Large anterior MI, mechanical complications (VSR, acute MR, free wall rupture)</li>
                        <li><strong>Acute decompensated HF:</strong> On chronic cardiomyopathy</li>
                        <li><strong>Acute valvular:</strong> Acute severe MR (papillary muscle rupture, endocarditis), acute severe AR (endocarditis, dissection)</li>
                        <li><strong>Myocarditis:</strong> Fulminant, usually viral or autoimmune</li>
                        <li><strong>RV failure:</strong> Massive PE, RV infarction</li>
                        <li><strong>Arrhythmia:</strong> Sustained VT, bradycardia, uncontrolled AFib with RVR</li>
                        <li><strong>Tako-tsubo (stress cardiomyopathy):</strong> Apical ballooning, mimics MI</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause:</strong> Emergent revascularization (PCI/CABG) for MI, surgery for mechanical complications, cardioversion for arrhythmia</li>
                        <li><strong>Optimize preload:</strong> Careful fluid management (avoid overload if already congested, give fluids if underfilled - esp RV MI)</li>
                        <li><strong>Improve contractility:</strong> Inotropes</li>
                        <li><strong>Reduce afterload:</strong> Vasodilators (if adequate BP)</li>
                        <li><strong>Mechanical circulatory support:</strong> If refractory to medical therapy</li>
                    </ul>
                    
                    <p><span class="label">Inotropes (ICU - arterial line required):</span></p>
                    <ul>
                        <li><strong>Dobutamine:</strong> 2.5-20mcg/kg/min. First-line. Œ≤‚ÇÅ agonist, increases contractility and reduces afterload. Risk: tachycardia, arrhythmias</li>
                        <li><strong>Milrinone:</strong> Load 50mcg/kg over 10min, then 0.375-0.75mcg/kg/min. PDE-3 inhibitor, inotrope + vasodilator. Avoid if hypotensive. Risk: hypotension, arrhythmias</li>
                        <li><strong>Dopamine:</strong> 5-20mcg/kg/min. Œ≤ and Œ± effects at higher doses (vasoconstriction). More arrhythmogenic than dobutamine</li>
                        <li><strong>Epinephrine:</strong> 0.05-0.5mcg/kg/min. For refractory shock. Potent inotrope + vasoconstrictor. Risk: tachycardia, ischemia, lactic acidosis</li>
                        <li><strong>Norepinephrine:</strong> Add if persistent hypotension despite inotropes (provides vasoconstriction)</li>
                    </ul>
                    
                    <p><span class="label">Vasodilators (only if adequate BP, SBP >90):</span></p>
                    <ul>
                        <li><strong>Nitroprusside:</strong> 0.25-10mcg/kg/min. Reduces afterload, improves forward flow. Watch for cyanide toxicity (>48hr high doses)</li>
                        <li><strong>Nitroglycerin:</strong> Reduces preload (less afterload reduction than nitroprusside)</li>
                    </ul>
                    
                    <p><span class="label">Mechanical Circulatory Support (MCS) - Cardiology/CT Surgery Consult:</span></p>
                    <ul>
                        <li><strong>Intra-aortic balloon pump (IABP):</strong> Inflates in diastole (improves coronary perfusion), deflates in systole (reduces afterload). Modest improvement in hemodynamics. No mortality benefit per IABP-SHOCK II trial, but still used as bridge</li>
                        <li><strong>Impella:</strong> Percutaneous ventricular assist device. Greater hemodynamic support than IABP. Can be placed at catheterization</li>
                        <li><strong>VA-ECMO:</strong> Veno-arterial ECMO. Complete cardiopulmonary support. For refractory shock. Bridge to recovery, bridge to decision, or bridge to durable VAD/transplant</li>
                        <li><strong>Surgical VAD:</strong> For bridge to transplant or destination therapy in refractory chronic cardiogenic shock</li>
                    </ul>
                    
                    <p><span class="label">Specific Scenarios:</span></p>
                    <ul>
                        <li><strong>STEMI with shock:</strong> Emergent PCI (or CABG if anatomy requires). Revascularization reduces mortality 50%. Consider MCS if refractory</li>
                        <li><strong>Mechanical complications post-MI:</strong> Surgery (VSD repair, MV repair/replacement, free wall rupture repair). Temporize with IABP/Impella until surgery</li>
                        <li><strong>RV MI/shock:</strong> AVOID diuretics/nitrates (need preload). Give IV fluids aggressively, maintain preload. Revascularization of RCA. May need inotropes</li>
                        <li><strong>Fulminant myocarditis:</strong> Supportive, mechanical support (ECMO). Most recover with bridge support</li>
                    </ul>
                    
                    <p><span class="label">Avoid in Cardiogenic Shock:</span></p>
                    <ul>
                        <li><strong>Œ≤-blockers:</strong> Worsen contractility and shock (restart when stabilized)</li>
                        <li><strong>ACE-I/ARB:</strong> Worsen hypotension acutely (restart when stabilized)</li>
                        <li><strong>Excessive fluids:</strong> If already volume overloaded (worsens pulmonary edema). Tailor to individual (RV MI needs fluids!)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>"Time is muscle":</strong> In MI-related cardiogenic shock, door-to-balloon time <90min reduces mortality. Revascularization is MOST important intervention</li>
                    <li><strong>Warm vs Cold, Dry vs Wet:</strong> Cold = hypoperfused (needs inotropes ¬± MCS), Warm = adequate perfusion. Wet = congested (needs diuresis), Dry = needs volume. Most CS is "cold and wet"</li>
                    <li><strong>Lactate trends matter:</strong> Elevated and rising lactate = worsening shock, need for escalation. Clearing lactate = improving</li>
                    <li><strong>RV MI is different:</strong> Hypotension + clear lungs + JVD. Give fluids, NOT diuretics. Revascularize RCA</li>
                    <li><strong>Mechanical complications timing:</strong> VSR (1-5 days post-MI), free wall rupture (3-5 days), papillary muscle rupture (2-7 days). New murmur + shock = echo STAT!</li>
                    <li><strong>Mortality remains high:</strong> Despite advances, CS mortality 40-50%. Early recognition and aggressive treatment (revascularization, MCS) improve outcomes</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL cardiogenic shock patients require ICU</li>
                        <li>Need for inotropes/pressors</li>
                        <li>Hypotension (SBP <90mmHg)</li>
                        <li>End-organ hypoperfusion (oliguria, AMS, lactate >2)</li>
                        <li>Mechanical circulatory support</li>
                        <li>Post-cardiac catheterization/surgery</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì ICU ‚Üí FLOOR CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable off inotropes ‚â•24hr</li>
                        <li>SBP >90-100mmHg consistently</li>
                        <li>Adequate end-organ perfusion (normal lactate, UOP, mentation)</li>
                        <li>No mechanical support</li>
                        <li>Underlying cause treated (revascularized, etc)</li>
                        <li>Transitioned to oral heart failure medications</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Death (40-50% mortality), multi-organ failure (renal, hepatic, intestinal ischemia), arrhythmias, cardiac arrest, limb ischemia (from MCS), stroke</p>
                    <p><strong>MCS-related:</strong> Bleeding, vascular injury, infection, hemolysis (ECMO), limb ischemia (IABP, Impella), LV distension/thrombus (VA-ECMO)</p>
                    <p><strong>Chronic (survivors):</strong> Chronic heart failure, need for transplant, durable VAD, recurrent ischemic events, chronic kidney disease</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 45: SYMPTOMATIC BRADYCARDIA/HEART BLOCK -->
<!-- ============================================ -->
        <div id="bradycardia" class="condition-page">
            <div class="page-header">
                <h2>45. SYMPTOMATIC BRADYCARDIA/HEART BLOCK (PACING)</h2>
                <div class="subtitle">Sinus Bradycardia ‚Ä¢ AV Block ‚Ä¢ Pacing Indications</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Lightheadedness, presyncope, syncope, dyspnea, chest pain, fatigue with bradycardia (HR <50-60). May be asymptomatic if chronic and compensated</p>
                    <p><span class="label">Emergency Presentations:</span></p>
                    <ul>
                        <li><strong>Syncope:</strong> Sudden loss of consciousness from inadequate cerebral perfusion</li>
                        <li><strong>Shock/hypotension:</strong> Bradycardia-induced low cardiac output</li>
                        <li><strong>Heart failure:</strong> Pulmonary edema from inadequate heart rate compensation</li>
                        <li><strong>Ventricular escape rhythms:</strong> Wide-complex slow rhythms (unreliable, unstable)</li>
                    </ul>
                    <p><span class="label">Types of Bradycardia:</span></p>
                    <ul>
                        <li><strong>Sinus bradycardia:</strong> Normal P waves, normal PR, slow rate. Can be physiologic (athletes) or pathologic</li>
                        <li><strong>1¬∞ AV block:</strong> PR >200ms. Every P conducted. Usually benign, no treatment needed</li>
                        <li><strong>2¬∞ AV block Mobitz I (Wenckebach):</strong> Progressive PR prolongation until dropped QRS. Usually benign unless symptomatic</li>
                        <li><strong>2¬∞ AV block Mobitz II:</strong> Fixed PR with intermittent dropped QRS. High risk of complete heart block. Often needs pacing</li>
                        <li><strong>3¬∞ AV block (complete):</strong> No AV conduction. Atria and ventricles beat independently. Always pathologic</li>
                        <li><strong>High-grade AV block:</strong> ‚â•2 consecutive P waves not conducted. Unstable, high-risk</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">ECG:</span> Characterize rhythm, measure intervals, identify level of block (AV node vs infranodal)</p>
                    <ul>
                        <li><strong>Narrow QRS escape:</strong> Block at AV node (more benign, responds to atropine)</li>
                        <li><strong>Wide QRS escape:</strong> Infranodal block (His-Purkinje). More unstable, less responsive to atropine, needs pacing</li>
                    </ul>
                    <p><span class="label">Labs:</span> Electrolytes (K, Mg, Ca), digoxin level if on digoxin, TSH, troponin (if concern for MI)</p>
                    <p><span class="label">Imaging:</span> Echocardiogram (assess for structural disease, pericardial effusion/tamponade if suspected)</p>
                    <p><span class="label">Identify Reversible Causes:</span></p>
                    <ul>
                        <li><strong>Medications:</strong> Œ≤-blockers, CCBs (diltiazem/verapamil), digoxin, antiarrhythmics (amiodarone, sotalol)</li>
                        <li><strong>Ischemia:</strong> Inferior MI (RCA ‚Üí AV node), anterior MI with BBB/complete heart block (LAD ‚Üí His-Purkinje)</li>
                        <li><strong>Infiltrative:</strong> Sarcoid, amyloid, hemochromatosis</li>
                        <li><strong>Inflammatory:</strong> Lyme disease (endemic areas), endocarditis (perivalvular abscess)</li>
                        <li><strong>Metabolic:</strong> Hypothyroidism, hyperkalemia, hypoxia</li>
                        <li><strong>Increased vagal tone:</strong> Athletes, sleep, vasovagal</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ACLS for Unstable Bradycardia:</span></p>
                    <ul>
                        <li><strong>Atropine:</strong> 1mg IV (can repeat q3-5min, max 3mg). First-line for symptomatic bradycardia. Blocks vagal tone. Works for AV nodal block, not infranodal</li>
                        <li><strong>Transcutaneous pacing (TCP):</strong> If atropine ineffective or severe symptoms. Apply pads, set rate 60-80, increase output until capture (usually 50-100mA). Sedate if conscious!</li>
                        <li><strong>Dopamine:</strong> 5-20mcg/kg/min. If atropine ineffective and TCP not available/not working</li>
                        <li><strong>Epinephrine:</strong> 2-10mcg/min infusion. Alternative to dopamine</li>
                    </ul>
                    
                    <p><span class="label">Transvenous Pacing (Temporary):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Symptomatic bradycardia refractory to medical therapy, unstable 2¬∞ Mobitz II or 3¬∞ AVB, post-MI with high-grade block</li>
                        <li><strong>Approach:</strong> Central venous access (IJ or subclavian), fluoroscopy-guided wire into RV apex. Set rate 60-80, output 2√ó threshold</li>
                        <li><strong>Temporary bridge:</strong> To permanent pacemaker or until reversible cause resolves</li>
                    </ul>
                    
                    <p><span class="label">Permanent Pacemaker Indications (Cardiology Consult):</span></p>
                    <ul>
                        <li><strong>Class I (Definite):</strong></li>
                        <ul>
                            <li>3¬∞ AVB or advanced 2¬∞ AVB (any level) with symptomatic bradycardia, pauses >3sec while awake, or escape rate <40</li>
                            <li>3¬∞ AVB or advanced 2¬∞ AVB at any anatomic level associated with arrhythmias or medical conditions requiring drugs that result in symptomatic bradycardia</li>
                            <li>Persistent 2¬∞ Mobitz II AVB or 3¬∞ AVB after MI (even if asymptomatic)</li>
                            <li>Sinus node dysfunction with symptomatic bradycardia or pauses</li>
                            <li>Symptomatic chronotropic incompetence</li>
                            <li>Alternating BBB</li>
                        </ul>
                        <li><strong>Post-MI:</strong> Persistent 2¬∞ Mobitz II, 3¬∞ AVB, alternating BBB (even if asymptomatic) - permanent pacemaker indicated. Transient block with inferior MI usually resolves</li>
                        <li><strong>Type of pacemaker:</strong> Dual-chamber (DDD) vs single-chamber (VVI) depending on underlying rhythm and conduction</li>
                    </ul>
                    
                    <p><span class="label">Treating Reversible Causes:</span></p>
                    <ul>
                        <li><strong>Medications:</strong> Hold or reduce offending agents (Œ≤-blockers, CCBs, digoxin). Consider digibind for digoxin toxicity</li>
                        <li><strong>Ischemia:</strong> Revascularization. Inferior MI with AV block often temporary (RCA supplies AV node). Anterior MI with high-grade block is more permanent (LAD supplies His bundle)</li>
                        <li><strong>Hypothyroidism:</strong> Levothyroxine replacement (bradycardia improves over weeks)</li>
                        <li><strong>Lyme carditis:</strong> Ceftriaxone 2g IV daily √ó 14-21 days. Often resolves, may need temporary pacing</li>
                        <li><strong>Hyperkalemia:</strong> Treat hyperkalemia (calcium, insulin/D50, kayexelate, dialysis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Mobitz I vs Mobitz II:</strong> Mobitz I (Wenckebach) = progressive PR prolongation, block at AV node, usually benign. Mobitz II = sudden dropped beat without PR change, infranodal block, high risk of complete heart block, often needs pacing</li>
                    <li><strong>Atropine can worsen infranodal block:</strong> By increasing sinus rate, more beats reach diseased His-Purkinje ‚Üí paradoxical worsening. Use cautiously if wide-complex escape or known infranodal disease</li>
                    <li><strong>Inferior MI vs Anterior MI:</strong> Inferior (RCA occlusion) ‚Üí AV nodal ischemia ‚Üí transient block, usually resolves. Anterior (LAD) ‚Üí septal infarct, His-Purkinje damage ‚Üí often permanent, needs PPM</li>
                    <li><strong>High-grade AV block ‚â† 3¬∞ AVB:</strong> High-grade = ‚â•2 consecutive non-conducted P waves but occasional conduction still present. Still dangerous, often progresses to complete</li>
                    <li><strong>PPM after MI timing:</strong> If persistent block (not resolved by day 5-7), permanent pacemaker indicated. Transient block with inferior MI often resolves</li>
                    <li><strong>Lyme carditis can cause ANY degree of AV block:</strong> Think Lyme in endemic areas (Northeast US) with new AV block, especially if young, no CAD. Usually reversible with antibiotics</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Unstable vital signs (hypotension, shock)</li>
                        <li>Syncope/presyncope</li>
                        <li>3¬∞ AV block or high-grade 2¬∞ AV block</li>
                        <li>Mobitz II 2¬∞ AV block</li>
                        <li>Need for temporary pacing (TCP or transvenous)</li>
                        <li>Bradycardia + acute MI</li>
                        <li>Ventricular escape rhythm</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Asymptomatic on telemetry monitoring</li>
                        <li>Reversible cause identified and treated</li>
                        <li>If permanent pacemaker placed: functioning appropriately, no complications</li>
                        <li>Stable heart rate and rhythm ‚â•24-48hr</li>
                        <li>No syncope/presyncope episodes</li>
                        <li>Device check arranged (if PPM placed)</li>
                        <li>Cardiology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Syncope/falls, progression to complete heart block, asystole, ventricular escape rhythms (unstable), cardiogenic shock</p>
                    <p><strong>Post-PPM:</strong> Pneumothorax (CXR post-placement), lead dislodgment, infection (pocket or endocarditis), hematoma, venous thrombosis, pacemaker syndrome (AV dyssynchrony in VVI pacing)</p>
                    <p><strong>Chronic:</strong> Pacemaker-dependent (if complete heart block), need for generator replacement (battery life 5-15 years), lead complications, heart failure (if excessive RV pacing)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 46: VENTRICULAR TACHYCARDIA/VENTRICULAR FIBRILLATION -->
<!-- ============================================ -->
        <div id="vt-vf" class="condition-page">
            <div class="page-header">
                <h2>46. VENTRICULAR TACHYCARDIA/VENTRICULAR FIBRILLATION</h2>
                <div class="subtitle">Wide Complex Tachycardia ‚Ä¢ Sudden Cardiac Arrest ‚Ä¢ ICD</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">VT (Ventricular Tachycardia):</span> Wide-complex (QRS >120ms) tachycardia at rate >100bpm. Can be stable or unstable</p>
                    <ul>
                        <li><strong>Stable (Monomorphic VT):</strong> Palpitations, dyspnea, chest pain, presyncope. Hemodynamically stable, conscious</li>
                        <li><strong>Unstable:</strong> Syncope, hypotension (SBP <90), altered mental status, pulmonary edema, shock</li>
                        <li><strong>Pulseless VT:</strong> Cardiac arrest. No pulse, unconscious. Treat as VF</li>
                    </ul>
                    <p><span class="label">VF (Ventricular Fibrillation):</span> Chaotic ventricular activity, no organized QRS complexes. Cardiac arrest. Pulseless, unconscious. Rapidly fatal without defibrillation</p>
                    <p><span class="label">Special Types:</span></p>
                    <ul>
                        <li><strong>Polymorphic VT:</strong> Varying QRS morphology. Often degenerates to VF. If QT prolonged = Torsades de Pointes</li>
                        <li><strong>Torsades de Pointes:</strong> Polymorphic VT with prolonged QT (>500ms). "Twisting of the points". Caused by QT-prolonging drugs, electrolyte abnormalities</li>
                        <li><strong>Ischemic VT:</strong> Post-MI scar-related reentry. Most common in adults</li>
                        <li><strong>Non-ischemic VT:</strong> Dilated cardiomyopathy, sarcoid, ARVD, genetic (Brugada, Long QT)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate (During Event):</span></p>
                    <ul>
                        <li><strong>ECG/Telemetry:</strong> Document rhythm. Assess QRS width, morphology, rate, AV dissociation</li>
                        <li><strong>Differentiate VT from SVT with aberrancy:</strong> Brugada criteria, AV dissociation (diagnostic of VT), capture/fusion beats, very wide QRS (>140ms), extreme axis deviation</li>
                        <li><strong>Pearl:</strong> If wide-complex tachycardia and unsure, assume VT (safer). "When in doubt, it's VT"</li>
                    </ul>
                    <p><span class="label">Post-Event Workup:</span></p>
                    <ul>
                        <li><strong>Labs:</strong> Troponin (MI trigger?), BMP (K, Mg - correct abnormalities), CBC, digoxin level if on digoxin</li>
                        <li><strong>ECG:</strong> Baseline rhythm, assess for MI, QT interval, epsilon wave (ARVD), Brugada pattern, pre-excitation</li>
                        <li><strong>Echo:</strong> Assess EF, wall motion (scar), structural disease</li>
                        <li><strong>Coronary angiography:</strong> If concern for ischemia/MI as trigger</li>
                        <li><strong>Cardiac MRI:</strong> Assess for scar, infiltrative disease (sarcoid, ARVD), myocarditis</li>
                        <li><strong>EP study:</strong> If recurrent VT, to map and potentially ablate VT circuit</li>
                    </ul>
                    <p><span class="label">Identify Triggers/Causes:</span></p>
                    <ul>
                        <li><strong>Ischemia/MI:</strong> Most common. VT/VF in first 48hr of MI is electrical instability. VT >48hr post-MI is scar-related</li>
                        <li><strong>Cardiomyopathy:</strong> Low EF (<35%) is strongest predictor of sudden death</li>
                        <li><strong>Electrolytes:</strong> Hypokalemia, hypomagnesemia, hypocalcemia (prolong QT ‚Üí Torsades)</li>
                        <li><strong>Medications:</strong> QT-prolonging drugs (antiarrhythmics, antipsychotics, fluoroquinolones, macrolides)</li>
                        <li><strong>Genetic:</strong> Long QT syndrome, Brugada, ARVD, catecholaminergic polymorphic VT (CPVT), hypertrophic cardiomyopathy</li>
                        <li><strong>Toxic:</strong> Cocaine, methamphetamine, digoxin toxicity</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Pulseless VT/VF (Cardiac Arrest - ACLS):</span></p>
                    <ul>
                        <li><strong>Immediate defibrillation:</strong> 200J biphasic (or 360J monophasic). Resume CPR immediately after shock</li>
                        <li><strong>CPR:</strong> High-quality compressions (‚â•100/min, depth ‚â•2 inches), minimize interruptions</li>
                        <li><strong>Epinephrine:</strong> 1mg IV/IO q3-5min</li>
                        <li><strong>Amiodarone:</strong> 300mg IV/IO first dose, then 150mg if recurrent VF/VT</li>
                        <li><strong>Treat reversible causes:</strong> H's and T's (Hypovolemia, Hypoxia, H‚Å∫ [acidosis], Hypo/Hyperkalemia, Hypothermia, Toxins, Tamponade, Tension pneumothorax, Thrombosis [coronary or pulmonary], Trauma)</li>
                    </ul>
                    
                    <p><span class="label">Unstable VT (With Pulse, SBP <90, AMS, pulmonary edema):</span></p>
                    <ul>
                        <li><strong>Synchronized cardioversion:</strong> 100J, then 150J, 200J if unsuccessful. Sedate if conscious!</li>
                        <li><strong>If polymorphic VT:</strong> Treat as VF (unsynchronized high-energy shock 200J)</li>
                        <li><strong>Post-cardioversion:</strong> Amiodarone 150mg IV over 10min, then 1mg/min √ó 6hr, then 0.5mg/min</li>
                    </ul>
                    
                    <p><span class="label">Stable Monomorphic VT (With Pulse, Hemodynamically Stable):</span></p>
                    <ul>
                        <li><strong>Amiodarone:</strong> 150mg IV over 10min (can repeat), then 1mg/min √ó 6hr, then 0.5mg/min √ó 18hr</li>
                        <li><strong>Procainamide:</strong> Alternative if normal EF. 20-50mg/min IV (max 17mg/kg). Monitor QT and BP</li>
                        <li><strong>Sotalol:</strong> Another alternative. 1.5mg/kg IV over 5min. Monitor QT</li>
                        <li><strong>If refractory:</strong> Synchronized cardioversion (consider sedation)</li>
                    </ul>
                    
                    <p><span class="label">Torsades de Pointes (Polymorphic VT with Long QT):</span></p>
                    <ul>
                        <li><strong>Magnesium sulfate:</strong> 2g IV over 5-20min (even if Mg normal). First-line. Stabilizes membrane</li>
                        <li><strong>Correct electrolytes:</strong> K >4.5, Mg >2</li>
                        <li><strong>Increase heart rate:</strong> Isoproterenol infusion (1-4mcg/min) or overdrive pacing (rate 100-120) to shorten QT</li>
                        <li><strong>STOP QT-prolonging agents:</strong> Review medication list, discontinue offending drugs</li>
                        <li><strong>If unstable:</strong> Unsynchronized defibrillation (as VF)</li>
                    </ul>
                    
                    <p><span class="label">VT Storm (Recurrent VT, ‚â•3 episodes in 24hr):</span></p>
                    <ul>
                        <li><strong>Amiodarone infusion:</strong> Load 150mg, then continuous infusion</li>
                        <li><strong>Œ≤-blockers:</strong> Metoprolol or esmolol (reduce sympathetic drive)</li>
                        <li><strong>Sedation:</strong> Reduce sympathetic tone (propofol, benzodiazepines)</li>
                        <li><strong>Correct triggers:</strong> Ischemia (revascularization), electrolytes, medications</li>
                        <li><strong>Catheter ablation:</strong> Consider urgent EP study and ablation if refractory</li>
                    </ul>
                    
                    <p><span class="label">Secondary Prevention (ICD Placement - Cardiology/EP Consult):</span></p>
                    <ul>
                        <li><strong>Class I Indications (Definite):</strong></li>
                        <ul>
                            <li>Cardiac arrest due to VF/VT not due to reversible cause</li>
                            <li>Spontaneous sustained VT with structural heart disease</li>
                            <li>Unexplained syncope with inducible VT/VF at EP study</li>
                        </ul>
                        <li><strong>Primary Prevention ICD:</strong> EF ‚â§35% despite optimal medical therapy ‚â•3 months (ischemic) or ‚â•3 months (non-ischemic), NYHA Class II-III</li>
                        <li><strong>Wearable defibrillator (LifeVest):</strong> Bridge to ICD assessment if not ready for permanent device (e.g., waiting for EF reassessment, infection, etc)</li>
                    </ul>
                    
                    <p><span class="label">Treating Underlying Causes:</span></p>
                    <ul>
                        <li><strong>Ischemia:</strong> Urgent PCI/CABG. VT/VF in acute MI is electrical, may not recur after revascularization</li>
                        <li><strong>Electrolytes:</strong> K >4, Mg >2 (higher targets in setting of VT/VF)</li>
                        <li><strong>Long QT syndrome:</strong> Œ≤-blockers (propranolol, nadolol). ICD if syncope/VT despite therapy</li>
                        <li><strong>Brugada:</strong> ICD. No proven pharmacologic therapy. Avoid drugs that unmask (procainamide, flecainide)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Wide complex tachycardia = VT until proven otherwise:</strong> Especially with structural heart disease. Treating VT as SVT can be fatal (e.g., adenosine in VT can cause VF). When in doubt, use amiodarone</li>
                    <li><strong>AV dissociation proves VT:</strong> P waves and QRS complexes independent. Capture beats (narrow QRS when P captures ventricle) and fusion beats also diagnostic</li>
                    <li><strong>Early post-MI VT/VF (first 48hr) doesn't need ICD:</strong> Electrical instability of ischemic myocardium. Treat with revascularization. VT >48hr post-MI is scar-related and needs ICD</li>
                    <li><strong>Torsades = Magnesium first:</strong> Even if serum Mg normal. Increases heart rate to shorten QT</li>
                    <li><strong>Never give adenosine for wide-complex tachycardia unless certain it's SVT:</strong> Can cause VF in VT, can precipitate AF with rapid conduction in WPW</li>
                    <li><strong>ICD is NOT primary treatment:</strong> ICD prevents sudden death but doesn't treat VT. Still need optimal medical therapy (Œ≤-blockers, ACE-I, etc) and treatment of underlying cause</li>
                    <li><strong>VT storm is an emergency:</strong> Recurrent shocks from ICD, severe sympathetic surge. Sedate, amiodarone, consider urgent ablation</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Pulseless VT/VF (post-ROSC)</li>
                        <li>Unstable VT (hypotension, AMS, pulmonary edema)</li>
                        <li>VT storm (recurrent episodes)</li>
                        <li>Post-cardioversion/defibrillation</li>
                        <li>Continuous antiarrhythmic infusions</li>
                        <li>Acute MI with ventricular arrhythmias</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Stable rhythm ‚â•24-48hr on telemetry</li>
                        <li>No recurrent VT/VF</li>
                        <li>Hemodynamically stable</li>
                        <li>Underlying cause identified and treated</li>
                        <li>If ICD candidate: Device placed or LifeVest prescribed</li>
                        <li>Optimal medical therapy initiated (Œ≤-blockers, etc)</li>
                        <li>Cardiology/EP follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Sudden cardiac death (if not defibrillated), cardiogenic shock, hypoxic brain injury (post-arrest), recurrent VT/VF (VT storm), ICD shocks (painful, psychological impact)</p>
                    <p><strong>Post-ICD:</strong> Inappropriate shocks (lead malfunction, SVT misdetected), infection (pocket or lead endocarditis), lead dislodgment, pneumothorax, psychological impact of living with ICD</p>
                    <p><strong>Chronic:</strong> Recurrent VT (may need ablation), progression of heart failure, need for transplant, complications of underlying disease (CAD, cardiomyopathy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 47: ACUTE LIMB ISCHEMIA -->
<!-- ============================================ -->
        <div id="limb-ischemia" class="condition-page">
            <div class="page-header">
                <h2>47. ACUTE LIMB ISCHEMIA</h2>
                <div class="subtitle">Vascular Emergency ‚Ä¢ 6 P's ‚Ä¢ Revascularization</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic 6 P's:</span></p>
                    <ul>
                        <li><strong>Pain:</strong> Severe, sudden onset. Often at rest</li>
                        <li><strong>Pallor:</strong> White, mottled appearance</li>
                        <li><strong>Pulselessness:</strong> Absent distal pulses (femoral, popliteal, DP, PT)</li>
                        <li><strong>Paresthesias:</strong> Numbness, tingling. Early sign of nerve ischemia</li>
                        <li><strong>Paralysis:</strong> Weakness, inability to move limb. LATE finding, indicates severe ischemia</li>
                        <li><strong>Poikilothermia:</strong> Cool to touch compared to contralateral limb</li>
                    </ul>
                    <p><span class="label">Severity Classification (Rutherford):</span></p>
                    <ul>
                        <li><strong>Class I (Viable):</strong> No immediate threat. No sensory/motor deficit. Audible Doppler signals</li>
                        <li><strong>Class IIA (Marginally threatened):</strong> Salvageable if promptly treated. Minimal sensory loss, no motor deficit. Inaudible Doppler</li>
                        <li><strong>Class IIB (Immediately threatened):</strong> Salvageable with immediate revascularization. Sensory loss beyond toes, mild-moderate motor deficit. Inaudible Doppler</li>
                        <li><strong>Class III (Irreversible):</strong> Major tissue loss inevitable. Profound sensory/motor deficit, rigor. Skin marbling. Amputation likely</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Embolism (40%):</strong> Sudden onset, no prior claudication. AF (cardiac source), MI (LV thrombus), endocarditis, paradoxical embolus. Typically lodges at arterial bifurcations</li>
                        <li><strong>Thrombosis (40%):</strong> Progressive onset, history of claudication/PAD. Atherosclerotic disease with superimposed thrombosis</li>
                        <li><strong>Trauma:</strong> Fracture, dislocation, penetrating injury, iatrogenic (catheterization)</li>
                        <li><strong>Other:</strong> Aortic dissection, compartment syndrome, popliteal aneurysm thrombosis, hypercoagulable state</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Exam:</span> Vascular exam (pulses, capillary refill, temperature, color), neurologic exam (sensation, motor function), compare to contralateral limb</p>
                    <p><span class="label">Doppler Ultrasound:</span> Bedside assessment of flow. Audible signals suggest viability. Inaudible signals in threatened/irreversible ischemia</p>
                    <p><span class="label">Labs:</span> CBC, BMP (creatinine - may worsen with revascularization/rhabdo), CK (rhabdomyolysis if elevated), lactate, coagulation studies, type & screen</p>
                    <p><span class="label">ECG:</span> Assess for AF (cardioembolic source), recent MI</p>
                    <p><span class="label">Imaging (don't delay revascularization if Class IIB/III):</span></p>
                    <ul>
                        <li><strong>CT Angiography (CTA):</strong> Gold standard for anatomy. Identifies level of occlusion, collaterals, assess for aneurysm/dissection. Fast</li>
                        <li><strong>Conventional angiography:</strong> Diagnostic + therapeutic (catheter-directed thrombolysis). Done in angio suite</li>
                        <li><strong>Duplex ultrasound:</strong> If concern for DVT, popliteal aneurysm</li>
                    </ul>
                    <p><span class="label">Echocardiogram:</span> If embolic source suspected (AF, LV thrombus, endocarditis, PFO)</p>
                    <p><span class="label">Embolism vs Thrombosis Clues:</span></p>
                    <ul>
                        <li><strong>Embolism:</strong> Sudden onset, no prior symptoms, AF, normal contralateral pulses, emboli elsewhere</li>
                        <li><strong>Thrombosis:</strong> Progressive symptoms, history of claudication, abnormal contralateral pulses, chronic PAD</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (All Patients):</span></p>
                    <ul>
                        <li><strong>URGENT Vascular Surgery Consult:</strong> Time = limb! Revascularization within 6 hours optimal</li>
                        <li><strong>IV Heparin:</strong> Bolus 80 units/kg, then 18 units/kg/hr. Prevents propagation of thrombus/embolus. DO NOT delay for imaging</li>
                        <li><strong>Analgesia:</strong> IV opioids for severe pain</li>
                        <li><strong>IV fluids:</strong> Aggressive hydration (prevent contrast-induced nephropathy, prepare for reperfusion injury)</li>
                        <li><strong>Keep limb in dependent position:</strong> Improves blood flow. Do NOT elevate</li>
                        <li><strong>Keep warm:</strong> Room warm, but avoid direct heat to limb (can increase metabolic demand)</li>
                        <li><strong>Avoid flexing knee:</strong> Can worsen ischemia by compressing popliteal artery</li>
                    </ul>
                    
                    <p><span class="label">Revascularization Strategies (Vascular Surgery):</span></p>
                    <ul>
                        <li><strong>Catheter-directed thrombolysis:</strong> For Class I/IIA. Infuse tPA directly into thrombus. Takes 12-24hr. For less severe ischemia, or if patient not surgical candidate</li>
                        <li><strong>Surgical thromboembolectomy:</strong> For Class IIB/III (immediate threat). Fogarty catheter to remove clot. Faster than thrombolysis</li>
                        <li><strong>Bypass surgery:</strong> If severe underlying PAD, long-segment occlusion, or failed endovascular approach</li>
                        <li><strong>Hybrid approach:</strong> Combination of surgical and endovascular techniques</li>
                    </ul>
                    
                    <p><span class="label">Reperfusion Injury Prevention:</span></p>
                    <ul>
                        <li><strong>IV fluids:</strong> Aggressive hydration to maintain UOP >1mL/kg/hr (prevent myoglobin-induced AKI)</li>
                        <li><strong>Bicarbonate:</strong> Consider alkalinizing urine if rhabdomyolysis (keeps myoglobin soluble)</li>
                        <li><strong>Monitor electrolytes:</strong> Watch for hyperkalemia (reperfusion releases K from ischemic muscle)</li>
                        <li><strong>Fasciotomy:</strong> If compartment syndrome develops (swelling, pain, palpable tension). Prophylactic if prolonged ischemia (>6hr)</li>
                    </ul>
                    
                    <p><span class="label">Post-Revascularization Care:</span></p>
                    <ul>
                        <li><strong>Monitor for compartment syndrome:</strong> Severe pain (out of proportion), pain with passive stretch, tense compartments, paresthesias. SURGICAL EMERGENCY - fasciotomy</li>
                        <li><strong>Continue anticoagulation:</strong> Heparin bridge to warfarin or DOAC (if embolic source). Lifelong if AF, LV thrombus</li>
                        <li><strong>Antiplatelet:</strong> ASA + P2Y12 inhibitor (clopidogrel) if thrombotic/PAD</li>
                        <li><strong>Statin:</strong> High-intensity (PAD management)</li>
                        <li><strong>Monitor CK, potassium, creatinine:</strong> For rhabdomyolysis and AKI</li>
                    </ul>
                    
                    <p><span class="label">If Irreversible (Class III):</span></p>
                    <ul>
                        <li><strong>Amputation:</strong> To prevent systemic complications (rhabdomyolysis, sepsis from necrotic tissue)</li>
                        <li><strong>Supportive care:</strong> Aggressive hydration, treat hyperkalemia, monitor for systemic toxicity</li>
                        <li><strong>Do NOT revascularize:</strong> Reperfusion of necrotic tissue releases toxins (K, myoglobin, lactate) ‚Üí systemic collapse</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>"Time is limb":</strong> Revascularization within 6 hours gives best outcomes. Muscle tolerates 4-6hr ischemia, nerves 2-4hr. Paralysis = LATE finding, needs emergent revascularization</li>
                    <li><strong>Heparin first, imaging second:</strong> Start heparin immediately based on clinical diagnosis. Don't delay for imaging confirmation</li>
                    <li><strong>Paralysis is bad:</strong> Motor deficit indicates advanced ischemia (nerve damage). Urgent revascularization needed. Sensation goes before motor</li>
                    <li><strong>Compartment syndrome after revascularization:</strong> Reperfusion causes swelling. High index of suspicion. Pain out of proportion, pain with passive stretch. Don't wait for pulselessness or pressure measurement - clinical diagnosis!</li>
                    <li><strong>Blue toe syndrome:</strong> Emboli to digital arteries from proximal atherosclerotic plaque. Still palpable pulses. Suggests proximal source (aorta, iliac, popliteal aneurysm)</li>
                    <li><strong>Don't revascularize Class III:</strong> Reperfusion of necrotic tissue causes systemic toxicity (hyperkalemia, myoglobin ‚Üí cardiac arrest, AKI). Amputation is life-saving</li>
                    <li><strong>Check for bilateral involvement:</strong> Emboli can lodge in multiple locations. Assess contralateral limb, visceral arteries</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Class IIB/III (threatened or irreversible ischemia)</li>
                        <li>Hemodynamic instability</li>
                        <li>Post-revascularization (monitor for reperfusion injury)</li>
                        <li>Rhabdomyolysis (CK >5000, rising creatinine)</li>
                        <li>Severe hyperkalemia</li>
                        <li>Compartment syndrome requiring fasciotomy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Successful revascularization with palpable pulses</li>
                        <li>No signs of compartment syndrome</li>
                        <li>Stable renal function (no rhabdo-induced AKI)</li>
                        <li>Electrolytes normalized</li>
                        <li>On appropriate anticoagulation/antiplatelet</li>
                        <li>Vascular surgery follow-up arranged</li>
                        <li>If embolic: Cardiology follow-up, address source (AF, LV thrombus)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Limb loss (amputation 10-30% depending on severity), compartment syndrome (post-reperfusion swelling), rhabdomyolysis ‚Üí AKI, hyperkalemia ‚Üí cardiac arrest, sepsis from necrotic tissue, death (15-20% in-hospital mortality)</p>
                    <p><strong>Post-reperfusion:</strong> Compartment syndrome, reperfusion injury (release of toxins ‚Üí systemic inflammation), AKI (myoglobin), cardiac arrhythmias (hyperkalemia), recurrent thrombosis/embolism</p>
                    <p><strong>Chronic:</strong> Chronic limb ischemia (incomplete revascularization), nerve damage (foot drop from peroneal nerve), chronic pain, graft/stent thrombosis, recurrent events if embolic source not addressed</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 48: DEEP VEIN THROMBOSIS -->
<!-- ============================================ -->
        <div id="dvt" class="condition-page">
            <div class="page-header">
                <h2>48. DEEP VEIN THROMBOSIS (DVT)</h2>
                <div class="subtitle">Lower Extremity ‚Ä¢ Wells Criteria ‚Ä¢ Anticoagulation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Unilateral leg swelling, pain, warmth, erythema. Calf tenderness, palpable cord. Homan's sign (pain with dorsiflexion) unreliable</p>
                    <p><span class="label">Location:</span></p>
                    <ul>
                        <li><strong>Proximal DVT:</strong> Popliteal, femoral, iliac veins. Higher risk for PE (50% without treatment)</li>
                        <li><strong>Distal DVT:</strong> Calf veins (tibial, peroneal). Lower PE risk (~5%), but 20% propagate proximally</li>
                        <li><strong>Upper extremity DVT:</strong> Subclavian, axillary veins. Often related to central line, PICC, pacemaker lead. Can still embolize to lungs</li>
                    </ul>
                    <p><span class="label">Special Presentations:</span></p>
                    <ul>
                        <li><strong>Phlegmasia cerulea dolens:</strong> Massive ileofemoral DVT ‚Üí entire leg swollen, cyanotic, painful. Venous gangrene risk. EMERGENCY</li>
                        <li><strong>Bilateral leg swelling:</strong> Think IVC thrombosis, pelvic mass, or bilateral DVT (rare)</li>
                        <li><strong>Asymptomatic:</strong> 50% of DVT discovered incidentally or when presents as PE</li>
                    </ul>
                    <p><span class="label">Risk Factors (Virchow's Triad - Stasis, Hypercoagulability, Endothelial Injury):</span></p>
                    <ul>
                        <li><strong>Surgery:</strong> Especially orthopedic (hip/knee replacement), pelvic, abdominal</li>
                        <li><strong>Immobility:</strong> Prolonged bed rest, long flights (>6hr), paralysis, casting</li>
                        <li><strong>Malignancy:</strong> Pancreas, lung, GI, ovarian. Hypercoagulable state (Trousseau syndrome)</li>
                        <li><strong>Hypercoagulable states:</strong> Factor V Leiden, prothrombin G20210A, antiphospholipid syndrome, protein C/S deficiency</li>
                        <li><strong>Hormonal:</strong> Pregnancy, OCP, HRT, postpartum (6 weeks)</li>
                        <li><strong>Prior VTE:</strong> 30% recurrence rate off anticoagulation</li>
                        <li><strong>Other:</strong> CHF, obesity, smoking, central venous catheter, IBD, nephrotic syndrome</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Prediction (Wells Criteria for DVT):</span></p>
                    <ul>
                        <li>Active cancer (+1)</li>
                        <li>Paralysis, paresis, or recent plaster immobilization (+1)</li>
                        <li>Recently bedridden >3 days or major surgery within 12 weeks (+1)</li>
                        <li>Localized tenderness along deep venous system (+1)</li>
                        <li>Entire leg swollen (+1)</li>
                        <li>Calf swelling >3cm compared to other leg (+1)</li>
                        <li>Pitting edema in symptomatic leg (+1)</li>
                        <li>Collateral superficial veins (+1)</li>
                        <li>Previously documented DVT (+1)</li>
                        <li>Alternative diagnosis as likely or more likely than DVT (-2)</li>
                        <li><strong>Interpretation:</strong> ‚â§0 = low prob (3% DVT), 1-2 = moderate (17%), ‚â•3 = high (75%)</li>
                    </ul>
                    <p><span class="label">D-dimer:</span></p>
                    <ul>
                        <li><strong>Use:</strong> Rule-out test if low/moderate probability. High sensitivity (>95%), low specificity</li>
                        <li><strong>Negative D-dimer + low/moderate Wells:</strong> DVT excluded, no further testing needed</li>
                        <li><strong>Elevated D-dimer OR high Wells:</strong> Proceed to imaging</li>
                        <li><strong>False positives:</strong> Pregnancy, malignancy, surgery, infection, advanced age, hospitalization</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Compression ultrasound with Doppler:</strong> GOLD STANDARD. Sensitivity/specificity >95% for proximal DVT. Non-compressible vein = thrombus. Less sensitive for calf veins (70%)</li>
                        <li><strong>Repeat ultrasound:</strong> If negative but high suspicion, repeat in 1 week (may miss early thrombus or calf DVT that propagates)</li>
                        <li><strong>CT/MR venography:</strong> If US non-diagnostic or concern for pelvic/IVC thrombus</li>
                        <li><strong>Venography:</strong> Rarely needed. Gold standard but invasive</li>
                    </ul>
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC, BMP, PT/PTT:</strong> Baseline before anticoagulation</li>
                        <li><strong>Consider hypercoagulable workup:</strong> If unprovoked DVT, age <50, recurrent VTE, strong family history, unusual site (mesenteric, cerebral). Test AFTER acute event treated (factor levels affected by acute clot)</li>
                        <li><strong>Malignancy screening:</strong> Age-appropriate cancer screening if unprovoked DVT (occult malignancy in 10%)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Anticoagulation (Start ASAP if high clinical suspicion, don't wait for imaging):</span></p>
                    <ul>
                        <li><strong>First-line: DOACs (Direct Oral Anticoagulants)</strong></li>
                        <ul>
                            <li><strong>Apixaban:</strong> 10mg BID √ó 7 days, then 5mg BID (no bridging needed)</li>
                            <li><strong>Rivaroxaban:</strong> 15mg BID √ó 21 days, then 20mg daily (no bridging needed)</li>
                            <li><strong>Dabigatran:</strong> Requires 5-day heparin/LMWH lead-in, then 150mg BID</li>
                            <li><strong>Edoxaban:</strong> Requires 5-day heparin/LMWH lead-in, then 60mg daily</li>
                        </ul>
                        <li><strong>Advantages DOACs:</strong> No monitoring, fixed dosing, rapid onset, lower bleeding risk than warfarin</li>
                        <li><strong>Avoid DOACs if:</strong> CrCl <30, mechanical valve, antiphospholipid syndrome (warfarin preferred), pregnancy (use LMWH)</li>
                    </ul>
                    
                    <p><span class="label">Alternative Anticoagulation:</span></p>
                    <ul>
                        <li><strong>LMWH (Enoxaparin):</strong> 1mg/kg SQ BID or 1.5mg/kg daily. Bridge to warfarin or use as monotherapy (cancer-associated VTE). Safe in renal insufficiency (dose-adjust if CrCl <30)</li>
                        <li><strong>Unfractionated heparin:</strong> IV bolus 80 units/kg, then 18 units/kg/hr. Use if CrCl <30, high bleeding risk, need for procedures (shorter half-life). Bridge to warfarin</li>
                        <li><strong>Warfarin:</strong> Start with LMWH/heparin bridge. Goal INR 2-3. Requires frequent monitoring. Use if DOAC contraindicated or cost issue</li>
                        <li><strong>Fondaparinux:</strong> Weight-based SQ dosing. Bridge to warfarin. Alternative if HIT</li>
                    </ul>
                    
                    <p><span class="label">Duration of Anticoagulation:</span></p>
                    <ul>
                        <li><strong>Provoked DVT (surgery, trauma, temporary risk):</strong> 3 months minimum</li>
                        <li><strong>Unprovoked DVT:</strong> Minimum 3 months, consider indefinite (weigh bleeding risk vs recurrence risk)</li>
                        <li><strong>Cancer-associated DVT:</strong> Minimum 3-6 months, often indefinite while cancer active. LMWH preferred over warfarin/DOACs</li>
                        <li><strong>Recurrent VTE:</strong> Indefinite anticoagulation</li>
                        <li><strong>Thrombophilia (Factor V Leiden, etc):</strong> 3 months if heterozygous + provoked. Consider indefinite if homozygous or unprovoked</li>
                    </ul>
                    
                    <p><span class="label">Isolated Distal (Calf) DVT:</span></p>
                    <ul>
                        <li><strong>Symptomatic:</strong> Anticoagulate √ó 3 months (same as proximal)</li>
                        <li><strong>Asymptomatic:</strong> Options include anticoagulation OR serial imaging (repeat US in 1 week) to monitor for propagation</li>
                    </ul>
                    
                    <p><span class="label">IVC Filter:</span></p>
                    <ul>
                        <li><strong>Indications (rare):</strong> Absolute contraindication to anticoagulation (active bleeding), recurrent PE despite therapeutic anticoagulation, extensive proximal DVT with limited cardiopulmonary reserve</li>
                        <li><strong>Retrievable filters:</strong> Remove when safe to anticoagulate</li>
                        <li><strong>Complications:</strong> Filter thrombosis, IVC thrombosis, migration, perforation</li>
                    </ul>
                    
                    <p><span class="label">Catheter-Directed Thrombolysis:</strong></p>
                    <ul>
                        <li><strong>Consider for:</strong> Phlegmasia cerulea dolens, extensive ileofemoral DVT in young patient with good functional status, limb-threatening ischemia</li>
                        <li><strong>Goal:</strong> Prevent post-thrombotic syndrome, preserve valve function</li>
                        <li><strong>NOT routine:</strong> Increased bleeding risk, no mortality benefit</li>
                    </ul>
                    
                    <p><span class="label">Adjunctive Measures:</span></p>
                    <ul>
                        <li><strong>Compression stockings:</strong> Controversial. May reduce post-thrombotic syndrome. Knee-high 30-40mmHg for 2 years</li>
                        <li><strong>Early mobilization:</strong> Safe and encouraged (does NOT increase PE risk). Bed rest is OUTDATED</li>
                        <li><strong>Leg elevation:</strong> When resting, reduces swelling</li>
                        <li><strong>Analgesia:</strong> NSAIDs or acetaminophen for pain</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't wait for imaging if high suspicion:</strong> Start anticoagulation empirically while arranging ultrasound. DVT can propagate/embolize quickly</li>
                    <li><strong>D-dimer is a rule-out test:</strong> Negative D-dimer + low probability = DVT excluded. Don't order if high probability (always positive, not helpful). Specificity decreases with age, hospitalization</li>
                    <li><strong>Homan's sign is useless:</strong> Sensitivity and specificity both ~50%. Don't rely on it</li>
                    <li><strong>DOACs are first-line:</strong> Unless contraindication (severe renal insufficiency, mechanical valve, APS, pregnancy). No bridge needed with apixaban/rivaroxaban</li>
                    <li><strong>Cancer + VTE = LMWH:</strong> LMWH (enoxaparin) superior to warfarin for cancer-associated thrombosis. Lower recurrence rate</li>
                    <li><strong>Early mobilization is safe:</strong> Bed rest does NOT prevent PE and increases risk of complications (pneumonia, deconditioning). Walk!</li>
                    <li><strong>Post-thrombotic syndrome:</strong> Chronic leg pain, swelling, skin changes (hyperpigmentation, ulceration) in 20-50% of DVT patients. Caused by venous valvular incompetence from clot damage</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Phlegmasia cerulea dolens (limb-threatening)</li>
                        <li>Concurrent PE with hemodynamic instability</li>
                        <li>Need for thrombolysis</li>
                        <li>Bleeding on anticoagulation</li>
                        <li>Bilateral extensive DVT</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Proximal DVT: Anticoagulation initiated, stable on oral regimen or LMWH bridge arranged</li>
                        <li>Distal DVT: Anticoagulation started OR serial imaging plan arranged</li>
                        <li>No evidence of PE (or stable PE)</li>
                        <li>Pain controlled</li>
                        <li>Able to ambulate</li>
                        <li>Patient education on anticoagulation, bleeding precautions</li>
                        <li>Follow-up arranged (anticoagulation clinic, hematology if unprovoked/recurrent)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Pulmonary embolism (most feared, 50% risk if untreated proximal DVT), phlegmasia cerulea dolens (venous gangrene), compartment syndrome (rare), propagation to IVC</p>
                    <p><strong>Treatment-related:</strong> Bleeding (major bleeding 1-3%/year on anticoagulation), HIT (with heparin), recurrent VTE despite anticoagulation</p>
                    <p><strong>Chronic:</strong> Post-thrombotic syndrome (20-50%, chronic leg pain/swelling/ulceration), recurrent DVT (30% over 10 years if unprovoked), chronic thromboembolic disease</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 49: PLEURAL EFFUSION -->
<!-- ============================================ -->
        <div id="pleural-effusion" class="condition-page">
            <div class="page-header">
                <h2>49. PLEURAL EFFUSION</h2>
                <div class="subtitle">Transudate vs Exudate ‚Ä¢ Light's Criteria ‚Ä¢ Thoracentesis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic:</span> Dyspnea (most common), pleuritic chest pain, cough. May be asymptomatic if small</p>
                    <p><span class="label">Physical Exam:</span> Decreased breath sounds, dullness to percussion, decreased tactile fremitus. Tracheal deviation away from effusion if massive</p>
                    <p><span class="label">Severity:</span></p>
                    <ul>
                        <li><strong>Small:</strong> <300mL. Often asymptomatic. Blunting of costophrenic angle on CXR</li>
                        <li><strong>Moderate:</strong> 300-1000mL. Dyspnea on exertion. Visible on CXR (meniscus sign)</li>
                        <li><strong>Large:</strong> >1000mL. Dyspnea at rest. Occupies significant hemithorax</li>
                        <li><strong>Massive:</strong> Complete white-out of hemithorax. Severe respiratory distress</li>
                    </ul>
                    <p><span class="label">Common Etiologies:</span></p>
                    <ul>
                        <li><strong>Transudates (‚Üìoncotic pressure or ‚Üëhydrostatic pressure):</strong> CHF (most common overall), cirrhosis, nephrotic syndrome, PE</li>
                        <li><strong>Exudates (inflammation/infection):</strong> Pneumonia (parapneumonic), malignancy, TB, PE, pancreatitis, esophageal rupture, autoimmune (lupus, RA)</li>
                        <li><strong>Hemorrhagic:</strong> Trauma, malignancy, PE, post-procedure</li>
                        <li><strong>Chylous:</strong> Lymphatic disruption (thoracic duct injury, malignancy, trauma)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Blunting of costophrenic angle (>200mL), meniscus sign. Lateral decubitus view shows layering of free-flowing effusion</li>
                        <li><strong>Ultrasound:</strong> More sensitive than CXR. Detects small effusions (50mL). Guides thoracentesis (reduces pneumothorax risk)</li>
                        <li><strong>CT chest:</strong> Distinguishes pleural fluid from consolidation, identifies loculations, evaluates for underlying lung pathology (malignancy, pneumonia, PE)</li>
                    </ul>
                    <p><span class="label">Thoracentesis Indications:</span></p>
                    <ul>
                        <li><strong>Diagnostic:</strong> New effusion of unknown etiology, >10mm on lateral decubitus CXR or US</li>
                        <li><strong>Therapeutic:</strong> Symptomatic dyspnea from large effusion</li>
                        <li><strong>Exceptions (don't tap):</strong> Clear CHF exacerbation with symmetric bilateral effusions responding to diuresis, small effusions <10mm</li>
                    </ul>
                    <p><span class="label">Pleural Fluid Analysis:</span></p>
                    <ul>
                        <li><strong>Appearance:</strong> Straw-colored (transudate/exudate), bloody (malignancy, PE, trauma), turbid/purulent (empyema), milky (chylothorax)</li>
                        <li><strong>Cell count with differential:</strong> WBC >10,000 suggests infection. Neutrophils (bacterial), lymphocytes (TB, malignancy)</li>
                        <li><strong>Chemistry:</strong> Protein, LDH, glucose, pH (send in heparinized syringe on ice)</li>
                        <li><strong>Microbiology:</strong> Gram stain, culture (aerobic, anaerobic), AFB smear and culture if TB suspected</li>
                        <li><strong>Cytology:</strong> If malignancy suspected. Sensitivity 60-70%, higher with repeated taps</li>
                        <li><strong>Additional tests (if indicated):</strong> Triglycerides (>110mg/dL = chylothorax), amylase (pancreatitis, esophageal rupture), ADA (>40 U/L suggests TB), pH (empyema <7.2)</li>
                    </ul>
                    <p><span class="label">Light's Criteria (Transudate vs Exudate):</span></p>
                    <ul>
                        <li><strong>Exudate if ANY of following:</strong></li>
                        <ul>
                            <li>Pleural fluid protein / Serum protein >0.5</li>
                            <li>Pleural fluid LDH / Serum LDH >0.6</li>
                            <li>Pleural fluid LDH > 2/3 upper limit of normal serum LDH</li>
                        </ul>
                        <li><strong>Transudate:</strong> None of above criteria met</li>
                        <li><strong>Sensitivity/Specificity:</strong> 98% for identifying exudates. Occasionally misclassifies diuretic-treated CHF as exudate</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Treat Underlying Cause:</span></p>
                    <ul>
                        <li><strong>CHF:</strong> Diuretics, afterload reduction. Effusions typically resolve with treatment</li>
                        <li><strong>Pneumonia (parapneumonic effusion):</strong> Antibiotics. If uncomplicated (pH >7.2, glucose >60, LDH <1000, no bacteria), monitor. If complicated, needs drainage</li>
                        <li><strong>Empyema:</strong> Pus in pleural space. Chest tube drainage + antibiotics. Criteria: gross pus, positive gram stain/culture, pH <7.2, glucose <60, LDH >1000</li>
                        <li><strong>Malignant effusion:</strong> Recurrent, often large. Therapeutic thoracentesis for symptoms. Consider pleurodesis or indwelling pleural catheter for recurrent effusions</li>
                        <li><strong>TB effusion:</strong> Lymphocyte-predominant, ADA >40. Treat TB with RIPE regimen. May need steroid taper to prevent pleural thickening</li>
                    </ul>
                    
                    <p><span class="label">Therapeutic Thoracentesis:</span></p>
                    <ul>
                        <li><strong>Volume:</strong> Remove up to 1-1.5L in one sitting. Stop if chest pain, cough (re-expansion pulmonary edema), or if chest pain develops</li>
                        <li><strong>Ultrasound-guided:</strong> Preferred (reduces pneumothorax risk by 50%)</li>
                        <li><strong>Contraindications:</strong> Coagulopathy (relative, correct if possible), mechanical ventilation (higher risk), small effusion (<10mm)</li>
                        <li><strong>Post-procedure CXR:</strong> Only if symptomatic (chest pain, dyspnea, cough). Routine CXR not needed if US-guided and uncomplicated</li>
                    </ul>
                    
                    <p><span class="label">Chest Tube Drainage:</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Empyema, complicated parapneumonic effusion, hemothorax, recurrent symptomatic malignant effusion not amenable to pleurodesis</li>
                        <li><strong>Size:</strong> Large-bore (28-32Fr) for empyema/hemothorax. Small-bore (10-14Fr) adequate for most other effusions</li>
                        <li><strong>Fibrinolytics:</strong> Consider for loculated empyema/complicated parapneumonic (tPA + DNase intrapleural). Improves drainage, reduces need for surgery</li>
                    </ul>
                    
                    <p><span class="label">Pleurodesis (For Recurrent Malignant Effusions):</span></p>
                    <ul>
                        <li><strong>Chemical:</strong> Talc (most effective, 90% success), doxycycline, bleomycin. Instilled via chest tube or at thoracoscopy</li>
                        <li><strong>Criteria:</strong> Lung fully expanded (trapped lung won't pleurodese), life expectancy >3 months</li>
                        <li><strong>Indwelling pleural catheter (PleurX):</strong> Alternative to pleurodesis. Allows outpatient drainage. Better for trapped lung</li>
                    </ul>
                    
                    <p><span class="label">Specific Etiologies:</span></p>
                    <ul>
                        <li><strong>Chylothorax:</strong> Milky appearance, triglycerides >110. Conservative management (low-fat diet, MCT oil) or thoracic duct ligation/embolization if high output</li>
                        <li><strong>Hemothorax:</strong> Trauma, malignancy, PE. Chest tube drainage. Surgery if >1500mL immediate or >200mL/hr continued bleeding</li>
                        <li><strong>Post-CABG effusion:</strong> Common (30-60%). Usually small, resolves spontaneously. Tap if large/symptomatic</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Light's Criteria is 98% sensitive:</strong> If exudate criteria met, it's almost certainly an exudate. If transudate, look for CHF/cirrhosis/nephrotic syndrome</li>
                    <li><strong>Bilateral effusions = CHF until proven otherwise:</strong> If symmetric and patient has CHF, can treat without tapping. If asymmetric or not responding to diuresis, tap</li>
                    <li><strong>Yellow nail syndrome:</strong> Lymphedema + yellow nails + pleural effusion. Rare cause of exudative effusion</li>
                    <li><strong>Empyema needs drainage:</strong> Antibiotics alone are insufficient. Chest tube + antibiotics. If loculated, consider fibrinolytics or VATS</li>
                    <li><strong>Malignant effusion = poor prognosis:</strong> Usually incurable, median survival 4-6 months. Focus on palliation (pleurodesis or indwelling catheter)</li>
                    <li><strong>Re-expansion pulmonary edema:</strong> Rare complication of large-volume thoracentesis (>1.5L). Presents with cough, chest tightness, hypoxia. Usually self-limited</li>
                    <li><strong>Post-thoracentesis CXR only if symptomatic:</strong> Routine CXR no longer recommended if uncomplicated US-guided procedure. Check only if chest pain, dyspnea, or cough</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Empyema with sepsis/septic shock</li>
                        <li>Massive effusion with respiratory failure</li>
                        <li>Hemothorax (ongoing bleeding, shock)</li>
                        <li>Post-thoracentesis pneumothorax requiring chest tube</li>
                        <li>Re-expansion pulmonary edema</li>
                        <li>Chylothorax with high output (>1L/day)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Effusion drained or small/stable</li>
                        <li>No respiratory distress</li>
                        <li>Underlying cause identified and treated (or plan in place)</li>
                        <li>If empyema: Chest tube removed, afebrile, stable WBC</li>
                        <li>If malignant: Pleurodesis done or PleurX catheter placed with patient/family education</li>
                        <li>Follow-up arranged (repeat imaging in 4-6 weeks if needed)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Thoracentesis complications:</strong> Pneumothorax (3-15%, lower with US guidance), bleeding (rare, <1%), re-expansion pulmonary edema (if >1.5L removed), pain, infection (rare), splenic/liver laceration (rare)</p>
                    <p><strong>Chest tube complications:</strong> Bleeding, infection (empyema), lung injury, malposition, persistent air leak, failure to drain (if loculated)</p>
                    <p><strong>Chronic:</strong> Pleural thickening (TB, empyema), trapped lung (malignancy, chronic effusion), recurrent effusion (malignancy, CHF), chronic dyspnea</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 50: PNEUMOTHORAX/TENSION PNEUMOTHORAX -->
<!-- ============================================ -->
        <div id="pneumothorax" class="condition-page">
            <div class="page-header">
                <h2>50. PNEUMOTHORAX/TENSION PNEUMOTHORAX</h2>
                <div class="subtitle">Primary ‚Ä¢ Secondary ‚Ä¢ Tension Physiology</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Simple Pneumothorax:</span> Sudden-onset pleuritic chest pain, dyspnea. May be asymptomatic if small</p>
                    <p><span class="label">Physical Exam:</span> Decreased breath sounds, hyperresonance to percussion, decreased tactile fremitus on affected side</p>
                    <p><span class="label">Tension Pneumothorax (EMERGENCY):</span> Severe respiratory distress, hypotension, shock, tracheal deviation away from affected side, JVD, hypoxia, tachycardia. CLINICAL DIAGNOSIS - don't wait for imaging!</p>
                    <p><span class="label">Types:</span></p>
                    <ul>
                        <li><strong>Primary spontaneous:</strong> Tall, thin, young males (20s-30s). Smoking. Rupture of apical blebs. No underlying lung disease</li>
                        <li><strong>Secondary spontaneous:</strong> Underlying lung disease (COPD, asthma, cystic fibrosis, PCP pneumonia, TB, lung cancer). Higher risk of complications</li>
                        <li><strong>Traumatic:</strong> Blunt or penetrating chest trauma, rib fracture with lung puncture</li>
                        <li><strong>Iatrogenic:</strong> Central line placement (subclavian most common), thoracentesis, lung biopsy, mechanical ventilation (barotrauma), CPR</li>
                        <li><strong>Catamenial:</strong> Occurs with menstruation. Associated with endometriosis (thoracic endometrial implants). Recurrent, right-sided, within 72hr of menses</li>
                    </ul>
                    <p><span class="label">Size Classification:</span></p>
                    <ul>
                        <li><strong>Small:</strong> <2cm rim of air between lung and chest wall at hilum level</li>
                        <li><strong>Large:</strong> ‚â•2cm rim of air. Or >50% hemithorax volume</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR (upright PA):</strong> Visceral pleural line separated from chest wall. No lung markings beyond line. Best seen at apex</li>
                        <li><strong>Expiratory CXR:</strong> May make small pneumothorax more visible (lung gets smaller, pneumothorax stays same). Not routinely needed</li>
                        <li><strong>CT chest:</strong> Most sensitive. Identifies small pneumothorax missed on CXR, evaluates for underlying lung disease, detects blebs/bullae</li>
                        <li><strong>Ultrasound:</strong> Absence of lung sliding, absence of B-lines, lung point sign (transition from normal to pneumothorax). Useful in trauma/ICU setting</li>
                        <li><strong>DO NOT delay treatment for imaging if tension pneumothorax suspected!</strong></li>
                    </ul>
                    <p><span class="label">ABG:</span> If significant dyspnea or underlying lung disease. May show hypoxemia, respiratory alkalosis (hyperventilation)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Tension Pneumothorax (EMERGENCY - Life-threatening):</span></p>
                    <ul>
                        <li><strong>Immediate needle decompression:</strong> BEFORE imaging! 14-16G angiocath in 2nd intercostal space, midclavicular line (or 4th-5th ICS, anterior axillary line). Remove needle, leave catheter. Rush of air confirms diagnosis</li>
                        <li><strong>Follow with chest tube:</strong> Definitive management. Large-bore (28-32Fr)</li>
                        <li><strong>DO NOT wait for CXR if tension pneumothorax suspected clinically!</strong></li>
                    </ul>
                    
                    <p><span class="label">Primary Spontaneous Pneumothorax (No underlying lung disease):</span></p>
                    <ul>
                        <li><strong>Small (<2cm) + minimal symptoms:</strong> Observation + supplemental O‚ÇÇ (increases reabsorption 4√ó). Repeat CXR in 6hr and 24hr. Discharge if stable and reliable</li>
                        <li><strong>Large (‚â•2cm) OR symptomatic:</strong> Aspiration first attempt. If successful (lung expanded, <2cm residual), observe and repeat CXR. If fails or re-expands, chest tube</li>
                        <li><strong>Aspiration technique:</strong> 16-18G catheter, 2nd ICS MCL or 4th-5th ICS AAL. Aspirate up to 2.5L. If lung expands and patient improved, can observe without tube</li>
                    </ul>
                    
                    <p><span class="label">Secondary Spontaneous Pneumothorax (Underlying lung disease - COPD, asthma, etc):</span></p>
                    <ul>
                        <li><strong>Small (<1cm at hilum) + minimal symptoms:</strong> Observation + supplemental O‚ÇÇ. Admit for 24hr observation (higher risk of complications)</li>
                        <li><strong>Small (1-2cm) OR any symptoms:</strong> Aspiration attempt. If successful, admit for observation</li>
                        <li><strong>Large (‚â•2cm) OR failed aspiration:</strong> Chest tube. Lower threshold for tube placement than primary (worse lung reserve, higher complication rate)</li>
                        <li><strong>Note:</strong> Secondary pneumothorax has higher morbidity/mortality. Lower threshold for intervention</li>
                    </ul>
                    
                    <p><span class="label">Chest Tube Placement:</span></p>
                    <ul>
                        <li><strong>Size:</strong> Small-bore (12-14Fr) adequate for simple pneumothorax. Large-bore (28-32Fr) for hemothorax, tension PTX, or if on mechanical ventilation</li>
                        <li><strong>Location:</strong> 4th-5th ICS, anterior to mid-axillary line ("safe triangle"). Avoid 2nd ICS due to vessels</li>
                        <li><strong>Suction:</strong> -20cmH‚ÇÇO. Helps lung re-expand</li>
                        <li><strong>Removal criteria:</strong> No air leak √ó 24hr, lung fully expanded on CXR, patient off suction (water seal trial)</li>
                    </ul>
                    
                    <p><span class="label">Indications for Surgery (VATS/Thoracotomy):</span></p>
                    <ul>
                        <li><strong>Persistent air leak:</strong> >5-7 days despite chest tube</li>
                        <li><strong>Recurrent ipsilateral:</strong> 2nd episode on same side (50% recurrence after 1st PTX, 80% after 2nd)</li>
                        <li><strong>Bilateral:</strong> Simultaneous or history of contralateral PTX</li>
                        <li><strong>First episode in high-risk occupation:</strong> Pilots, divers (cannot have recurrence risk)</li>
                        <li><strong>Hemopneumothorax:</strong> Significant bleeding component</li>
                        <li><strong>Procedure:</strong> Pleurodesis (mechanical or chemical) ¬± bleb resection</li>
                    </ul>
                    
                    <p><span class="label">Special Scenarios:</span></p>
                    <ul>
                        <li><strong>Mechanical ventilation:</strong> Always place chest tube (high risk of tension). Increase PEEP cautiously</li>
                        <li><strong>Iatrogenic (post-procedure):</strong> Small and asymptomatic often resolve spontaneously with observation. Larger or symptomatic need aspiration/tube</li>
                        <li><strong>Air travel:</strong> Contraindicated until fully resolved. Pressure changes at altitude can expand pneumothorax</li>
                        <li><strong>Catamenial:</strong> Hormonal suppression (OCPs, GnRH agonists). May need thoracoscopy to resect endometrial implants. Pleurodesis for recurrent</li>
                    </ul>
                    
                    <p><span class="label">Discharge Planning:</span></p>
                    <ul>
                        <li><strong>Activity:</strong> No strenuous activity, no flying, no diving until cleared (minimum 2 weeks after full resolution)</li>
                        <li><strong>Smoking cessation:</strong> Decreases recurrence risk 10-fold. CRITICAL</li>
                        <li><strong>Return precautions:</strong> Worsening dyspnea, chest pain, signs of recurrence</li>
                        <li><strong>Follow-up CXR:</strong> 2-4 weeks to confirm full resolution</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Tension pneumothorax is CLINICAL diagnosis:</strong> Respiratory distress + hypotension + unilateral absent breath sounds + tracheal deviation. Needle decompress immediately, don't wait for CXR!</li>
                    <li><strong>Not all pneumothorax has tracheal deviation:</strong> Tracheal deviation is a late finding and may be absent even in tension PTX. Don't rely on it!</li>
                    <li><strong>Supplemental O‚ÇÇ helps reabsorption:</strong> High-flow O‚ÇÇ increases nitrogen gradient, speeds reabsorption by 4√ó. Useful in observation strategy</li>
                    <li><strong>Recurrence rates:</strong> 30% after 1st, 50% after 2nd primary spontaneous PTX. Consider pleurodesis after 2nd episode</li>
                    <li><strong>Size matters less than symptoms:</strong> Symptomatic small pneumothorax needs intervention. Asymptomatic large pneumothorax in young healthy person might be observed</li>
                    <li><strong>Secondary PTX is higher risk:</strong> Poor lung reserve (COPD, asthma). Lower threshold for chest tube. Higher morbidity</li>
                    <li><strong>Heimlich valve:</strong> One-way flutter valve on chest tube allows outpatient management in stable patients. Allows air out but not in</li>
                    <li><strong>Re-expansion pulmonary edema:</strong> Rare complication after rapid lung re-expansion (more common if pneumothorax >3 days or aggressive suction). Usually self-limited</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Tension pneumothorax (even after decompression - post-resuscitation care)</li>
                        <li>Respiratory failure requiring mechanical ventilation</li>
                        <li>Hemodynamic instability</li>
                        <li>Large pneumothorax with significant underlying lung disease (COPD, severe asthma)</li>
                        <li>Bilateral pneumothorax</li>
                        <li>Persistent air leak despite chest tube</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Pneumothorax resolved or stable/small (<1-2cm)</li>
                        <li>No respiratory distress, O‚ÇÇ sat >90% on room air</li>
                        <li>If chest tube: Removed after no air leak √ó 24hr and lung fully expanded</li>
                        <li>Reliable for follow-up and understands return precautions</li>
                        <li>Smoking cessation counseling provided (critical!)</li>
                        <li>Activity restrictions explained (no flying, no diving, no strenuous activity)</li>
                        <li>Follow-up CXR arranged in 2-4 weeks</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Tension pneumothorax (cardiovascular collapse if not decompressed), respiratory failure, hemopneumothorax (bleeding into pleural space), re-expansion pulmonary edema (post-drainage)</p>
                    <p><strong>Treatment-related:</strong> Chest tube complications (bleeding, infection, malposition, persistent air leak, pain), failed re-expansion (trapped lung, persistent air leak needing VATS)</p>
                    <p><strong>Chronic:</strong> Recurrent pneumothorax (30-50% risk, higher without pleurodesis), chronic air leak, pleural thickening, chronic dyspnea (if underlying lung disease worsened)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 51: ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE -->
<!-- ============================================ -->
<div class="condition" id="ild">
    <h2>Acute Exacerbation of Interstitial Lung Disease (ILD)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 52: HEMOPTYSIS (MASSIVE) -->
<!-- ============================================ -->
<div class="condition" id="hemoptysis">
    <h2>Hemoptysis (Massive)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 53: ACUTE HYPERCAPNIC RESPIRATORY FAILURE -->
<!-- ============================================ -->
<div class="condition" id="hypercapnic-failure">
    <h2>Acute Hypercapnic Respiratory Failure</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 54: TRANSIENT ISCHEMIC ATTACK (TIA) -->
<!-- ============================================ -->
        <div id="tia" class="condition-page">
            <div class="page-header">
                <h2>51. TRANSIENT ISCHEMIC ATTACK (TIA)</h2>
                <div class="subtitle">Stroke Warning ‚Ä¢ ABCD¬≤ Score ‚Ä¢ Urgent Workup</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Definition:</span> Transient episode of neurologic dysfunction from focal brain, spinal cord, or retinal ischemia WITHOUT acute infarction. Symptoms resolve within 24hr (most <1hr)</p>
                    <p><span class="label">Classic Symptoms (sudden onset, focal):</span></p>
                    <ul>
                        <li><strong>Motor:</strong> Unilateral weakness (face, arm, leg). Arm drift, facial droop</li>
                        <li><strong>Sensory:</strong> Unilateral numbness, paresthesias</li>
                        <li><strong>Speech:</strong> Aphasia (expressive or receptive), dysarthria (slurred speech)</li>
                        <li><strong>Visual:</strong> Monocular vision loss (amaurosis fugax - retinal TIA), hemianopia, diplopia</li>
                        <li><strong>Ataxia:</strong> Unsteady gait, incoordination (posterior circulation)</li>
                        <li><strong>Vertigo:</strong> With other posterior circulation symptoms (NOT isolated vertigo)</li>
                    </ul>
                    <p><span class="label">TIA Mimics (NOT TIA):</span> Seizure with Todd's paralysis, migraine with aura, hypoglycemia, syncope, peripheral vertigo alone, isolated sensory symptoms without other deficits</p>
                    <p><span class="label">High-Risk Features:</span></p>
                    <ul>
                        <li>Multiple TIAs in short period (crescendo TIAs)</li>
                        <li>Symptoms >1 hour</li>
                        <li>Carotid stenosis >50%</li>
                        <li>AF or cardioembolic source</li>
                        <li>ABCD¬≤ score ‚â•4</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urgent Imaging (within 24hr, ideally emergently):</span></p>
                    <ul>
                        <li><strong>Brain MRI with DWI:</strong> GOLD STANDARD. Detects acute infarction in 30-50% of "TIAs". DWI-positive = stroke, not TIA</li>
                        <li><strong>CT head (if MRI unavailable):</strong> Rule out hemorrhage, large stroke. Less sensitive for acute ischemia</li>
                        <li><strong>CTA or MRA head/neck:</strong> Assess for large vessel stenosis/occlusion (carotid, vertebral, intracranial). Identify surgical candidates</li>
                    </ul>
                    <p><span class="label">Vascular Studies:</span></p>
                    <ul>
                        <li><strong>Carotid Doppler ultrasound:</strong> Screen for carotid stenosis. If >50% stenosis, confirm with CTA/MRA</li>
                        <li><strong>Consider CTA chest:</strong> If concern for aortic arch atheroma</li>
                    </ul>
                    <p><span class="label">Cardiac Workup:</span></p>
                    <ul>
                        <li><strong>ECG:</strong> Assess for AF (most important modifiable risk factor for cardioembolic stroke)</li>
                        <li><strong>Telemetry:</strong> 24hr minimum. Consider prolonged monitoring (30-day event monitor) if no AF found and high suspicion</li>
                        <li><strong>Transthoracic echo (TTE):</strong> Assess for cardioembolic source (LV thrombus, valvular disease, reduced EF)</li>
                        <li><strong>TEE:</strong> If high suspicion for cardioembolic source and TTE negative. Better visualization of LA appendage (thrombus), PFO, aortic arch atheroma</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC, BMP, lipid panel, HbA1c, PT/PTT (if anticoagulation planned), ESR (if vasculitis concern), hypercoagulable workup (if age <50, unprovoked, recurrent)</p>
                    <p><span class="label">ABCD¬≤ Score (Stroke Risk Stratification):</span></p>
                    <ul>
                        <li><strong>Age ‚â•60:</strong> 1 point</li>
                        <li><strong>BP ‚â•140/90:</strong> 1 point</li>
                        <li><strong>Clinical features:</strong> Unilateral weakness (2 points), Speech impairment without weakness (1 point)</li>
                        <li><strong>Duration:</strong> ‚â•60min (2 points), 10-59min (1 point)</li>
                        <li><strong>Diabetes:</strong> 1 point</li>
                        <li><strong>Score 0-3:</strong> Low risk (1% 2-day stroke risk). Outpatient workup possible if reliable</li>
                        <li><strong>Score 4-5:</strong> Moderate risk (4% 2-day stroke risk). Admit for expedited workup</li>
                        <li><strong>Score 6-7:</strong> High risk (8% 2-day stroke risk). Admit for urgent workup</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (Goal: Prevent stroke within 48-90 days):</span></p>
                    <ul>
                        <li><strong>Aspirin:</strong> 325mg loading dose immediately (if not already on antiplatelet). Reduces early stroke risk by 80%</li>
                        <li><strong>Dual antiplatelet therapy (DAPT):</strong> Aspirin 81mg + clopidogrel 75mg daily √ó 21 days, then aspirin alone. Reduces stroke risk by 32% compared to aspirin alone (POINT/CHANCE trials). Start within 24hr of symptom onset</li>
                        <li><strong>BP management:</strong> Goal <140/90 long-term. Avoid aggressive lowering in acute phase unless hypertensive emergency</li>
                        <li><strong>Statin:</strong> High-intensity (atorvastatin 40-80mg or rosuvastatin 20-40mg). Start immediately regardless of LDL. Reduces recurrent stroke</li>
                    </ul>
                    
                    <p><span class="label">Etiology-Specific Treatment:</span></p>
                    <ul>
                        <li><strong>Atrial fibrillation:</strong> Anticoagulation (DOAC preferred: apixaban, rivaroxaban, edoxaban, dabigatran). Start within 4-14 days depending on stroke risk. CHA‚ÇÇDS‚ÇÇ-VASc score guides decision</li>
                        <li><strong>Carotid stenosis 70-99% (symptomatic):</strong> Urgent CEA (carotid endarterectomy) within 2 weeks. NNT=6 to prevent stroke. Consider CAS (carotid artery stenting) if high surgical risk</li>
                        <li><strong>Carotid stenosis 50-69%:</strong> CEA beneficial (NNT=15). Consider if good surgical candidate</li>
                        <li><strong>Carotid stenosis <50%:</strong> Medical management. No benefit from CEA</li>
                        <li><strong>Intracranial stenosis:</strong> Aggressive medical management (dual antiplatelet √ó 90 days, statin, BP control). Stenting NOT superior to medical therapy</li>
                        <li><strong>Cardioembolic (not AF):</strong> Antiplatelet vs anticoagulation depending on source. TEE to identify source</li>
                        <li><strong>Cryptogenic (no identified cause):</strong> Aspirin. Consider extended cardiac monitoring for paroxysmal AF. PFO closure if large PFO + no other cause (controversial, age <60)</li>
                    </ul>
                    
                    <p><span class="label">Risk Factor Modification (CRITICAL):</span></p>
                    <ul>
                        <li><strong>BP control:</strong> Goal <130/80 (ACC/AHA) or <140/90 (ESH/ESC). ACE-I or ARB preferred</li>
                        <li><strong>Diabetes control:</strong> HbA1c <7%</li>
                        <li><strong>Lipids:</strong> LDL <70mg/dL (consider <55 if very high risk)</li>
                        <li><strong>Smoking cessation:</strong> Doubles stroke risk. Counsel + pharmacotherapy (varenicline, bupropion, NRT)</li>
                        <li><strong>Exercise:</strong> 30min moderate activity 5√ó week</li>
                        <li><strong>Diet:</strong> Mediterranean diet, low sodium</li>
                        <li><strong>Weight loss:</strong> If overweight/obese</li>
                    </ul>
                    
                    <p><span class="label">Admission vs Outpatient:</span></p>
                    <ul>
                        <li><strong>Admit:</strong> ABCD¬≤ ‚â•4, crescendo TIAs, within 48hr of symptom onset, unreliable for follow-up, unable to complete workup as outpatient</li>
                        <li><strong>Outpatient:</strong> ABCD¬≤ <3, reliable patient, can complete MRI/vascular imaging/echo within 48hr, no high-risk features</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>TIA = stroke until proven otherwise:</strong> 30-50% of "TIAs" have infarction on DWI-MRI. If DWI-positive, it's a stroke, not TIA. Treat aggressively either way</li>
                    <li><strong>Highest stroke risk is within 48hr:</strong> 5-10% have stroke within 90 days, half of those within 48hr. TIA is an EMERGENCY. Expedited workup prevents stroke</li>
                    <li><strong>Dual antiplatelet (ASA + clopidogrel) for 21 days:</strong> POINT and CHANCE trials showed 32% relative risk reduction. Start within 24hr. Then continue aspirin alone</li>
                    <li><strong>Amaurosis fugax = retinal TIA:</strong> Transient monocular blindness ("curtain coming down"). Ipsilateral carotid stenosis or emboli. Same stroke risk as hemispheric TIA</li>
                    <li><strong>NOT all transient neuro symptoms are TIA:</strong> Isolated vertigo, isolated diplopia, isolated sensory symptoms = low likelihood. Need focal symptoms (motor/speech/visual field loss)</li>
                    <li><strong>Carotid stenosis timing matters:</strong> Symptomatic stenosis 70-99% needs CEA within 2 weeks. Benefit diminishes after that. Asymptomatic stenosis has different indications</li>
                    <li><strong>Extended cardiac monitoring increases AF detection:</strong> 30-day monitors detect AF in 10-20% of cryptogenic TIA/stroke. Consider if no cause found</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE/ADMIT IF:</div>
                    <ul>
                        <li>ABCD¬≤ score ‚â•4 (moderate-high risk)</li>
                        <li>Crescendo TIAs (multiple in short period)</li>
                        <li>Symptoms occurred within 48hr</li>
                        <li>Carotid stenosis >50% (needs urgent evaluation for CEA)</li>
                        <li>Atrial fibrillation (needs anticoagulation)</li>
                        <li>Unable to complete urgent outpatient workup</li>
                        <li>Unreliable for follow-up</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Imaging complete (MRI/CTA or CT/carotid Doppler)</li>
                        <li>Cardiac evaluation done (ECG, telemetry ‚â•24hr, echo)</li>
                        <li>Started on appropriate therapy (antiplatelet or anticoagulation + statin)</li>
                        <li>If carotid stenosis >50%: Vascular surgery consult, CEA scheduled</li>
                        <li>Risk factors addressed (BP, lipids, diabetes)</li>
                        <li>Neurology follow-up arranged (within 1-2 weeks)</li>
                        <li>Patient educated on stroke warning signs</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Stroke (5-10% within 90 days, highest risk first 48hr), recurrent TIA (15-20% have another TIA), progression to stroke during evaluation</p>
                    <p><strong>Procedural:</strong> CEA complications (stroke 2-3%, MI, cranial nerve injury, bleeding), CAS complications (stroke, dissection, access site complications)</p>
                    <p><strong>Chronic:</strong> Recurrent stroke/TIA (if risk factors not controlled), bleeding on antiplatelets/anticoagulation, cognitive decline (vascular dementia), disability from eventual stroke if not treated aggressively</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 55: GUILLAIN-BARR√â SYNDROME -->
<!-- ============================================ -->
        <div id="gbs" class="condition-page">
            <div class="page-header">
                <h2>52. GUILLAIN-BARR√â SYNDROME (GBS)</h2>
                <div class="subtitle">Acute Inflammatory Demyelinating Polyneuropathy ‚Ä¢ Ascending Paralysis ‚Ä¢ IVIG/Plasmapheresis</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Progressive symmetric weakness, (2) Areflexia/hyporeflexia, (3) Symptoms progress over days-weeks (peak at 2-4 weeks)</p>
                    <p><span class="label">Typical Presentation:</span> Ascending symmetric weakness starting in legs ‚Üí arms ‚Üí bulbar ‚Üí respiratory muscles. Paresthesias in hands/feet (glove-stocking distribution). Preceding illness 1-3 weeks prior (URI, GI infection)</p>
                    <p><span class="label">Motor Findings:</span></p>
                    <ul>
                        <li><strong>Weakness:</strong> Symmetric, ascending (legs before arms typically). Proximal and distal affected</li>
                        <li><strong>Areflexia:</strong> Absent or markedly diminished deep tendon reflexes (hallmark finding)</li>
                        <li><strong>Bulbar involvement:</strong> Facial weakness (bilateral), dysphagia, dysarthria (30-50%)</li>
                        <li><strong>Respiratory failure:</strong> 20-30% require mechanical ventilation. Progressive weakness of diaphragm/intercostals</li>
                    </ul>
                    <p><span class="label">Sensory Findings:</span> Paresthesias, numbness (glove-stocking). Pain (back, radicular) in 50%. Sensory exam often normal despite symptoms</p>
                    <p><span class="label">Autonomic Dysfunction (60%):</span> Tachycardia, bradycardia, arrhythmias, labile BP (hyper/hypotension), ileus, urinary retention, SIADH</p>
                    <p><span class="label">Variants:</span></p>
                    <ul>
                        <li><strong>AIDP (Acute Inflammatory Demyelinating Polyneuropathy):</strong> Most common in US/Europe (90%). Classic ascending paralysis</li>
                        <li><strong>AMAN/AMSAN (Axonal variants):</strong> More common in Asia. Axonal damage. Worse prognosis</li>
                        <li><strong>Miller Fisher syndrome:</strong> Triad of ataxia, areflexia, ophthalmoplegia. Anti-GQ1b antibodies (90%)</li>
                        <li><strong>Pharyngeal-cervical-brachial variant:</strong> Starts with bulbar/arm weakness</li>
                    </ul>
                    <p><span class="label">Triggers (preceding infection in 60-70%):</span></p>
                    <ul>
                        <li><strong>Campylobacter jejuni (30%):</strong> Most common. Diarrheal illness 1-3 weeks prior</li>
                        <li><strong>Upper respiratory infections:</strong> CMV, EBV, Mycoplasma</li>
                        <li><strong>Other:</strong> Zika virus, COVID-19, vaccines (rare, <1 per million), surgery, trauma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis (primarily):</span> Brighton Criteria or Asbury & Cornblath Criteria. Diagnosis based on clinical features + CSF + EMG</p>
                    <p><span class="label">Lumbar Puncture (CSF Analysis):</span></p>
                    <ul>
                        <li><strong>Albuminocytologic dissociation (CLASSIC):</strong> Elevated protein (>45mg/dL) with normal or mildly elevated WBC (<10 cells/¬µL)</li>
                        <li><strong>Timing:</strong> Protein elevation may not appear until week 2. If early and normal, repeat LP in 1 week if high suspicion</li>
                        <li><strong>WBC >50:</strong> Consider alternative diagnosis (infection, malignancy, sarcoid)</li>
                    </ul>
                    <p><span class="label">Electrodiagnostic Studies (EMG/NCS):</span></p>
                    <ul>
                        <li><strong>Findings:</strong> Prolonged distal latencies, slowed conduction velocities, conduction block, prolonged/absent F-waves (demyelination)</li>
                        <li><strong>Timing:</strong> Abnormalities may not appear until 2 weeks. Early studies may be normal</li>
                        <li><strong>Axonal variants (AMAN/AMSAN):</strong> Low-amplitude CMAPs with normal velocities</li>
                    </ul>
                    <p><span class="label">Bedside Respiratory Assessment (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Vital capacity (VC):</strong> Measure q4-6hr if progressive. VC <20mL/kg or rapidly declining = high risk for intubation</li>
                        <li><strong>Negative inspiratory force (NIF):</strong> <-30cmH‚ÇÇO = respiratory muscle weakness</li>
                        <li><strong>Single-breath count:</strong> Unable to count to 20 in one breath = severe weakness</li>
                        <li><strong>20/30/40 rule:</strong> VC <20mL/kg, NIF >-30cmH‚ÇÇO, MIP <40cmH‚ÇÇO = likely need intubation</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC, CMP, LFTs (baseline before IVIG), ABG (if respiratory concern), serology for infections (Campylobacter, CMV, EBV, Mycoplasma), anti-ganglioside antibodies (anti-GM1, anti-GQ1b - supportive but not required)</p>
                    <p><span class="label">MRI spine:</strong> Consider to rule out mimics (cord compression, transverse myelitis). May show nerve root enhancement in GBS</p>
                    <p><span class="label">Mimics to Rule Out:</span> Spinal cord compression, transverse myelitis, myasthenia gravis, botulism, tick paralysis, acute intermittent porphyria, critical illness polyneuropathy, vasculitis, HIV, Lyme, West Nile virus</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immunotherapy (Equally Effective - choose one):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin):</strong> 0.4g/kg/day √ó 5 days (total 2g/kg). First-line in most centers. Easier to administer than plasmapheresis</li>
                        <li><strong>Plasmapheresis (Plasma Exchange):</strong> 5 exchanges over 7-14 days (200-250mL/kg total). Equally effective as IVIG. Use if IVIG contraindicated (IgA deficiency) or failed</li>
                        <li><strong>NO benefit to combination:</strong> IVIG + plasmapheresis NOT better than either alone</li>
                        <li><strong>Timing:</strong> Start within 2 weeks of symptom onset for maximum benefit. Still beneficial up to 4 weeks</li>
                        <li><strong>Steroids NOT beneficial:</strong> Corticosteroids do not work in GBS. Do NOT use</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Management (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Monitor closely:</strong> Vital capacity, NIF q4-6hr if progressive weakness</li>
                        <li><strong>Indications for intubation:</strong> VC <15-20mL/kg, rapidly declining VC, NIF >-30cmH‚ÇÇO, hypoxia, hypercapnia, inability to clear secretions, bulbar weakness with aspiration</li>
                        <li><strong>Intubation considerations:</strong> Avoid succinylcholine (hyperkalemia risk in denervation). Use non-depolarizing paralytics</li>
                        <li><strong>Ventilation strategy:</strong> Lung-protective ventilation. Avoid over-sedation (need to assess neuro status)</li>
                        <li><strong>Tracheostomy:</strong> Consider if anticipated ventilation >2 weeks (many GBS patients)</li>
                    </ul>
                    
                    <p><span class="label">Autonomic Management:</span></p>
                    <ul>
                        <li><strong>Cardiac monitoring:</strong> Telemetry for all patients. Risk of arrhythmias (brady, tachy, heart block)</li>
                        <li><strong>BP lability:</strong> Avoid aggressive treatment of transient hyper/hypotension. Short-acting agents if needed. Fluid boluses for hypotension</li>
                        <li><strong>Avoid:</strong> Œ≤-blockers (can worsen bradycardia), aggressive BP lowering (can precipitate hypotension)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH (high risk due to immobility)</li>
                        <li><strong>GI:</strong> Proton pump inhibitor (stress ulcer prophylaxis), bowel regimen (ileus common)</li>
                        <li><strong>Bladder:</strong> Foley catheter if urinary retention</li>
                        <li><strong>Pain management:</strong> Gabapentin, pregabalin for neuropathic pain. Opioids if needed</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when stable. Prevent contractures</li>
                        <li><strong>Nutrition:</strong> Consider NG/NJ tube if dysphagia. Assess swallow before PO</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Areflexia is the key finding:</strong> Absent reflexes + ascending weakness = GBS until proven otherwise. DTRs are lost early and universally</li>
                    <li><strong>Respiratory failure is the biggest risk:</strong> 20-30% need intubation. Monitor VC closely. Don't wait for hypoxia/hypercapnia (late findings). Intubate early if declining</li>
                    <li><strong>CSF protein may be normal early:</strong> Classic albuminocytologic dissociation may not appear until week 2. Repeat LP if high suspicion and initially normal</li>
                    <li><strong>IVIG = Plasmapheresis in efficacy:</strong> Both equally effective. IVIG easier to give. Combination NOT better. Start within 2 weeks of symptom onset</li>
                    <li><strong>Steroids don't work in GBS:</strong> Unlike most autoimmune conditions, corticosteroids are NOT beneficial and should NOT be used</li>
                    <li><strong>Prognosis overall good but slow:</strong> 80-85% recover fully, but takes months-year. 5-10% permanent disability. 3-5% mortality (respiratory failure, autonomic dysfunction)</li>
                    <li><strong>Campylobacter-associated GBS has worse prognosis:</strong> More likely to be axonal variant (AMAN). Slower recovery, more residual deficits</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL GBS patients need ICU or stepdown with close monitoring</li>
                        <li>VC <20mL/kg or rapidly declining</li>
                        <li>NIF >-30cmH‚ÇÇO</li>
                        <li>Bulbar weakness (dysphagia, dysarthria)</li>
                        <li>Autonomic instability (arrhythmias, labile BP)</li>
                        <li>Rapid progression (can't walk ‚Üí respiratory failure in days)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Respiratory status stable (if intubated, successfully extubated)</li>
                        <li>No autonomic instability √ó 72hr</li>
                        <li>Weakness plateaued or improving</li>
                        <li>Completed course of IVIG or plasmapheresis</li>
                        <li>Able to swallow safely (speech/swallow eval)</li>
                        <li>DVT prophylaxis in place</li>
                        <li>Inpatient rehab arranged (most need extensive PT/OT)</li>
                        <li>Neurology follow-up arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure (20-30%, #1 cause of death), autonomic dysfunction (arrhythmias, labile BP, sudden death), aspiration pneumonia, DVT/PE (immobility), ileus, urinary retention, pressure ulcers</p>
                    <p><strong>Treatment-related:</strong> IVIG (aseptic meningitis, hemolysis, thrombosis, renal failure), Plasmapheresis (hypotension, line infection, citrate toxicity, bleeding)</p>
                    <p><strong>Chronic:</strong> Residual weakness (10-15% permanent disability), chronic neuropathic pain (30%), fatigue (persistent in 50%), relapse (3-5%, usually within 2 months - consider CIDP if relapses), CIDP (chronic inflammatory demyelinating polyneuropathy - GBS-like but chronic/relapsing)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 56: MYASTHENIA GRAVIS CRISIS -->
<!-- ============================================ -->
        <div id="myasthenia" class="condition-page">
            <div class="page-header">
                <h2>53. MYASTHENIA GRAVIS CRISIS</h2>
                <div class="subtitle">Neuromuscular Junction ‚Ä¢ Respiratory Failure ‚Ä¢ IVIG/PLEX</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Myasthenia Gravis (Baseline):</span> Autoimmune disorder causing fluctuating muscle weakness from antibodies blocking acetylcholine receptors at neuromuscular junction. Weakness worsens with activity, improves with rest</p>
                    <p><span class="label">Classic MG Symptoms:</span></p>
                    <ul>
                        <li><strong>Ocular (85% at presentation):</strong> Ptosis (drooping eyelids), diplopia (double vision). Often first symptoms</li>
                        <li><strong>Bulbar (60%):</strong> Dysphagia, dysarthria, nasal speech, difficulty chewing</li>
                        <li><strong>Limb weakness (50%):</strong> Proximal > distal. Arms > legs. Can't raise arms, difficulty climbing stairs</li>
                        <li><strong>Neck weakness:</strong> Head drop, difficulty holding head up</li>
                        <li><strong>Fatigable weakness:</strong> HALLMARK. Worse at end of day, after repeated activity. Improves with rest</li>
                    </ul>
                    <p><span class="label">Myasthenic Crisis (EMERGENCY):</span> Severe worsening of MG leading to respiratory failure requiring intubation. 15-20% of MG patients experience crisis at least once</p>
                    <p><span class="label">Crisis Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory failure:</strong> Dyspnea, tachypnea, inability to clear secretions, hypoxia, hypercapnia. Can progress rapidly</li>
                        <li><strong>Bulbar crisis:</strong> Severe dysphagia, aspiration risk, inability to manage secretions</li>
                        <li><strong>Generalized weakness:</strong> Unable to sit up, lift head, limb weakness</li>
                    </ul>
                    <p><span class="label">Crisis Triggers:</span></p>
                    <ul>
                        <li><strong>Infection (30-40%):</strong> Most common. Pneumonia, UTI, URI</li>
                        <li><strong>Medications:</strong> Aminoglycosides, fluoroquinolones, macrolides, Œ≤-blockers, CCBs, statins, steroids (paradoxical worsening first 2 weeks), neuromuscular blockers</li>
                        <li><strong>Surgery/anesthesia:</strong> Stress, medications</li>
                        <li><strong>Thyroid dysfunction:</strong> Hyper or hypothyroidism</li>
                        <li><strong>Pregnancy/postpartum:</strong> Hormonal changes</li>
                        <li><strong>Medication non-compliance:</strong> Stopped pyridostigmine or immunosuppressants</li>
                        <li><strong>Aspiration pneumonia:</strong> From bulbar weakness</li>
                    </ul>
                    <p><span class="label">Cholinergic Crisis (Rare):</span> Overdose of acetylcholinesterase inhibitors (pyridostigmine). Weakness from EXCESS acetylcholine. Associated with SLUDGE symptoms (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) + miosis, bronchorrhea, bradycardia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Bedside Respiratory Assessment (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Vital capacity (VC):</strong> <15-20mL/kg = high risk for intubation. Monitor q2-4hr</li>
                        <li><strong>Negative inspiratory force (NIF):</strong> >-30cmH‚ÇÇO = severe weakness</li>
                        <li><strong>ABG:</strong> Hypercapnia (pCO‚ÇÇ >45) and hypoxia = impending respiratory failure. Don't wait for ABG to intubate</li>
                        <li><strong>Single-breath count:</strong> Unable to count to 15-20 in one breath = severe weakness</li>
                        <li><strong>Signs of impending failure:</strong> Tachypnea, accessory muscle use, paradoxical breathing, inability to cough or clear secretions</li>
                    </ul>
                    <p><span class="label">Myasthenic vs Cholinergic Crisis (Differentiate):</span></p>
                    <ul>
                        <li><strong>Clinical:</strong> Cholinergic has SLUDGE symptoms + fasciculations + miosis. Myasthenic does not</li>
                        <li><strong>Edrophonium (Tensilon) test:</strong> Short-acting acetylcholinesterase inhibitor. Myasthenic crisis improves. Cholinergic crisis worsens. RARELY done (dangerous in crisis)</li>
                        <li><strong>Practical approach:</strong> Hold pyridostigmine in crisis. Treat with IVIG/PLEX (works for both). Restart pyridostigmine when improving</li>
                    </ul>
                    <p><span class="label">Confirm MG Diagnosis (if not already diagnosed):</span></p>
                    <ul>
                        <li><strong>Antibodies:</strong> Anti-AChR (acetylcholine receptor) antibodies (80-85% sensitivity). Anti-MuSK antibodies (5-10% if AChR-negative). Anti-LRP4 (<5%)</li>
                        <li><strong>Repetitive nerve stimulation (RNS):</strong> >10% decrement in CMAP amplitude with low-frequency (2-3Hz) stimulation. Sensitivity 50-75%</li>
                        <li><strong>Single-fiber EMG:</strong> Most sensitive (95%). Shows increased jitter. Not widely available</li>
                        <li><strong>Edrophonium test:</strong> Improves strength transiently (3-5min). Rarely used (can cause bradycardia, bronchospasm)</li>
                    </ul>
                    <p><span class="label">Labs:</span> CBC (infection), CMP (electrolytes), ABG (respiratory status), CK (normal in MG, unlike muscular dystrophy), TSH (thyroid disease common in MG), troponin (stress from respiratory failure)</p>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CT chest:</strong> Assess for thymoma (present in 10-15% of MG). Thymic hyperplasia in 60-70%</li>
                        <li><strong>CXR:</strong> Rule out pneumonia (common trigger)</li>
                    </ul>
                    <p><span class="label">Search for Triggers:</span> Blood cultures, UA/UCx, CXR, review medications, TSH</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Airway/Respiratory Management (Priority #1):</span></p>
                    <ul>
                        <li><strong>Intubation criteria:</strong> VC <15mL/kg, NIF >-30cmH‚ÇÇO, hypercapnia, inability to protect airway/clear secretions, impending respiratory failure</li>
                        <li><strong>Intubation considerations:</strong> AVOID succinylcholine (unpredictable response). Use non-depolarizing agents at reduced dose (increased sensitivity). Rocuronium 0.3-0.6mg/kg (half normal dose)</li>
                        <li><strong>Ventilation:</strong> Lung-protective strategy. Low tidal volume (6mL/kg IBW). Adequate PEEP</li>
                        <li><strong>Extubation:</strong> When VC >15-20mL/kg, NIF <-30cmH‚ÇÇO, able to protect airway. Often takes 1-2 weeks after treatment</li>
                    </ul>
                    
                    <p><span class="label">Immunotherapy for Crisis (Start Immediately):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin):</strong> 0.4g/kg/day √ó 5 days OR 1g/kg/day √ó 2 days (total 2g/kg). First-line. Improvement in 3-7 days</li>
                        <li><strong>Plasmapheresis (Plasma Exchange):</strong> 5 exchanges over 7-14 days. Equivalent efficacy to IVIG. Improvement in 2-4 days (faster than IVIG). Use if IVIG failed or contraindicated</li>
                        <li><strong>Duration of benefit:</strong> Temporary (weeks-months). Need long-term immunosuppression</li>
                    </ul>
                    
                    <p><span class="label">Acetylcholinesterase Inhibitor Management:</span></p>
                    <ul>
                        <li><strong>HOLD pyridostigmine during crisis:</strong> Respiratory failure impairs clearance of secretions (cholinergic side effect). Resume when extubated</li>
                        <li><strong>When stable:</strong> Pyridostigmine 30-60mg PO q4-6hr (typical dose 60mg q4hr). Max 120mg/dose. Adjust based on response</li>
                    </ul>
                    
                    <p><span class="label">Corticosteroids (Long-term, NOT in acute crisis):</span></p>
                    <ul>
                        <li><strong>NOT for acute crisis:</strong> Can cause paradoxical worsening in first 1-2 weeks</li>
                        <li><strong>For chronic MG control:</strong> Prednisone 20-100mg daily (start low if outpatient to avoid worsening). Taper slowly after improvement</li>
                        <li><strong>Steroid-sparing agents:</strong> Azathioprine, mycophenolate, cyclosporine, tacrolimus. Takes months to work</li>
                    </ul>
                    
                    <p><span class="label">Treat Triggers:</span></p>
                    <ul>
                        <li><strong>Infection:</strong> Antibiotics. Avoid contraindicated agents (aminoglycosides, fluoroquinolones, macrolides)</li>
                        <li><strong>Aspiration pneumonia:</strong> NPO until swallow safe. Aspiration precautions</li>
                        <li><strong>Medication review:</strong> Stop all potentially exacerbating medications</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH</li>
                        <li><strong>GI:</strong> PPI for stress ulcer prophylaxis. NPO if intubated or severe bulbar weakness</li>
                        <li><strong>Nutrition:</strong> NG tube for feeding if prolonged intubation or severe dysphagia</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when stable</li>
                    </ul>
                    
                    <p><span class="label">Thymectomy:</span> Improves long-term outcomes in generalized MG, especially if thymoma present. Usually done electively, not during crisis. Discuss with neurology/thoracic surgery</p>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Fatigable weakness is pathognomonic:</strong> Worse with activity, improves with rest. Ptosis worsens when looking up √ó 1min. This distinguishes MG from other causes of weakness</li>
                    <li><strong>Crisis can develop rapidly:</strong> Can go from stable to intubated within hours. Monitor VC closely. Don't wait for ABG abnormalities (late finding)</li>
                    <li><strong>Ice pack test for ptosis:</strong> Apply ice to closed eyelid √ó 2min. Ptosis improves in MG (cold improves NMJ transmission). Simple bedside test</li>
                    <li><strong>Avoid succinylcholine:</strong> Unpredictable response in MG. May have prolonged paralysis. Use non-depolarizing agents at REDUCED doses (increased sensitivity)</li>
                    <li><strong>Hold pyridostigmine in crisis:</strong> Increases secretions which impairs ventilation. Resume when extubated and improving</li>
                    <li><strong>IVIG and PLEX are temporizing:</strong> Provide weeks-months of benefit. Need long-term immunosuppression (prednisone, azathioprine, etc) for disease control</li>
                    <li><strong>Seronegative MG exists (10-15%):</strong> Negative antibodies don't rule out MG. Use clinical features + EMG (RNS or single-fiber)</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL myasthenic crisis patients need ICU</li>
                        <li>VC <20mL/kg or rapidly declining</li>
                        <li>NIF >-30cmH‚ÇÇO</li>
                        <li>Severe bulbar weakness (aspiration risk)</li>
                        <li>Inability to clear secretions</li>
                        <li>Respiratory distress (tachypnea, accessory muscle use)</li>
                        <li>Need for intubation</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Successfully extubated with stable respiratory status</li>
                        <li>VC >20mL/kg, NIF <-30cmH‚ÇÇO</li>
                        <li>Completed IVIG or plasmapheresis</li>
                        <li>Swallow safe (passed speech/swallow eval)</li>
                        <li>Pyridostigmine restarted at stable dose</li>
                        <li>Long-term immunosuppression plan in place</li>
                        <li>Trigger identified and treated (infection, etc)</li>
                        <li>Neurology follow-up arranged (close follow-up needed)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Respiratory failure (15-20% of MG patients have crisis), aspiration pneumonia (bulbar weakness), prolonged intubation, ventilator-associated pneumonia, DVT/PE, pressure ulcers</p>
                    <p><strong>Treatment-related:</strong> IVIG complications (aseptic meningitis, hemolysis, thrombosis, renal failure), Plasmapheresis complications (hypotension, line infection, citrate toxicity), Steroid complications (hyperglycemia, infection, osteoporosis, psychosis)</p>
                    <p><strong>Chronic:</strong> Recurrent crises (30% have >1 crisis), medication side effects (chronic steroids), thymoma (10-15%, can be malignant), need for chronic immunosuppression, disability from weakness</p>
                    <p><strong>Mortality:</strong> 4-8% mortality from myasthenic crisis (improved from 40% in pre-ICU era)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 57: ACUTE DELIRIUM (NON-ALCOHOL) -->
<!-- ============================================ -->
<div class="condition" id="delirium">
    <h2>Acute Delirium (Non-Alcohol)</h2>
    <p><em>[Content to be added in Phase 3]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 58: INCREASED INTRACRANIAL PRESSURE -->
<!-- ============================================ -->
        <div id="increased-icp" class="condition-page">
            <div class="page-header">
                <h2>54. INCREASED INTRACRANIAL PRESSURE (ICP)</h2>
                <div class="subtitle">Cushing's Triad ‚Ä¢ Herniation Syndromes ‚Ä¢ Emergency Management</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Normal ICP:</span> 5-15 mmHg. Increased ICP = sustained elevation >20 mmHg. Life-threatening when >30 mmHg or when herniation occurs</p>
                    <p><span class="label">Cushing's Triad (LATE finding, indicates impending herniation):</span></p>
                    <ul>
                        <li><strong>Hypertension:</strong> Widened pulse pressure (elevated systolic, normal/low diastolic)</li>
                        <li><strong>Bradycardia:</strong> Reflex response to hypertension</li>
                        <li><strong>Irregular respirations:</strong> Cheyne-Stokes, apneustic, or ataxic breathing</li>
                        <li><strong>Pearl:</strong> Cushing's triad is a pre-terminal sign. Don't wait for it - treat earlier symptoms!</li>
                    </ul>
                    <p><span class="label">Early/Progressive Symptoms:</span></p>
                    <ul>
                        <li><strong>Headache:</strong> Severe, worse in morning, worse with Valsalva (cough, sneeze, straining)</li>
                        <li><strong>Nausea/vomiting:</strong> Projectile vomiting (without nausea sometimes)</li>
                        <li><strong>Altered mental status:</strong> Confusion, lethargy, obtundation ‚Üí coma</li>
                        <li><strong>Papilledema:</strong> Swollen optic discs on fundoscopy. Takes hours-days to develop</li>
                        <li><strong>Vision changes:</strong> Blurry vision, diplopia, transient visual obscurations</li>
                        <li><strong>Seizures:</strong> From mass effect or ischemia</li>
                    </ul>
                    <p><span class="label">Herniation Syndromes (EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Uncal herniation (most common):</strong> Ipsilateral dilated pupil (CN III compression), contralateral hemiparesis (compression of cerebral peduncle), Cushing's triad, coma</li>
                        <li><strong>Central herniation:</strong> Small reactive pupils ‚Üí bilateral dilated pupils, decorticate ‚Üí decerebrate posturing, coma</li>
                        <li><strong>Tonsillar herniation:</strong> Cerebellar tonsils herniate through foramen magnum. Apnea, sudden death from medullary compression</li>
                        <li><strong>Subfalcine herniation:</strong> Often asymptomatic until late. Can cause ACA stroke</li>
                    </ul>
                    <p><span class="label">Common Causes:</span></p>
                    <ul>
                        <li><strong>Traumatic brain injury (TBI):</strong> Epidural hematoma, subdural hematoma, cerebral contusion, diffuse axonal injury</li>
                        <li><strong>Hemorrhagic stroke:</strong> Intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) with hydrocephalus</li>
                        <li><strong>Ischemic stroke:</strong> Large MCA territory infarct with edema (malignant MCA syndrome)</li>
                        <li><strong>Tumor:</strong> Primary or metastatic brain tumors with mass effect</li>
                        <li><strong>Infection:</strong> Brain abscess, meningitis, encephalitis</li>
                        <li><strong>Hydrocephalus:</strong> Obstructive (tumor, blood) or communicating</li>
                        <li><strong>Idiopathic intracranial hypertension (IIH):</strong> Pseudotumor cerebri. Young obese women. Chronic headache, papilledema, vision loss</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Immediate Imaging (Don't Delay):</span></p>
                    <ul>
                        <li><strong>CT head (non-contrast):</strong> FIRST-LINE. Fast, identifies hemorrhage, mass lesions, hydrocephalus, midline shift, herniation. Signs of increased ICP: effaced sulci, compressed ventricles, loss of gray-white differentiation, midline shift</li>
                        <li><strong>MRI brain:</strong> Better detail but takes longer. Use if CT non-diagnostic or for specific concerns (abscess, posterior fossa, tumor characterization)</li>
                    </ul>
                    <p><span class="label">ICP Monitoring (Neurosurgery):</span></p>
                    <ul>
                        <li><strong>Indications:</strong> Severe TBI (GCS ‚â§8) with abnormal CT, intraparenchymal hemorrhage requiring surgery, SAH with poor grade, refractory elevated ICP</li>
                        <li><strong>Types:</strong> External ventricular drain (EVD) - gold standard, allows CSF drainage + monitoring. Intraparenchymal monitor (fiberoptic) - monitoring only</li>
                        <li><strong>Goal ICP:</strong> <20 mmHg. Treat if >22 sustained</li>
                        <li><strong>Cerebral perfusion pressure (CPP) = MAP - ICP:</strong> Goal CPP 60-70 mmHg</li>
                    </ul>
                    <p><span class="label">Fundoscopy:</span> Look for papilledema (blurred disc margins, disc elevation, venous engorgement). Absence doesn't rule out increased ICP (takes time to develop)</p>
                    <p><span class="label">Labs:</span> CBC, CMP, coags (before procedures), osmolality (if using hyperosmolar therapy), ABG (avoid hypercapnia - vasodilates cerebral vessels)</p>
                    <p><span class="label">DO NOT perform LP if increased ICP!</span> Risk of herniation. Only after imaging rules out mass lesion and no signs of herniation</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>Treat underlying cause:</strong> Evacuate hematoma, resect tumor, drain abscess, treat infection, drain CSF (EVD for hydrocephalus)</li>
                        <li><strong>Reduce ICP:</strong> Medical management + surgical if indicated</li>
                        <li><strong>Maintain cerebral perfusion:</strong> CPP = MAP - ICP. Goal CPP 60-70 mmHg</li>
                    </ul>
                    
                    <p><span class="label">Immediate Medical Management (if signs of herniation or ICP >22):</span></p>
                    <ul>
                        <li><strong>Head of bed elevation:</strong> 30 degrees. Improves venous drainage. Keep head midline (no neck rotation - obstructs jugular veins)</li>
                        <li><strong>Hyperosmolar therapy:</strong></li>
                        <ul>
                            <li><strong>Mannitol:</strong> 0.25-1g/kg IV bolus (typical 100g = 500mL of 20% solution). Repeat q4-6hr PRN. Monitor serum osmolality (keep <320 mOsm/kg). Watch for hypovolemia, AKI</li>
                            <li><strong>Hypertonic saline:</strong> 3% NaCl 250mL bolus over 10-20min. Or 23.4% NaCl 30mL bolus via central line. Repeat PRN. Monitor Na (keep <160 mEq/L). May be superior to mannitol</li>
                        </ul>
                        <li><strong>Hyperventilation (TEMPORIZING ONLY):</strong> Target pCO‚ÇÇ 30-35 mmHg. Causes cerebral vasoconstriction ‚Üí reduces cerebral blood volume ‚Üí lowers ICP. ONLY for emergent herniation (buys time for definitive treatment). Prolonged use causes ischemia</li>
                        <li><strong>Sedation:</strong> Propofol or midazolam. Reduces cerebral metabolic demand. Intubate first if severe</li>
                        <li><strong>Seizure prophylaxis:</strong> Levetiracetam 500-1000mg IV. Seizures increase ICP</li>
                    </ul>
                    
                    <p><span class="label">Supportive ICU Care:</span></p>
                    <ul>
                        <li><strong>Intubation:</strong> If GCS ‚â§8, inability to protect airway, need for hyperventilation. Use RSI with lidocaine pretreatment (blunts ICP spike from intubation)</li>
                        <li><strong>Ventilation:</strong> Target pCO‚ÇÇ 35-40 mmHg (normal). Avoid hypercapnia (vasodilates) and excessive hypocapnia (causes ischemia)</li>
                        <li><strong>Oxygenation:</strong> Keep O‚ÇÇ sat >90%. Hypoxia worsens cerebral edema</li>
                        <li><strong>Blood pressure:</strong> Maintain adequate MAP to achieve CPP 60-70 mmHg. May need vasopressors (norepinephrine)</li>
                        <li><strong>Temperature:</strong> Avoid hyperthermia (increases metabolic demand). Goal normothermia. Consider therapeutic hypothermia (32-36¬∞C) if refractory (controversial)</li>
                        <li><strong>Glucose:</strong> Avoid hyper and hypoglycemia. Goal 140-180 mg/dL</li>
                        <li><strong>Avoid:</strong> Hypotonic fluids (worsens cerebral edema). Use isotonic (0.9% NaCl) or hypertonic</li>
                    </ul>
                    
                    <p><span class="label">Surgical Management (Neurosurgery Consult):</span></p>
                    <ul>
                        <li><strong>Hematoma evacuation:</strong> Epidural, subdural, or intraparenchymal hematoma with mass effect</li>
                        <li><strong>External ventricular drain (EVD):</strong> Drains CSF, reduces ICP. For hydrocephalus or as ICP monitor</li>
                        <li><strong>Decompressive craniectomy:</strong> Remove part of skull to allow brain to swell outward. For malignant MCA syndrome, refractory TBI. Reduces mortality but increases severe disability</li>
                        <li><strong>Tumor resection/abscess drainage:</strong> If mass lesion causing ICP</li>
                    </ul>
                    
                    <p><span class="label">Refractory ICP (if above measures fail):</span></p>
                    <ul>
                        <li><strong>Barbiturate coma:</strong> Pentobarbital load 5-10mg/kg, then 1-4mg/kg/hr. Reduces cerebral metabolic rate. Requires continuous EEG monitoring. High complication rate (hypotension, infection)</li>
                        <li><strong>Decompressive craniectomy:</strong> Last resort for refractory ICP</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Cushing's triad is a late/pre-terminal sign:</strong> Don't wait for it! Treat based on symptoms, imaging, and ICP monitoring. By the time Cushing's triad appears, herniation is imminent</li>
                    <li><strong>Herniation kills via brainstem compression:</strong> Respiratory centers (apnea), cardiovascular centers (shock), reticular activating system (coma). Uncal herniation ‚Üí ipsilateral blown pupil is classic</li>
                    <li><strong>Hyperventilation is temporizing only:</strong> Buys 15-30 minutes by vasoconstricting cerebral vessels. Prolonged use causes ischemia. Use only for emergent herniation while preparing for definitive treatment</li>
                    <li><strong>Mannitol vs hypertonic saline:</strong> Both work. Hypertonic saline may be superior (no osmotic diuresis, longer duration). Hypertonic saline preferred in hypovolemic patients</li>
                    <li><strong>Avoid LP if increased ICP:</strong> Removing CSF creates pressure gradient ‚Üí brainstem herniates through foramen magnum (tonsillar herniation) ‚Üí death. Always image first!</li>
                    <li><strong>Head of bed 30¬∞, not flat:</strong> Improves venous drainage, reduces ICP. Keep head midline (turning neck obstructs jugular veins ‚Üí worsens ICP)</li>
                    <li><strong>CPP matters more than ICP:</strong> Brain needs perfusion. CPP = MAP - ICP. Goal CPP 60-70 mmHg. May need to increase MAP with pressors even if ICP elevated</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ALL increased ICP patients need ICU</li>
                        <li>GCS ‚â§8</li>
                        <li>Signs of herniation (blown pupil, posturing, Cushing's triad)</li>
                        <li>Need for ICP monitoring</li>
                        <li>Need for hyperosmolar therapy or hyperventilation</li>
                        <li>Neurosurgical emergency</li>
                        <li>Intubated for airway protection</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì ICU ‚Üí FLOOR CRITERIA</div>
                    <ul>
                        <li>ICP controlled (<20 mmHg sustained)</li>
                        <li>No herniation risk</li>
                        <li>Underlying cause treated (hematoma evacuated, CSF draining, etc)</li>
                        <li>Off hyperosmolar therapy √ó 24hr</li>
                        <li>Extubated (if intubated)</li>
                        <li>Neurologically stable or improving</li>
                        <li>Can remove ICP monitor if placed</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Herniation (uncal, central, tonsillar) ‚Üí death or severe disability, ischemic stroke (from low CPP or herniation-related vascular compression), seizures, vision loss (optic nerve compression from papilledema), brainstem injury</p>
                    <p><strong>Treatment-related:</strong> Hyperventilation ‚Üí cerebral ischemia, Mannitol ‚Üí hypovolemia, AKI, rebound cerebral edema, Hypertonic saline ‚Üí hypernatremia, central pontine myelinolysis (if Na corrected too fast), Decompressive craniectomy ‚Üí infection, seizures, need for cranioplasty</p>
                    <p><strong>Chronic:</strong> Cognitive impairment, motor deficits, vision loss (from chronic papilledema), seizure disorder, chronic disability, death (mortality varies by etiology: TBI 20-50%, malignant stroke 80% without craniectomy)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 59: SPINAL CORD COMPRESSION -->
<!-- ============================================ -->
        <div id="cord-compression" class="condition-page">
            <div class="page-header">
                <h2>55. SPINAL CORD COMPRESSION</h2>
                <div class="subtitle">Oncologic Emergency ‚Ä¢ Cauda Equina ‚Ä¢ Urgent MRI/Decompression</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Classic Triad:</span> (1) Back pain, (2) Motor weakness, (3) Sensory level. Autonomic dysfunction (bowel/bladder) is LATE finding</p>
                    <p><span class="label">Back Pain (>90%, often first symptom):</span></p>
                    <ul>
                        <li><strong>Characteristics:</strong> Severe, progressive, localized to site of compression. Worse with recumbency, Valsalva (cough, sneeze)</li>
                        <li><strong>Radicular pain:</strong> Shooting pain down extremity (dermatome distribution)</li>
                        <li><strong>Percussion tenderness:</strong> Tenderness over spinous process at level of compression</li>
                    </ul>
                    <p><span class="label">Motor Findings:</span></p>
                    <ul>
                        <li><strong>Weakness:</strong> Progressive, bilateral (though may start asymmetric). Upper motor neuron pattern (hyperreflexia, spasticity, upgoing Babinski) if compression above conus. Lower motor neuron if conus/cauda equina</li>
                        <li><strong>Gait disturbance:</strong> Difficulty walking, ataxia</li>
                        <li><strong>Severity:</strong> Can progress from subtle weakness to paraplegia in hours-days</li>
                    </ul>
                    <p><span class="label">Sensory Findings:</span></p>
                    <ul>
                        <li><strong>Sensory level:</strong> Decreased sensation below dermatome corresponding to compression level. Test pinprick from feet upward</li>
                        <li><strong>Paresthesias:</strong> Numbness, tingling in legs/arms</li>
                        <li><strong>Band-like sensation:</strong> Tight band around chest/abdomen at level of compression</li>
                    </ul>
                    <p><span class="label">Autonomic Dysfunction (LATE, indicates severe compression):</span></p>
                    <ul>
                        <li><strong>Bladder dysfunction:</strong> Urinary retention (most common), overflow incontinence, loss of urge sensation</li>
                        <li><strong>Bowel dysfunction:</strong> Constipation, fecal incontinence</li>
                        <li><strong>Sexual dysfunction:</strong> Erectile dysfunction, loss of sensation</li>
                        <li><strong>Loss of anal sphincter tone:</strong> Decreased rectal tone on exam (check rectal exam!)</li>
                    </ul>
                    <p><span class="label">Cauda Equina Syndrome (Compression Below L1-L2):</span></p>
                    <ul>
                        <li><strong>Classic:</strong> Severe back/leg pain, saddle anesthesia (perineum, buttocks, inner thighs), bilateral leg weakness (lower motor neuron - areflexia), bowel/bladder dysfunction, decreased anal tone</li>
                        <li><strong>Pearl:</strong> Lower motor neuron findings (flaccid weakness, areflexia, muscle atrophy) vs cord compression (upper motor neuron)</li>
                    </ul>
                    <p><span class="label">Etiologies:</span></p>
                    <ul>
                        <li><strong>Metastatic cancer (50-70%):</strong> Most common cause. Breast, lung, prostate, renal, melanoma, myeloma. Vertebral body ‚Üí epidural extension</li>
                        <li><strong>Epidural abscess (5-10%):</strong> Staph aureus most common. Preceding bacteremia, IVDU, spinal procedure, immunosuppression</li>
                        <li><strong>Epidural hematoma:</strong> Trauma, anticoagulation, spinal procedure (epidural, LP)</li>
                        <li><strong>Disc herniation:</strong> Large central or posterolateral disc. Acute (trauma) or chronic (degenerative)</li>
                        <li><strong>Spinal stenosis:</strong> Chronic compression from degenerative changes. Progressive symptoms</li>
                        <li><strong>Primary cord tumor:</strong> Astrocytoma, ependymoma (intramedullary)</li>
                        <li><strong>Trauma:</strong> Vertebral fracture, subluxation</li>
                        <li><strong>Other:</strong> Transverse myelitis, spinal AVM, spontaneous epidural hematoma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">MRI Spine with Gadolinium (URGENT, <24hr):</span></p>
                    <ul>
                        <li><strong>GOLD STANDARD:</strong> Identifies level and cause of compression. Visualizes entire spine (metastases can be multiple levels)</li>
                        <li><strong>Image entire spine:</strong> Cervical, thoracic, lumbar. 20-30% have lesions at multiple non-contiguous levels</li>
                        <li><strong>Timing:</strong> STAT MRI if progressive motor weakness or bowel/bladder dysfunction (hours matter!). Within 24hr if concerning symptoms</li>
                        <li><strong>Contraindications:</strong> Pacemaker, metallic implants (some), severe claustrophobia</li>
                    </ul>
                    <p><span class="label">CT Myelography (if MRI contraindicated or unavailable):</span></p>
                    <ul>
                        <li><strong>Requires LP:</strong> Inject contrast into subarachnoid space, then CT spine. Shows obstruction to flow</li>
                        <li><strong>Risk:</strong> If complete block, LP can worsen compression. MRI preferred</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis (abscess), anemia (malignancy)</li>
                        <li><strong>ESR/CRP:</strong> Elevated (abscess, malignancy)</li>
                        <li><strong>Blood cultures:</strong> If concern for epidural abscess (fever, elevated WBC)</li>
                        <li><strong>PSA:</strong> If prostate cancer suspected</li>
                        <li><strong>Coags:</strong> If epidural hematoma suspected (anticoagulation, bleeding disorder)</li>
                    </ul>
                    <p><span class="label">Rectal Exam (MANDATORY):</span> Assess anal tone, perianal sensation. Decreased tone = cauda equina or severe cord compression</p>
                    <p><span class="label">Post-Void Residual (PVR):</span> Bladder scan after patient voids. PVR >100-200mL = retention (indicates autonomic dysfunction)</p>
                    <p><span class="label">Red Flags Requiring URGENT MRI:</span></p>
                    <ul>
                        <li>New bowel/bladder dysfunction</li>
                        <li>Saddle anesthesia</li>
                        <li>Progressive motor weakness</li>
                        <li>Known cancer with new back pain or neurologic symptoms</li>
                        <li>Fever + back pain (epidural abscess)</li>
                        <li>Severe back pain after trauma</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Immediate Management (BEFORE definitive treatment):</span></p>
                    <ul>
                        <li><strong>Dexamethasone (if malignancy suspected):</strong> 10mg IV STAT, then 4mg IV q6hr. Reduces cord edema. Give IMMEDIATELY while arranging MRI. Do NOT delay for imaging</li>
                        <li><strong>Hold steroids if abscess suspected:</strong> Can worsen infection. Give antibiotics first</li>
                        <li><strong>Pain control:</strong> Opioids as needed. Pain can be severe</li>
                        <li><strong>Bladder catheterization:</strong> Foley if urinary retention</li>
                        <li><strong>Spinal precautions:</strong> If trauma, keep spine immobilized</li>
                    </ul>
                    
                    <p><span class="label">Definitive Treatment by Etiology:</span></p>
                    <ul>
                        <li><strong>Metastatic Epidural Spinal Cord Compression (MESCC):</strong></li>
                        <ul>
                            <li><strong>Surgery:</strong> Decompressive laminectomy + tumor resection. Indications: radiosensitive tumor, spinal instability, neurologic decline on radiation, unclear diagnosis needing biopsy. Better outcomes than radiation alone if ambulatory pre-op</li>
                            <li><strong>Radiation therapy:</strong> For radiosensitive tumors (lymphoma, myeloma, small cell lung, prostate). 8-10 Gy √ó 1-2 fractions emergently. Can preserve ambulation</li>
                            <li><strong>Combination:</strong> Surgery followed by radiation for local control</li>
                            <li><strong>Dexamethasone:</strong> Continue √ó 3-7 days, then taper over 2-4 weeks</li>
                        </ul>
                        <li><strong>Epidural Abscess:</strong></li>
                        <ul>
                            <li><strong>Antibiotics:</strong> Empiric vancomycin 15mg/kg IV q12hr + ceftriaxone 2g IV q24hr OR cefepime 2g IV q8hr. Adjust based on cultures</li>
                            <li><strong>Surgery:</strong> Urgent laminectomy and drainage if neurologic deficits, spinal instability, or failed medical therapy. Source control critical</li>
                            <li><strong>Medical management alone:</strong> Consider if no neuro deficits, small abscess, high surgical risk. Requires close monitoring</li>
                            <li><strong>Duration:</strong> 4-8 weeks IV antibiotics (longer if osteomyelitis)</li>
                        </ul>
                        <li><strong>Epidural Hematoma:</strong></li>
                        <ul>
                            <li><strong>Reverse anticoagulation:</strong> Vitamin K, FFP, PCC, or idarucizumab/andexanet depending on agent</li>
                            <li><strong>Surgery:</strong> Urgent decompression if neurologic deficits</li>
                            <li><strong>Conservative:</strong> Small hematoma without neuro deficits can be observed</li>
                        </ul>
                        <li><strong>Disc Herniation/Cauda Equina:</strong></li>
                        <ul>
                            <li><strong>Surgery:</strong> EMERGENT discectomy (within 24-48hr). Outcomes worsen with delay. Cauda equina = surgical emergency</li>
                            <li><strong>Medical management:</strong> Only if no red flags, no progressive deficits. NSAIDs, PT</li>
                        </ul>
                    </ul>
                    
                    <p><span class="label">Surgical Timing (Critical):</span></p>
                    <ul>
                        <li><strong>Cauda equina:</strong> Within 24-48hr. Every hour delay worsens outcomes (bowel/bladder recovery)</li>
                        <li><strong>Progressive motor weakness:</strong> Emergent (hours). Pre-op ambulatory status predicts post-op ambulation</li>
                        <li><strong>Paraplegia >48hr:</strong> Unlikely to recover ambulation even with surgery. Still decompress for pain, bowel/bladder</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>DVT prophylaxis:</strong> SCDs + heparin/LMWH (unless hematoma)</li>
                        <li><strong>Bowel regimen:</strong> Prevent constipation (ileus common)</li>
                        <li><strong>Bladder management:</strong> Foley if retention. Intermittent cath when stable</li>
                        <li><strong>Skin care:</strong> Turn q2hr, pressure ulcer prevention</li>
                        <li><strong>Physical therapy:</strong> Early mobilization when safe</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Back pain + cancer = MRI until proven otherwise:</strong> 95% of MESCC patients have back pain. Any cancer patient with new/worsening back pain needs urgent spine MRI</li>
                    <li><strong>Autonomic dysfunction = LATE finding:</strong> Bowel/bladder involvement indicates severe compression. Don't wait for it - intervene earlier based on motor/sensory findings</li>
                    <li><strong>Ambulatory status predicts outcome:</strong> If ambulatory before treatment, 90% remain ambulatory. If paraplegic, only 10-20% regain ambulation. TIMING MATTERS</li>
                    <li><strong>Give steroids BEFORE MRI if malignancy suspected:</strong> Dexamethasone 10mg IV immediately. Reduces cord edema while waiting for imaging/surgery. Don't delay for diagnosis</li>
                    <li><strong>Check rectal tone!</strong> Mandatory part of exam. Decreased tone = cauda equina or severe compression requiring emergent intervention</li>
                    <li><strong>Cauda equina = surgical emergency:</strong> Decompress within 24-48hr. Permanent bowel/bladder/sexual dysfunction if delayed. Saddle anesthesia + bladder retention + bilateral leg weakness = OR now</li>
                    <li><strong>Epidural abscess triad:</strong> Back pain + fever + neurologic deficits. But only 10-15% have all three. High index of suspicion in IVDU, recent spinal procedure, or bacteremia</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è URGENT NEUROSURGERY CONSULT IF:</div>
                    <ul>
                        <li>ANY cord compression on imaging with neurologic deficits</li>
                        <li>Cauda equina syndrome (surgical emergency)</li>
                        <li>Progressive motor weakness</li>
                        <li>Bowel/bladder dysfunction</li>
                        <li>Epidural abscess with neuro deficits</li>
                        <li>Epidural hematoma with neuro deficits</li>
                        <li>Large disc herniation with cauda equina</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neurologically stable or improving</li>
                        <li>Post-surgical if operated (wound healing, no infection)</li>
                        <li>Pain controlled on oral regimen</li>
                        <li>Bladder function recovered OR able to self-cath</li>
                        <li>Bowel regimen established</li>
                        <li>If abscess: Appropriate antibiotics, plan for weeks-long course</li>
                        <li>Inpatient rehab arranged (many need extensive PT/OT)</li>
                        <li>Oncology follow-up (if malignancy)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Permanent paraplegia (if delayed treatment), respiratory failure (if high cervical lesion), neurogenic shock (spinal shock - hypotension, bradycardia from loss of sympathetic tone), DVT/PE (immobility), pressure ulcers, urinary retention ‚Üí hydronephrosis</p>
                    <p><strong>Surgical:</strong> Wound infection, CSF leak, worsening neurologic deficits, spinal instability, epidural hematoma</p>
                    <p><strong>Chronic:</strong> Permanent bowel/bladder dysfunction (30-70% if cauda equina), chronic pain, sexual dysfunction, spasticity, recurrent UTIs (neurogenic bladder), pressure ulcers, DVT, depression, need for lifelong assistance/wheelchair</p>
                    <p><strong>Prognosis:</strong> Depends on etiology, severity at presentation, and time to treatment. Pre-op ambulatory status is most important predictor. Paraplegia >48hr rarely recovers</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 60: INFLUENZA/SEVERE VIRAL PNEUMONIA -->
<!-- ============================================ -->
        <div id="influenza" class="condition-page">
            <div class="page-header">
                <h2>56. INFLUENZA/SEVERE VIRAL PNEUMONIA</h2>
                <div class="subtitle">Viral Respiratory Illness ‚Ä¢ Primary Viral Pneumonia ‚Ä¢ Oseltamivir/Supportive Care</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Influenza (Uncomplicated):</span> Abrupt onset fever, myalgias, headache, malaise, dry cough, sore throat. Self-limited in 3-7 days in healthy individuals</p>
                    <p><span class="label">Severe Influenza/Primary Viral Pneumonia:</span> Progressive dyspnea, hypoxemia, bilateral infiltrates despite antiviral therapy. Can rapidly progress to ARDS. More common in high-risk patients</p>
                    <p><span class="label">Classic Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory:</strong> Dyspnea, tachypnea, hypoxemia (O‚ÇÇ sat <90%), cough (initially dry, may become productive), pleuritic chest pain</li>
                        <li><strong>Systemic:</strong> High fever (>38.5¬∞C), severe myalgias, fatigue, headache</li>
                        <li><strong>Timeline:</strong> Initial flu symptoms ‚Üí worsening respiratory status over 2-5 days ‚Üí ARDS (severe cases)</li>
                    </ul>
                    <p><span class="label">High-Risk Groups (for Severe Disease):</span></p>
                    <ul>
                        <li><strong>Age:</strong> <5 years (especially <2 years), ‚â•65 years</li>
                        <li><strong>Chronic conditions:</strong> Asthma, COPD, heart disease, diabetes, chronic kidney disease, liver disease, obesity (BMI ‚â•40)</li>
                        <li><strong>Immunocompromised:</strong> HIV, malignancy, transplant, chronic steroids</li>
                        <li><strong>Pregnancy/postpartum:</strong> Up to 2 weeks postpartum</li>
                        <li><strong>Nursing home residents:</strong> Frail, multiple comorbidities</li>
                    </ul>
                    <p><span class="label">Complications:</span></p>
                    <ul>
                        <li><strong>Primary viral pneumonia:</strong> Diffuse bilateral infiltrates, hypoxemia, rapid progression to ARDS</li>
                        <li><strong>Secondary bacterial pneumonia:</strong> S. aureus (including MRSA), S. pneumoniae, H. influenzae. Suspect if improvement followed by clinical worsening, new fever, purulent sputum</li>
                        <li><strong>ARDS:</strong> Acute respiratory distress syndrome. P/F ratio <300. Bilateral infiltrates. High mortality</li>
                        <li><strong>Myocarditis:</strong> Troponin elevation, arrhythmias, heart failure</li>
                        <li><strong>Rhabdomyolysis:</strong> Severe myalgias, elevated CK, acute kidney injury</li>
                        <li><strong>Encephalopathy/encephalitis:</strong> Altered mental status, seizures (more common in children)</li>
                    </ul>
                    <p><span class="label">Influenza Subtypes:</span> Type A (H1N1, H3N2 - cause pandemics), Type B (seasonal, less severe). Type A more virulent. Novel strains (e.g., H1N1 pdm09, avian H5N1, H7N9) can cause severe disease in previously healthy adults</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Rapid Influenza Testing:</span></p>
                    <ul>
                        <li><strong>Rapid antigen tests (RIDT):</strong> Results in 15-30min. Sensitivity 50-70% (low). Specificity >90%. Negative test does NOT rule out influenza</li>
                        <li><strong>Molecular tests (PCR):</strong> GOLD STANDARD. High sensitivity (90-95%). Results in 1-8hr. Can differentiate influenza A vs B, subtypes. Preferred in hospitalized patients</li>
                        <li><strong>Multiplex respiratory panel:</strong> Tests for influenza + RSV, adenovirus, parainfluenza, coronavirus, others. Useful for ruling in/out other pathogens. Helps determine need for isolation precautions</li>
                        <li><strong>Timing:</strong> Test within first 4 days of illness (viral shedding highest). Can test up to 7 days if hospitalized or immunocompromised</li>
                        <li><strong>Sample:</strong> Nasopharyngeal swab (preferred), nasal swab, throat swab. Lower respiratory samples (BAL, sputum) if intubated</li>
                    </ul>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukopenia or normal WBC (lymphopenia common). Leukocytosis suggests bacterial superinfection</li>
                        <li><strong>CMP:</strong> Assess renal function (before antivirals), electrolytes</li>
                        <li><strong>Blood cultures:</strong> If bacterial superinfection suspected (fever after initial improvement, leukocytosis)</li>
                        <li><strong>Sputum culture:</strong> If productive cough, suspicion for bacterial pneumonia</li>
                        <li><strong>Procalcitonin:</strong> Low in viral infection (<0.25). Elevated in bacterial co-infection (>0.5)</li>
                        <li><strong>CK:</strong> If severe myalgias (check for rhabdomyolysis)</li>
                        <li><strong>Troponin:</strong> If chest pain, ECG changes (myocarditis/myopericarditis can occur)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> May be normal early. Bilateral interstitial infiltrates (viral pneumonia). Lobar consolidation (bacterial superinfection). Diffuse bilateral infiltrates (ARDS)</li>
                        <li><strong>CT chest:</strong> Ground-glass opacities (viral), tree-in-bud (bronchiolitis), consolidation. More sensitive than CXR but not routinely needed</li>
                    </ul>
                    <p><span class="label">ABG:</span> If hypoxemia (O‚ÇÇ sat <90%). Assess P/F ratio (PaO‚ÇÇ/FiO‚ÇÇ). <300 = ARDS</p>
                    <p><span class="label">Clinical Diagnosis:</span> In outbreak setting with typical symptoms, clinical diagnosis is acceptable. Testing confirms diagnosis and guides treatment/isolation</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Antiviral Therapy (CRITICAL):</span></p>
                    <ul>
                        <li><strong>Oseltamivir (Tamiflu):</strong> 75mg PO BID √ó 5 days. FIRST-LINE. Neuraminidase inhibitor. Reduces duration of illness by 1-2 days. Reduces complications and mortality in hospitalized patients</li>
                        <li><strong>Zanamivir (Relenza):</strong> 10mg inhaled BID √ó 5 days. Alternative if oseltamivir not available. Contraindicated in asthma/COPD (bronchospasm risk)</li>
                        <li><strong>Peramivir (Rapivab):</strong> 600mg IV once daily √ó 5 days. For hospitalized patients unable to take PO/inhaled</li>
                        <li><strong>Baloxavir (Xofluza):</strong> Single dose (40-80mg PO based on weight). Newer agent. Polymerase inhibitor. Not preferred in hospitalized patients (limited data)</li>
                        <li><strong>Timing:</strong> START WITHIN 48 HOURS of symptom onset for maximum benefit. Still beneficial if started >48hr in hospitalized/severe cases. DO NOT delay treatment for test results in hospitalized patients</li>
                        <li><strong>Who to treat:</strong> ALL hospitalized patients with confirmed or suspected influenza, regardless of illness duration. Outpatients with high-risk conditions. Severe illness (pneumonia, hypoxemia, respiratory failure)</li>
                        <li><strong>Duration:</strong> Standard 5 days. Consider longer course (10 days) in immunocompromised, severe disease, or persistent viral shedding</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Support:</span></p>
                    <ul>
                        <li><strong>Supplemental oxygen:</strong> Target O‚ÇÇ sat ‚â•90-92%. Nasal cannula ‚Üí face mask ‚Üí high-flow nasal cannula ‚Üí NIPPV</li>
                        <li><strong>High-flow nasal cannula (HFNC):</strong> 40-60L/min, FiO‚ÇÇ 0.4-1.0. May avoid intubation in hypoxemic respiratory failure</li>
                        <li><strong>NIPPV (BiPAP/CPAP):</strong> Consider if HFNC insufficient. Caution: increased risk of aerosolization (use negative pressure room)</li>
                        <li><strong>Mechanical ventilation:</strong> If refractory hypoxemia, work of breathing, altered mental status. Lung-protective ventilation (TV 6mL/kg IBW, plateau pressure <30cmH‚ÇÇO, PEEP titrated)</li>
                        <li><strong>Prone positioning:</strong> Consider if P/F <150 (severe ARDS). Improves oxygenation and mortality</li>
                        <li><strong>ECMO:</strong> Consider in refractory ARDS despite maximal support. Transfer to ECMO center if available</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (for Bacterial Superinfection):</span></p>
                    <ul>
                        <li><strong>When to add:</strong> Lobar consolidation on imaging, purulent sputum, leukocytosis, clinical worsening after initial improvement, procalcitonin >0.5, positive bacterial cultures</li>
                        <li><strong>Community-acquired pneumonia coverage:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV daily OR levofloxacin 750mg IV daily</li>
                        <li><strong>MRSA coverage (if suspected):</strong> ADD vancomycin 15-20mg/kg IV q8-12hr OR linezolid 600mg IV q12hr. Post-influenza MRSA pneumonia is severe (necrotizing, high mortality)</li>
                        <li><strong>Duration:</strong> 5-7 days for CAP. Longer if slow response or complicated (empyema, abscess)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Hydration:</strong> IV fluids (NS or LR) for dehydration. Maintain euvolemia (avoid fluid overload in ARDS)</li>
                        <li><strong>Antipyretics:</strong> Acetaminophen 650-1000mg q6hr PRN or ibuprofen 400-600mg q6hr PRN for fever/myalgias</li>
                        <li><strong>Cough suppressants:</strong> Dextromethorphan or benzonatate PRN (use sparingly - cough clears secretions)</li>
                        <li><strong>DVT prophylaxis:</strong> Heparin 5000 units SQ q8-12hr or LMWH (unless contraindicated)</li>
                        <li><strong>Stress ulcer prophylaxis:</strong> PPI if mechanically ventilated or high bleeding risk</li>
                    </ul>
                    
                    <p><span class="label">Corticosteroids (CONTROVERSIAL):</span></p>
                    <ul>
                        <li><strong>NOT routinely recommended:</strong> May prolong viral shedding, increase secondary infections</li>
                        <li><strong>Consider in refractory shock:</strong> Hydrocortisone 50mg IV q6hr if vasopressor-dependent shock</li>
                        <li><strong>Consider in ARDS:</strong> Low-dose methylprednisolone (1mg/kg/day) in severe ARDS (P/F <150) - controversial, mixed data</li>
                    </ul>
                    
                    <p><span class="label">Infection Control:</span></p>
                    <ul>
                        <li><strong>Droplet precautions:</strong> Surgical mask for healthcare workers. Private room preferred. Respirators (N95) for aerosol-generating procedures</li>
                        <li><strong>Duration of isolation:</strong> Until 24hr afebrile without antipyretics AND improvement in respiratory symptoms. Immunocompromised: may shed virus for weeks (consult ID)</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Don't delay antivirals:</strong> Start oseltamivir empirically in hospitalized patients with suspected influenza BEFORE test results. Greatest benefit if started within 48hr, but still beneficial in severe cases started later</li>
                    <li><strong>Post-influenza S. aureus pneumonia is deadly:</strong> Classic scenario: Patient improves, then worsens 3-7 days later with new fever, leukocytosis, necrotizing pneumonia. Add vancomycin or linezolid immediately</li>
                    <li><strong>Negative rapid flu test doesn't rule out influenza:</strong> RIDT sensitivity only 50-70%. If high clinical suspicion, send PCR and treat empirically</li>
                    <li><strong>Primary viral pneumonia can cause ARDS rapidly:</strong> Young, healthy patients can deteriorate quickly (24-72hr). Early ICU transfer and aggressive respiratory support</li>
                    <li><strong>Procalcitonin helps guide antibiotics:</strong> Low PCT (<0.25) = viral. High PCT (>0.5) = bacterial co-infection. Can help avoid unnecessary antibiotics</li>
                    <li><strong>Influenza myocarditis is underrecognized:</strong> Check troponin in severe cases, especially with chest pain or arrhythmias. Can cause acute heart failure</li>
                    <li><strong>Zanamivir is inhaled - avoid in lung disease:</strong> Can cause bronchospasm in asthma/COPD patients. Use oseltamivir instead</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Hypoxemic respiratory failure (O‚ÇÇ sat <90% despite supplemental O‚ÇÇ)</li>
                        <li>Need for HFNC, NIPPV, or mechanical ventilation</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>ARDS (P/F ratio <300)</li>
                        <li>Altered mental status, encephalopathy</li>
                        <li>Lactic acidosis (lactate >4mmol/L)</li>
                        <li>Rapid clinical deterioration despite therapy</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile ‚â•24hr without antipyretics</li>
                        <li>O‚ÇÇ sat ‚â•90% on room air (or back to baseline if chronic lung disease)</li>
                        <li>Respiratory rate <24/min at rest</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Completed 5-day course of oseltamivir (or at least 48hr and improving)</li>
                        <li>No evidence of bacterial superinfection (or completed appropriate antibiotic course)</li>
                        <li>Able to perform ADLs or return to baseline function</li>
                        <li>Follow-up arranged (PCP within 1 week)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Primary viral pneumonia ‚Üí ARDS (P/F <200, high mortality), secondary bacterial pneumonia (S. aureus, S. pneumoniae - most common), septic shock, myocarditis (troponin elevation, arrhythmias, cardiogenic shock), rhabdomyolysis (CK >10,000, AKI), encephalitis/encephalopathy (altered mental status, seizures, especially children), exacerbation of underlying conditions (asthma, COPD, heart failure)</p>
                    <p><strong>Chronic:</strong> Post-viral chronic cough (weeks-months), persistent fatigue, prolonged recovery in elderly/frail patients, cardiovascular events (MI, stroke in first 2 weeks post-infection - 3-5x increased risk)</p>
                    <p><strong>Prevention:</strong> Annual influenza vaccine (inactivated or live attenuated). Highest priority: healthcare workers, elderly, chronic disease, pregnant women, young children. Vaccine reduces risk of hospitalization by 40-60%. Post-exposure prophylaxis with oseltamivir 75mg daily √ó 10 days for high-risk unvaccinated contacts</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 61: COVID-19 SEVERE DISEASE -->
<!-- ============================================ -->
        <div id="covid" class="condition-page">
            <div class="page-header">
                <h2>57. COVID-19 SEVERE DISEASE</h2>
                <div class="subtitle">SARS-CoV-2 ‚Ä¢ Viral Pneumonia ‚Üí ARDS ‚Ä¢ Dexamethasone + Supportive Care</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Disease Severity Classification (NIH):</span></p>
                    <ul>
                        <li><strong>Mild:</strong> Any symptoms (fever, cough, fatigue) without dyspnea or abnormal imaging</li>
                        <li><strong>Moderate:</strong> Evidence of lower respiratory disease (clinical or imaging) + O‚ÇÇ sat ‚â•94% on room air</li>
                        <li><strong>SEVERE:</strong> O‚ÇÇ sat <94% on room air, P/F ratio <300, RR >30/min, or lung infiltrates >50%</li>
                        <li><strong>CRITICAL:</strong> Respiratory failure (requiring mechanical ventilation, HFNC, NIPPV), septic shock, multiorgan dysfunction</li>
                    </ul>
                    <p><span class="label">Severe/Critical COVID-19 Presentation:</span></p>
                    <ul>
                        <li><strong>Respiratory:</strong> Progressive dyspnea (typically 5-10 days after symptom onset), tachypnea (RR >30/min), hypoxemia (O‚ÇÇ sat <94%), increased work of breathing, bilateral pneumonia</li>
                        <li><strong>Systemic:</strong> Persistent fever, fatigue, myalgias, anorexia</li>
                        <li><strong>GI:</strong> Diarrhea (20-30%), nausea, abdominal pain</li>
                        <li><strong>Neurologic:</strong> Confusion, delirium, headache, anosmia/ageusia (loss of smell/taste)</li>
                        <li><strong>Thromboembolic:</strong> DVT, PE, stroke, MI (hypercoagulable state)</li>
                    </ul>
                    <p><span class="label">High-Risk Groups (for Severe Disease):</span></p>
                    <ul>
                        <li><strong>Age:</strong> ‚â•65 years (risk increases exponentially with age)</li>
                        <li><strong>Chronic conditions:</strong> Obesity (BMI ‚â•30), diabetes, hypertension, cardiovascular disease, chronic lung disease (COPD, asthma), chronic kidney disease, liver disease</li>
                        <li><strong>Immunocompromised:</strong> Solid organ transplant, hematologic malignancy, chemotherapy, HIV (CD4 <200), chronic high-dose steroids (‚â•20mg prednisone daily), immunosuppressive medications</li>
                        <li><strong>Pregnancy:</strong> Increased risk of severe disease, preterm birth, ICU admission</li>
                        <li><strong>Other:</strong> Smoking, sickle cell disease, Down syndrome, neurologic conditions, tuberculosis</li>
                    </ul>
                    <p><span class="label">Typical Timeline:</span> Symptom onset (day 0) ‚Üí fever/cough/fatigue (days 1-4) ‚Üí hypoxemia/dyspnea (days 5-8) ‚Üí ARDS/critical illness (days 8-12) ‚Üí recovery or multiorgan failure (weeks 2-4+)</p>
                    <p><span class="label">Key Features Distinguishing COVID-19 ARDS:</span> "Silent hypoxemia" (profound hypoxemia with minimal dyspnea), preserved lung compliance early, hypercoagulability (elevated D-dimer), inflammatory cytokine storm (elevated CRP, ferritin, IL-6)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">SARS-CoV-2 Testing:</span></p>
                    <ul>
                        <li><strong>Nucleic acid amplification (NAAT/PCR):</strong> GOLD STANDARD. Nasopharyngeal swab. Sensitivity 80-90%. Detects active infection</li>
                        <li><strong>Rapid antigen test:</strong> Results in 15-30min. Sensitivity 60-80% (lower than PCR). Best within first 5-7 days of symptoms. False negatives common</li>
                        <li><strong>Timing:</strong> Test all hospitalized patients with respiratory symptoms. PCR preferred. Antigen OK for screening, but confirm negatives with PCR if high suspicion</li>
                        <li><strong>Repeat testing:</strong> If initial negative but high suspicion, repeat in 24-48hr or send lower respiratory sample (sputum, BAL)</li>
                    </ul>
                    <p><span class="label">Labs (for Severity Assessment & Prognostication):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Lymphopenia (common, correlates with severity), thrombocytopenia (severe disease)</li>
                        <li><strong>CMP:</strong> BUN/Cr (AKI in 20-40% of hospitalized), transaminitis (ALT/AST elevation), hypoalbuminemia (poor prognosis)</li>
                        <li><strong>Inflammatory markers:</strong> CRP, ferritin, LDH (elevated in severe disease, correlate with mortality), IL-6 (if available - very high in cytokine storm)</li>
                        <li><strong>D-dimer:</strong> Elevated in >70% of severe cases. Markedly elevated (>5,000ng/mL) = poor prognosis, high VTE risk</li>
                        <li><strong>Procalcitonin:</strong> Usually low-normal in viral infection. Elevation suggests bacterial superinfection</li>
                        <li><strong>Troponin:</strong> Elevated in 20-30% of hospitalized patients (myocardial injury, myocarditis). Associated with increased mortality</li>
                        <li><strong>BNP:</strong> If heart failure suspected (COVID-19 can precipitate HF)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Bilateral patchy infiltrates, consolidation, ground-glass opacities. Peripheral distribution. Normal CXR does NOT exclude COVID-19 pneumonia</li>
                        <li><strong>CT chest:</strong> More sensitive. Bilateral ground-glass opacities (GGO) with peripheral distribution, "crazy-paving" pattern, consolidation. Useful if CXR nondiagnostic. CT not needed for diagnosis/management in typical cases</li>
                    </ul>
                    <p><span class="label">ABG:</span> Assess P/F ratio if hypoxemic. <300 = ARDS. A-a gradient typically elevated</p>
                    <p><span class="label">Other Testing (as indicated):</span></p>
                    <ul>
                        <li><strong>ECG:</strong> If chest pain, troponin elevation (check for STEMI, arrhythmias, myocarditis)</li>
                        <li><strong>Blood cultures:</strong> If bacterial superinfection suspected</li>
                        <li><strong>Respiratory viral panel:</strong> Rule out co-infections (influenza, RSV) if early in illness</li>
                        <li><strong>VTE workup:</strong> CT-PE if high suspicion (tachycardia, hypoxemia out of proportion to lung findings, elevated D-dimer >5,000)</li>
                    </ul>
                    <p><span class="label">Poor Prognostic Indicators:</span> Age >65, oxygen requirement, elevated inflammatory markers (CRP >100mg/L, D-dimer >5,000ng/mL, ferritin >1,000ng/mL, LDH >400U/L), lymphopenia (<800/¬µL), thrombocytopenia, AKI, troponin elevation, obesity (BMI ‚â•35)</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Corticosteroids (PROVEN MORTALITY BENEFIT - MAINSTAY):</span></p>
                    <ul>
                        <li><strong>Dexamethasone 6mg IV/PO daily √ó 10 days (or until discharge):</strong> RECOVERY trial showed 30% reduction in mortality at 28 days in patients requiring oxygen. Number needed to treat = 8 (for supplemental O‚ÇÇ), 4 (for mechanical ventilation)</li>
                        <li><strong>Alternatives (if dexamethasone unavailable):</strong> Prednisone 40mg daily, methylprednisolone 32mg daily, hydrocortisone 160mg daily (divided doses)</li>
                        <li><strong>Who to treat:</strong> ALL patients requiring supplemental oxygen or mechanical ventilation</li>
                        <li><strong>Who NOT to treat:</strong> Mild COVID-19 not requiring oxygen (may cause harm)</li>
                        <li><strong>Duration:</strong> 10 days or until discharge (whichever comes first). Can stop earlier if no longer requiring oxygen</li>
                    </ul>
                    
                    <p><span class="label">Antiviral Therapy:</span></p>
                    <ul>
                        <li><strong>Remdesivir (Veklury):</strong> 200mg IV loading dose, then 100mg IV daily √ó 4 days (total 5 days). Modest benefit - reduces time to recovery by 5 days in hospitalized patients requiring oxygen (not ventilated). Consider in severe COVID-19 within 10 days of symptom onset. Less effective in mechanically ventilated patients. NOT a mortality benefit drug</li>
                        <li><strong>Timing:</strong> Start within 10 days of symptom onset for maximum benefit</li>
                        <li><strong>Contraindications:</strong> eGFR <30mL/min, ALT >10√ó ULN. Use cautiously if eGFR 30-60</li>
                        <li><strong>Note:</strong> Other antivirals (nirmatrelvir-ritonavir/Paxlovid, molnupiravir) are for OUTPATIENTS only (within 5 days of symptoms). NOT for hospitalized patients with severe disease</li>
                    </ul>
                    
                    <p><span class="label">IL-6 Receptor Antagonists (Anti-Cytokine Therapy):</span></p>
                    <ul>
                        <li><strong>Tocilizumab (Actemra) 8mg/kg IV once (max 800mg):</strong> Consider in patients with rapidly increasing oxygen requirements, CRP >75mg/L, within 24hr of ICU admission. Reduces mortality in severe/critical COVID-19 when combined with dexamethasone</li>
                        <li><strong>Baricitinib (Olumiant) 4mg PO daily √ó 14 days:</strong> JAK inhibitor. Alternative to tocilizumab. Reduces mortality when combined with dexamethasone. Easier administration (oral). Contraindicated if ALC <200/¬µL, ANC <500/¬µL</li>
                        <li><strong>Use ONE (not both):</strong> Tocilizumab OR baricitinib, in combination with dexamethasone</li>
                        <li><strong>Screen for infections:</strong> Before use, rule out active bacterial/fungal infections</li>
                    </ul>
                    
                    <p><span class="label">Respiratory Support:</span></p>
                    <ul>
                        <li><strong>Supplemental oxygen:</strong> Target O‚ÇÇ sat 92-96% (or 88-92% if COPD). Start with nasal cannula</li>
                        <li><strong>High-flow nasal cannula (HFNC):</strong> 40-60L/min, FiO‚ÇÇ 0.4-1.0. Effective in preventing intubation in many patients. ROX index (SpO‚ÇÇ/FiO‚ÇÇ √ó RR) <3.85 after 12hr = high risk of HFNC failure</li>
                        <li><strong>Prone positioning (AWAKE PRONING):</strong> Patient prone for 2-4hr several times daily while on HFNC. Improves oxygenation, may prevent intubation</li>
                        <li><strong>NIPPV (BiPAP/CPAP):</strong> Use cautiously (risk of aerosolization, delayed intubation). Consider in select patients who decline intubation or as bridge</li>
                        <li><strong>Mechanical ventilation:</strong> Intubate if worsening hypoxemia (P/F <150), work of breathing, or altered mental status. LUNG-PROTECTIVE VENTILATION: TV 6mL/kg IBW, plateau pressure <30cmH‚ÇÇO, PEEP 10-15cmH‚ÇÇO (higher PEEP in COVID-19), driving pressure <15cmH‚ÇÇO</li>
                        <li><strong>Prone positioning (INTUBATED):</strong> For P/F <150 (moderate-severe ARDS). 16hr prone daily. Improves mortality</li>
                        <li><strong>ECMO:</strong> Consider for refractory hypoxemia despite maximal support. Transfer to ECMO center</li>
                    </ul>
                    
                    <p><span class="label">Anticoagulation (CRITICAL - Hypercoagulable State):</span></p>
                    <ul>
                        <li><strong>Prophylactic anticoagulation:</strong> ALL hospitalized patients unless contraindicated. Enoxaparin 40mg SQ daily (preferred) or heparin 5000 units SQ TID. Consider higher prophylactic dose (enoxaparin 0.5mg/kg BID) if BMI >40 or D-dimer >5,000</li>
                        <li><strong>Therapeutic anticoagulation:</strong> If confirmed VTE (PE, DVT). NOT routinely for all severe COVID-19 patients (trials showed no benefit, increased bleeding in non-ICU patients)</li>
                        <li><strong>Monitor D-dimer:</strong> Trending D-dimer useful. Persistently elevated or rising = higher VTE risk</li>
                        <li><strong>Low threshold for CT-PE:</strong> If worsening hypoxemia, tachycardia, elevated D-dimer</li>
                    </ul>
                    
                    <p><span class="label">Antibiotics (for Bacterial Superinfection ONLY):</span></p>
                    <ul>
                        <li><strong>When to add:</strong> Clinical worsening after 7-10 days, new fever, leukocytosis, procalcitonin >0.5, positive bacterial cultures, lobar consolidation (new or worsening)</li>
                        <li><strong>Initial therapy:</strong> Ceftriaxone 1-2g IV daily + azithromycin 500mg IV daily (community-acquired pneumonia coverage). Consider vancomycin if MRSA risk (ICU, prior MRSA, necrotizing pneumonia)</li>
                        <li><strong>De-escalate:</strong> Stop antibiotics if procalcitonin <0.25 and no bacterial source identified. COVID-19 itself does NOT require antibiotics</li>
                        <li><strong>Bacterial co-infection uncommon:</strong> Only 8-15% of hospitalized COVID-19 patients have bacterial co-infection. Secondary bacterial pneumonia more common after 7-10 days (S. aureus, Pseudomonas, Enterobacterales)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Fluids:</strong> Conservative fluid strategy (avoid fluid overload - worsens ARDS). Target euvolemia. Use vasopressors early if shock</li>
                        <li><strong>Vasopressors:</strong> Norepinephrine first-line for shock. Target MAP ‚â•65mmHg</li>
                        <li><strong>Sedation/analgesia:</strong> Light sedation if mechanically ventilated (target RASS -1 to 0). Daily sedation interruption</li>
                        <li><strong>Neuromuscular blockade:</strong> Consider in severe ARDS (P/F <150) with ventilator dyssynchrony. Time-limited (‚â§48hr). Increased risk of ICU weakness</li>
                        <li><strong>Nutrition:</strong> Early enteral nutrition (within 48hr). NG/NJ tube if unable to tolerate PO</li>
                        <li><strong>Stress ulcer prophylaxis:</strong> PPI for mechanically ventilated patients</li>
                        <li><strong>Glycemic control:</strong> Target glucose 140-180mg/dL (avoid hypoglycemia). Hyperglycemia common with dexamethasone</li>
                    </ul>
                    
                    <p><span class="label">Therapies NO LONGER RECOMMENDED (Ineffective or Harmful):</span></p>
                    <ul>
                        <li><strong>Hydroxychloroquine:</strong> NO benefit. DO NOT USE</li>
                        <li><strong>Ivermectin:</strong> NO benefit. DO NOT USE</li>
                        <li><strong>Convalescent plasma:</strong> NO mortality benefit. Not recommended</li>
                        <li><strong>Vitamin C, vitamin D, zinc:</strong> No proven benefit in treatment (prevention data mixed)</li>
                        <li><strong>Azithromycin alone:</strong> NO antiviral effect. Only use if bacterial superinfection</li>
                    </ul>
                    
                    <p><span class="label">Infection Control:</span></p>
                    <ul>
                        <li><strong>Airborne + contact precautions:</strong> N95 respirator, gown, gloves, eye protection for all healthcare workers</li>
                        <li><strong>Negative pressure room:</strong> Preferred for hospitalized patients, especially if aerosol-generating procedures</li>
                        <li><strong>Duration of isolation:</strong> ‚â•10 days from symptom onset AND ‚â•24hr afebrile without antipyretics AND improvement in symptoms. Immunocompromised: ‚â•20 days (or negative PCR). Consult infection control</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Dexamethasone saves lives in severe COVID-19:</strong> 30% mortality reduction if requiring oxygen. Give to ALL patients on O‚ÇÇ. Don't give to mild cases not requiring O‚ÇÇ</li>
                    <li><strong>"Silent hypoxemia" is real:</strong> Patients can have O‚ÇÇ sat 70-80% with minimal dyspnea. Check pulse ox on ALL suspected COVID-19 patients</li>
                    <li><strong>Timing matters for progression:</strong> Most patients who worsen do so around days 7-10. Close monitoring during this window</li>
                    <li><strong>COVID-19 is a hypercoagulable state:</strong> Elevated D-dimer in 70%. High VTE risk (10-30%). Low threshold for CT-PE. Prophylactic anticoagulation for all hospitalized patients</li>
                    <li><strong>Bacterial co-infection is uncommon:</strong> Only 8-15% at admission. Don't reflexively start antibiotics. Check procalcitonin. Stop if <0.25 and no bacterial source</li>
                    <li><strong>Awake proning works:</strong> Have patients on HFNC lie prone 2-4hr multiple times daily. Improves oxygenation and may prevent intubation</li>
                    <li><strong>Most antivirals don't work in severe disease:</strong> Remdesivir has modest benefit. Paxlovid is for OUTPATIENTS only (within 5 days). Dexamethasone is the most important drug</li>
                    <li><strong>Avoid fluid overload:</strong> COVID-19 ARDS - keep patients dry. Aggressive fluids worsen respiratory status. Use vasopressors early if needed</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>O‚ÇÇ sat <90% despite supplemental O‚ÇÇ >6L/min</li>
                        <li>Need for HFNC, NIPPV, or mechanical ventilation</li>
                        <li>Rapidly increasing oxygen requirements (>2L/hr escalation)</li>
                        <li>RR >30/min with accessory muscle use</li>
                        <li>Altered mental status, confusion, obtundation</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>P/F ratio <200</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>O‚ÇÇ sat ‚â•92% on room air at rest and with ambulation (or baseline if chronic lung disease)</li>
                        <li>Afebrile ‚â•24hr without antipyretics</li>
                        <li>Respiratory rate <24/min at rest</li>
                        <li>Clinical improvement (resolving symptoms)</li>
                        <li>Completed minimum 5 days of treatment (dexamethasone)</li>
                        <li>Able to perform ADLs independently</li>
                        <li>Adequate home support, especially if elderly/high-risk</li>
                        <li>Follow-up arranged (telehealth or in-person within 3-7 days)</li>
                        <li>Pulse oximeter for home monitoring if marginal O‚ÇÇ sats</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute (During Hospitalization):</strong> ARDS (20-40% of hospitalized patients, high mortality), secondary bacterial/fungal infections (aspergillosis, candidemia after prolonged steroids/ICU stay), thromboembolic disease (PE, DVT, stroke, MI - 10-30% incidence), acute kidney injury (20-40%, poor prognosis), myocardial injury (troponin elevation, myocarditis, stress cardiomyopathy), arrhythmias, shock (septic, cardiogenic), multiorgan failure</p>
                    <p><strong>Subacute/Chronic (Post-Discharge):</strong> Post-COVID syndrome/"Long COVID" (30% of hospitalized patients - fatigue, dyspnea, cognitive impairment, lasting months), pulmonary fibrosis (after severe ARDS), chronic thromboembolic disease, persistent cardiac dysfunction (reduced EF, myocarditis sequelae), post-ICU syndrome (weakness, PTSD, depression), organizing pneumonia (can occur weeks post-infection)</p>
                    <p><strong>Follow-up:</strong> All hospitalized patients should have follow-up within 1-2 weeks post-discharge. Assess for persistent symptoms, oxygen needs, functional status. Chest imaging (CXR or CT) at 4-12 weeks if severe disease or persistent symptoms. Pulmonary function testing if dyspnea persists. Consider post-COVID clinic referral for prolonged symptoms</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 62: CLOSTRIDIOIDES DIFFICILE COLITIS -->
<!-- ============================================ -->
<div class="condition" id="cdiff">
    <h2>Clostridioides difficile Colitis</h2>
    <p><em>[Content to be added in Phase 4]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 63: UTI/PYELONEPHRITIS (COMPLICATED) -->
<!-- ============================================ -->
        <div id="pyelo" class="condition-page">
            <div class="page-header">
                <h2>58. UTI/PYELONEPHRITIS (COMPLICATED)</h2>
                <div class="subtitle">Upper Urinary Tract Infection ‚Ä¢ Sepsis Risk ‚Ä¢ Broad-Spectrum Antibiotics ‚Üí Narrow</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Pyelonephritis (Acute Kidney Infection):</span> Bacterial infection of the renal parenchyma and collecting system. Can lead to sepsis, renal abscess, or chronic kidney disease if untreated</p>
                    <p><span class="label">Complicated vs Uncomplicated UTI/Pyelonephritis:</span></p>
                    <ul>
                        <li><strong>UNCOMPLICATED:</strong> Otherwise healthy, non-pregnant women with no structural/functional urinary tract abnormalities. Typically outpatient management</li>
                        <li><strong>COMPLICATED (Requires Hospitalization):</strong> Men, pregnant women, structural abnormalities (stones, obstruction, neurogenic bladder, indwelling catheter), functional abnormalities (vesicoureteral reflux), immunocompromised, diabetes, renal transplant, recent instrumentation, recent antibiotic use, or signs of sepsis/severe illness</li>
                    </ul>
                    <p><span class="label">Classic Pyelonephritis Presentation:</span></p>
                    <ul>
                        <li><strong>Fever:</strong> High-grade (>38.5¬∞C), rigors, chills</li>
                        <li><strong>Flank pain:</strong> Unilateral or bilateral. Costovertebral angle (CVA) tenderness on exam (classic finding)</li>
                        <li><strong>Lower urinary tract symptoms:</strong> Dysuria, frequency, urgency (may or may not be present)</li>
                        <li><strong>GI symptoms:</strong> Nausea, vomiting (50%), anorexia</li>
                        <li><strong>Systemic:</strong> Malaise, myalgias, headache</li>
                    </ul>
                    <p><span class="label">Indications for Hospitalization (Complicated Pyelonephritis):</span></p>
                    <ul>
                        <li><strong>Sepsis/systemic illness:</strong> Hypotension, tachycardia, altered mental status, lactate elevation, signs of organ dysfunction</li>
                        <li><strong>Unable to tolerate PO:</strong> Severe nausea/vomiting, dehydration</li>
                        <li><strong>Pregnancy:</strong> ALL pregnant women with pyelonephritis should be hospitalized</li>
                        <li><strong>Urinary obstruction:</strong> Stones, mass, anatomic abnormality requiring intervention</li>
                        <li><strong>Immunocompromised:</strong> Diabetes, HIV, transplant, chronic steroids, neutropenia</li>
                        <li><strong>Recent hospitalization/antibiotics:</strong> Risk of resistant organisms (ESBL, Pseudomonas, Enterococcus)</li>
                        <li><strong>Indwelling catheter/recent instrumentation:</strong> Higher risk of complications</li>
                        <li><strong>Failed outpatient therapy:</strong> No improvement after 48-72hr of oral antibiotics</li>
                        <li><strong>Age extremes:</strong> Elderly (>65), frail patients with limited support</li>
                    </ul>
                    <p><span class="label">Severe Complications (Requiring ICU):</span></p>
                    <ul>
                        <li><strong>Urosepsis:</strong> Septic shock requiring vasopressors. High mortality if obstructed</li>
                        <li><strong>Renal abscess:</strong> Fever persisting >72hr despite antibiotics. Requires drainage</li>
                        <li><strong>Perinephric abscess:</strong> Extension beyond renal capsule. More severe than renal abscess</li>
                        <li><strong>Emphysematous pyelonephritis:</strong> Gas-forming infection (diabetes, obstruction). Life-threatening. May require nephrectomy</li>
                        <li><strong>Papillary necrosis:</strong> Ischemic necrosis of renal papillae (diabetes, sickle cell, NSAIDs, obstruction)</li>
                        <li><strong>Acute kidney injury:</strong> From infection, dehydration, sepsis</li>
                    </ul>
                    <p><span class="label">Common Pathogens:</span></p>
                    <ul>
                        <li><strong>E. coli (75-80%):</strong> Most common cause. Increasing rates of fluoroquinolone resistance, ESBL producers</li>
                        <li><strong>Klebsiella:</strong> ESBL-producing strains increasingly common</li>
                        <li><strong>Proteus mirabilis:</strong> Associated with struvite stones (triple phosphate)</li>
                        <li><strong>Enterococcus:</strong> Healthcare-associated infections, instrumentation, catheters. VRE risk</li>
                        <li><strong>Pseudomonas aeruginosa:</strong> Recent antibiotics, healthcare-associated, structural abnormalities</li>
                        <li><strong>Staphylococcus aureus:</strong> Hematogenous spread (bacteremia, endocarditis). Consider if bacteremia/endocarditis</li>
                        <li><strong>Candida species:</strong> Prolonged catheterization, recent antibiotics, diabetes, immunocompromised</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Urinalysis (UA) with Microscopy:</span></p>
                    <ul>
                        <li><strong>Pyuria:</strong> WBC >10/hpf (or >10 WBC/¬µL on dipstick). Highly sensitive but NOT specific (can be from any inflammation)</li>
                        <li><strong>Bacteriuria:</strong> Bacteria present on microscopy or dipstick positive for leukocyte esterase/nitrites</li>
                        <li><strong>WBC casts:</strong> SPECIFIC for pyelonephritis (upper tract infection). Indicates renal parenchymal involvement</li>
                        <li><strong>Hematuria:</strong> Microscopic or gross (present in 30-50%)</li>
                        <li><strong>Proteinuria:</strong> Mild (trace to 1+). NOT nephrotic range</li>
                        <li><strong>Nitrites:</strong> Positive if Gram-negative bacteria (E. coli, Klebsiella, Proteus). False negatives with Enterococcus, Pseudomonas, Staph</li>
                    </ul>
                    <p><span class="label">Urine Culture & Sensitivity (ESSENTIAL):</span></p>
                    <ul>
                        <li><strong>Obtain BEFORE starting antibiotics:</strong> Critical for identifying organism and tailoring therapy</li>
                        <li><strong>Collection:</strong> Clean-catch midstream (females: spread labia, males: retract foreskin). Catheterized specimen if unable to provide clean catch</li>
                        <li><strong>Interpretation:</strong> ‚â•10‚Åµ CFU/mL = significant bacteriuria. ‚â•10‚Å¥ CFU/mL acceptable in symptomatic patients or catheterized specimens</li>
                        <li><strong>Results:</strong> Preliminary at 24hr (Gram stain, growth), final at 48-72hr (organism, sensitivities)</li>
                    </ul>
                    <p><span class="label">Blood Cultures:</span> Obtain in ALL hospitalized patients with pyelonephritis. Bacteremia present in 10-30%. Positive cultures indicate higher risk of complications, metastatic infection. Draw 2 sets from separate sites before antibiotics</p>
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis (WBC >15,000 suggests severe infection). Bandemia (left shift) indicates bacterial infection</li>
                        <li><strong>CMP:</strong> BUN/Cr (assess renal function, AKI), electrolytes (hypokalemia from vomiting)</li>
                        <li><strong>Lactate:</strong> If sepsis suspected. >2mmol/L = tissue hypoperfusion. >4mmol/L = severe sepsis</li>
                        <li><strong>Procalcitonin:</strong> Elevated (>0.5ng/mL) in bacterial infection. Helps differentiate from colonization/contamination</li>
                    </ul>
                    <p><span class="label">Imaging (When to Obtain):</span></p>
                    <ul>
                        <li><strong>CT abdomen/pelvis with IV contrast (CT urogram):</strong> GOLD STANDARD for complicated pyelonephritis. Obtain if: (1) No improvement after 48-72hr of antibiotics, (2) Sepsis/severe illness, (3) Suspected obstruction (hydronephrosis), (4) Suspected abscess, (5) Recurrent pyelonephritis, (6) History of stones, (7) Immunocompromised, (8) Men (higher risk of structural abnormality), (9) Pregnancy (but use MRI instead - no radiation)</li>
                        <li><strong>Renal ultrasound:</strong> First-line in pregnancy. Can detect hydronephrosis, large stones, abscess. Less sensitive than CT</li>
                        <li><strong>MRI:</strong> Alternative to CT if contrast contraindicated or pregnancy. No radiation</li>
                    </ul>
                    <p><span class="label">Imaging Findings:</span></p>
                    <ul>
                        <li><strong>Pyelonephritis:</strong> Wedge-shaped areas of decreased enhancement (striated nephrogram), renal enlargement, perinephric fat stranding</li>
                        <li><strong>Obstruction:</strong> Hydronephrosis (dilated collecting system), hydroureter, obstructing stone</li>
                        <li><strong>Abscess:</strong> Focal fluid collection with rim enhancement (renal or perinephric)</li>
                        <li><strong>Emphysematous pyelonephritis:</strong> Gas within renal parenchyma (surgical emergency)</li>
                    </ul>
                    <p><span class="label">When NOT to Image Initially:</strong> Young, otherwise healthy women with classic pyelonephritis symptoms, normal vital signs, no prior history of stones/urologic issues, who are responding to antibiotics within 48-72hr. Can manage without imaging</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">Empiric Antibiotic Therapy (Start IMMEDIATELY after cultures):</span></p>
                    <ul>
                        <li><strong>FIRST-LINE (No Recent Antibiotics, No Risk Factors for Resistance):</strong></li>
                        <ul>
                            <li><strong>Ceftriaxone 1-2g IV daily:</strong> Excellent Gram-negative coverage. Safe, well-tolerated. Preferred first-line</li>
                            <li><strong>Alternatives:</strong> Cefepime 1-2g IV q8-12hr (broader, covers Pseudomonas), Ertapenem 1g IV daily (ESBL coverage, carbapenem-sparing), Piperacillin-tazobactam 3.375g IV q6hr or 4.5g IV q8hr (Pseudomonas coverage)</li>
                        </ul>
                        <li><strong>RISK FACTORS FOR RESISTANCE (Recent antibiotics within 3mo, healthcare-associated, recent hospitalization, known ESBL colonization):</strong></li>
                        <ul>
                            <li><strong>Piperacillin-tazobactam 4.5g IV q6hr:</strong> Covers ESBL (inoculum effect), Pseudomonas, Enterococcus</li>
                            <li><strong>Cefepime 2g IV q8hr:</strong> Broader than ceftriaxone, covers Pseudomonas</li>
                            <li><strong>Carbapenems (if high ESBL prevalence or documented ESBL):</strong> Meropenem 1g IV q8hr OR Imipenem 500mg IV q6hr. Reserve for documented ESBL or severe sepsis with high ESBL risk</li>
                        </ul>
                        <li><strong>ADD VANCOMYCIN 15-20mg/kg IV q8-12hr (target trough 15-20) IF:</strong></li>
                        <ul>
                            <li>Risk for Enterococcus (recent antibiotics, instrumentation, catheter, chronic kidney disease)</li>
                            <li>Gram-positive cocci in blood cultures</li>
                            <li>Severe sepsis/septic shock with unknown organism</li>
                        </ul>
                        <li><strong>ADD ANTIFUNGAL (Fluconazole 400mg IV daily) IF:</strong></li>
                        <ul>
                            <li>Yeast/Candida on UA or culture</li>
                            <li>Prolonged catheterization, diabetes, recent antibiotics, immunocompromised</li>
                            <li>Consider micafungin 100mg IV daily if candidemia or critically ill</li>
                        </ul>
                    </ul>
                    
                    <p><span class="label">Antibiotic De-escalation & Duration:</span></p>
                    <ul>
                        <li><strong>Step 1 (24-48hr):</strong> Review culture results. Narrow to targeted therapy based on sensitivities</li>
                        <li><strong>Step 2 (48-72hr):</strong> If clinically improved (afebrile, improved symptoms), transition to PO antibiotics to complete course</li>
                        <li><strong>PO Step-Down Options (based on sensitivities):</strong></li>
                        <ul>
                            <li><strong>Fluoroquinolones:</strong> Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily (excellent bioavailability, tissue penetration)</li>
                            <li><strong>Cephalosporins:</strong> Cefpodoxime 200mg PO BID OR Cefixime 400mg PO daily (3rd-generation oral cephalosporin)</li>
                            <li><strong>TMP-SMX:</strong> 1 DS (160/800mg) PO BID (if susceptible, no longer first-line due to resistance)</li>
                            <li><strong>Amoxicillin-clavulanate:</strong> 875/125mg PO BID (if susceptible, covers E. coli, Enterococcus)</li>
                        </ul>
                        <li><strong>Duration:</strong> 5-7 days for uncomplicated pyelonephritis responding to therapy. 10-14 days for complicated pyelonephritis (men, obstruction, abscess, bacteremia, immunocompromised, slow response)</li>
                        <li><strong>IV-to-PO criteria:</strong> Afebrile >24hr, able to tolerate PO, hemodynamically stable, clinical improvement, organism identified with PO-sensitive antibiotic available</li>
                    </ul>
                    
                    <p><span class="label">Management of Obstruction (URGENT):</span></p>
                    <ul>
                        <li><strong>Obstructed infected system = EMERGENCY:</strong> High mortality if not drained urgently. Antibiotics alone will FAIL</li>
                        <li><strong>Indications for urgent decompression:</strong> Hydronephrosis + fever/sepsis, obstructing stone with infection, pyonephrosis (pus in collecting system)</li>
                        <li><strong>Decompression options:</strong></li>
                        <ul>
                            <li><strong>Percutaneous nephrostomy tube (PCN):</strong> Placed by interventional radiology. Immediate drainage. Preferred if unstable, coagulopathy, or failed cystoscopy</li>
                            <li><strong>Ureteral stent (double-J stent):</strong> Placed by urology cystoscopically. Allows internal drainage. Preferred if stable and feasible</li>
                        </ul>
                        <li><strong>Timing:</strong> Decompression within 24hr of diagnosis. Don't delay for OR scheduling. Can be done at bedside (PCN) or in cysto suite</li>
                    </ul>
                    
                    <p><span class="label">Management of Abscess:</span></p>
                    <ul>
                        <li><strong>Renal abscess <3cm:</strong> May respond to antibiotics alone. Monitor closely with repeat imaging</li>
                        <li><strong>Renal abscess >3-5cm OR perinephric abscess:</strong> Requires drainage. Percutaneous drainage (IR-guided) vs surgical</li>
                        <li><strong>Emphysematous pyelonephritis:</strong> SURGICAL EMERGENCY. High mortality. Requires nephrectomy in severe cases. ICU, broad-spectrum antibiotics, urgent urology/surgery consult</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>IV fluids:</strong> NS or LR 1-2L bolus if dehydrated/septic, then 100-150mL/hr maintenance. Monitor urine output (goal >0.5mL/kg/hr)</li>
                        <li><strong>Antipyretics:</strong> Acetaminophen 650-1000mg q6hr PRN or ibuprofen 400-600mg q6hr PRN for fever/pain</li>
                        <li><strong>Antiemetics:</strong> Ondansetron 4-8mg IV q8hr PRN for nausea/vomiting</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ketorolac 15-30mg IV q6hr √ó 48hr max) or opioids (hydromorphone 0.5-1mg IV q4hr PRN) for flank pain</li>
                        <li><strong>Urinary alkalization (if Proteus):</strong> Potassium citrate or sodium bicarbonate. Helps prevent stone formation (Proteus produces urease ‚Üí alkaline urine ‚Üí struvite stones)</li>
                    </ul>
                    
                    <p><span class="label">Monitoring Response to Therapy:</span></p>
                    <ul>
                        <li><strong>Clinical improvement expected by 48-72hr:</strong> Defervescence, improved pain, stable vital signs</li>
                        <li><strong>If NOT improving by 72hr:</strong> Obtain imaging (CT) to rule out obstruction, abscess, resistant organism. Review culture sensitivities. Broaden antibiotics if needed</li>
                        <li><strong>Daily assessment:</strong> Vital signs, symptom improvement, tolerance of PO, urine output</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>WBC casts = pyelonephritis:</strong> Specific for upper tract infection (renal parenchymal involvement). Differentiates pyelonephritis from cystitis</li>
                    <li><strong>Obstructed infected kidney = EMERGENCY:</strong> Septic shock, high mortality if not drained within 24hr. Get imaging early if high suspicion. Call urology/IR urgently</li>
                    <li><strong>All hospitalized pyelo patients need blood AND urine cultures:</strong> 10-30% have bacteremia. Positive blood cultures = higher risk of complications, metastatic infection, longer treatment needed</li>
                    <li><strong>Don't rely on UA alone:</strong> Pyuria (WBCs in urine) is sensitive but NOT specific. Can be from STI, contamination, catheter, sterile inflammation. Must have positive culture to diagnose UTI</li>
                    <li><strong>CT if not improving in 72hr:</strong> Persistent fever despite antibiotics = obstruction, abscess, resistant organism, or wrong diagnosis. Don't wait - get imaging</li>
                    <li><strong>Start broad, narrow quickly:</strong> Empiric therapy should cover E. coli, Klebsiella, Enterococcus (if catheter/instrumentation). Narrow to targeted therapy at 24-48hr when cultures result</li>
                    <li><strong>Fluoroquinolones are NOT first-line anymore:</strong> High resistance rates (20-30% E. coli resistance). Use ceftriaxone first-line. Reserve fluoroquinolones for step-down therapy if susceptible</li>
                    <li><strong>Men with pyelonephritis need imaging:</strong> Higher risk of structural abnormality (stones, obstruction, prostate disease). Always image men, especially first episode</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>Lactate >4mmol/L or rising</li>
                        <li>Altered mental status, confusion</li>
                        <li>Acute kidney injury with oliguria (UOP <0.5mL/kg/hr)</li>
                        <li>Respiratory distress (ARDS from sepsis)</li>
                        <li>Emphysematous pyelonephritis (gas in kidney on imaging)</li>
                        <li>Obstructed infected system not responding to decompression</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile ‚â•24hr without antipyretics</li>
                        <li>Hemodynamically stable (no tachycardia, normal BP)</li>
                        <li>Tolerating PO intake and medications</li>
                        <li>Pain controlled with PO analgesics</li>
                        <li>Clinically improving (resolving flank pain, nausea)</li>
                        <li>Urine culture with identified organism and sensitivities</li>
                        <li>Appropriate PO antibiotic available to complete course (5-14 days)</li>
                        <li>No obstruction or abscess requiring intervention (or successfully treated)</li>
                        <li>Follow-up arranged (PCP or urology within 7-14 days)</li>
                        <li>Repeat UA/culture in 1-2 weeks if symptoms persist</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute:</strong> Urosepsis/septic shock (10-15%, high mortality if obstructed), acute kidney injury (15-25%, from ATN, obstruction, or direct infection), renal abscess (2-10%, requires drainage if >3-5cm), perinephric abscess (extension beyond Gerota's fascia, more severe), emphysematous pyelonephritis (gas-forming infection, diabetics, 20% mortality, may need nephrectomy), papillary necrosis (ischemic necrosis of papillae - diabetes, sickle cell, NSAIDs), bacteremia/metastatic infection (endocarditis, vertebral osteomyelitis, epidural abscess if S. aureus)</p>
                    <p><strong>Chronic:</strong> Recurrent pyelonephritis (10-30% within 1 year - investigate for structural abnormality, stones, vesicoureteral reflux), chronic pyelonephritis (repeated infections ‚Üí scarring ‚Üí CKD), renal scarring (especially children with VUR), hypertension (from renal damage), xanthogranulomatous pyelonephritis (chronic destructive process, mimics renal cell carcinoma on imaging)</p>
                    <p><strong>Special Populations:</strong> Pregnant women - risk of preterm labor, low birth weight (all pregnant women with pyelo should be hospitalized). Kidney transplant recipients - risk of graft dysfunction, rejection (treat aggressively). Diabetes - higher risk of emphysematous pyelonephritis, abscess, worse outcomes</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 64: SKIN/SOFT TISSUE INFECTIONS -->
<!-- ============================================ -->
        <div id="ssti" class="condition-page">
            <div class="page-header">
                <h2>59. SKIN/SOFT TISSUE INFECTIONS (CELLULITIS, NECROTIZING FASCIITIS)</h2>
                <div class="subtitle">Bacterial Skin Infection ‚Ä¢ Cellulitis vs Necrotizing ‚Ä¢ Early Surgery Saves Lives</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Cellulitis (Non-Necrotizing SSTI):</span> Acute bacterial infection of dermis and subcutaneous tissue. Characterized by erythema, warmth, swelling, tenderness. Usually unilateral lower extremity</p>
                    <p><span class="label">Cellulitis Presentation:</span></p>
                    <ul>
                        <li><strong>Erythema:</strong> Red, poorly demarcated area. Spreads centrifugally from entry site</li>
                        <li><strong>Warmth:</strong> Affected area warm to touch compared to surrounding skin</li>
                        <li><strong>Swelling:</strong> Edema of affected limb. May have peau d'orange appearance</li>
                        <li><strong>Tenderness:</strong> Pain with palpation. Pain usually proportionate to appearance</li>
                        <li><strong>Systemic symptoms (50%):</strong> Fever, chills, malaise. More common in severe cases</li>
                        <li><strong>Regional lymphadenopathy:</strong> Inguinal nodes (lower extremity cellulitis), axillary nodes (upper extremity)</li>
                        <li><strong>Lymphangitis (30%):</strong> Red linear streaking from site toward regional lymph nodes</li>
                    </ul>
                    <p><span class="label">Common Sites:</span> Lower extremities (60-70%), upper extremities (20%), face (5-10%), trunk (rare). Look for portal of entry (trauma, insect bite, tinea pedis, chronic venous insufficiency, lymphedema)</p>
                    <p><span class="label">Risk Factors for Cellulitis:</span> Tinea pedis (athlete's foot - toe web spaces), venous insufficiency, lymphedema (prior surgery, radiation), obesity, diabetes, peripheral vascular disease, chronic kidney disease, immunosuppression, IV drug use, prior cellulitis (recurrence rate 20-30%)</p>
                    
                    <p><span class="label">NECROTIZING SOFT TISSUE INFECTIONS (SURGICAL EMERGENCY):</span></p>
                    <ul>
                        <li><strong>Necrotizing Fasciitis (NF):</strong> Rapidly progressive infection of fascia and subcutaneous tissue with necrosis. High mortality (20-30%). REQUIRES URGENT SURGICAL DEBRIDEMENT</li>
                        <li><strong>Type I NF (Polymicrobial, 70-80%):</strong> Mixed aerobic + anaerobic bacteria (Streptococcus, E. coli, Bacteroides, Clostridium). Risk factors: diabetes, peripheral vascular disease, obesity, immunocompromised. Often post-surgical, perineal (Fournier's gangrene)</li>
                        <li><strong>Type II NF (Monomicrobial, 20-30%):</strong> Group A Streptococcus (Strep pyogenes) OR Staphylococcus aureus (including CA-MRSA). Younger, healthier patients. Post-trauma, varicella, NSAIDs use</li>
                    </ul>
                    <p><span class="label">RED FLAGS for Necrotizing Fasciitis (Think NF!):</span></p>
                    <ul>
                        <li><strong>Severe pain OUT OF PROPORTION to physical findings:</strong> CLASSIC. Severe pain but skin may look relatively benign initially</li>
                        <li><strong>Rapidly progressive erythema/swelling:</strong> Spreads within hours, not days</li>
                        <li><strong>Systemic toxicity:</strong> High fever, tachycardia (HR >120), hypotension, altered mental status, septic shock</li>
                        <li><strong>Skin changes (LATE findings):</strong> Dusky/purple discoloration, hemorrhagic bullae (blood-filled blisters), crepitus (gas in soft tissue), skin necrosis, anesthesia (nerve involvement)</li>
                        <li><strong>Wooden hard induration:</strong> Firm, boardlike feel to subcutaneous tissue</li>
                        <li><strong>Gas on imaging:</strong> Crepitus on exam or gas in soft tissue on X-ray/CT</li>
                        <li><strong>Lab abnormalities:</strong> WBC >15,000, lactate >4, Cr elevated, CK elevated (myonecrosis), severe metabolic acidosis, thrombocytopenia</li>
                    </ul>
                    <p><span class="label">LRINEC Score (Laboratory Risk Indicator for Necrotizing Fasciitis):</span> CRP ‚â•150mg/L (4 pts), WBC <15 or >25K (1-2 pts), Hgb <11g/dL (2 pts), Na <135mEq/L (2 pts), Cr >1.6mg/dL (2 pts), glucose >180mg/dL (1 pt). Score ‚â•6 = intermediate risk (50% PPV), ‚â•8 = high risk (75% PPV) for NF. HOWEVER: Clinical suspicion trumps score. Don't delay surgery for scoring</p>
                    
                    <p><span class="label">Other Necrotizing Infections:</span></p>
                    <ul>
                        <li><strong>Fournier's Gangrene:</strong> Necrotizing fasciitis of perineum/genitalia. Diabetics, elderly men. Polymicrobial. Extremely high mortality (20-40%)</li>
                        <li><strong>Clostridial Myonecrosis (Gas Gangrene):</strong> Clostridium perfringens. Post-trauma (crush injury), post-surgical, spontaneous (malignancy, immunocompromised). Crepitus, serosanguinous discharge, rapid progression. Very high mortality</li>
                        <li><strong>Streptococcal Toxic Shock Syndrome (STSS):</strong> Group A Strep with necrotizing fasciitis + shock + multiorgan failure. Mortality >30%</li>
                    </ul>
                    
                    <p><span class="label">Common Pathogens by Infection Type:</span></p>
                    <ul>
                        <li><strong>Non-purulent cellulitis:</strong> Œ≤-hemolytic Streptococcus (Group A, C, G most common), S. aureus (less common)</li>
                        <li><strong>Purulent cellulitis (abscess):</strong> S. aureus (including MRSA)</li>
                        <li><strong>Water exposure:</strong> Vibrio vulnificus (seawater), Aeromonas (freshwater)</li>
                        <li><strong>Animal bites:</strong> Pasteurella (cats/dogs), Capnocytophaga (dogs), Eikenella (human bites)</li>
                        <li><strong>Immunocompromised:</strong> Pseudomonas, fungal (Mucor, Rhizopus)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Clinical Diagnosis (Cellulitis):</span> Diagnosis is clinical based on characteristic findings (erythema, warmth, swelling, tenderness). Imaging and lab tests NOT routinely needed for uncomplicated cellulitis</p>
                    <p><span class="label">Labs (for Severe or Complicated Infections):</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Leukocytosis (WBC >15,000 suggests severe infection or necrotizing process). Bandemia (left shift). Thrombocytopenia (in sepsis, necrotizing infection)</li>
                        <li><strong>CMP:</strong> BUN/Cr (assess renal function, AKI in sepsis), glucose (hyperglycemia in stress/infection, especially diabetes)</li>
                        <li><strong>CRP:</strong> Elevated in bacterial infection. CRP >150mg/L increases suspicion for necrotizing infection (LRINEC score component)</li>
                        <li><strong>CK:</strong> Markedly elevated (>1,000) suggests myonecrosis (muscle involvement). Concerning for clostridial myonecrosis or necrotizing infection</li>
                        <li><strong>Lactate:</strong> >2mmol/L suggests hypoperfusion. >4mmol/L = severe sepsis. Associated with necrotizing infection</li>
                        <li><strong>Blood cultures:</strong> Obtain in: fever + systemic toxicity, immunocompromised, diabetic with severe infection, suspected necrotizing infection, hemodynamic instability. Positive in only 5-10% of cellulitis cases</li>
                    </ul>
                    <p><span class="label">Microbiology (Limited Role in Cellulitis):</span></p>
                    <ul>
                        <li><strong>Blood cultures:</strong> Low yield (5-10%) in uncomplicated cellulitis. Obtain if septic, immunocompromised, or severe infection</li>
                        <li><strong>Wound culture:</strong> Only if purulent drainage present (abscess). Swab of intact skin NOT useful (contaminated). Aspirate of abscess preferred</li>
                        <li><strong>Tissue biopsy/culture:</strong> Reserved for: (1) Failed empiric therapy, (2) Immunocompromised (atypical organisms), (3) Surgical debridement (send tissue for culture)</li>
                    </ul>
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>Plain X-ray:</strong> Limited utility. Can detect gas in soft tissue (crepitus), foreign body, osteomyelitis (if concern for bone involvement). ALWAYS obtain if crepitus present</li>
                        <li><strong>Ultrasound:</strong> Can differentiate cellulitis from abscess (hypoechoic fluid collection). Useful at bedside. "Cobblestoning" pattern suggests abscess. Can guide drainage</li>
                        <li><strong>CT with IV contrast:</strong> GOLD STANDARD for necrotizing infections. Obtain urgently if high suspicion for NF. Findings: gas in fascial planes, fascial thickening, fluid tracking along fascial planes, lack of enhancement (necrosis), muscle involvement</li>
                        <li><strong>MRI:</strong> Most sensitive for soft tissue infections. Can differentiate cellulitis, abscess, necrotizing fasciitis, myositis. Useful for deep infections, spinal/pelvic infections. NOT needed for routine cellulitis. Too slow if suspecting NF (do CT, then OR)</li>
                    </ul>
                    <p><span class="label">When to Image:</span></p>
                    <ul>
                        <li><strong>URGENT CT (within 1-2hr):</strong> Suspected necrotizing fasciitis (pain out of proportion, crepitus, skin necrosis, septic shock, LRINEC ‚â•6)</li>
                        <li><strong>Ultrasound:</strong> Suspected abscess (fluctuance, purulent drainage). Guide I&D</li>
                        <li><strong>X-ray:</strong> Crepitus on exam, foreign body, suspected osteomyelitis (bone tenderness, chronic wound)</li>
                        <li><strong>NO imaging needed:</strong> Uncomplicated cellulitis with clear diagnosis, no red flags</li>
                    </ul>
                    <p><span class="label">Surgical Exploration (Diagnostic & Therapeutic):</span> If high suspicion for NF but CT equivocal, proceed to OR for direct visualization. "Finger test" - blunt dissection along fascial planes. In NF, fascia separates easily ("dishwater" fluid, necrotic tissue, lack of bleeding). Don't delay surgery waiting for imaging</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">CELLULITIS (Non-Necrotizing) Management:</span></p>
                    <p><span class="label">Non-Purulent Cellulitis (No Abscess):</span></p>
                    <ul>
                        <li><strong>Mild (outpatient):</strong> Cephalexin 500mg PO QID √ó 5-7 days OR Dicloxacillin 500mg PO QID OR Cefadroxil 1g PO BID</li>
                        <li><strong>Moderate-Severe (hospitalized, no MRSA risk):</strong></li>
                        <ul>
                            <li><strong>Cefazolin 1-2g IV q8hr:</strong> First-line. Excellent Strep/MSSA coverage</li>
                            <li><strong>Alternatives:</strong> Nafcillin 1-2g IV q4-6hr, Oxacillin 1-2g IV q4-6hr</li>
                            <li><strong>Penicillin allergy (non-anaphylactic):</strong> Ceftriaxone 1-2g IV daily (low cross-reactivity)</li>
                            <li><strong>Penicillin anaphylaxis:</strong> Clindamycin 600-900mg IV q8hr OR Vancomycin 15-20mg/kg IV q8-12hr</li>
                        </ul>
                    </ul>
                    <p><span class="label">MRSA Risk Factors:</span> Prior MRSA infection, injection drug use, incarceration, close contact with MRSA-infected person, purulent drainage, abscess</p>
                    <p><span class="label">Purulent Cellulitis/Abscess OR MRSA Risk:</span></p>
                    <ul>
                        <li><strong>Abscess management:</strong> Incision & drainage (I&D) is PRIMARY treatment. Antibiotics are ADJUNCT if surrounding cellulitis or systemic symptoms</li>
                        <li><strong>Empiric MRSA coverage (if systemic symptoms or extensive cellulitis):</strong></li>
                        <ul>
                            <li><strong>Vancomycin 15-20mg/kg IV q8-12hr (target trough 15-20):</strong> First-line IV MRSA coverage</li>
                            <li><strong>Alternatives:</strong> Linezolid 600mg IV/PO q12hr, Daptomycin 4-6mg/kg IV daily (NOT for pneumonia), Ceftaroline 600mg IV q12hr</li>
                        </ul>
                        <li><strong>Outpatient MRSA coverage (mild purulent cellulitis post-I&D):</strong> TMP-SMX 1-2 DS PO BID + Cephalexin 500mg QID (for Strep coverage) OR Doxycycline 100mg PO BID OR Clindamycin 300-450mg PO TID</li>
                    </ul>
                    
                    <p><span class="label">NECROTIZING FASCIITIS Management (SURGICAL EMERGENCY):</span></p>
                    <p><span class="label">Step 1: URGENT SURGICAL CONSULTATION (STAT):</span> Surgery is LIFE-SAVING. Time to OR directly correlates with mortality. Goal: debridement within 6 hours of diagnosis. "Time is tissue, tissue is life"</p>
                    <p><span class="label">Step 2: Aggressive Resuscitation & Support:</span></p>
                    <ul>
                        <li><strong>IV fluids:</strong> 30mL/kg crystalloid bolus (NS or LR) within first hour. Continue aggressive fluid resuscitation. May need 4-10L in first 24hr</li>
                        <li><strong>Vasopressors:</strong> Norepinephrine if hypotensive despite fluids. Target MAP ‚â•65mmHg</li>
                        <li><strong>ICU admission:</strong> ALL suspected/confirmed NF patients</li>
                        <li><strong>Blood cultures:</strong> 2 sets before antibiotics</li>
                        <li><strong>Lactate:</strong> Follow serial lactates q2-4hr. Goal: lactate clearance (normalize within 6hr)</li>
                    </ul>
                    <p><span class="label">Step 3: BROAD-SPECTRUM Antibiotics (Start IMMEDIATELY, before OR):</span></p>
                    <ul>
                        <li><strong>Empiric Regimen for Necrotizing Fasciitis:</strong></li>
                        <ul>
                            <li><strong>Vancomycin 15-20mg/kg IV q8-12hr (for MRSA, Strep)</strong></li>
                            <li><strong>PLUS Piperacillin-tazobactam 4.5g IV q6hr (broad Gram-neg, anaerobic coverage)</strong></li>
                            <li><strong>PLUS Clindamycin 600-900mg IV q8hr (CRITICAL - stops toxin production in Group A Strep, covers anaerobes, penetrates necrotic tissue)</strong></li>
                        </ul>
                        <li><strong>Alternative regimens:</strong></li>
                        <ul>
                            <li>Vancomycin + Meropenem 1g IV q8hr + Clindamycin (if severe sepsis, immunocompromised)</li>
                            <li>Vancomycin + Ceftriaxone 2g IV daily + Metronidazole 500mg IV q8hr + Clindamycin</li>
                        </ul>
                        <li><strong>If Clostridial myonecrosis suspected (gas gangrene):</strong></li>
                        <ul>
                            <li><strong>Penicillin G 4 million units IV q4hr + Clindamycin 900mg IV q8hr</strong></li>
                            <li>Consider hyperbaric oxygen therapy (HBOT) if available (controversial, delays surgery)</li>
                        </ul>
                    </ul>
                    <p><span class="label">Step 4: Surgical Debridement (URGENT):</span></p>
                    <ul>
                        <li><strong>Aggressive wide debridement:</strong> Remove ALL necrotic tissue, fascia, muscle. May require multiple trips to OR (second-look within 24-48hr). Debride until healthy bleeding tissue</li>
                        <li><strong>Amputation:</strong> May be necessary for limb salvage if extensive involvement or refractory sepsis</li>
                        <li><strong>Fournier's gangrene:</strong> Debride perineum, scrotum. Diverting colostomy if rectal involvement</li>
                        <li><strong>Negative pressure wound therapy (VAC):</strong> After debridement. Promotes healing, facilitates subsequent closures</li>
                    </ul>
                    <p><span class="label">Step 5: Adjunctive Therapies (for Streptococcal Toxic Shock):</span></p>
                    <ul>
                        <li><strong>IVIG (Intravenous Immunoglobulin) 1-2g/kg IV once:</strong> Consider in Group A Strep NF with toxic shock syndrome. Neutralizes streptococcal superantigens. May reduce mortality (controversial, limited data)</li>
                        <li><strong>Clindamycin is ESSENTIAL:</strong> Inhibits toxin production (unlike Œ≤-lactams which increase toxin release as bacteria lyse)</li>
                    </ul>
                    
                    <p><span class="label">Duration of Antibiotics:</span></p>
                    <ul>
                        <li><strong>Uncomplicated cellulitis:</strong> 5-7 days (or until clinical improvement + afebrile 48hr)</li>
                        <li><strong>Severe cellulitis:</strong> 7-10 days</li>
                        <li><strong>Necrotizing fasciitis:</strong> 10-14 days (or longer until all necrotic tissue debrided and clinically improving)</li>
                    </ul>
                    
                    <p><span class="label">Supportive Care for Cellulitis:</span></p>
                    <ul>
                        <li><strong>Elevation:</strong> Elevate affected limb above heart level. Reduces edema, improves lymphatic drainage</li>
                        <li><strong>Mark borders:</strong> Outline erythema with marker to track progression/improvement</li>
                        <li><strong>Analgesia:</strong> NSAIDs (ibuprofen 400-600mg PO q6-8hr) or acetaminophen 650-1000mg q6hr. Avoid NSAIDs in Group A Strep (theoretical increased risk of NF progression - controversial)</li>
                        <li><strong>Treat predisposing conditions:</strong> Tinea pedis (antifungal cream), venous stasis (compression), edema (diuretics if CHF), optimize diabetes control</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>Pain out of proportion = necrotizing fasciitis until proven otherwise:</strong> Don't be fooled by benign-appearing skin. Severe pain with minimal skin findings is CLASSIC for NF. Call surgery immediately</li>
                    <li><strong>Crepitus = gas in tissue = EMERGENCY:</strong> Crepitus (crackling feel) on palpation indicates gas-forming organisms (Clostridium, Streptococcus, polymicrobial NF). Get imaging (X-ray or CT) and call surgery STAT</li>
                    <li><strong>Time to OR = survival in NF:</strong> Mortality increases 7-9% for every hour delay to surgery. Don't wait for CT if high clinical suspicion. "Stabilize in the OR, not the ICU"</li>
                    <li><strong>Clindamycin is critical in Group A Strep NF:</strong> Stops toxin production (Œ≤-lactams don't). Add clindamycin to all suspected NF empiric regimens</li>
                    <li><strong>Most cellulitis is streptococcal, not MRSA:</strong> Non-purulent cellulitis without risk factors ‚Üí don't need MRSA coverage. Cefazolin is appropriate. Reserve vancomycin for purulent infections or MRSA risk factors</li>
                    <li><strong>Blood cultures are low-yield in cellulitis:</strong> Only 5-10% positive. Reserve for severe cases, sepsis, immunocompromised</li>
                    <li><strong>Abscess = I&D, not just antibiotics:</strong> Antibiotics don't penetrate abscesses well. I&D is primary treatment. Antibiotics only needed if surrounding cellulitis or systemic symptoms</li>
                    <li><strong>LRINEC score helps but don't rely on it:</strong> Score ‚â•6 raises suspicion for NF. But NF can occur with low scores. Clinical gestalt and imaging trump the score</li>
                    <li><strong>Treat the source:</strong> Tinea pedis (athlete's foot) is the most common portal of entry for lower extremity cellulitis. Treat with topical antifungals to prevent recurrence</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>ANY suspicion for necrotizing fasciitis</li>
                        <li>Septic shock (hypotension requiring vasopressors)</li>
                        <li>Severe pain out of proportion to exam findings</li>
                        <li>Skin necrosis, hemorrhagic bullae, crepitus</li>
                        <li>Lactate >4mmol/L</li>
                        <li>Altered mental status, confusion</li>
                        <li>WBC >25,000 or <4,000</li>
                        <li>Rapidly progressive erythema (spreading over hours)</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Afebrile ‚â•24hr without antipyretics</li>
                        <li>Erythema improving (use marked borders to track)</li>
                        <li>Decreased swelling and tenderness</li>
                        <li>Able to ambulate (if lower extremity)</li>
                        <li>Tolerating PO antibiotics</li>
                        <li>Appropriate outpatient antibiotic regimen selected</li>
                        <li>Source control achieved (abscess drained, if applicable)</li>
                        <li>Follow-up arranged (PCP or ID within 3-5 days)</li>
                        <li>Patient educated on warning signs (worsening erythema, fever, systemic symptoms)</li>
                        <li>Predisposing factors addressed (tinea pedis treatment, wound care)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Cellulitis Complications:</strong> Abscess formation (requires I&D), bacteremia/sepsis (5-10%), lymphangitis (ascending infection toward lymph nodes), recurrent cellulitis (20-30% within 3 years - higher if lymphedema, chronic venous insufficiency, or tinea pedis not treated), chronic lymphedema (from repeated episodes damaging lymphatics), post-cellulitis venous thrombosis (thrombophlebitis)</p>
                    <p><strong>Necrotizing Fasciitis Complications:</strong> Septic shock (30-50%, high mortality), multiorgan failure (renal, respiratory, cardiac), limb loss (amputation needed in 20-30%), extensive scarring/disfigurement, chronic pain (neuropathic from nerve damage), functional impairment (prolonged rehabilitation), mortality (overall 20-30%, up to 50% if shock, 70-80% if clostridial myonecrosis)</p>
                    <p><strong>Prevention of Recurrent Cellulitis:</strong> Treat tinea pedis aggressively (topical or oral antifungals - terbinafine 250mg daily √ó 2-4 weeks), compression stockings for venous insufficiency/lymphedema, elevate legs regularly, emollients for dry/cracked skin, prompt treatment of skin injuries/wounds, consider antibiotic prophylaxis if ‚â•3 episodes per year (penicillin VK 250-500mg daily OR erythromycin 250mg daily)</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 65: TUBERCULOSIS (ACTIVE) -->
<!-- ============================================ -->
        <div id="tb" class="condition-page">
            <div class="page-header">
                <h2>60. TUBERCULOSIS (ACTIVE DISEASE)</h2>
                <div class="subtitle">Mycobacterium tuberculosis ‚Ä¢ Pulmonary + Extrapulmonary ‚Ä¢ Multi-Drug Regimen ‚Ä¢ Airborne Isolation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Tuberculosis (TB) Overview:</span> Infectious disease caused by Mycobacterium tuberculosis. Transmitted via airborne droplets. Can affect lungs (pulmonary TB, 80-85%) or other organs (extrapulmonary TB, 15-20%). Highly contagious. Public health emergency requiring isolation and reporting</p>
                    <p><span class="label">Latent TB vs Active TB:</span></p>
                    <ul>
                        <li><strong>Latent TB Infection (LTBI):</strong> Infected with M. tuberculosis but no symptoms, not contagious. Positive TST/IGRA, normal CXR. 5-10% lifetime risk of reactivation (higher if immunocompromised)</li>
                        <li><strong>Active TB Disease:</strong> Symptomatic, contagious (if pulmonary/laryngeal), abnormal CXR, positive AFB smear/culture. Requires multi-drug treatment</li>
                    </ul>
                    
                    <p><span class="label">PULMONARY TB (Most Common, 80-85%):</span></p>
                    <p><span class="label">Classic Presentation (Subacute/Chronic):</span></p>
                    <ul>
                        <li><strong>Chronic cough:</strong> ‚â•3 weeks duration. Initially dry, becomes productive. Hallmark symptom</li>
                        <li><strong>Hemoptysis:</strong> Blood-tinged sputum (25-50%). Can be massive in cavitary disease</li>
                        <li><strong>Constitutional symptoms ("B symptoms"):</strong> Fever (low-grade, evening), night sweats (drenching, change clothes), weight loss (>10% body weight), anorexia, malaise, fatigue</li>
                        <li><strong>Chest pain:</strong> Pleuritic (if pleural involvement), dull ache</li>
                        <li><strong>Dyspnea:</strong> If extensive disease, pleural effusion, or miliary TB</li>
                    </ul>
                    <p><span class="label">Physical Exam (Often Unremarkable):</span> May have rales/crackles over involved lung fields, dullness to percussion (consolidation, effusion), amphoric breath sounds (cavity), cachexia (advanced disease). Exam may be entirely normal despite extensive radiographic disease</p>
                    
                    <p><span class="label">EXTRAPULMONARY TB (15-20%, Higher in HIV/Immunocompromised):</span></p>
                    <ul>
                        <li><strong>Tuberculous Lymphadenitis (Most Common EPTB):</strong> Painless, firm, matted cervical or supraclavicular lymph nodes. May suppurate (cold abscess). Slow progression over weeks-months</li>
                        <li><strong>Pleural TB:</strong> Exudative pleural effusion. Pleuritic chest pain, dyspnea. Effusion often lymphocyte-predominant. Pleural fluid ADA (adenosine deaminase) >40 U/L highly suggestive</li>
                        <li><strong>Tuberculous Meningitis (TB Meningitis):</strong> Subacute headache, fever, altered mental status, cranial nerve palsies (especially CN VI), seizures. CSF: lymphocytic pleocytosis, low glucose, high protein. HIGH MORTALITY (20-50%) even with treatment</li>
                        <li><strong>Miliary TB (Disseminated):</strong> Hematogenous spread to multiple organs. High fever, weight loss, hepatosplenomegaly. CXR: bilateral diffuse miliary (millet seed) nodules (1-3mm). Often in HIV, elderly, immunocompromised</li>
                        <li><strong>Skeletal TB (Pott's Disease):</strong> Vertebral osteomyelitis (thoracic/lumbar spine most common). Back pain, paravertebral abscess, cord compression, gibbus deformity. MRI shows vertebral destruction, abscess</li>
                        <li><strong>Genitourinary TB:</strong> Dysuria, hematuria, flank pain, sterile pyuria. Can cause ureteral strictures, hydronephrosis, chronic kidney disease</li>
                        <li><strong>Pericardial TB:</strong> Pericardial effusion, tamponade, constrictive pericarditis (chronic). High mortality</li>
                        <li><strong>Abdominal TB:</strong> Peritonitis (ascites, abdominal pain), intestinal involvement (chronic diarrhea, obstruction, perforation). Ascites: high protein, lymphocyte-predominant, ADA >39 U/L</li>
                    </ul>
                    
                    <p><span class="label">High-Risk Populations:</span></p>
                    <ul>
                        <li><strong>HIV/AIDS (CD4 <200):</strong> 10-20x increased risk. More likely disseminated/extrapulmonary TB. TB accelerates HIV progression</li>
                        <li><strong>Immunosuppression:</strong> TNF-Œ± inhibitors (infliximab, adalimumab - screen before starting), transplant recipients, chronic steroids (‚â•15mg prednisone daily), chemotherapy</li>
                        <li><strong>Close contact:</strong> Household contact with active TB case (20-30% infection rate)</li>
                        <li><strong>Endemic areas:</strong> India, China, Southeast Asia, Sub-Saharan Africa, Latin America, Eastern Europe</li>
                        <li><strong>Congregate settings:</strong> Homeless shelters, prisons, nursing homes</li>
                        <li><strong>Healthcare workers:</strong> Exposure to undiagnosed TB patients</li>
                        <li><strong>Other:</strong> Diabetes, chronic kidney disease, silicosis, malignancy, malnutrition, alcoholism, IV drug use</li>
                    </ul>
                    
                    <p><span class="label">Drug-Resistant TB:</span></p>
                    <ul>
                        <li><strong>Multidrug-Resistant TB (MDR-TB):</strong> Resistant to isoniazid (INH) + rifampin (RIF). 5% of new cases globally. Higher in HIV, prior TB treatment. Requires ‚â•18-24 months treatment. Lower cure rates (50-70%)</li>
                        <li><strong>Extensively Drug-Resistant TB (XDR-TB):</strong> MDR-TB + resistance to fluoroquinolones + second-line injectable (amikacin, kanamycin, capreomycin). Very poor prognosis. Mortality 30-50%</li>
                        <li><strong>Risk factors for resistance:</strong> Prior TB treatment, non-adherence, endemic areas (Russia, South Africa, India), HIV co-infection, close contact with known drug-resistant case</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Tuberculin Skin Test (TST) & Interferon-Gamma Release Assay (IGRA):</span></p>
                    <ul>
                        <li><strong>Use:</strong> Screen for LATENT TB infection. NOT for diagnosis of active TB disease</li>
                        <li><strong>TST (Mantoux test):</strong> Intradermal injection. Read at 48-72hr. Induration ‚â•5mm (HIV, immunocompromised, close contact), ‚â•10mm (immigrants, healthcare workers, high-risk), ‚â•15mm (low-risk) considered positive</li>
                        <li><strong>IGRA (QuantiFERON-TB Gold, T-SPOT):</strong> Blood test. Measures T-cell response to TB antigens. Not affected by BCG vaccination (unlike TST). Preferred in BCG-vaccinated individuals</li>
                        <li><strong>Both can be negative in active TB:</strong> Anergy from severe illness, immunosuppression. Don't rule out active TB based on negative TST/IGRA alone</li>
                    </ul>
                    
                    <p><span class="label">Chest X-Ray (CXR) - Essential:</span></p>
                    <ul>
                        <li><strong>Primary TB (children, recent infection):</strong> Hilar/mediastinal lymphadenopathy, middle/lower lobe infiltrates, Ghon complex (calcified granuloma + lymph node)</li>
                        <li><strong>Reactivation TB (adults):</strong> Upper lobe infiltrates (apical/posterior segments), cavitary lesions (thin-walled cavities with air-fluid levels), fibronodular opacities, volume loss. Right upper lobe most common</li>
                        <li><strong>Miliary TB:</strong> Bilateral diffuse miliary (millet seed) nodules, 1-3mm</li>
                        <li><strong>Pleural effusion:</strong> Unilateral, moderate-large. May be only finding</li>
                        <li><strong>Advanced disease:</strong> Fibrosis, traction bronchiectasis, destroyed lung</li>
                    </ul>
                    <p><span class="label">Note:</span> CXR can be normal in early disease or extrapulmonary TB. HIV patients may have atypical or normal CXR despite active pulmonary TB</p>
                    
                    <p><span class="label">Sputum Testing (GOLD STANDARD for Pulmonary TB):</span></p>
                    <ul>
                        <li><strong>Collection:</strong> 3 separate sputum samples on 3 different days (ideally early morning, deep cough). If unable to produce sputum: induced sputum (nebulized hypertonic saline), bronchoscopy with BAL, gastric aspirate (children)</li>
                        <li><strong>AFB Smear (Acid-Fast Bacilli):</strong> Ziehl-Neelsen or Auramine-rhodamine stain. Results in 24hr. Positive = patient is infectious. Sensitivity 50-60% (needs 5,000-10,000 organisms/mL). Negative smear does NOT rule out TB. Semi-quantitative: 1+ to 4+ (higher = more infectious)</li>
                        <li><strong>Mycobacterial Culture (GOLD STANDARD):</strong> Solid media (Lowenstein-Jensen) takes 3-8 weeks. Liquid media (MGIT) faster (1-3 weeks). Definitive diagnosis. Allows drug susceptibility testing (DST). ESSENTIAL</li>
                        <li><strong>Nucleic Acid Amplification Test (NAAT):</strong></li>
                        <ul>
                            <li><strong>Xpert MTB/RIF (GeneXpert):</strong> Rapid PCR test (results in 2 hours). Detects M. tuberculosis + rifampin resistance. Sensitivity 80-90% (higher if smear-positive). WHO-recommended. Use on first sputum sample</li>
                            <li><strong>Cepheid Xpert MTB/RIF Ultra:</strong> Improved sensitivity (90-95%). Detects lower bacterial loads</li>
                        </ul>
                        <li><strong>Histopathology (if tissue available):</strong> Caseating granulomas with Langhans giant cells. Supportive but not specific (fungi, sarcoid can mimic)</li>
                    </ul>
                    
                    <p><span class="label">Extrapulmonary TB Diagnosis:</span></p>
                    <ul>
                        <li><strong>Pleural fluid:</strong> Lymphocyte-predominant exudate, ADA >40 U/L (90% sensitivity), low glucose, high protein. Pleural biopsy (caseating granulomas, culture) more sensitive than pleural fluid culture</li>
                        <li><strong>CSF (TB meningitis):</strong> Lymphocytic pleocytosis (50-500 cells/¬µL), low glucose (<45mg/dL or <50% serum), high protein (>100mg/dL). AFB smear low sensitivity (10-20%). Culture takes weeks. Large volume (6-10mL) increases yield. Xpert MTB/RIF on CSF (sensitivity 50-60%)</li>
                        <li><strong>Lymph node:</strong> Fine-needle aspiration (FNA) for AFB smear/culture, or excisional biopsy (caseating granulomas, culture)</li>
                        <li><strong>Urine:</strong> 3 early morning urine samples for AFB culture. Xpert MTB/RIF on urine (moderate sensitivity)</li>
                        <li><strong>Biopsy:</strong> Any suspected site (bone, peritoneum, pericardium) - send for AFB smear, culture, histopathology</li>
                    </ul>
                    
                    <p><span class="label">Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Anemia of chronic disease, lymphopenia (miliary TB), monocytosis</li>
                        <li><strong>CMP:</strong> Hyponatremia (SIADH in TB meningitis, miliary TB), elevated alkaline phosphatase (hepatic TB, drug toxicity)</li>
                        <li><strong>ESR/CRP:</strong> Elevated (nonspecific inflammatory markers)</li>
                        <li><strong>HIV test:</strong> Obtain in ALL TB patients. HIV/TB co-infection common</li>
                        <li><strong>Baseline LFTs:</strong> Before starting treatment (INH, RIF, PZA are hepatotoxic)</li>
                    </ul>
                    
                    <p><span class="label">Drug Susceptibility Testing (DST):</span> CRITICAL. Perform on all initial isolates. Guides therapy. Tests susceptibility to INH, RIF, PZA, ethambutol, fluoroquinolones, second-line drugs. Takes 2-4 weeks. Don't wait for results to start treatment. Adjust regimen when results available</p>
                    
                    <p><span class="label">Additional Testing:</span></p>
                    <ul>
                        <li><strong>CT chest:</strong> If CXR abnormal or high suspicion with normal CXR. Better delineates cavities, lymphadenopathy, complications</li>
                        <li><strong>Bronchoscopy with BAL:</strong> If unable to produce sputum, high suspicion with negative sputum, suspected endobronchial TB</li>
                        <li><strong>MRI spine:</strong> If Pott's disease suspected (back pain, neurologic deficits)</li>
                        <li><strong>Ophthalmology exam:</strong> Check for choroidal tubercles (miliary TB), before starting ethambutol (monitor for optic neuritis)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ISOLATION (CRITICAL - Airborne Precautions):</span></p>
                    <ul>
                        <li><strong>Airborne isolation room:</strong> Negative pressure, ‚â•6 air changes/hour, HEPA filtration. Private room. Door closed</li>
                        <li><strong>N95 respirators:</strong> For all healthcare workers entering room. Fit-tested. Surgical mask for patient when leaving room</li>
                        <li><strong>Duration:</strong> Until 3 consecutive negative AFB smears (usually 2-4 weeks of treatment) OR clinically improving + receiving appropriate therapy √ó 2 weeks. TB meningitis/extrapulmonary TB (non-pulmonary) generally NOT infectious - standard precautions</li>
                        <li><strong>Reporting:</strong> TB is REPORTABLE to public health department. Contact investigation for close contacts</li>
                    </ul>
                    
                    <p><span class="label">STANDARD TREATMENT REGIMEN (Drug-Susceptible TB):</span></p>
                    <p><span class="label">Intensive Phase (First 2 Months) - RIPE:</span></p>
                    <ul>
                        <li><strong>Rifampin (R): 600mg PO daily (or 10mg/kg/day, max 600mg)</strong></li>
                        <li><strong>Isoniazid (I/INH): 300mg PO daily (or 5mg/kg/day, max 300mg) + Pyridoxine (Vitamin B6) 25-50mg daily (prevent peripheral neuropathy)</strong></li>
                        <li><strong>Pyrazinamide (P/PZA): 1000-2000mg PO daily (weight-based: 40-55kg = 1000mg, 56-75kg = 1500mg, 76-90kg = 2000mg, >90kg = 2000mg)</strong></li>
                        <li><strong>Ethambutol (E): 800-1600mg PO daily (weight-based: 40-55kg = 800mg, 56-75kg = 1200mg, 76-90kg = 1600mg, >90kg = 1600mg)</strong></li>
                        <li><strong>Duration:</strong> 2 months (8 weeks) OR until AFB smear-negative and clinical improvement</li>
                    </ul>
                    
                    <p><span class="label">Continuation Phase (Next 4-7 Months) - Rifampin + Isoniazid:</span></p>
                    <ul>
                        <li><strong>Rifampin 600mg PO daily + Isoniazid 300mg PO daily (+ pyridoxine 25-50mg daily)</strong></li>
                        <li><strong>Duration:</strong></li>
                        <ul>
                            <li><strong>Uncomplicated pulmonary TB (cavitary disease, smear-negative at 2 months):</strong> 4 months continuation (total 6 months therapy)</li>
                            <li><strong>Cavitary disease + positive smear at 2 months:</strong> 7 months continuation (total 9 months)</li>
                            <li><strong>TB meningitis, miliary TB, bone/joint TB:</strong> 10-12 months continuation (total 12 months therapy)</li>
                        </ul>
                    </ul>
                    
                    <p><span class="label">Total Treatment Duration:</span></p>
                    <ul>
                        <li><strong>Drug-susceptible pulmonary TB:</strong> 6 months (2 months RIPE, then 4 months RI)</li>
                        <li><strong>Extrapulmonary TB (lymph nodes, pleura):</strong> 6 months (same as pulmonary)</li>
                        <li><strong>TB meningitis, miliary TB, bone/spine TB:</strong> 9-12 months</li>
                        <li><strong>MDR-TB:</strong> 18-24 months (complex regimen, consult ID/TB specialist)</li>
                    </ul>
                    
                    <p><span class="label">Directly Observed Therapy (DOT):</span> STRONGLY RECOMMENDED for all TB patients. Healthcare worker observes patient taking medications (3-5 times/week or daily). Ensures adherence, prevents resistance, improves cure rates. Public health department coordinates DOT</p>
                    
                    <p><span class="label">Alternative Dosing (Intermittent Therapy):</span> 3 times weekly dosing (after initial 2 weeks daily therapy) acceptable if DOT ensured. Used in resource-limited settings. Doses higher than daily dosing (consult ID/TB expert for dosing)</p>
                    
                    <p><span class="label">Drug-Resistant TB:</span></p>
                    <ul>
                        <li><strong>Rifampin-Resistant (RR-TB):</strong> Detected by Xpert MTB/RIF. Treat as MDR-TB until full DST results</li>
                        <li><strong>MDR-TB (INH + RIF resistant):</strong> Requires 4-5 drugs including fluoroquinolone (levofloxacin, moxifloxacin) + second-line injectable (amikacin, capreomycin) + pyrazinamide + ethambutol + others (linezolid, bedaquiline, delamanid). CONSULT ID/TB SPECIALIST. Treatment 18-24 months</li>
                        <li><strong>XDR-TB:</strong> MDR + resistant to fluoroquinolones + injectable. Very limited options. Newer drugs: bedaquiline, delamanid, pretomanid. MUST consult TB expert</li>
                    </ul>
                    
                    <p><span class="label">HIV Co-Infection (TB-HIV):</span></p>
                    <ul>
                        <li><strong>Start TB treatment immediately:</strong> Don't delay for ART initiation</li>
                        <li><strong>When to start ART:</strong></li>
                        <ul>
                            <li><strong>CD4 <50:</strong> Start ART within 2 weeks of starting TB treatment (balance immune reconstitution vs TB treatment)</li>
                            <li><strong>CD4 >50:</strong> Start ART within 8 weeks of TB treatment</li>
                            <li><strong>TB meningitis:</strong> DELAY ART until 8 weeks (risk of IRIS with neurologic worsening)</li>
                        </ul>
                        <li><strong>Drug interactions:</strong> Rifampin induces CYP450 (decreases ART levels). Integrase inhibitors (dolutegravir, raltegravir) or efavirenz preferred. Avoid protease inhibitors with rifampin. Consider rifabutin (less CYP induction) instead of rifampin if needed</li>
                    </ul>
                    
                    <p><span class="label">TB Meningitis (Special Considerations):</span></p>
                    <ul>
                        <li><strong>Adjunctive corticosteroids:</strong> Dexamethasone 0.3-0.4mg/kg/day IV √ó 4 weeks, then taper over 4 weeks. Reduces mortality and disability. START WITH FIRST DOSE OF TB DRUGS</li>
                        <li><strong>Duration:</strong> 9-12 months total treatment</li>
                        <li><strong>Monitor:</strong> Repeat lumbar punctures if worsening symptoms (hydrocephalus, increased ICP). Shunt if needed</li>
                    </ul>
                    
                    <p><span class="label">Monitoring During Treatment:</span></p>
                    <ul>
                        <li><strong>Clinical:</strong> Weekly initially, then monthly. Assess adherence, symptoms, side effects</li>
                        <li><strong>Sputum smears:</strong> Monthly until 2 consecutive negatives, then at end of treatment</li>
                        <li><strong>LFTs:</strong> Baseline, then monthly (or sooner if symptoms of hepatitis). Hold drugs if ALT >3√ó ULN with symptoms or >5√ó ULN asymptomatic</li>
                        <li><strong>CMP:</strong> Monitor creatinine (ethambutol cleared renally), uric acid (pyrazinamide causes hyperuricemia)</li>
                        <li><strong>Visual acuity & color vision:</strong> Monthly (ethambutol optic neuritis). Baseline ophthalmology exam</li>
                        <li><strong>CXR:</strong> At 2 months, end of treatment, then as needed. Improvement may lag clinical improvement</li>
                    </ul>
                    
                    <p><span class="label">Treatment Failure:</span> Persistent positive sputum cultures after 4 months of treatment. Suggests drug resistance, non-adherence, malabsorption. Repeat DST. Consult ID/TB specialist. Do NOT add single drug to failing regimen (creates resistance)</p>
                    
                    <p><span class="label">Supportive Care:</span></p>
                    <ul>
                        <li><strong>Nutrition:</strong> High-calorie, high-protein diet. Many patients malnourished</li>
                        <li><strong>Diabetes control:</strong> Rifampin decreases efficacy of oral hypoglycemics. May need insulin</li>
                        <li><strong>Symptom management:</strong> Cough suppressants, antipyretics, analgesics PRN</li>
                        <li><strong>Contact investigation:</strong> Public health screens close contacts (TST/IGRA, CXR). Treat LTBI if indicated</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearl-box">
                <div class="pearl-title">üîë TEACHING PEARLS</div>
                <ul>
                    <li><strong>TB is "the great mimicker":</strong> Can present as pneumonia, lymphoma, cancer, chronic meningitis, osteomyelitis. High index of suspicion in endemic areas, immunocompromised, chronic symptoms</li>
                    <li><strong>Don't wait for culture to treat:</strong> Cultures take weeks. Start treatment based on clinical/radiographic suspicion and positive AFB smear or Xpert. Adjust when DST results available</li>
                    <li><strong>Never add a single drug to a failing regimen:</strong> Creates resistance. If treatment failing, add ‚â•2 new drugs and consult TB specialist</li>
                    <li><strong>Rifampin turns body fluids orange:</strong> Warn patients (urine, tears, sweat). Contact lenses permanently stained. Not harmful</li>
                    <li><strong>INH peripheral neuropathy is preventable:</strong> Give pyridoxine (vitamin B6) 25-50mg daily with INH to ALL patients. Essential in diabetics, HIV, pregnant women, alcoholics, malnourished</li>
                    <li><strong>Ethambutol optic neuritis is dose-dependent:</strong> Monitor visual acuity and color vision monthly. Mostly reversible if caught early. Higher risk if renal insufficiency (dose-adjust) or >2 months use</li>
                    <li><strong>TB-HIV co-infection is deadly but treatable:</strong> Start TB treatment first, then ART (within 2-8 weeks depending on CD4). Watch for IRIS (immune reconstitution inflammatory syndrome) - paradoxical worsening when starting ART</li>
                    <li><strong>TB meningitis needs steroids:</strong> Dexamethasone reduces mortality and disability. Start with first dose of TB drugs. Delay ART until 8 weeks (risk of IRIS neurologic worsening)</li>
                    <li><strong>Sputum cultures must be done:</strong> Only way to confirm diagnosis and perform drug susceptibility testing. Negative smears don't rule out TB (sensitivity only 50-60%). Culture is gold standard</li>
                    <li><strong>Adherence is everything:</strong> Non-adherence ‚Üí treatment failure ‚Üí drug resistance ‚Üí MDR-TB/XDR-TB. DOT (directly observed therapy) is highly effective and recommended for ALL patients</li>
                </ul>
            </div>
            
            <div class="two-column">
                <div class="box">
                    <div class="box-title">‚ö†Ô∏è ESCALATE TO ICU IF:</div>
                    <ul>
                        <li>Respiratory failure requiring mechanical ventilation (extensive TB pneumonia, ARDS)</li>
                        <li>TB meningitis with decreased consciousness (GCS <13), increased ICP, neurologic deterioration</li>
                        <li>Hemodynamically unstable (septic shock rare but possible)</li>
                        <li>Massive hemoptysis (>200mL in 24hr)</li>
                        <li>Drug-induced hepatotoxicity (ALT >10√ó ULN, coagulopathy, encephalopathy)</li>
                        <li>Severe IRIS (immune reconstitution inflammatory syndrome) in HIV patients starting ART</li>
                    </ul>
                </div>
                
                <div class="box">
                    <div class="box-title">‚úì DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Clinically stable and improving (no fever, improved symptoms)</li>
                        <li>Tolerating PO medications</li>
                        <li>3 consecutive negative AFB smears (pulmonary TB) OR clinically improving on treatment √ó 2 weeks</li>
                        <li>Appropriate outpatient TB regimen prescribed (DOT arranged)</li>
                        <li>Public health notified (contact investigation underway)</li>
                        <li>Close follow-up arranged (ID clinic, public health DOT program)</li>
                        <li>Patient counseled on adherence, side effects, infectivity</li>
                        <li>Isolation precautions no longer needed (3 negative smears or appropriate duration on therapy)</li>
                        <li>Directly Observed Therapy (DOT) arranged through public health</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">COMPLICATIONS TO MONITOR</div>
                <div class="section-content">
                    <p><strong>Acute (During Active Disease):</strong> Respiratory failure (extensive pneumonia, ARDS), massive hemoptysis (eroded pulmonary artery - requires bronchial artery embolization or surgery), pneumothorax (cavitary disease rupture), empyema (pleural space infection), pericardial tamponade (pericardial TB), spinal cord compression (Pott's disease with epidural abscess), obstructive hydrocephalus (TB meningitis - may need shunt), ARDS (miliary TB, severe pneumonia)</p>
                    <p><strong>Treatment-Related Complications:</strong></p>
                    <ul>
                        <li><strong>Hepatotoxicity (INH, RIF, PZA):</strong> Transaminitis (10-20%), symptomatic hepatitis (1-3%). Monitor LFTs monthly. Hold drugs if ALT >5√ó ULN or >3√ó ULN with symptoms. Rechallenge drugs sequentially when LFTs normalize. INH most hepatotoxic</li>
                        <li><strong>Peripheral neuropathy (INH):</strong> Prevented by pyridoxine (vitamin B6). Higher risk in diabetes, HIV, alcohol, malnutrition</li>
                        <li><strong>Optic neuritis (Ethambutol):</strong> Decreased visual acuity, red-green color blindness. Monitor monthly. Usually reversible if caught early. Dose-adjust in renal insufficiency</li>
                        <li><strong>Hyperuricemia/gout (Pyrazinamide):</strong> Elevated uric acid. Treat with NSAIDs, colchicine. Allopurinol if recurrent gout (but wait until after PZA phase)</li>
                        <li><strong>Thrombocytopenia (Rifampin):</strong> Immune-mediated. Stop rifampin. Can use rifabutin instead</li>
                        <li><strong>Orange discoloration (Rifampin):</strong> Body fluids (urine, tears, sweat) turn orange-red. Harmless. Warn patients (contact lenses stained)</li>
                        <li><strong>Drug interactions (Rifampin):</strong> CYP450 inducer. Decreases levels of: oral contraceptives (use barrier method), warfarin, anticonvulsants, antiretrovirals, immunosuppressants</li>
                        <li><strong>IRIS (Immune Reconstitution Inflammatory Syndrome):</strong> Paradoxical worsening when starting ART in HIV patients on TB treatment. Inflammatory reaction to dead/dying TB. Can be severe (lymph node enlargement, worsening infiltrates, fever). Manage with NSAIDs or steroids. Don't stop ART or TB drugs</li>
                    </ul>
                    <p><strong>Chronic (Post-Treatment):</strong> Chronic pulmonary sequelae (fibrosis, bronchiectasis, destroyed lung, aspergilloma in old cavities - hemoptysis risk), chronic pericarditis (constrictive - may need pericardiectomy), chronic meningitis sequelae (hydrocephalus, seizures, cranial nerve palsies, cognitive impairment), skeletal deformities (gibbus deformity from vertebral collapse), chronic kidney disease (GU TB), relapse (5% after adequate treatment - usually within 1 year, higher if HIV, drug-resistant TB, non-adherence)</p>
                    <p><strong>Prevention:</strong> Treat LTBI (latent TB infection) in high-risk individuals: INH 300mg daily √ó 9 months OR rifampin 600mg daily √ó 4 months OR INH-rifapentine weekly √ó 3 months (3HP). BCG vaccine (limited efficacy in adults, not used in US). Infection control (airborne precautions, N95 respirators). Contact investigation and treatment of close contacts</p>
                </div>
            </div>
            
            <a href="#toc" class="back-to-top">‚Üë Back to Table of Contents</a>
        </div>

<!-- ============================================ -->
<!-- CONDITION 66: HIV/AIDS COMPLICATIONS -->
<!-- ============================================ -->
        <div id="hiv-aids" class="condition-page">
            <div class="page-header">
                <h2>66. HIV/AIDS COMPLICATIONS</h2>
                <div class="subtitle">Immunodeficiency ‚Ä¢ Opportunistic Infections ‚Ä¢ Malignancies ‚Ä¢ ART Initiation</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">HIV Disease Stages (CDC Classification):</span></p>
                    <ul>
                        <li><strong>Stage 1 (Acute HIV):</strong> Acute retroviral syndrome 2-4 weeks post-exposure. Fever, pharyngitis, rash, lymphadenopathy, myalgia. High viral load, CD4 normal/transiently decreased. Many asymptomatic</li>
                        <li><strong>Stage 2 (Chronic/Asymptomatic):</strong> CD4 ‚â•200. No AIDS-defining conditions. Can last years without treatment</li>
                        <li><strong>Stage 3 (AIDS):</strong> CD4 <200 OR presence of AIDS-defining condition (regardless of CD4). High risk for opportunistic infections, malignancies</li>
                    </ul>
                    
                    <p><span class="label">Common Hospitalization Scenarios:</span></p>
                    <ul>
                        <li><strong>Newly diagnosed HIV with acute illness:</strong> Patient presents with opportunistic infection, found to have HIV during workup</li>
                        <li><strong>Known HIV, poor adherence to ART:</strong> Immunosuppression progresses ‚Üí opportunistic infections</li>
                        <li><strong>Immune reconstitution inflammatory syndrome (IRIS):</strong> Paradoxical worsening after starting ART (usually 2 weeks-3 months after ART initiation)</li>
                        <li><strong>ART-related complications:</strong> Drug toxicity, interactions, side effects</li>
                    </ul>
                    
                    <p><span class="label">OPPORTUNISTIC INFECTIONS BY CD4 COUNT:</span></p>
                    <p><span class="label">CD4 <200 cells/¬µL:</span></p>
                    <ul>
                        <li><strong>Pneumocystis jirovecii pneumonia (PCP):</strong> Subacute onset (days-weeks). Fever, nonproductive cough, dyspnea on exertion, hypoxemia. CXR: diffuse bilateral interstitial infiltrates or normal. LDH elevated. Dx: sputum/BAL for DFA/PCR. Rx: TMP-SMX high-dose 15-20mg/kg/day (TMP component) + prednisone if PaO2 <70 or A-a gradient >35</li>
                        <li><strong>Candida esophagitis:</strong> Odynophagia, dysphagia, retrosternal pain. Thrush often present. Dx: endoscopy shows white plaques. Rx: fluconazole 200-400mg daily √ó 14-21 days</li>
                        <li><strong>Toxoplasma encephalitis:</strong> Headache, confusion, focal neurologic deficits, seizures. MRI: multiple ring-enhancing lesions (basal ganglia, corticomedullary junction). Dx: clinical + imaging, serum toxoplasma IgG positive. Rx: pyrimethamine + sulfadiazine + leucovorin</li>
                        <li><strong>Progressive multifocal leukoencephalopathy (PML):</strong> JC virus reactivation. Rapidly progressive neurologic decline, weakness, ataxia, visual changes. MRI: non-enhancing white matter lesions. NO treatment except ART. 30-50% mortality</li>
                    </ul>
                    
                    <p><span class="label">CD4 <100 cells/¬µL:</span></p>
                    <ul>
                        <li><strong>Cryptococcal meningitis:</strong> Subacute headache, fever, altered mental status. Minimal meningismus. Dx: LP shows elevated opening pressure (>25cm H2O), low glucose, high protein, positive CSF cryptococcal antigen (>95% sensitive). India ink 50% sensitive. Rx: amphotericin B + flucytosine √ó 2 weeks, then fluconazole consolidation. Therapeutic LP if OP >25cm</li>
                        <li><strong>CMV retinitis:</strong> Painless vision loss, floaters. Fundoscopy: "pizza pie" appearance (hemorrhages + exudates). Dx: dilated eye exam. Rx: ganciclovir or foscarnet</li>
                        <li><strong>CMV colitis/esophagitis:</strong> Diarrhea (often bloody), abdominal pain. Dx: colonoscopy with biopsy (CMV inclusion bodies). Rx: ganciclovir</li>
                    </ul>
                    
                    <p><span class="label">CD4 <50 cells/¬µL:</span></p>
                    <ul>
                        <li><strong>Mycobacterium avium complex (MAC/MAI):</strong> Disseminated infection. High fever, night sweats, weight loss, diarrhea, hepatosplenomegaly, anemia. Blood cultures grow MAC (takes 2-4 weeks). Rx: azithromycin + ethambutol</li>
                        <li><strong>CMV disease:</strong> See above</li>
                    </ul>
                    
                    <p><span class="label">ANY CD4 COUNT (but more common with low CD4):</span></p>
                    <ul>
                        <li><strong>Tuberculosis (TB):</strong> Can occur at any CD4. More likely extrapulmonary/disseminated with CD4 <200. Chronic cough, fever, night sweats, weight loss. AFB smear/culture. Rx: RIPE therapy</li>
                        <li><strong>Bacterial pneumonia (S. pneumoniae, H. influenzae):</strong> Increased risk even with preserved CD4. Acute onset fever, productive cough, infiltrate on CXR. Rx: standard CAP antibiotics</li>
                        <li><strong>Kaposi sarcoma (KS):</strong> HHV-8 associated. Violaceous skin lesions, can involve GI tract, lungs. Dx: biopsy. Rx: ART (immune reconstitution treats KS), chemotherapy if severe</li>
                        <li><strong>Non-Hodgkin lymphoma (NHL):</strong> Primary CNS lymphoma (ring-enhancing mass, single lesion - ddx from toxo). Rx: chemo + ART</li>
                    </ul>
                    
                    <p><span class="label">IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS):</span></p>
                    <ul>
                        <li><strong>Definition:</strong> Paradoxical worsening of infection symptoms after starting ART due to recovering immune system. Typically occurs 2 weeks - 3 months after ART start</li>
                        <li><strong>Presentation:</strong> New fever, worsening symptoms of prior infection (e.g., enlarging TB lymph nodes, worsening PCP infiltrates), new organ dysfunction</li>
                        <li><strong>Common IRIS triggers:</strong> Mycobacterial infections (TB, MAC), cryptococcal meningitis, CMV, PCP, hepatitis B/C</li>
                        <li><strong>Management:</strong> Continue ART (do NOT stop). Treat underlying infection. NSAIDs or corticosteroids for severe symptoms</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">HIV Testing (if newly diagnosed):</span></p>
                    <ul>
                        <li><strong>4th generation Ag/Ab combo test:</strong> Detects HIV-1/2 antibodies + p24 antigen. Positive as early as 2-3 weeks post-exposure</li>
                        <li><strong>Confirm with HIV-1/HIV-2 differentiation assay</strong></li>
                        <li><strong>HIV viral load (HIV RNA PCR):</strong> Quantifies virus. Used for monitoring, not diagnosis (can be falsely positive)</li>
                    </ul>
                    
                    <p><span class="label">Baseline Labs (New Diagnosis or Hospitalization):</span></p>
                    <ul>
                        <li><strong>CD4 count:</strong> Determines stage, guides prophylaxis, predicts OI risk</li>
                        <li><strong>HIV viral load:</strong> Baseline for monitoring ART response</li>
                        <li><strong>CBC with diff:</strong> Anemia, thrombocytopenia, leukopenia common</li>
                        <li><strong>CMP:</strong> Renal function (ART dosing), LFTs (hepatotoxicity risk, coinfection)</li>
                        <li><strong>Hepatitis B and C serology:</strong> High coinfection rates. HBV/HCV accelerate HIV progression</li>
                        <li><strong>Syphilis (RPR/VDRL):</strong> High coinfection rates, atypical presentations common</li>
                        <li><strong>Toxoplasma IgG:</strong> If positive, at risk for reactivation when CD4 <100</li>
                        <li><strong>CMV IgG:</strong> If positive, risk for reactivation when CD4 <50</li>
                        <li><strong>Glucose, lipid panel:</strong> Baseline for metabolic complications of ART</li>
                        <li><strong>Pregnancy test (if applicable):</strong> ART regimen selection differs in pregnancy</li>
                    </ul>
                    
                    <p><span class="label">Resistance Testing:</span></p>
                    <ul>
                        <li><strong>HIV genotype:</strong> Check for drug resistance mutations BEFORE starting ART. Guides regimen selection</li>
                    </ul>
                    
                    <p><span class="label">Workup for Suspected Opportunistic Infection:</span></p>
                    <ul>
                        <li><strong>If respiratory symptoms:</strong> CXR, pulse ox/ABG, sputum for bacterial culture, AFB, PCP (DFA/PCR), fungal culture. Consider CT chest if CXR nondiagnostic. Blood cultures</li>
                        <li><strong>If neurologic symptoms:</strong> MRI brain with contrast (ring-enhancing lesions: toxo vs lymphoma vs abscess). LP if meningitis suspected (opening pressure, cell count, protein, glucose, Gram stain, bacterial/fungal cultures, cryptococcal Ag, VDRL). Serum cryptococcal Ag (very sensitive for disseminated crypto)</li>
                        <li><strong>If GI symptoms:</strong> Stool studies (C. diff, bacterial pathogens, ova/parasites, Cryptosporidium, Microsporidium). Consider endoscopy/colonoscopy for persistent diarrhea or GI bleeding (CMV, KS, lymphoma)</li>
                        <li><strong>If fever without source:</strong> Blood cultures (bacterial and mycobacterial), serum cryptococcal Ag, CMV PCR, CT chest/abdomen/pelvis. Consider bone marrow biopsy if pancytopenia</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">ANTIRETROVIRAL THERAPY (ART) - WHEN TO START:</span></p>
                    <ul>
                        <li><strong>START ART AS SOON AS POSSIBLE in all patients with HIV</strong> regardless of CD4 count (2023 DHHS guidelines)</li>
                        <li><strong>Timing in hospitalized patients:</strong>
                            <ul>
                                <li>If NO active opportunistic infection: Start ART immediately (within days)</li>
                                <li>If active OI present: Start OI treatment first, then ART within 2 weeks (exceptions below)</li>
                                <li>DELAY ART if: (1) TB meningitis (wait 8 weeks), (2) cryptococcal meningitis (wait 4-6 weeks after starting antifungals AND CSF sterilized), (3) other CNS infections where IRIS could cause herniation</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">INITIAL ART REGIMENS (Treatment-Naive):</span></p>
                    <p><strong>Preferred regimens (2023 DHHS):</strong></p>
                    <ul>
                        <li><strong>Biktarvy (bictegravir/TAF/FTC):</strong> 1 tablet PO daily. Well-tolerated, high barrier to resistance, minimal drug interactions. Most common first-line choice</li>
                        <li><strong>Dovato (dolutegravir/lamivudine):</strong> 1 tablet PO daily. Two-drug regimen, less nephrotoxicity. Cannot use if: HBV coinfection, HIV RNA >500,000, or before resistance testing</li>
                        <li><strong>Triumeq (dolutegravir/abacavir/lamivudine):</strong> 1 tablet PO daily. REQUIRES HLA-B*5701 testing (abacavir hypersensitivity). Avoid if high cardiovascular risk</li>
                        <li><strong>Symtuza (darunavir/cobicistat/TAF/FTC):</strong> 1 tablet PO daily with food. Protease inhibitor-based. Good for high viral loads or suspected resistance</li>
                    </ul>
                    
                    <p><span class="label">ART in Special Populations:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong> Start immediately. Preferred: dolutegravir-based or darunavir/ritonavir-based regimens. Avoid efavirenz (teratogenic)</li>
                        <li><strong>Chronic kidney disease (CrCl <50):</strong> Avoid tenofovir disoproxil fumarate (TDF). Use tenofovir alafenamide (TAF) instead, or non-tenofovir regimens</li>
                        <li><strong>Chronic hepatitis B coinfection:</strong> Must use ART regimen that treats both (tenofovir + emtricitabine or lamivudine). If stopping ART, monitor for HBV flare</li>
                        <li><strong>TB coinfection:</strong> Drug interactions with rifamycins. Use dolutegravir 50mg BID (instead of daily) if on rifampin, or use efavirenz-based regimen</li>
                    </ul>
                    
                    <p><span class="label">OPPORTUNISTIC INFECTION PROPHYLAXIS:</span></p>
                    <p><strong>CD4 <200:</strong></p>
                    <ul>
                        <li><strong>PCP prophylaxis:</strong> TMP-SMX DS 1 tablet daily (or 3x/week). Alternative: dapsone 100mg daily, atovaquone 1500mg daily, or inhaled pentamidine 300mg monthly</li>
                        <li><strong>Toxoplasmosis prophylaxis (if Toxo IgG positive):</strong> TMP-SMX DS provides dual prophylaxis for PCP + Toxo</li>
                    </ul>
                    <p><strong>CD4 <100:</strong></p>
                    <ul>
                        <li><strong>Toxoplasmosis prophylaxis (if not on TMP-SMX):</strong> Same as above</li>
                    </ul>
                    <p><strong>CD4 <50:</strong></p>
                    <ul>
                        <li><strong>MAC prophylaxis:</strong> Azithromycin 1200mg weekly (or 600mg twice weekly). Alternative: clarithromycin 500mg BID</li>
                    </ul>
                    <p><strong>CAN DISCONTINUE prophylaxis when:</strong> CD4 >200 for ‚â•3 months on ART with undetectable viral load</p>
                    
                    <p><span class="label">SUPPORTIVE CARE:</span></p>
                    <ul>
                        <li><strong>Nutrition:</strong> High-calorie, high-protein diet. Consider appetite stimulants if severe wasting (megestrol, dronabinol)</li>
                        <li><strong>Vaccinations (once CD4 >200 on ART):</strong> Pneumococcal (PCV20 or PCV15 + PPSV23), influenza annually, COVID-19, Tdap, hepatitis A/B (if non-immune), HPV (if age <26), meningococcal, varicella/zoster (if CD4 >200). NO live vaccines if CD4 <200</li>
                        <li><strong>Smoking cessation, substance use treatment:</strong> Critical for reducing comorbidities</li>
                    </ul>
                    
                    <p><span class="label">MONITORING ART RESPONSE:</span></p>
                    <ul>
                        <li><strong>Viral load:</strong> Check 2-4 weeks after starting ART, then q4-8 weeks until undetectable (<50 copies/mL), then q3-6 months</li>
                        <li><strong>CD4 count:</strong> Check q3-6 months until consistently >200-300, then annually</li>
                        <li><strong>Goal:</strong> Undetectable viral load (<50) within 6 months. CD4 should increase 50-150 cells/¬µL per year</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearls-box">
                <div class="pearls-title">üí° TEACHING PEARLS: HIV/AIDS COMPLICATIONS</div>
                <ul>
                    <li><strong>CD4 <200 = Start PCP prophylaxis IMMEDIATELY</strong> (don't wait for first episode). TMP-SMX DS daily is gold standard</li>
                    <li><strong>Toxo encephalitis vs CNS lymphoma:</strong> Toxo = multiple ring-enhancing lesions, Toxo IgG positive, responds to empiric pyrimethamine/sulfadiazine within 7-14 days. Lymphoma = single lesion, no Toxo IgG, needs biopsy. Empiric trial of toxo treatment reasonable before brain biopsy</li>
                    <li><strong>Cryptococcal meningitis = Check opening pressure and reduce if >25cm H2O</strong> (therapeutic LP). Elevated ICP causes most deaths. Repeat LPs daily if needed to keep OP <20cm</li>
                    <li><strong>PCP can present with normal CXR</strong> in early disease. If high clinical suspicion + hypoxemia + elevated LDH ‚Üí empiric treatment reasonable. Gallium scan or high-res CT more sensitive</li>
                    <li><strong>CMV retinitis is a CLINICAL diagnosis</strong> by ophthalmology. Don't wait for PCR. Untreated ‚Üí blindness within weeks</li>
                    <li><strong>IRIS typically occurs 2 weeks to 3 months after starting ART.</strong> Paradoxical worsening of TB, cryptococcus, or MAC. Continue ART + treat OI + add steroids for severe cases</li>
                    <li><strong>MAC bacteremia occurs at CD4 <50.</strong> Fever, night sweats, diarrhea, hepatosplenomegaly. Blood cultures take 2-4 weeks to grow. Start prophylaxis (azithromycin) if CD4 <50</li>
                    <li><strong>HIV patients with bacterial pneumonia:</strong> Higher rates of S. pneumoniae, H. influenzae, and S. aureus. More severe disease. Treat like CAP but consider broader coverage</li>
                    <li><strong>START ART in hospital if no contraindication</strong> (CNS OI, crypto meningitis, TB meningitis). Early ART improves outcomes. Consult ID if unsure</li>
                    <li><strong>Abacavir hypersensitivity:</strong> Check HLA-B*5701 BEFORE starting. If positive, never give abacavir (can cause fatal reaction). If patient develops fever/rash/GI symptoms within 6 weeks of starting abacavir ‚Üí stop immediately, never rechallenge</li>
                    <li><strong>Drug interactions with ART:</strong> Integrase inhibitors (dolutegravir, bictegravir) have fewest interactions. Protease inhibitors (ritonavir, cobicistat) are major CYP3A4 inhibitors ‚Üí many interactions. Check every new drug</li>
                    <li><strong>Undetectable = Untransmittable (U=U).</strong> Patients with undetectable viral load on ART do not transmit HIV sexually. Important for patient counseling and reducing stigma</li>
                </ul>
            </div>
            
            <div class="two-column-criteria">
                <div class="criteria-column">
                    <div class="criteria-title">üö® ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Respiratory failure requiring intubation (PCP-ARDS, severe CAP)</li>
                        <li>Septic shock requiring vasopressors</li>
                        <li>Altered mental status with concern for herniation (toxo, crypto, PML, lymphoma)</li>
                        <li>Severe lactic acidosis from sepsis or antiretrovirals</li>
                        <li>Refractory seizures (toxo, CNS lymphoma, HIV encephalopathy)</li>
                        <li>Massive GI bleeding (CMV colitis, KS, lymphoma)</li>
                    </ul>
                </div>
                <div class="criteria-column">
                    <div class="criteria-title">‚úÖ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Opportunistic infection improving on treatment</li>
                        <li>ART initiated (or patient on stable ART regimen)</li>
                        <li>Tolerating PO intake, medications</li>
                        <li>Appropriate outpatient follow-up arranged:
                            <ul>
                                <li>HIV specialist within 1-2 weeks</li>
                                <li>Prophylaxis prescriptions filled (if CD4 <200)</li>
                                <li>Case management, social work support</li>
                            </ul>
                        </li>
                        <li>Patient counseled on medication adherence, safe sex practices, U=U</li>
                        <li>If new diagnosis: Ryan White services, mental health support arranged</li>
                    </ul>
                </div>
            </div>
            
            <div class="complications-section">
                <div class="complications-title">‚ö†Ô∏è COMPLICATIONS TO MONITOR</div>
                <div class="complications-grid">
                    <div class="complication-item">
                        <strong>ART Toxicities:</strong> Nephrotoxicity (tenofovir), hepatotoxicity, rash (especially NNRTIs), GI intolerance, metabolic (hyperlipidemia, hyperglycemia, lipodystrophy), bone loss (tenofovir), neuropsychiatric effects (efavirenz, dolutegravir)
                    </div>
                    <div class="complication-item">
                        <strong>Immune Reconstitution Inflammatory Syndrome (IRIS):</strong> Worsening of OI after ART initiation. Common with TB, MAC, cryptococcus. Occurs 2 weeks-3 months post-ART. Continue ART, treat OI, add steroids for severe IRIS
                    </div>
                    <div class="complication-item">
                        <strong>Drug Resistance:</strong> Develop if poor adherence. Check resistance testing if virologic failure (VL >200 after initial suppression). Switch to new regimen based on resistance mutations
                    </div>
                    <div class="complication-item">
                        <strong>Chronic Comorbidities:</strong> Increased cardiovascular disease (integrate statins, ASA), chronic kidney disease (avoid tenofovir), osteoporosis (bone density screening), malignancies (especially cervical cancer, anal cancer - screen regularly)
                    </div>
                    <div class="complication-item">
                        <strong>Mental Health:</strong> Depression, anxiety, substance use common. Screen regularly. Adherence counseling critical
                    </div>
                    <div class="complication-item">
                        <strong>Hepatitis B/C Coinfection:</strong> Accelerates liver disease. Treat both. If stopping ART with HBV coinfection ‚Üí risk of fulminant hepatitis B flare
                    </div>
                </div>
            </div>
            
            <div class="back-to-top">
                <a href="#top" onclick="document.getElementById('search-box').scrollIntoView({behavior: 'smooth'}); return false;">‚Üë Back to Top</a>
            </div>
        </div>

<!-- CONDITION 67: OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOST -->
<!-- ============================================ -->
        <div id="opportunistic" class="condition-page">
            <div class="page-header">
                <h2>67. OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED HOST</h2>
                <div class="subtitle">Non-HIV Immunosuppression ‚Ä¢ Transplant ‚Ä¢ Chemotherapy ‚Ä¢ Biologics ‚Ä¢ High-Index Suspicion</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Immunocompromised Populations at Risk:</span></p>
                    <ul>
                        <li><strong>Solid organ transplant recipients:</strong> On chronic immunosuppression (tacrolimus, mycophenolate, prednisone). Highest risk first 6 months post-transplant</li>
                        <li><strong>Hematopoietic stem cell transplant (HSCT):</strong> Profound immunosuppression. Risk varies by time post-transplant and GVHD status</li>
                        <li><strong>Hematologic malignancies:</strong> Leukemia, lymphoma, multiple myeloma. Disease + chemotherapy cause immunosuppression</li>
                        <li><strong>Solid tumor malignancies on chemotherapy:</strong> Neutropenia (ANC <500) is major risk factor</li>
                        <li><strong>Chronic high-dose corticosteroids:</strong> ‚â•20mg prednisone daily √ó ‚â•2 weeks. Risk proportional to dose + duration</li>
                        <li><strong>Biologic immunosuppressants:</strong> TNF-Œ± inhibitors (infliximab, adalimumab, etanercept), rituximab (anti-CD20), JAK inhibitors. Risk of reactivation TB, fungal infections, viral reactivation</li>
                        <li><strong>Chronic kidney disease (dialysis):</strong> Impaired cell-mediated immunity, uremia effects</li>
                        <li><strong>Diabetes mellitus:</strong> Increased risk bacterial, fungal infections (especially if poor glucose control)</li>
                        <li><strong>Cirrhosis/end-stage liver disease:</strong> Impaired opsonization, complement deficiency, bacterial translocation</li>
                        <li><strong>Asplenia (surgical or functional):</strong> Encapsulated organism risk (S. pneumoniae, H. influenzae, N. meningitidis, Capnocytophaga)</li>
                    </ul>
                    
                    <p><span class="label">Timing of Infections Post-Transplant:</span></p>
                    <p><strong>Early (<1 month):</strong></p>
                    <ul>
                        <li>Nosocomial infections (surgical site, catheter-related, Clostridioides difficile, aspiration pneumonia)</li>
                        <li>Donor-derived infections</li>
                    </ul>
                    <p><strong>Intermediate (1-6 months):</strong></p>
                    <ul>
                        <li><strong>Highest OI risk period.</strong> Peak immunosuppression</li>
                        <li>CMV disease, EBV (PTLD), BK virus (kidney transplant), HHV-6</li>
                        <li>Pneumocystis jirovecii pneumonia (if no prophylaxis)</li>
                        <li>Invasive fungal infections: Aspergillus, Mucorales, endemic fungi (Histoplasma, Coccidioides, Blastomyces)</li>
                        <li>Toxoplasma (heart transplant from Toxo+ donor)</li>
                        <li>Nocardia, Listeria meningitis</li>
                    </ul>
                    <p><strong>Late (>6 months):</strong></p>
                    <ul>
                        <li>Community-acquired infections (similar to general population)</li>
                        <li>Reactivation of latent infections (TB, strongyloidiasis, Chagas, endemic fungi)</li>
                        <li>CMV if chronic rejection requiring increased immunosuppression</li>
                    </ul>
                    
                    <p><span class="label">KEY OPPORTUNISTIC PATHOGENS BY TYPE:</span></p>
                    <p><span class="label">FUNGAL INFECTIONS:</span></p>
                    <ul>
                        <li><strong>Invasive Aspergillosis:</strong> Prolonged neutropenia, HSCT, lung transplant, high-dose steroids. Fever unresponsive to antibiotics, cough, hemoptysis, pleuritic pain. CT chest: nodules with "halo sign" (ground-glass opacity around nodule), "air crescent sign" (later). Galactomannan in serum/BAL. Rx: voriconazole 6mg/kg IV q12h √ó2 doses ‚Üí 4mg/kg IV q12h. Alternative: isavuconazole, liposomal amphotericin B</li>
                        <li><strong>Mucormycosis (Zygomycosis):</strong> Diabetes (DKA), neutropenia, iron overload, deferoxamine therapy. RAPIDLY PROGRESSIVE. Rhinocerebral (facial pain, nasal necrosis, black eschar, vision changes), pulmonary (hemoptysis), disseminated. CT: sinus opacification, bone destruction. Dx: tissue biopsy (broad nonseptate hyphae). Rx: urgent surgical debridement + liposomal amphotericin B 5-10mg/kg/day. High mortality (30-70%)</li>
                        <li><strong>Cryptococcus (non-HIV):</strong> Solid organ transplant, TNF-Œ± inhibitors, chronic steroids. Meningitis (headache, fever, AMS). Pulmonary nodules/infiltrates. Dx: serum/CSF cryptococcal Ag, CSF culture. Rx: amphotericin B + flucytosine</li>
                        <li><strong>Endemic Mycoses:</strong>
                            <ul>
                                <li><strong>Histoplasmosis:</strong> Ohio/Mississippi River valleys. Disseminated disease in immunocompromised (fever, hepatosplenomegaly, pancytopenia). Urine/serum Histoplasma Ag. Rx: liposomal amphotericin B (severe) or itraconazole (mild-moderate)</li>
                                <li><strong>Coccidioidomycosis:</strong> Southwest US. Pulmonary or disseminated (meningitis, bone/joint). CF test, coccidioidal Ab. Rx: fluconazole (meningitis), amphotericin B (severe)</li>
                                <li><strong>Blastomycosis:</strong> Midwest/Southeast US. Pulmonary + skin lesions. Dx: culture, Blasto Ag urine. Rx: itraconazole or amphotericin B</li>
                            </ul>
                        </li>
                        <li><strong>Candida:</strong> Bloodstream infection (candidemia), hepatosplenic candidiasis, esophagitis. Remove central lines. Rx: echinocandin (caspofungin, micafungin) first-line. Fluconazole if susceptible species + stable patient</li>
                    </ul>
                    
                    <p><span class="label">VIRAL INFECTIONS:</span></p>
                    <ul>
                        <li><strong>Cytomegalovirus (CMV):</strong> Transplant recipients (especially if donor+/recipient-), HSCT. CMV syndrome (fever, malaise, leukopenia, thrombocytopenia), end-organ disease (pneumonitis, colitis, hepatitis, retinitis). Dx: CMV PCR (quantitative viral load), tissue biopsy ("owl's eye" inclusion bodies). Rx: ganciclovir 5mg/kg IV q12h or valganciclovir 900mg PO BID √ó 2-3 weeks, then maintenance if ongoing immunosuppression</li>
                        <li><strong>BK virus:</strong> Kidney transplant recipients. BK nephropathy ‚Üí graft dysfunction, hematuria. Urine/plasma BK PCR. Rx: reduce immunosuppression, cidofovir or leflunomide (off-label)</li>
                        <li><strong>EBV (Post-Transplant Lymphoproliferative Disorder - PTLD):</strong> B-cell lymphoma driven by EBV. Lymphadenopathy, extranodal masses, organ dysfunction. Elevated EBV PCR. Dx: biopsy. Rx: reduce immunosuppression, rituximab, chemotherapy</li>
                        <li><strong>Varicella-Zoster Virus (VZV):</strong> Reactivation ‚Üí disseminated zoster (multi-dermatomal, visceral involvement). Rx: acyclovir 10-15mg/kg IV q8h</li>
                        <li><strong>Herpes Simplex Virus (HSV):</strong> Severe mucocutaneous disease, esophagitis, encephalitis. Rx: acyclovir IV</li>
                        <li><strong>Adenovirus:</strong> HSCT, pediatric transplants. Pneumonia, hepatitis, hemorrhagic cystitis, disseminated disease. Dx: PCR. Rx: cidofovir (nephrotoxic), reduce immunosuppression</li>
                        <li><strong>Respiratory viruses (RSV, influenza, parainfluenza, human metapneumovirus):</strong> Severe pneumonia in immunocompromised. Dx: respiratory viral panel (PCR). Rx: supportive, oseltamivir (influenza), ribavirin (RSV - off-label)</li>
                    </ul>
                    
                    <p><span class="label">BACTERIAL INFECTIONS:</span></p>
                    <ul>
                        <li><strong>Listeria monocytogenes:</strong> Meningitis, bacteremia. Transplant recipients, chronic steroids, elderly. Rx: ampicillin 2g IV q4h + gentamicin</li>
                        <li><strong>Nocardia:</strong> Chronic steroids, transplant recipients. Pulmonary nodules/cavities, brain abscesses, disseminated. Dx: culture (slow-growing, modified AFB stain). Rx: TMP-SMX high-dose, prolonged therapy (6-12 months)</li>
                        <li><strong>Mycobacterium tuberculosis:</strong> Reactivation common in TNF-Œ± inhibitor users, transplant recipients. Screen with IGRA before starting biologics. Rx: standard RIPE therapy, but watch drug interactions (rifampin ‚Üì immunosuppressant levels)</li>
                        <li><strong>Nontuberculous mycobacteria (NTM):</strong> M. avium complex, M. abscessus. Pulmonary disease, disseminated. Dx: culture. Rx: macrolide-based multi-drug regimens</li>
                        <li><strong>Encapsulated organisms (asplenia):</strong> S. pneumoniae, H. influenzae, N. meningitidis. Overwhelming post-splenectomy sepsis (OPSS). Rx: immediate broad-spectrum antibiotics (ceftriaxone + vancomycin), aggressive resuscitation</li>
                        <li><strong>Legionella:</strong> Transplant recipients. Severe pneumonia. Dx: urinary Ag. Rx: fluoroquinolone or azithromycin</li>
                    </ul>
                    
                    <p><span class="label">PARASITIC INFECTIONS:</span></p>
                    <ul>
                        <li><strong>Toxoplasma gondii:</strong> Heart transplant (donor+/recipient-), HSCT. Encephalitis (fever, AMS, focal deficits, seizures), myocarditis. MRI: ring-enhancing lesions. Dx: serology, PCR, biopsy. Rx: pyrimethamine + sulfadiazine + leucovorin</li>
                        <li><strong>Strongyloides stercoralis hyperinfection:</strong> HTLV-1 coinfection, corticosteroids, transplant. GI symptoms (diarrhea, abdominal pain), pulmonary infiltrates, Gram-negative bacteremia/meningitis (larvae carry bacteria). Dx: stool O&P (insensitive), serology, BAL. Rx: ivermectin 200mcg/kg/day √ó ‚â•2 days (may need prolonged)</li>
                        <li><strong>Cryptosporidium, Microsporidia, Isospora:</strong> Chronic diarrhea. Dx: stool special stains. Rx: nitazoxanide (Crypto), albendazole (Microsporidia), TMP-SMX (Isospora)</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Initial Assessment:</span></p>
                    <ul>
                        <li><strong>History:</strong> Type of immunosuppression, duration, specific agents, recent changes in regimen. Prior infections, prophylaxis medications. Travel history, exposures, endemic area residence</li>
                        <li><strong>Physical exam:</strong> Skin lesions (fungal, viral, Nocardia), oropharynx (thrush), lung exam, neurologic exam, fundoscopy (CMV retinitis)</li>
                    </ul>
                    
                    <p><span class="label">Laboratory Studies:</span></p>
                    <ul>
                        <li><strong>CBC with diff:</strong> Neutropenia (ANC), lymphopenia, anemia, thrombocytopenia</li>
                        <li><strong>CMP:</strong> Renal function (drug dosing, nephrotoxicity), LFTs (hepatitis, drug toxicity)</li>
                        <li><strong>Inflammatory markers:</strong> CRP, ESR (may be blunted in immunosuppressed)</li>
                        <li><strong>Blood cultures:</strong> Bacterial, fungal (hold ‚â•5 days for fungal)</li>
                        <li><strong>Serum fungal biomarkers:</strong> Galactomannan (Aspergillus), (1,3)-Œ≤-D-glucan (most invasive fungi), Cryptococcal Ag, Histoplasma Ag, Blastomyces Ag, Coccidioides Ab</li>
                        <li><strong>Viral PCR:</strong> CMV quantitative PCR, EBV PCR, BK virus PCR (urine/plasma)</li>
                        <li><strong>Immunosuppressant drug levels:</strong> Tacrolimus, cyclosporine, sirolimus (under-immunosuppression ‚Üí rejection, over ‚Üí infections)</li>
                    </ul>
                    
                    <p><span class="label">Imaging:</span></p>
                    <ul>
                        <li><strong>CXR:</strong> Initial screening. Nodules, infiltrates, cavities</li>
                        <li><strong>CT chest (high-resolution, with contrast):</strong> More sensitive for pulmonary infections. Look for: halo sign (Aspergillus), nodules, tree-in-bud (atypical mycobacteria), cavitation (Nocardia, TB, fungi)</li>
                        <li><strong>CT sinuses:</strong> If facial pain, headache (Mucor, Aspergillus)</li>
                        <li><strong>MRI brain with contrast:</strong> If neurologic symptoms. Ring-enhancing lesions (Toxo, Nocardia, fungi, abscess), meningeal enhancement (Listeria, Crypto, TB)</li>
                        <li><strong>CT abdomen/pelvis:</strong> Hepatosplenic candidiasis, CMV colitis, typhlitis</li>
                    </ul>
                    
                    <p><span class="label">Invasive Diagnostics (Often Necessary):</span></p>
                    <ul>
                        <li><strong>Bronchoscopy with BAL:</strong> Send for: bacterial/fungal/AFB/viral cultures, Galactomannan, PCP DFA/PCR, cytology, CMV PCR. Consider transbronchial biopsy</li>
                        <li><strong>Lumbar puncture:</strong> If meningitis suspected. Opening pressure, cell count, protein, glucose, Gram stain, bacterial/fungal/AFB cultures, Cryptococcal Ag, VDRL, HSV/VZV PCR, CMV PCR, Toxoplasma PCR</li>
                        <li><strong>Tissue biopsy:</strong> Skin lesions, lymph nodes, lung nodules. Send for histopathology (special stains: GMS, PAS, AFB) + culture (bacterial, fungal, AFB, viral). CRITICAL for diagnosing invasive fungal infections</li>
                        <li><strong>Bone marrow biopsy:</strong> If fever without source + pancytopenia. Culture for fungi, AFB, Histoplasma Ag</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">General Principles:</span></p>
                    <ul>
                        <li><strong>LOW THRESHOLD for empiric broad-spectrum therapy.</strong> Immunocompromised patients deteriorate rapidly</li>
                        <li><strong>Consider reducing immunosuppression</strong> (coordinate with transplant team or oncologist). Balance infection control vs rejection/GVHD risk</li>
                        <li><strong>Prolonged treatment courses</strong> often needed (weeks to months)</li>
                        <li><strong>Combination therapy</strong> for invasive fungal infections</li>
                        <li><strong>Monitor drug levels</strong> and interactions (especially azoles with calcineurin inhibitors)</li>
                    </ul>
                    
                    <p><span class="label">Empiric Therapy for Fever in Neutropenic Patient (ANC <500):</span></p>
                    <ul>
                        <li><strong>Piperacillin-tazobactam 4.5g IV q6h</strong> OR <strong>cefepime 2g IV q8h</strong> OR <strong>meropenem 1g IV q8h</strong> (if high MDRO risk, prior resistant organisms, or severe sepsis)</li>
                        <li><strong>Add vancomycin</strong> if: skin/soft tissue infection, catheter-related infection, hemodynamic instability, or known MRSA colonization</li>
                        <li><strong>Add antifungal</strong> if fever persists >4-7 days on antibiotics: Start empiric echinocandin (caspofungin 70mg load ‚Üí 50mg daily, or micafungin 100mg daily) OR liposomal amphotericin B 3-5mg/kg/day</li>
                    </ul>
                    
                    <p><span class="label">Empiric Therapy for Pulmonary Infiltrates:</span></p>
                    <ul>
                        <li><strong>Bacterial coverage:</strong> Piperacillin-tazobactam or cefepime or meropenem (as above) + azithromycin 500mg IV daily (atypical coverage)</li>
                        <li><strong>PCP coverage:</strong> TMP-SMX 15-20mg/kg/day (TMP component) divided q6-8h. Add prednisone 40mg BID if moderate-severe hypoxemia (PaO2 <70 or A-a gradient >35)</li>
                        <li><strong>Aspergillus/mold coverage:</strong> Voriconazole 6mg/kg IV q12h √ó2 doses ‚Üí 4mg/kg q12h. Consider if: prolonged neutropenia, HSCT, lung transplant, nodules on CT, hemoptysis</li>
                    </ul>
                    
                    <p><span class="label">Specific Treatments (see Clinical Presentation for details):</span></p>
                    <ul>
                        <li><strong>Invasive Aspergillosis:</strong> Voriconazole (first-line) OR isavuconazole OR liposomal amphotericin B. Consider combination therapy (vori + echinocandin) for severe disease</li>
                        <li><strong>Mucormycosis:</strong> Urgent surgical debridement + liposomal amphotericin B 5-10mg/kg/day. Add posaconazole or isavuconazole as step-down. HIGH MORTALITY</li>
                        <li><strong>CMV disease:</strong> Ganciclovir 5mg/kg IV q12h (induction) √ó 2-3 weeks ‚Üí valganciclovir 900mg daily (maintenance). Alternative: foscarnet (if ganciclovir-resistant or severe myelosuppression). Monitor CMV PCR to guide duration</li>
                        <li><strong>Toxoplasma encephalitis:</strong> Pyrimethamine 200mg loading ‚Üí 50-75mg daily + sulfadiazine 1-1.5g q6h + leucovorin 10-25mg daily √ó ‚â•6 weeks</li>
                        <li><strong>Nocardia:</strong> TMP-SMX 5mg/kg (TMP component) IV q6-8h √ó 6-12 months. Add imipenem or amikacin for CNS disease or severe infection</li>
                        <li><strong>Listeria meningitis:</strong> Ampicillin 2g IV q4h + gentamicin 5-7mg/kg/day √ó ‚â•21 days</li>
                        <li><strong>Strongyloides hyperinfection:</strong> Ivermectin 200mcg/kg/day √ó ‚â•2 days (may need weeks for disseminated). Add albendazole if severe. Treat concurrent Gram-negative sepsis</li>
                    </ul>
                    
                    <p><span class="label">Prophylaxis (Prevention):</span></p>
                    <ul>
                        <li><strong>PCP prophylaxis:</strong> TMP-SMX DS 1 tab daily or 3x/week. Indicated for: HSCT, high-dose steroids (‚â•20mg prednisone √ó‚â•1 month), hematologic malignancies, selected solid organ transplants. Alternative: dapsone, atovaquone, inhaled pentamidine</li>
                        <li><strong>Fungal prophylaxis:</strong> Fluconazole (Candida) or posaconazole/voriconazole (mold) for high-risk patients (HSCT, AML/MDS with prolonged neutropenia)</li>
                        <li><strong>CMV prophylaxis (transplant):</strong> Valganciclovir 900mg daily (adjust for CrCl) if high-risk (D+/R-, lung transplant, treatment of rejection). Monitor CMV PCR (preemptive strategy)</li>
                        <li><strong>HSV/VZV prophylaxis:</strong> Acyclovir 400mg BID or valacyclovir 500mg daily for HSCT or frequent reactivations</li>
                    </ul>
                    
                    <p><span class="label">Immunomodulation:</span></p>
                    <ul>
                        <li><strong>G-CSF (filgrastim, pegfilgrastim):</strong> For prolonged neutropenia after chemotherapy. Accelerates neutrophil recovery</li>
                        <li><strong>IVIG:</strong> For hypogammaglobulinemia (IgG <400mg/dL) with recurrent infections</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearls-box">
                <div class="pearls-title">üí° TEACHING PEARLS: OPPORTUNISTIC INFECTIONS IN IMMUNOCOMPROMISED</div>
                <ul>
                    <li><strong>"Fever + neutropenia = Emergency."</strong> ANC <500 + fever (‚â•38.3¬∞C or ‚â•38¬∞C √ó 1hr) = neutropenic fever. Start broad-spectrum antibiotics within 1 hour. Don't wait for cultures</li>
                    <li><strong>Invasive Aspergillus: Think "halo sign" on CT chest</strong> (ground-glass opacity surrounding nodule). Classic for angioinvasive Aspergillus in neutropenic patients. Air crescent sign appears later (healing phase)</li>
                    <li><strong>Mucormycosis = SURGICAL EMERGENCY.</strong> Rapidly progressive, angioinvasive. Black nasal eschar, facial pain, vision changes. Amphotericin B + urgent surgical debridement. Don't delay for biopsy if high suspicion</li>
                    <li><strong>TNF-Œ± inhibitors ‚Üí Reactivation TB and invasive fungal infections.</strong> Screen for latent TB (IGRA) and endemic fungi before starting biologics. Treat LTBI with isoniazid √ó 9 months or rifampin √ó 4 months before starting biologic</li>
                    <li><strong>Strongyloides hyperinfection in steroid users:</strong> Can disseminate when steroids given. Presents with severe diarrhea, Gram-negative sepsis/meningitis (larvae carry gut bacteria). Screen for Strongyloides serology before starting immunosuppression in endemic areas. Treat with ivermectin if positive</li>
                    <li><strong>CMV in transplant: "Donor+/Recipient-" = HIGHEST RISK.</strong> Seropositive donor ‚Üí seronegative recipient. Give prophylaxis (valganciclovir) or preemptive therapy (monitor CMV PCR weekly, treat if positive)</li>
                    <li><strong>PCP prophylaxis = TMP-SMX DS daily or 3x/week.</strong> Indicated for chronic steroids ‚â•20mg √ó ‚â•1 month, HSCT, hematologic malignancies on chemotherapy, selected transplants. CD4 <200 also indication (HIV)</li>
                    <li><strong>Nocardia presents with "brain abscess + lung nodules"</strong> in chronically immunosuppressed. Modified AFB stain positive (weakly acid-fast). Long treatment (TMP-SMX √ó 6-12 months)</li>
                    <li><strong>Listeria meningitis in transplant/elderly:</strong> CSF shows lymphocytic pleocytosis (mimics viral). Gram stain: Gram-positive rods. MUST use ampicillin (cephalosporins don't work). Add gentamicin for synergy</li>
                    <li><strong>Cryptococcus in non-HIV:</strong> More likely disseminated disease (meningitis + pulmonary). Check serum Cryptococcal Ag (highly sensitive). LP: opening pressure, CSF Crypto Ag. Rx: amphotericin B + flucytosine</li>
                    <li><strong>Galactomannan: Aspergillus screening test.</strong> Serum galactomannan (sensitivity 70-80% for invasive aspergillosis). BAL galactomannan more sensitive (>90%). False positives: piperacillin-tazobactam, some food</li>
                    <li><strong>Asplenia ‚Üí Encapsulated organism risk (S. pneumoniae, H. influenzae, N. meningitidis).</strong> Vaccinate 2 weeks before splenectomy if elective: PCV20/PCV15+PPSV23, Hib, MenACWY + MenB. If emergent splenectomy, vaccinate 2 weeks post-op. Lifetime penicillin prophylaxis (PCN VK 250mg BID or amoxicillin 250mg BID) controversial but reasonable</li>
                </ul>
            </div>
            
            <div class="two-column-criteria">
                <div class="criteria-column">
                    <div class="criteria-title">üö® ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Neutropenic septic shock requiring vasopressors</li>
                        <li>Respiratory failure requiring intubation (invasive Aspergillus ARDS, PCP, CMV pneumonitis)</li>
                        <li>Severe mucormycosis requiring urgent surgical debridement</li>
                        <li>CNS infection with concern for herniation (Toxo, Nocardia abscess, Listeria meningitis, fungal)</li>
                        <li>Multi-organ dysfunction from sepsis</li>
                        <li>Typhlitis (neutropenic colitis) with perforation risk</li>
                    </ul>
                </div>
                <div class="criteria-column">
                    <div class="criteria-title">‚úÖ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Neutropenia resolved (ANC >500) or improving trend</li>
                        <li>Afebrile ‚â•24-48 hours</li>
                        <li>Infection controlled on oral antimicrobials (or IV with home infusion arranged)</li>
                        <li>Hemodynamically stable</li>
                        <li>Tolerating PO intake</li>
                        <li>Appropriate outpatient follow-up:
                            <ul>
                                <li>Transplant ID or Oncology within 1 week</li>
                                <li>Home health for IV antibiotics if needed</li>
                                <li>Prophylaxis medications prescribed</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            
            <div class="complications-section">
                <div class="complications-title">‚ö†Ô∏è COMPLICATIONS TO MONITOR</div>
                <div class="complications-grid">
                    <div class="complication-item">
                        <strong>Septic Shock:</strong> Rapid deterioration despite antibiotics. Early goal-directed therapy (fluids, vasopressors, source control). Consider G-CSF if neutropenic
                    </div>
                    <div class="complication-item">
                        <strong>Respiratory Failure:</strong> ARDS from PCP, invasive Aspergillus, CMV pneumonitis. High mortality if mechanical ventilation required. Early bronchoscopy for diagnosis
                    </div>
                    <div class="complication-item">
                        <strong>Drug Toxicities:</strong> Nephrotoxicity (amphotericin B, aminoglycosides, foscarnet, cidofovir), hepatotoxicity (azoles, TMP-SMX), myelosuppression (ganciclovir, TMP-SMX, flucytosine). Monitor levels, adjust doses, supportive care
                    </div>
                    <div class="complication-item">
                        <strong>Drug Interactions:</strong> Azoles (voriconazole, posaconazole) are CYP3A4 inhibitors ‚Üí increase tacrolimus/cyclosporine/sirolimus levels. Monitor drug levels closely, adjust doses. Rifampin decreases immunosuppressant levels ‚Üí rejection risk
                    </div>
                    <div class="complication-item">
                        <strong>Multi-Drug Resistant Organisms:</strong> ESBL, CRE, VRE, MRSA. Common in transplant recipients with frequent hospitalizations. Carbapenem or polymyxin-based regimens. Infection control precautions
                    </div>
                    <div class="complication-item">
                        <strong>Relapse/Recurrence:</strong> Common if immunosuppression continues. Secondary prophylaxis often needed (e.g., fluconazole after candidemia, voriconazole after Aspergillus). Prolonged treatment courses
                    </div>
                </div>
            </div>
            
            <div class="back-to-top">
                <a href="#top" onclick="document.getElementById('search-box').scrollIntoView({behavior: 'smooth'}); return false;">‚Üë Back to Top</a>
            </div>
        </div>

<!-- CONDITION 68: HYPERTHYROIDISM/THYROTOXICOSIS -->
<!-- ============================================ -->
        <div id="hyperthyroid" class="condition-page">
            <div class="page-header">
                <h2>68. HYPERTHYROIDISM/THYROTOXICOSIS (NON-STORM)</h2>
                <div class="subtitle">Graves Disease ‚Ä¢ Toxic Adenoma ‚Ä¢ Thyroiditis ‚Ä¢ Beta-Blockers + Thiou

reas</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Note:</span> This section covers NON-STORM hyperthyroidism. For Thyroid Storm (life-threatening emergency), see Condition #31</p>
                    
                    <p><span class="label">Common Etiologies:</span></p>
                    <ul>
                        <li><strong>Graves disease (60-80%):</strong> Autoimmune (TSI antibodies stimulate TSH receptor). Diffuse toxic goiter. Associated findings: exophthalmos (proptosis), pretibial myxedema, thyroid acromegaly (hand swelling)</li>
                        <li><strong>Toxic multinodular goiter (15-20%):</strong> Autonomously functioning nodules. More common in elderly. Gradual onset</li>
                        <li><strong>Toxic adenoma (solitary hot nodule, 3-5%):</strong> Single hyperfunctioning nodule. Uptake in nodule, suppression of rest of gland on scan</li>
                        <li><strong>Thyroiditis (subacute, silent, postpartum):</strong> Transient hyperthyroid phase (thyroid inflammation ‚Üí hormone release) followed by hypothyroid phase. Tender thyroid (subacute), painless (silent/postpartum). LOW radioiodine uptake (vs high in Graves/toxic nodules)</li>
                        <li><strong>Iodine-induced (Jod-Basedow phenomenon):</strong> Excess iodine exposure (contrast, amiodarone, iodine supplements) ‚Üí thyrotoxicosis in patients with underlying thyroid disease</li>
                        <li><strong>Amiodarone-induced thyrotoxicosis (AIT):</strong> Type 1 (iodine-induced, pre-existing thyroid disease) vs Type 2 (destructive thyroiditis from amiodarone)</li>
                        <li><strong>Exogenous thyroid hormone:</strong> Over-replacement, factitious thyrotoxicosis (thyrotoxicosis factitia), weight-loss supplements</li>
                    </ul>
                    
                    <p><span class="label">Classic Symptoms:</span></p>
                    <ul>
                        <li><strong>Metabolic:</strong> Weight loss despite increased appetite (most common presenting symptom), heat intolerance, increased sweating</li>
                        <li><strong>Cardiovascular:</strong> Palpitations, tachycardia (often sinus), atrial fibrillation (10-15%, especially elderly), increased pulse pressure (wide), systolic hypertension</li>
                        <li><strong>Neuropsychiatric:</strong> Anxiety, nervousness, emotional lability, insomnia, tremor (fine), hyperreflexia, proximal muscle weakness</li>
                        <li><strong>GI:</strong> Increased frequency of bowel movements (not frank diarrhea usually), nausea</li>
                        <li><strong>Reproductive:</strong> Oligomenorrhea or amenorrhea (women), decreased libido, gynecomastia (men)</li>
                        <li><strong>Dermatologic:</strong> Warm, moist skin, fine hair, onycholysis (nail separation), pretibial myxedema (Graves), palmar erythema</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam Findings:</span></p>
                    <ul>
                        <li><strong>Goiter:</strong> Diffusely enlarged (Graves), nodular (toxic MNG/adenoma), or tender (thyroiditis)</li>
                        <li><strong>Thyroid bruit:</strong> Audible over thyroid (Graves - increased vascularity)</li>
                        <li><strong>Ocular:</strong> Lid lag, lid retraction, stare. Exophthalmos/proptosis (Graves only - infiltrative ophthalmopathy from TSI antibodies)</li>
                        <li><strong>Cardiovascular:</strong> Tachycardia, widened pulse pressure, systolic flow murmur (high output)</li>
                        <li><strong>Neuromuscular:</strong> Fine tremor, hyperreflexia, proximal muscle weakness</li>
                    </ul>
                    
                    <p><span class="label">Apathetic Thyrotoxicosis (Elderly):</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Atypical, "apathetic" - Depression, lethargy, weight loss, atrial fibrillation, heart failure. LACK hyperadrenergic symptoms (anxiety, tremor, heat intolerance). High index of suspicion needed</li>
                    </ul>
                    
                    <p><span class="label">Thyrotoxic Periodic Paralysis:</span></p>
                    <ul>
                        <li><strong>Presentation:</strong> Sudden-onset muscle weakness/paralysis (usually lower extremities). Hypokalemia (K+ shifts intracellularly). More common in Asian males. Triggered by high-carb meals, exercise. Treat hypokalemia + underlying thyrotoxicosis</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Thyroid Function Tests:</span></p>
                    <ul>
                        <li><strong>TSH:</strong> Suppressed (<0.01 mIU/L) in primary hyperthyroidism. FIRST test to order</li>
                        <li><strong>Free T4:</strong> Elevated (>1.8 ng/dL). Confirms hyperthyroidism if TSH low</li>
                        <li><strong>Free T3:</strong> Elevated (>4.0 pg/mL). Can be elevated when T4 normal (T3 toxicosis). Check if TSH low but T4 normal</li>
                        <li><strong>Interpretation:</strong>
                            <ul>
                                <li>Low TSH + High Free T4/T3 = Primary hyperthyroidism (thyroid gland problem)</li>
                                <li>Low TSH + Normal Free T4/T3 = Subclinical hyperthyroidism</li>
                                <li>High TSH + High Free T4 = Central hyperthyroidism (pituitary adenoma - rare) or assay interference</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Etiology Workup (Determine Cause):</span></p>
                    <ul>
                        <li><strong>TSI (Thyroid-Stimulating Immunoglobulin) or TRAb (TSH Receptor Antibody):</strong> Positive in Graves disease (95%). Confirms autoimmune etiology. Order if Graves suspected</li>
                        <li><strong>Radioactive Iodine Uptake (RAIU) scan:</strong> Determines etiology based on uptake pattern:
                            <ul>
                                <li><strong>HIGH uptake (>30% at 24hr):</strong> Graves disease (diffuse uptake), toxic multinodular goiter (patchy uptake), toxic adenoma (focal uptake with suppression elsewhere)</li>
                                <li><strong>LOW uptake (<5%):</strong> Thyroiditis (subacute, silent, postpartum), exogenous thyroid hormone, iodine-induced, amiodarone type 2, struma ovarii (ectopic thyroid tissue in ovary)</li>
                            </ul>
                        </li>
                        <li><strong>Thyroid ultrasound:</strong> Evaluate nodules, goiter size/character. Increased vascularity (Doppler) suggests Graves. Hypoechoic, heterogeneous suggests thyroiditis</li>
                        <li><strong>ESR/CRP:</strong> Elevated in subacute thyroiditis (painful). Normal in Graves, toxic nodules</li>
                        <li><strong>Thyroglobulin:</strong> Elevated in thyroiditis (thyroid destruction releases Tg). Suppressed in exogenous hormone use</li>
                    </ul>
                    
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Mild normocytic anemia possible</li>
                        <li><strong>CMP:</strong> Hypercalcemia (10-15%, increased bone turnover), elevated alkaline phosphatase (bone isoform), transaminitis (mild)</li>
                        <li><strong>Lipid panel:</strong> Low LDL, low total cholesterol</li>
                        <li><strong>ECG:</strong> Sinus tachycardia, atrial fibrillation (10-15%), shortened PR interval</li>
                        <li><strong>Potassium:</strong> If periodic paralysis suspected</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">SYMPTOMATIC CONTROL (All Patients):</span></p>
                    <ul>
                        <li><strong>Beta-blockers:</strong>
                            <ul>
                                <li><strong>Propranolol 10-40mg PO q6-8h</strong> (also decreases T4‚ÜíT3 conversion). Titrate to HR <90, symptom control</li>
                                <li><strong>Alternatives:</strong> Metoprolol 25-50mg PO BID-TID, atenolol 25-100mg daily</li>
                                <li><strong>Use:</strong> Controls tachycardia, tremor, anxiety. Does NOT treat underlying hyperthyroidism. Continue until euthyroid</li>
                                <li><strong>Caution:</strong> Avoid in severe asthma/COPD (use cardioselective like metoprolol), decompensated HF</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">DEFINITIVE TREATMENT (Etiology-Specific):</span></p>
                    <p><strong>GRAVES DISEASE / TOXIC NODULES:</strong></p>
                    <ul>
                        <li><strong>Thionamides (Antithyroid Drugs):</strong>
                            <ul>
                                <li><strong>Methimazole 15-30mg PO daily:</strong> PREFERRED (once-daily dosing, less hepatotoxicity). Start 15mg if mild, 30-40mg if severe. Adjust dose based on Free T4 (goal: euthyroid in 4-8 weeks). Maintenance: 5-10mg daily</li>
                                <li><strong>Propylthiouracil (PTU) 100mg PO TID:</strong> Use ONLY in: (1) First trimester pregnancy (methimazole teratogenic), (2) Thyroid storm, (3) Methimazole allergy/side effects. Higher hepatotoxicity risk</li>
                                <li><strong>Mechanism:</strong> Block thyroid peroxidase ‚Üí inhibit thyroid hormone synthesis. PTU also blocks T4‚ÜíT3 conversion</li>
                                <li><strong>Monitoring:</strong> Check Free T4/TSH q4-6 weeks initially, then q3 months once stable. Monitor CBC, LFTs baseline and if symptoms (see complications)</li>
                                <li><strong>Duration:</strong> Graves: 12-18 months, then trial off (40-60% remission rate). Toxic nodules: lifelong or definitive therapy (RAI/surgery)</li>
                            </ul>
                        </li>
                        <li><strong>Radioactive Iodine (RAI) Ablation:</strong>
                            <ul>
                                <li><strong>Indications:</strong> Definitive treatment for Graves, toxic MNG, toxic adenoma. Preferred for patients >40, large goiters, relapse after thionamides</li>
                                <li><strong>Process:</strong> Oral I-131 uptake by thyroid ‚Üí destroys thyroid tissue. Outpatient. Takes 3-6 months for full effect</li>
                                <li><strong>Outcome:</strong> 80-90% cure rate. Most become hypothyroid ‚Üí lifelong levothyroxine</li>
                                <li><strong>Contraindications:</strong> Pregnancy (causes fetal hypothyroidism), breastfeeding, uncontrolled thyrotoxicosis (risk of thyroid storm post-RAI). Active/severe Graves ophthalmopathy (can worsen eye disease - give steroids if mild ophthalmopathy)</li>
                                <li><strong>Pre-treatment:</strong> May give methimazole to achieve euthyroid state first (stop 3-5 days before RAI to allow uptake). Beta-blocker continuation OK</li>
                            </ul>
                        </li>
                        <li><strong>Thyroidectomy (Surgical):</strong>
                            <ul>
                                <li><strong>Indications:</strong> Large goiter with compressive symptoms, contraindication to RAI (pregnancy, severe ophthalmopathy), patient preference, suspicion of malignancy</li>
                                <li><strong>Pre-op preparation:</strong> MUST achieve euthyroid state with thionamides first (4-8 weeks). Add iodine solution 10-14 days pre-op (SSKI or Lugol's solution) to decrease vascularity</li>
                                <li><strong>Complications:</strong> Hypocalcemia (hypoparathyroidism), recurrent laryngeal nerve injury (hoarseness), hypothyroidism (total thyroidectomy), hematoma/bleeding</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><strong>THYROIDITIS (Subacute, Silent, Postpartum):</strong></p>
                    <ul>
                        <li><strong>Treatment:</strong> SELF-LIMITED (hyperthyroid phase lasts 1-3 months ‚Üí hypothyroid phase ‚Üí recovery in 6-12 months). Symptomatic control only</li>
                        <li><strong>Beta-blockers:</strong> Propranolol or metoprolol for symptom control</li>
                        <li><strong>NSAIDs or steroids:</strong> For pain in subacute thyroiditis (prednisone 40mg daily √ó 1 week, then taper if severe)</li>
                        <li><strong>NO thionamides</strong> (not making new hormone, just releasing stored hormone). Would be ineffective</li>
                        <li><strong>Monitor:</strong> TSH/Free T4 q4-6 weeks. May need levothyroxine if prolonged hypothyroid phase</li>
                    </ul>
                    
                    <p><strong>AMIODARONE-INDUCED THYROTOXICOSIS (AIT):</strong></p>
                    <ul>
                        <li><strong>Type 1 AIT (Jod-Basedow):</strong> Pre-existing thyroid disease. RAIU increased (if can be done). Rx: Methimazole 40mg daily +/- perchlorate (blocks iodine uptake). May need RAI or surgery</li>
                        <li><strong>Type 2 AIT (Destructive thyroiditis):</strong> No pre-existing disease. RAIU low. Rx: Prednisone 40mg daily √ó 2-3 months (anti-inflammatory). Self-limited</li>
                        <li><strong>Mixed type:</strong> Treat with both methimazole + prednisone</li>
                        <li><strong>Discontinue amiodarone if possible</strong> (but long half-life means thyrotoxicosis can persist months after stopping)</li>
                    </ul>
                    
                    <p><strong>EXOGENOUS THYROID HORMONE:</strong></p>
                    <ul>
                        <li><strong>Treatment:</strong> Stop thyroid hormone. If intentional over-replacement, reduce dose. If factitious, address underlying psychiatric condition</li>
                    </ul>
                    
                    <p><span class="label">ATRIAL FIBRILLATION MANAGEMENT:</span></p>
                    <ul>
                        <li><strong>Anticoagulation:</strong> Calculate CHA2DS2-VASc score. If ‚â•2 (men) or ‚â•3 (women), anticoagulate with warfarin or DOAC</li>
                        <li><strong>Rate control:</strong> Beta-blockers (metoprolol, atenolol) or diltiazem. Target HR <110</li>
                        <li><strong>Cardioversion:</strong> 60% convert spontaneously to sinus rhythm once euthyroid. Consider cardioversion after 3-6 months of euthyroid state if still in AFib</li>
                    </ul>
                    
                    <p><span class="label">SPECIAL POPULATIONS:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong> PTU in first trimester (methimazole teratogenic). Switch to methimazole in 2nd/3rd trimester (PTU hepatotoxicity). Target Free T4 upper normal (avoid fetal hypothyroidism). RAI contraindicated</li>
                        <li><strong>Elderly:</strong> Lower doses of thionamides. High AFib risk - anticoagulate. Consider RAI as first-line</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearls-box">
                <div class="pearls-title">üí° TEACHING PEARLS: HYPERTHYROIDISM</div>
                <ul>
                    <li><strong>Distinguish thyrotoxicosis from thyroid storm:</strong> Storm = LIFE-THREATENING (fever >104¬∞F, tachycardia >140, AMS, HF, GI symptoms). Non-storm = stable, symptomatic but not critical. See Condition #31 for storm management</li>
                    <li><strong>RAIU scan differentiates destructive vs synthesis causes:</strong> HIGH uptake (Graves, toxic nodules) = thyroid making excess hormone ‚Üí treat with thionamides/RAI/surgery. LOW uptake (thyroiditis, exogenous) = hormone release, not synthesis ‚Üí symptomatic management only, self-limited</li>
                    <li><strong>Methimazole > PTU (except first trimester pregnancy):</strong> Once-daily dosing, better efficacy, less hepatotoxicity. PTU has black box warning for hepatotoxicity</li>
                    <li><strong>Agranulocytosis = RARE but serious complication of thionamides</strong> (0.1-0.5%). Presents with fever, sore throat, infection. Check CBC if symptoms. STOP thionamide immediately if ANC <1,000. Never rechallenge. Switch to RAI or surgery</li>
                    <li><strong>Graves ophthalmopathy is separate from hyperthyroidism</strong> (autoimmune, TSI-mediated orbital inflammation). Treat hyperthyroidism, but eye disease may persist/worsen. RAI can worsen ophthalmopathy (give steroids if mild eye disease, avoid RAI if severe)</li>
                    <li><strong>Atrial fibrillation in hyperthyroidism: 60% spontaneously convert to sinus rhythm</strong> once euthyroid. Anticoagulate based on CHA2DS2-VASc. Rate control with beta-blockers</li>
                    <li><strong>Thyrotoxic periodic paralysis:</strong> Sudden muscle weakness + hypokalemia in Asian males with thyrotoxicosis. K+ shifts intracellularly (NOT total body K+ deficiency). Give K+ cautiously (can rebound to hyperkalemia). Treat underlying hyperthyroidism with beta-blockers + thionamides</li>
                    <li><strong>Apathetic thyrotoxicosis in elderly:</strong> Atypical presentation (depression, weight loss, AFib, HF) WITHOUT classic hyperadrenergic symptoms. Check TSH in elderly with new AFib or unexplained weight loss</li>
                    <li><strong>Iodine-containing contrast can precipitate thyrotoxicosis</strong> (Jod-Basedow) in patients with nodular thyroid disease or iodine deficiency. Screen high-risk patients before contrast administration</li>
                    <li><strong>Amiodarone-induced thyrotoxicosis: Differentiate Type 1 vs Type 2.</strong> Type 1 = treat like Graves (methimazole +/- perchlorate). Type 2 = destructive thyroiditis (prednisone). Mixed type common (treat both). Discontinue amiodarone if cardiac status allows</li>
                    <li><strong>RAI is contraindicated in pregnancy/breastfeeding and uncontrolled thyrotoxicosis.</strong> Achieve euthyroid state with methimazole first before RAI (reduces risk of thyroid storm post-RAI). Stop thionamide 3-5 days before RAI to allow iodine uptake</li>
                    <li><strong>Monitoring thionamides: Free T4 normalizes BEFORE TSH.</strong> TSH can remain suppressed for months after T4 normalizes. Use Free T4 to guide dose adjustments (goal: normal T4). Check TSH q3 months once stable</li>
                </ul>
            </div>
            
            <div class="two-column-criteria">
                <div class="criteria-column">
                    <div class="criteria-title">üö® ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Progression to thyroid storm (fever >104¬∞F, HR >140, AMS, severe agitation, HF)</li>
                        <li>Atrial fibrillation with RVR + hemodynamic instability</li>
                        <li>Acute heart failure from high-output state</li>
                        <li>Thyrotoxic periodic paralysis with respiratory muscle weakness</li>
                        <li>Severe agranulocytosis from thionamides with sepsis</li>
                        <li>Post-thyroidectomy complications (airway hematoma, severe hypocalcemia with tetany/seizures)</li>
                    </ul>
                </div>
                <div class="criteria-column">
                    <div class="criteria-title">‚úÖ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Hemodynamically stable, symptoms controlled with beta-blockers</li>
                        <li>Thionamide therapy initiated (if indicated) + patient counseled on side effects</li>
                        <li>Atrial fibrillation rate-controlled + anticoagulation started if indicated</li>
                        <li>Endocrinology follow-up arranged within 1-2 weeks</li>
                        <li>Patient understands:
                            <ul>
                                <li>Medication adherence critical</li>
                                <li>Warning signs of agranulocytosis (fever, sore throat) ‚Üí stop med, seek care immediately</li>
                                <li>Return precautions: worsening symptoms, palpitations, dyspnea, confusion</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </div>
            
            <div class="complications-section">
                <div class="complications-title">‚ö†Ô∏è COMPLICATIONS TO MONITOR</div>
                <div class="complications-grid">
                    <div class="complication-item">
                        <strong>Thyroid Storm:</strong> Life-threatening decompensation. Triggered by infection, surgery, trauma, RAI, discontinuation of antithyroid drugs. See Condition #31 for management
                    </div>
                    <div class="complication-item">
                        <strong>Atrial Fibrillation/Flutter:</strong> 10-15% of hyperthyroid patients. Thromboembolic risk. Anticoagulate based on CHA2DS2-VASc. Rate control. 60% convert to sinus rhythm once euthyroid
                    </div>
                    <div class="complication-item">
                        <strong>Heart Failure (High-Output):</strong> Tachycardia-induced cardiomyopathy. Treat hyperthyroidism + beta-blockers + diuretics. Usually reversible once euthyroid
                    </div>
                    <div class="complication-item">
                        <strong>Thionamide Side Effects:</strong> (1) Agranulocytosis (0.1-0.5%): fever, sore throat ‚Üí check CBC, stop drug immediately. (2) Hepatotoxicity (PTU > methimazole): transaminitis, rare fulminant hepatic failure. (3) Rash, arthralgia (5-10%). (4) Vasculitis (rare, PTU). Monitor CBC, LFTs
                    </div>
                    <div class="complication-item">
                        <strong>Graves Ophthalmopathy:</strong> Proptosis, diplopia, vision loss (optic nerve compression). Smoking worsens. Manage with selenium, steroids, orbital decompression surgery, radiation. RAI can worsen (give steroids prophylactically)
                    </div>
                    <div class="complication-item">
                        <strong>Osteoporosis:</strong> Increased bone turnover ‚Üí bone loss. Screen with DEXA if prolonged hyperthyroidism. Treat with bisphosphonates if osteoporotic. Reversible with treatment
                    </div>
                </div>
            </div>
            
            <div class="back-to-top">
                <a href="#top" onclick="document.getElementById('search-box').scrollIntoView({behavior: 'smooth'}); return false;">‚Üë Back to Top</a>
            </div>
        </div>

<!-- CONDITION 69: HYPOTHYROIDISM -->
<!-- ============================================ -->
        <div id="hypothyroid" class="condition-page">
            <div class="page-header">
                <h2>69. HYPOTHYROIDISM (NON-MYXEDEMA)</h2>
                <div class="subtitle">Hashimoto ‚Ä¢ Iatrogenic ‚Ä¢ Levothyroxine Replacement</div>
            </div>
            
            <div class="section">
                <div class="section-title">CLINICAL PRESENTATION</div>
                <div class="section-content">
                    <p><span class="label">Note:</span> This section covers NON-COMA hypothyroidism. For Myxedema Coma (life-threatening emergency), see Condition #32</p>
                    
                    <p><span class="label">Common Etiologies:</span></p>
                    <ul>
                        <li><strong>Hashimoto thyroiditis (autoimmune, 90% in US):</strong> Anti-TPO antibodies, anti-thyroglobulin antibodies. Progressive thyroid destruction. Goiter early, atrophy late</li>
                        <li><strong>Iatrogenic:</strong> Post-radioiodine ablation (most common cause post-treatment), post-thyroidectomy, external beam radiation (neck, mediastinum)</li>
                        <li><strong>Medications:</strong> Lithium (inhibits T4 release), amiodarone (type 2 - destructive thyroiditis), tyrosine kinase inhibitors, interferon, immune checkpoint inhibitors</li>
                        <li><strong>Iodine deficiency:</strong> Most common worldwide (rare in US due to iodized salt)</li>
                        <li><strong>Central hypothyroidism (secondary/tertiary):</strong> Pituitary (TSH deficiency) or hypothalamic (TRH deficiency) disease. Tumor, surgery, radiation, infiltrative (sarcoidosis, hemochromatosis), Sheehan syndrome</li>
                        <li><strong>Transient:</strong> Thyroiditis (post-hyperthyroid phase), postpartum thyroiditis</li>
                    </ul>
                    
                    <p><span class="label">Symptoms (Insidious Onset, Nonspecific):</span></p>
                    <ul>
                        <li><strong>Metabolic:</strong> Fatigue, cold intolerance, weight gain (modest, 5-10 lbs), decreased appetite</li>
                        <li><strong>Cardiovascular:</strong> Bradycardia, diastolic hypertension, pericardial effusion</li>
                        <li><strong>Neuropsychiatric:</strong> Depression, cognitive impairment ("brain fog"), psychomotor slowing, memory problems, carpal tunnel syndrome, delayed deep tendon reflex relaxation</li>
                        <li><strong>GI:</strong> Constipation, decreased bowel sounds</li>
                        <li><strong>Reproductive:</strong> Menorrhagia (women), decreased libido, infertility, galactorrhea (elevated prolactin from TRH)</li>
                        <li><strong>Dermatologic:</strong> Dry, coarse skin, hair loss (especially lateral third of eyebrows), brittle nails, nonpitting edema (myxedema - mucopolysaccharide deposition)</li>
                        <li><strong>Musculoskeletal:</strong> Myalgia, arthralgia, muscle cramps, weakness</li>
                    </ul>
                    
                    <p><span class="label">Physical Exam:</span></p>
                    <ul>
                        <li>Goiter (Hashimoto's - firm, rubbery) or absent thyroid (post-ablation/surgery)</li>
                        <li>Bradycardia, diastolic HTN</li>
                        <li>Dry, cool, pale skin, periorbital puffiness, macroglossia</li>
                        <li>Delayed relaxation of deep tendon reflexes ("hung-up" reflexes)</li>
                    </ul>
                    
                    <p><span class="label">Subclinical Hypothyroidism:</span> Elevated TSH (5-10 mIU/L) + NORMAL Free T4. Mild symptoms or asymptomatic. Controversial whether to treat. Consider treatment if: TSH >10, anti-TPO positive, symptomatic, goiter, pregnancy/planning pregnancy, dyslipidemia</p>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">DIAGNOSTIC WORKUP</div>
                <div class="section-content">
                    <p><span class="label">Thyroid Function Tests:</span></p>
                    <ul>
                        <li><strong>TSH:</strong> Elevated (>4.5-5 mIU/L) in primary hypothyroidism. FIRST test</li>
                        <li><strong>Free T4:</strong> Low (<0.8 ng/dL) confirms overt hypothyroidism</li>
                        <li><strong>Free T3:</strong> Usually not needed (last to drop, nonspecific)</li>
                        <li><strong>Interpretation:</strong>
                            <ul>
                                <li>High TSH + Low Free T4 = Primary hypothyroidism (thyroid gland failure)</li>
                                <li>High TSH + Normal Free T4 = Subclinical hypothyroidism</li>
                                <li>Low/Normal TSH + Low Free T4 = Central hypothyroidism (pituitary/hypothalamic). Order MRI pituitary, assess other pituitary hormones</li>
                            </ul>
                        </li>
                    </ul>
                    
                    <p><span class="label">Etiology Workup:</span></p>
                    <ul>
                        <li><strong>Anti-TPO antibodies:</strong> Positive in Hashimoto's (90-95%). Confirms autoimmune etiology</li>
                        <li><strong>Thyroid ultrasound:</strong> Not routinely needed. Order if palpable nodule or goiter. Hashimoto's: heterogeneous, hypoechoic</li>
                        <li><strong>If central hypothyroidism suspected:</strong> MRI pituitary, cortisol, LH/FSH, prolactin, GH (assess for hypopituitarism)</li>
                    </ul>
                    
                    <p><span class="label">Additional Labs:</span></p>
                    <ul>
                        <li><strong>CBC:</strong> Normocytic or macrocytic anemia (decreased erythropoietin)</li>
                        <li><strong>CMP:</strong> Hyponatremia (impaired free water excretion), hypoglycemia, elevated creatinine (decreased GFR), transaminitis (mild)</li>
                        <li><strong>Lipid panel:</strong> Elevated LDL, total cholesterol, triglycerides</li>
                        <li><strong>CK:</strong> Elevated (myopathy)</li>
                        <li><strong>Prolactin:</strong> Mildly elevated (TRH stimulates prolactin)</li>
                        <li><strong>ECG:</strong> Sinus bradycardia, low voltage, prolonged QT, flattened/inverted T waves</li>
                    </ul>
                </div>
            </div>
            
            <div class="section">
                <div class="section-title">TREATMENT PROTOCOL</div>
                <div class="section-content">
                    <p><span class="label">LEVOTHYROXINE (T4) REPLACEMENT:</span></p>
                    <ul>
                        <li><strong>Dosing:</strong>
                            <ul>
                                <li><strong>Young, healthy patients:</strong> Start 1.6 mcg/kg/day PO (typical: 75-125 mcg daily). Can start full dose</li>
                                <li><strong>Elderly or cardiac disease:</strong> Start LOW (25-50 mcg daily), increase by 12.5-25 mcg q4-6 weeks. Risk of precipitating MI/arrhythmia</li>
                                <li><strong>Severe hypothyroidism + cardiac disease:</strong> Start 12.5-25 mcg daily, very slow titration</li>
                            </ul>
                        </li>
                        <li><strong>Administration:</strong> Take on empty stomach, 30-60 min before breakfast (or at bedtime, 4 hrs after last meal). Consistent timing. Avoid simultaneous: calcium, iron, PPIs, antacids, bile acid sequestrants (decrease absorption)</li>
                        <li><strong>Monitoring:</strong>
                            <ul>
                                <li>Check TSH in 6-8 weeks after starting or dose change</li>
                                <li>Goal TSH: 0.5-2.5 mIU/L (normal range: 0.4-4.5, but aim for lower half)</li>
                                <li>Once stable: Check TSH annually</li>
                            </ul>
                        </li>
                        <li><strong>Dose adjustments:</strong> If TSH >4: increase levothyroxine by 12.5-25 mcg. If TSH <0.5: decrease by 12.5-25 mcg</li>
                    </ul>
                    
                    <p><span class="label">SPECIAL POPULATIONS:</span></p>
                    <ul>
                        <li><strong>Pregnancy:</strong> Increase dose by 30-50% as soon as pregnancy confirmed (increased T4 requirements). Goal TSH <2.5 in 1st trimester, <3.0 in 2nd/3rd. Check TSH q4 weeks</li>
                        <li><strong>Central hypothyroidism:</strong> Dose by Free T4 level (NOT TSH, which is inappropriately low/normal). Goal: Free T4 in upper half of normal range. MUST treat adrenal insufficiency FIRST (before levothyroxine) to avoid precipitating adrenal crisis</li>
                        <li><strong>Cardiac disease:</strong> Start low (25 mcg), go slow (increase q4-6 weeks). Monitor for angina, arrhythmia</li>
                    </ul>
                    
                    <p><span class="label">TREATMENT OF SUBCLINICAL HYPOTHYROIDISM:</span></p>
                    <ul>
                        <li><strong>Indications for treatment:</strong> TSH >10 mIU/L, anti-TPO positive (will progress to overt), symptomatic, goiter, pregnancy/planning pregnancy, dyslipidemia</li>
                        <li><strong>If TSH 5-10 + asymptomatic + anti-TPO negative:</strong> Monitor TSH q6-12 months. May not need treatment</li>
                        <li><strong>Dose:</strong> Start low (25-50 mcg daily), titrate to TSH 0.5-2.5</li>
                    </ul>
                    
                    <p><span class="label">COMPLICATIONS OF OVER-TREATMENT (TSH <0.1):</span></p>
                    <ul>
                        <li>Atrial fibrillation (especially elderly)</li>
                        <li>Osteoporosis (increased bone turnover)</li>
                        <li>Hyperthyroid symptoms (palpitations, tremor, weight loss)</li>
                        <li>Reduce levothyroxine dose if TSH suppressed</li>
                    </ul>
                </div>
            </div>
            
            <div class="pearls-box">
                <div class="pearls-title">üí° TEACHING PEARLS: HYPOTHYROIDISM</div>
                <ul>
                    <li><strong>Hypothyroidism symptoms are NONSPECIFIC.</strong> Fatigue, weight gain, depression common in general population. Have LOW threshold to check TSH in at-risk patients (autoimmune disease, prior thyroid treatment, neck radiation, elderly)</li>
                    <li><strong>TSH is MOST sensitive test for primary hypothyroidism.</strong> Elevated TSH (>4.5-5) = thyroid dysfunction. Confirms diagnosis even before Free T4 drops (subclinical hypothyroidism)</li>
                    <li><strong>Start levothyroxine LOW and GO SLOW in elderly/cardiac disease.</strong> Rapid T4 replacement can precipitate MI, arrhythmia. Start 25 mcg, increase by 12.5-25 mcg q4-6 weeks</li>
                    <li><strong>Levothyroxine absorption affected by many meds/supplements.</strong> Take 30-60 min before breakfast, separate from calcium, iron, PPIs, antacids by 4 hrs. Consistent timing critical</li>
                    <li><strong>Pregnancy increases levothyroxine requirements by 30-50%.</strong> Increase dose as soon as pregnancy confirmed. Check TSH q4 weeks. Goal TSH <2.5 (1st trimester), <3.0 (2nd/3rd). Uncontrolled hypothyroidism ‚Üí miscarriage, preterm birth, impaired fetal neurodevelopment</li>
                    <li><strong>Central hypothyroidism: Dose by Free T4, NOT TSH.</strong> TSH inappropriately low/normal despite low T4. Goal: Free T4 in upper half of normal. TREAT ADRENAL INSUFFICIENCY FIRST (before levothyroxine) to avoid adrenal crisis</li>
                    <li><strong>Hashimoto's thyroiditis: Anti-TPO antibodies positive in 90-95%.</strong> Progressive autoimmune destruction. May have transient hyperthyroid phase initially (hashitoxicosis) from thyroid inflammation/hormone release</li>
                    <li><strong>Subclinical hypothyroidism: TSH 5-10 + Normal Free T4.</strong> Treat if: TSH >10, anti-TPO positive (will progress), symptomatic, pregnant. If asymptomatic + TSH 5-10 + anti-TPO negative ‚Üí monitor q6-12 months</li>
                    <li><strong>Check TSH 6-8 weeks after dose change</strong> (levothyroxine half-life 7 days, takes 4-6 weeks to reach steady state). Once stable, check TSH annually</li>
                    <li><strong>Over-replacement (TSH <0.1) ‚Üí Atrial fibrillation + osteoporosis.</strong> Especially in elderly. Aim for TSH 0.5-2.5, not suppressed</li>
                    <li><strong>Medications that increase levothyroxine requirements:</strong> Estrogen (increases TBG), rifampin (increases metabolism), phenytoin, carbamazepine, sertraline. Check TSH 6-8 weeks after starting these meds, may need dose increase</li>
                    <li><strong>Myxedema coma vs non-coma hypothyroidism:</strong> Coma = AMS, hypothermia (<95¬∞F), bradycardia, hypotension, hypoventilation, hyponatremia. MEDICAL EMERGENCY. See Condition #32. Non-coma = stable, symptomatic, can treat outpatient with levothyroxine</li>
                </ul>
            </div>
            
            <div class="two-column-criteria">
                <div class="criteria-column">
                    <div class="criteria-title">üö® ICU ESCALATION CRITERIA</div>
                    <ul>
                        <li>Progression to myxedema coma (AMS, hypothermia <95¬∞F, hypoventilation, hypotension)</li>
                        <li>Pericardial effusion with tamponade physiology</li>
                        <li>Severe hyponatremia (<120 mEq/L) with seizures</li>
                        <li>Acute MI precipitated by levothyroxine initiation</li>
                        <li>Respiratory failure (CO2 retention from hypoventilation)</li>
                    </ul>
                </div>
                <div class="criteria-column">
                    <div class="criteria-title">‚úÖ DISCHARGE CRITERIA</div>
                    <ul>
                        <li>Levothyroxine initiated at appropriate dose</li>
                        <li>Patient counseled on:
                            <ul>
                                <li>Take on empty stomach, 30-60 min before breakfast</li>
                                <li>Separate from calcium, iron, antacids by ‚â•4 hrs</li>
                                <li>Lifelong therapy (most cases)</li>
                                <li>Symptoms may take 4-6 weeks to improve</li>
                            </ul>
                        </li>
                        <li>Endocrinology or PCP follow-up in 6-8 weeks for TSH recheck</li>
                        <li>If cardiac disease: Close cardiology follow-up, ECG monitoring as needed</li>
                    </ul>
                </div>
            </div>
            
            <div class="complications-section">
                <div class="complications-title">‚ö†Ô∏è COMPLICATIONS TO MONITOR</div>
                <div class="complications-grid">
                    <div class="complication-item">
                        <strong>Myxedema Coma:</strong> Severe, life-threatening decompensation. Triggered by infection, cold exposure, trauma, sedatives. AMS, hypothermia, hypoventilation, hypotension. HIGH MORTALITY (20-50%). See Condition #32
                    </div>
                    <div class="complication-item">
                        <strong>Cardiovascular Complications:</strong> Pericardial effusion (resolves with treatment), diastolic dysfunction, atherosclerosis (elevated LDL), brady arrhythmias. Risk of MI/AFib if rapid levothyroxine replacement in elderly/cardiac patients
                    </div>
                    <div class="complication-item">
                        <strong>Psychiatric:</strong> Depression (treat hypothyroidism first before antidepressants), cognitive impairment ("myxedema madness"), psychosis (rare). Symptoms improve with levothyroxine
                    </div>
                    <div class="complication-item">
                        <strong>Hyponatremia:</strong> Impaired free water excretion. Dilutional hyponatremia. Treat underlying hypothyroidism + fluid restriction. Avoid rapid correction
                    </div>
                    <div class="complication-item">
                        <strong>Hyperlipidemia:</strong> Elevated LDL, total cholesterol, TG. Treat hypothyroidism first ‚Üí lipids improve in 3-6 months. May need statin if persistent
                    </div>
                    <div class="complication-item">
                        <strong>Pregnancy Complications (Untreated):</strong> Miscarriage, preterm birth, preeclampsia, placental abruption, impaired fetal neurodevelopment. Screen TSH in all pregnant women in 1st trimester (or preconception)
                    </div>
                </div>
            </div>
            
            <div class="back-to-top">
                <a href="#top" onclick="document.getElementById('search-box').scrollIntoView({behavior: 'smooth'}); return false;">‚Üë Back to Top</a>
            </div>
        </div>

<!-- ============================================ -->
<!-- CONDITION 70: DIABETIC FOOT INFECTION -->
<!-- ============================================ -->
<div class="condition" id="diabetic-foot">
    <h2>Diabetic Foot Infection</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 71: SIADH -->
<!-- ============================================ -->
<div class="condition" id="siadh">
    <h2>SIADH (Syndrome of Inappropriate ADH)</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 72: DIABETES INSIPIDUS -->
<!-- ============================================ -->
<div class="condition" id="diabetes-insipidus">
    <h2>Diabetes Insipidus</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 73: PHEOCHROMOCYTOMA CRISIS -->
<!-- ============================================ -->
<div class="condition" id="pheo">
    <h2>Pheochromocytoma Crisis</h2>
    <p><em>[Content to be added in Phase 5]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 74: BOWEL OBSTRUCTION -->
<!-- ============================================ -->
<div class="condition" id="bowel-obstruction">
    <h2>Bowel Obstruction (Small/Large)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 75: SEVERE ACUTE DIARRHEA/VOLUME DEPLETION -->
<!-- ============================================ -->
<div class="condition" id="acute-diarrhea">
    <h2>Severe Acute Diarrhea/Volume Depletion</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 76: INFLAMMATORY BOWEL DISEASE FLARE -->
<!-- ============================================ -->
<div class="condition" id="ibd">
    <h2>Inflammatory Bowel Disease (IBD) Flare</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 77: DIVERTICULITIS (COMPLICATED) -->
<!-- ============================================ -->
<div class="condition" id="diverticulitis">
    <h2>Diverticulitis (Complicated)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 78: CIRRHOSIS COMPLICATIONS -->
<!-- ============================================ -->
<div class="condition" id="cirrhosis-complications">
    <h2>Cirrhosis Complications (Variceal Bleeding, Hepatorenal Syndrome)</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 79: ACUTE-ON-CHRONIC LIVER FAILURE -->
<!-- ============================================ -->
<div class="condition" id="aclf">
    <h2>Acute-on-Chronic Liver Failure</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 80: ISCHEMIC BOWEL/MESENTERIC ISCHEMIA -->
<!-- ============================================ -->
<div class="condition" id="mesenteric-ischemia">
    <h2>Ischemic Bowel/Mesenteric Ischemia</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 81: CHRONIC KIDNEY DISEASE COMPLICATIONS -->
<!-- ============================================ -->
<div class="condition" id="ckd-complications">
    <h2>Chronic Kidney Disease Complications</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 82: UREMIC SYNDROME -->
<!-- ============================================ -->
<div class="condition" id="uremia">
    <h2>Uremic Syndrome</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 83: RHABDOMYOLYSIS -->
<!-- ============================================ -->
<div class="condition" id="rhabdo">
    <h2>Rhabdomyolysis</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 84: TUMOR LYSIS SYNDROME -->
<!-- ============================================ -->
<div class="condition" id="tls">
    <h2>Tumor Lysis Syndrome</h2>
    <p><em>[Content to be added in Phase 6]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 85: HYPOCALCEMIA -->
<!-- ============================================ -->
<div class="condition" id="hypocalcemia">
    <h2>Hypocalcemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 86: HYPERMAGNESEMIA/HYPOMAGNESEMIA -->
<!-- ============================================ -->
<div class="condition" id="magnesium">
    <h2>Hypermagnesemia/Hypomagnesemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 87: HYPERPHOSPHATEMIA/HYPOPHOSPHATEMIA -->
<!-- ============================================ -->
<div class="condition" id="phosphate">
    <h2>Hyperphosphatemia/Hypophosphatemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 88: METABOLIC ALKALOSIS -->
<!-- ============================================ -->
<div class="condition" id="metabolic-alkalosis">
    <h2>Metabolic Alkalosis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 89: THROMBOCYTOPENIA (ITP, HIT, TTP/HUS) -->
<!-- ============================================ -->
<div class="condition" id="thrombocytopenia">
    <h2>Thrombocytopenia (ITP, HIT, TTP/HUS)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 90: DISSEMINATED INTRAVASCULAR COAGULATION (DIC) -->
<!-- ============================================ -->
<div class="condition" id="dic">
    <h2>Disseminated Intravascular Coagulation (DIC)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 91: SICKLE CELL CRISIS -->
<!-- ============================================ -->
<div class="condition" id="sickle-cell">
    <h2>Sickle Cell Crisis (Vaso-occlusive, Acute Chest)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 92: HEMOLYTIC ANEMIA -->
<!-- ============================================ -->
<div class="condition" id="hemolytic-anemia">
    <h2>Hemolytic Anemia</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 93: ONCOLOGIC EMERGENCIES -->
<!-- ============================================ -->
<div class="condition" id="onc-emergencies">
    <h2>Oncologic Emergencies (SVC Syndrome, Cord Compression, Hypercalcemia of Malignancy)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 94: ANTICOAGULATION REVERSAL/MAJOR BLEEDING -->
<!-- ============================================ -->
<div class="condition" id="anticoag-reversal">
    <h2>Anticoagulation Reversal/Major Bleeding on Anticoagulants</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 95: ACUTE GOUT/PSEUDOGOUT -->
<!-- ============================================ -->
<div class="condition" id="gout">
    <h2>Acute Gout/Pseudogout (Crystal Arthropathy)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 96: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) FLARE -->
<!-- ============================================ -->
<div class="condition" id="sle">
    <h2>Systemic Lupus Erythematosus (SLE) Flare</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 97: GIANT CELL ARTERITIS/TEMPORAL ARTERITIS -->
<!-- ============================================ -->
<div class="condition" id="gca">
    <h2>Giant Cell Arteritis/Temporal Arteritis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 98: ANAPHYLAXIS -->
<!-- ============================================ -->
<div class="condition" id="anaphylaxis">
    <h2>Anaphylaxis</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 99: DRUG OVERDOSE/TOXIDROMES -->
<!-- ============================================ -->
<div class="condition" id="overdose">
    <h2>Drug Overdose/Toxidromes (Acetaminophen, Salicylates, TCA, etc.)</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>

<!-- ============================================ -->
<!-- CONDITION 100: OPIOID OVERDOSE/WITHDRAWAL -->
<!-- ============================================ -->
<div class="condition" id="opioid">
    <h2>Opioid Overdose/Withdrawal</h2>
    <p><em>[Content to be added in Phase 7]</em></p>
</div>
        <div class="footer-section">
            <p><strong>Internal Medicine Clinical Reference Guide</strong></p>
            <p>Evidence-based guidelines for hospital medicine</p>
            <p style="font-size: 8pt; margin-top: 15px;">Always consult institutional protocols and current literature. Updated 2025.</p>
        </div>
    </div>
    
    <script>
        // SEARCH FUNCTIONALITY
        document.addEventListener('DOMContentLoaded', function() {
            const searchInput = document.getElementById('conditionSearch');
            const searchResults = document.getElementById('searchResults');
            const tocItems = document.querySelectorAll('.toc-item');
            const totalConditions = tocItems.length;
            
            searchInput.addEventListener('input', function() {
                const searchTerm = this.value.toLowerCase().trim();
                let visibleCount = 0;
                
                tocItems.forEach(item => {
                    const text = item.textContent.toLowerCase();
                    if (searchTerm === '' || text.includes(searchTerm)) {
                        item.style.display = '';
                        visibleCount++;
                    } else {
                        item.style.display = 'none';
                    }
                });
                
                if (searchTerm === '') {
                    searchResults.textContent = '';
                } else {
                    searchResults.textContent = `Showing ${visibleCount} of ${totalConditions} conditions`;
                }
            });
        });
        
        // HEART Score Calculator
        function calculateHEART() {
            const history = parseInt(document.getElementById('heart-history').value);
            const ecg = parseInt(document.getElementById('heart-ecg').value);
            const age = parseInt(document.getElementById('heart-age').value);
            const risk = parseInt(document.getElementById('heart-risk').value);
            const trop = parseInt(document.getElementById('heart-trop').value);
            
            const score = history + ecg + age + risk + trop;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score <= 3) {
                interpretation = `Score: ${score}/10 - LOW RISK (0.9-1.7% adverse cardiac events at 6 weeks). Consider outpatient workup.`;
                riskClass = '';
            } else if (score <= 6) {
                interpretation = `Score: ${score}/10 - MODERATE RISK (12-16% adverse cardiac events at 6 weeks). Admit for observation and further evaluation.`;
                riskClass = '';
            } else {
                interpretation = `Score: ${score}/10 - HIGH RISK (50-65% adverse cardiac events at 6 weeks). Admit for aggressive management, consider early invasive strategy.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('heart-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // TIMI STEMI Calculator
        function calculateTIMI_STEMI() {
            let score = 0;
            
            if (document.getElementById('timi-stemi-age65').checked) score += 2;
            if (document.getElementById('timi-stemi-age75').checked) score += 3;
            if (document.getElementById('timi-stemi-dm').checked) score += 1;
            if (document.getElementById('timi-stemi-bp').checked) score += 3;
            if (document.getElementById('timi-stemi-hr').checked) score += 2;
            if (document.getElementById('timi-stemi-killip').checked) score += 2;
            if (document.getElementById('timi-stemi-weight').checked) score += 1;
            if (document.getElementById('timi-stemi-anterior').checked) score += 1;
            if (document.getElementById('timi-stemi-time').checked) score += 1;
            
            let mortality = '';
            let riskClass = '';
            
            if (score === 0) {
                mortality = '0.8%';
            } else if (score === 1) {
                mortality = '1.6%';
            } else if (score === 2) {
                mortality = '2.2%';
            } else if (score === 3) {
                mortality = '4.4%';
            } else if (score === 4) {
                mortality = '7.3%';
            } else if (score === 5) {
                mortality = '12.4%';
            } else if (score === 6) {
                mortality = '16.1%';
            } else if (score === 7) {
                mortality = '23.4%';
            } else if (score === 8) {
                mortality = '26.8%';
            } else {
                mortality = '35.9%';
                riskClass = 'high-risk';
            }
            
            if (score > 6) riskClass = 'high-risk';
            
            const interpretation = `Score: ${score} - Predicted 30-day mortality: ${mortality}`;
            
            document.getElementById('timi-stemi-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // TIMI NSTEMI Calculator
        function calculateTIMI_NSTEMI() {
            let score = 0;
            
            if (document.getElementById('timi-nstemi-age').checked) score += 1;
            if (document.getElementById('timi-nstemi-risk').checked) score += 1;
            if (document.getElementById('timi-nstemi-cad').checked) score += 1;
            if (document.getElementById('timi-nstemi-asa').checked) score += 1;
            if (document.getElementById('timi-nstemi-angina').checked) score += 1;
            if (document.getElementById('timi-nstemi-ecg').checked) score += 1;
            if (document.getElementById('timi-nstemi-trop').checked) score += 1;
            
            let risk = '';
            let riskClass = '';
            
            if (score <= 2) {
                risk = '5% risk of death, MI, or urgent revascularization at 14 days - LOW RISK';
            } else if (score <= 4) {
                risk = '13% risk of death, MI, or urgent revascularization at 14 days - MODERATE RISK';
            } else {
                risk = '41% risk of death, MI, or urgent revascularization at 14 days - HIGH RISK. Consider early invasive strategy.';
                riskClass = 'high-risk';
            }
            
            const interpretation = `Score: ${score}/7 - ${risk}`;
            
            document.getElementById('timi-nstemi-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // GRACE Score Calculator
        function calculateGRACE() {
            const age = parseInt(document.getElementById('grace-age').value) || 0;
            const hr = parseInt(document.getElementById('grace-hr').value) || 0;
            const sbp = parseInt(document.getElementById('grace-sbp').value) || 0;
            const cr = parseFloat(document.getElementById('grace-cr').value) || 0;
            
            // Age points
            let agePoints = 0;
            if (age < 30) agePoints = 0;
            else if (age < 40) agePoints = 8;
            else if (age < 50) agePoints = 25;
            else if (age < 60) agePoints = 41;
            else if (age < 70) agePoints = 58;
            else if (age < 80) agePoints = 75;
            else agePoints = 91;
            
            // HR points
            let hrPoints = 0;
            if (hr < 50) hrPoints = 0;
            else if (hr < 70) hrPoints = 3;
            else if (hr < 90) hrPoints = 9;
            else if (hr < 110) hrPoints = 15;
            else if (hr < 150) hrPoints = 24;
            else if (hr < 200) hrPoints = 38;
            else hrPoints = 46;
            
            // SBP points
            let sbpPoints = 0;
            if (sbp < 80) sbpPoints = 58;
            else if (sbp < 100) sbpPoints = 53;
            else if (sbp < 120) sbpPoints = 43;
            else if (sbp < 140) sbpPoints = 34;
            else if (sbp < 160) sbpPoints = 24;
            else if (sbp < 200) sbpPoints = 10;
            else sbpPoints = 0;
            
            // Creatinine points
            let crPoints = 0;
            if (cr < 0.4) crPoints = 1;
            else if (cr < 0.8) crPoints = 4;
            else if (cr < 1.2) crPoints = 7;
            else if (cr < 1.6) crPoints = 10;
            else if (cr < 2.0) crPoints = 13;
            else if (cr < 4.0) crPoints = 21;
            else crPoints = 28;
            
            const arrest = document.getElementById('grace-arrest').checked ? 39 : 0;
            const st = document.getElementById('grace-st').checked ? 28 : 0;
            const enzymes = document.getElementById('grace-enzymes').checked ? 14 : 0;
            const killip = parseInt(document.getElementById('grace-killip').value);
            
            const score = agePoints + hrPoints + sbpPoints + crPoints + arrest + st + enzymes + killip;
            
            let risk = '';
            let riskClass = '';
            
            if (score < 109) {
                risk = 'LOW RISK - <1% in-hospital mortality, <3% 6-month mortality';
            } else if (score < 140) {
                risk = 'INTERMEDIATE RISK - 1-3% in-hospital mortality, 3-8% 6-month mortality';
            } else {
                risk = 'HIGH RISK - >3% in-hospital mortality, >8% 6-month mortality. Consider aggressive management.';
                riskClass = 'high-risk';
            }
            
            const interpretation = `GRACE Score: ${score} - ${risk}`;
            
            document.getElementById('grace-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // Wells Score for PE Calculator
        function calculateWells() {
            let score = 0;
            
            if (document.getElementById('wells-dvt').checked) score += 3;
            if (document.getElementById('wells-alt').checked) score += 3;
            if (document.getElementById('wells-hr').checked) score += 1.5;
            if (document.getElementById('wells-immob').checked) score += 1.5;
            if (document.getElementById('wells-prior').checked) score += 1.5;
            if (document.getElementById('wells-hemo').checked) score += 1;
            if (document.getElementById('wells-cancer').checked) score += 1;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score <= 4) {
                interpretation = `Wells Score: ${score} - PE UNLIKELY. Consider D-dimer to rule out PE. If D-dimer negative, PE excluded.`;
            } else {
                interpretation = `Wells Score: ${score} - PE LIKELY. Proceed directly to CTPA or V/Q scan. Do not wait for D-dimer.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('wells-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // qSOFA Calculator
        function calculateQSOFA() {
            let score = 0;
            
            if (document.getElementById('qsofa-rr').checked) score += 1;
            if (document.getElementById('qsofa-ams').checked) score += 1;
            if (document.getElementById('qsofa-sbp').checked) score += 1;
            
            let interpretation = '';
            let riskClass = '';
            
            if (score < 2) {
                interpretation = `qSOFA Score: ${score}/3 - LOW RISK for poor outcomes. Does not exclude sepsis. Continue clinical assessment.`;
            } else {
                interpretation = `qSOFA Score: ${score}/3 - HIGH RISK for poor outcomes. Strongly consider sepsis. Calculate full SOFA score, obtain lactate, start sepsis bundle immediately.`;
                riskClass = 'high-risk';
            }
            
            document.getElementById('qsofa-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
        
        // FENa Calculator
        function calculateFENa() {
            const urineNa = parseFloat(document.getElementById('fena-urine-na').value);
            const serumNa = parseFloat(document.getElementById('fena-serum-na').value);
            const urineCr = parseFloat(document.getElementById('fena-urine-cr').value);
            const serumCr = parseFloat(document.getElementById('fena-serum-cr').value);
            
            if (!urineNa || !serumNa || !urineCr || !serumCr) {
                document.getElementById('fena-result').innerHTML = '<div class="calc-result">Please enter all values</div>';
                return;
            }
            
            // FENa = (Urine Na / Serum Na) / (Urine Cr / Serum Cr) √ó 100
            const fena = ((urineNa / serumNa) / (urineCr / serumCr)) * 100;
            
            let interpretation = '';
            let riskClass = '';
            
            if (fena < 1) {
                interpretation = `FENa: ${fena.toFixed(2)}% - Suggests PRERENAL AKI. Kidney is avidly retaining sodium (underperfused but functioning). Treat with fluids/optimize perfusion.`;
            } else if (fena <= 2) {
                interpretation = `FENa: ${fena.toFixed(2)}% - INDETERMINATE. Could be prerenal or early ATN. Consider clinical context and other findings.`;
                riskClass = '';
            } else {
                interpretation = `FENa: ${fena.toFixed(2)}% - Suggests INTRINSIC AKI (likely ATN). Kidney cannot conserve sodium (tubular damage). Supportive care, avoid nephrotoxins.`;
                riskClass = 'high-risk';
            }
            
            interpretation += '<br><br><strong>Note:</strong> FENa not valid if patient on diuretics. Use FEUrea instead (<35% = prerenal).';
            
            document.getElementById('fena-result').innerHTML = `<div class="calc-result ${riskClass}">${interpretation}</div>`;
        }
    </script>
    
</body>
</html>
